[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fV5WFC8bbUZI0obcdkuWmXcnjj8fkMr4daw7gdao7aBM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"University of Alabama at Birmingham",[4],1379,false,359,53,1213796,152,929,[14,17,20,23,26,28,31,34],{"name":15,"count":16},"Obesity",54,{"name":18,"count":19},"Hypertension",30,{"name":21,"count":22},"Breast Cancer",28,{"name":24,"count":25},"Stroke",23,{"name":27,"count":25},"HIV",{"name":29,"count":30},"Multiple Sclerosis",19,{"name":32,"count":33},"HIV Infections",17,{"name":35,"count":33},"Cystic Fibrosis",[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT01196936","Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors","2018-12-11","Tamoxifen Citrate",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT02062827","Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma","2022-09","M032",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04964466","Release Kinetics in PRF Versus GEM21S With and Without Bone Substitutes: An In Vitro Analysis","2023-07-31","Amount of PDGF-BB in PRF preparation vs. GEM21",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT03657576","Trial of C134 in Patients With Recurrent GBM","2024-10-25","C134",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05098470","Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity","2025-07-29","Metformin",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05438849","Improving Primary Care Access to Urinary Incontinence Treatment for Women Veterans","2025-11-21","Practice Facilitation",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT04542148","Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes","2025-11-30","Sliding Scale Insulin",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT05350371","Safety and Tolerability of Pirfenidone in Acute Pancreatitis","2026-02","Pirfenidone Oral",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT02344680","Liver Fibrosis in Zambian HIV-HBV Co-infected Patients","2026-04","Anti-HIV Agents",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT05414500","Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides","2026-04-30","Mogamulizumab",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,138,177,215,233,251,277,305,332,358,383,412,430,448,474,492,519,537,555,581,606,636,662,689,707,725,743,769,797,815,841,859,886,904,970,1036,1101,1128,1158,1235,1290,1321,1359,1388,1410,1435,1461,1486,1512,1540,1566,1584,1602,1627,1645,1663,1692,1720,1747,1765,1783,1804,1822,1840,1858,1876,1894,1912,1937,1955,1979,2003,2031,2049,2067,2085,2103,2127,2145,2173,2191,2213,2236,2262,2288,2313,2337,2355,2383,2401,2419,2437,2472,2509,2532,2550,2572,2597,2615,2638,2661,2683,2706,2724,2742,2765,2789,2807,2825,2853,2876,2898,2950,2988,3029,3055,3080,3103,3127,3153,3175,3193,3215,3238,3262,3302,3324,3348,3372,3396,3414,3432,3450,3476,3500,3533,3558,3581,3599,3617,3635,3659,3683,3701,3727,3751,3769,3787,3805,3826,3849,3871,3896,3931,3993,4041,4078,4114,4147,4188,4210,4232,4268,4304,4341,4370,4394,4417,4441,4459,4483,4506,4524,4549,4567,4585,4603,4626,4651,4677,4703,4727,4751,4769,4791,4816,4841,4866,4892,4910,4940,4958,4985,5009,5027,5051,5075,5098,5119,5148,5173,5197,5221,5239,5264,5289,5307,5325,5349,5367,5393,5411,5429,5454,5482,5505,5530,5548,5575,5604,5628,5652,5675,5697,5720,5743,5761,5779,5806,5829,5853,5880,5905,5929,5970,6011,6042,6076,6109,6146,6164,6182,6206,6233,6251,6276,6294,6317,6342,6368,6386,6404,6429,6447,6465,6490,6515,6539,6557,6581,6599,6617,6635,6653,6671,6689,6713,6731,6749,6767,6785,6811,6829,6852,6875,6899,6924,6948,6973,6999,7017,7044,7062,7128,7191,7221,7260,7288,7315,7352,7378,7416,7449,7471,7493,7515,7545,7578,7617,7640,7665,7683,7701,7726,7753,7777,7800,7824,7842,7866,7889,7912,7935,7953,7971,7995,8021,8039,8066,8084,8102,8126,8151,8169,8187,8212,8230,8255,8273,8291,8315,8333,8359,8377,8400,8425,8449,8467,8490,8512,8535,8553,8571,8589,8614,8632,8654,8678,8696,8718,8736,8760,8778,8804,8822,8840,8858,8876,8894,8919,8943,8965,8987,9012,9036,9059,9084,9102,9124,9149,9175,9196,9218,9236,9258,9282,9305,9328,9350,9373,9396,9414,9432,9454,9475,9501,9519,9544,9562,9584,9609,9627,9650,9668,9694,9717,9735,9758,9782,9800,9824,9842,9860,9882,9906,9924,9953,9979,9997,10028,10051,10075,10097,10120,10143,10166,10189,10212,10235,10253,10271,10295,10318,10336,10359,10382,10405,10423,10446,10464,10488,10511,10535,10558,10582,10606,10632,10650,10675,10693,10716,10734,10760,10778,10801,10825,10848,10872,10898,10920,10941,10965,10983,11006,11031,11053,11077,11095,11118,11140,11165,11187,11212,11230,11256,11274,11298,11316,11339,11369,11392,11418,11436,11460,11482,11503,11527,11553,11575,11601,11648,11692,11734,11779,11822,11863,11889,11915,11946,11976,11998,12032,12057,12084,12110,12133,12157,12175,12197,12221,12245,12267,12290,12313,12331,12349,12374,12397,12415,12433,12457,12482,12500,12521,12543,12567,12592,12610,12632,12657,12679,12697,12721,12748,12766,12784,12802,12820,12838,12860,12882,12905,12923,12949,12967,12985,13003,13021,13039,13065,13083,13108,13126,13144,13167,13192,13215,13239,13266,13284,13306,13330,13353,13379,13400],{"intervention":61,"totalTrials":96,"cells":97},2,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":119,"NA":136},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":118,"soonestReadout":60},[107],{"nctId":58,"briefTitle":59,"status":108,"phases":109,"primaryCompletion":60,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":115},"ACTIVE_NOT_RECRUITING",[91],"2026-07-29","2022-03-07",100,[114],"Type 2 Diabetes",[61,116,117],"Insulin Glargine","Dorzagliatin",1,{"trials":120,"activeCount":118,"soonestReadout":126},[121],{"nctId":122,"briefTitle":123,"status":124,"phases":125,"primaryCompletion":126,"completion":127,"start":128,"enrollment":112,"conditions":129,"interventions":133},"NCT06829238","Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use","RECRUITING",[92],"2028-11-30","2029-11-30","2025-04-07",[130,131,132,27],"Systemic Inflammation","Immune Dysregulation","Injection Drug Use",[61,134,135],"Jynneos","Capvaxvie",{"trials":137,"activeCount":100},[],{"intervention":139,"totalTrials":96,"cells":140},"Buprenorphine",{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":149,"NA":175},{"trials":142,"activeCount":100},[],{"trials":144,"activeCount":100},[],{"trials":146,"activeCount":100},[],{"trials":148,"activeCount":100},[],{"trials":150,"activeCount":118,"soonestReadout":156},[151,163],{"nctId":152,"briefTitle":153,"status":154,"phases":155,"primaryCompletion":156,"completion":156,"start":157,"enrollment":158,"conditions":159,"interventions":162},"NCT07485335","A Bundled Intervention to End Opioid Overdoses","NOT_YET_RECRUITING",[92],"2030-09-30","2026-09-07",160,[160,161],"Opioid Use Disorder","Opioid Overdose",[139],{"nctId":164,"briefTitle":165,"status":166,"phases":167,"primaryCompletion":168,"completion":169,"start":170,"enrollment":171,"conditions":172,"interventions":174},"NCT00763958","Relapse Prevention to Reduce HIV Among Women Prisoners","COMPLETED",[92],"2009-09","2010-09","2008-05",44,[173,27],"Opioid Dependence",[139],{"trials":176,"activeCount":100},[],{"intervention":178,"totalTrials":96,"cells":179},"Amoxicillin",{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":195,"PHASE3":197,"PHASE4":199,"NA":213},{"trials":181,"activeCount":100},[],{"trials":183,"activeCount":100},[184],{"nctId":185,"briefTitle":186,"status":166,"phases":187,"primaryCompletion":188,"completion":189,"start":190,"enrollment":191,"conditions":192,"interventions":194},"NCT05309928","Phase 1 Study of the Pharmacokinetics of Amoxicillin in Pregnancy",[89],"2025-01-16","2025-06-30","2023-08-29",13,[193],"Pregnancy Related",[178],{"trials":196,"activeCount":100},[],{"trials":198,"activeCount":100},[],{"trials":200,"activeCount":118,"soonestReadout":205},[201],{"nctId":202,"briefTitle":203,"status":154,"phases":204,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":209,"interventions":211},"NCT07457385","Congenital Syphilis Treatment Trial (CONSISTENT) in Neonates",[92],"2031-05-01","2031-08-31","2026-11-01",374,[210],"Syphilis, Congenital",[212,178],"Benzathine Penicillin",{"trials":214,"activeCount":100},[],{"intervention":134,"totalTrials":118,"cells":216},{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":223,"PHASE4":225,"NA":231},{"trials":218,"activeCount":100},[],{"trials":220,"activeCount":100},[],{"trials":222,"activeCount":100},[],{"trials":224,"activeCount":100},[],{"trials":226,"activeCount":118,"soonestReadout":126},[227],{"nctId":122,"briefTitle":123,"status":124,"phases":228,"primaryCompletion":126,"completion":127,"start":128,"enrollment":112,"conditions":229,"interventions":230},[92],[130,131,132,27],[61,134,135],{"trials":232,"activeCount":100},[],{"intervention":135,"totalTrials":118,"cells":234},{"EARLY_PHASE1":235,"PHASE1":237,"PHASE2":239,"PHASE3":241,"PHASE4":243,"NA":249},{"trials":236,"activeCount":100},[],{"trials":238,"activeCount":100},[],{"trials":240,"activeCount":100},[],{"trials":242,"activeCount":100},[],{"trials":244,"activeCount":118,"soonestReadout":126},[245],{"nctId":122,"briefTitle":123,"status":124,"phases":246,"primaryCompletion":126,"completion":127,"start":128,"enrollment":112,"conditions":247,"interventions":248},[92],[130,131,132,27],[61,134,135],{"trials":250,"activeCount":100},[],{"intervention":252,"totalTrials":118,"cells":253},"Bodewell Calming Cream",{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":260,"PHASE4":262,"NA":275},{"trials":255,"activeCount":100},[],{"trials":257,"activeCount":100},[],{"trials":259,"activeCount":100},[],{"trials":261,"activeCount":100},[],{"trials":263,"activeCount":118,"soonestReadout":268},[264],{"nctId":265,"briefTitle":266,"status":108,"phases":267,"primaryCompletion":268,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":274},"NCT05566262","Bodewell Products for the Treatment of Atopic Dermatitis",[92],"2027-02","2028-02","2023-11-01",15,[273],"Atopic Dermatitis",[252],{"trials":276,"activeCount":100},[],{"intervention":278,"totalTrials":118,"cells":279},"Caffeine citrate 20mg\u002Fkg\u002Fday",{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":286,"PHASE4":288,"NA":303},{"trials":281,"activeCount":100},[],{"trials":283,"activeCount":100},[],{"trials":285,"activeCount":100},[],{"trials":287,"activeCount":100},[],{"trials":289,"activeCount":118,"soonestReadout":294},[290],{"nctId":291,"briefTitle":292,"status":154,"phases":293,"primaryCompletion":294,"completion":295,"start":296,"enrollment":297,"conditions":298,"interventions":302},"NCT06518603","Caffeine Citrate in Preterm Infants at Risk of Apnea in Zambia",[92],"2027-05-31","2027-06-30","2026-06-01",340,[299,300,301],"Premature Infant Disease","Apnea of Prematurity","Development, Infant",[278],{"trials":304,"activeCount":100},[],{"intervention":306,"totalTrials":118,"cells":307},"Pneumococcal Vaccine",{"EARLY_PHASE1":308,"PHASE1":310,"PHASE2":312,"PHASE3":314,"PHASE4":316,"NA":330},{"trials":309,"activeCount":100},[],{"trials":311,"activeCount":100},[],{"trials":313,"activeCount":100},[],{"trials":315,"activeCount":100},[],{"trials":317,"activeCount":118,"soonestReadout":322},[318],{"nctId":319,"briefTitle":320,"status":124,"phases":321,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":326,"interventions":329},"NCT07135453","Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines",[92],"2027-03","2027-08","2026-05",70,[327,328],"Vaccine","Pneumococcal Disease",[306],{"trials":331,"activeCount":100},[],{"intervention":333,"totalTrials":118,"cells":334},"Hizentra",{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":341,"PHASE4":343,"NA":356},{"trials":336,"activeCount":100},[],{"trials":338,"activeCount":100},[],{"trials":340,"activeCount":100},[],{"trials":342,"activeCount":100},[],{"trials":344,"activeCount":118,"soonestReadout":349},[345],{"nctId":346,"briefTitle":347,"status":124,"phases":348,"primaryCompletion":349,"completion":350,"start":351,"enrollment":352,"conditions":353,"interventions":355},"NCT05193552","Usage of Spirometry in Managing IgG Therapy in CVID With Airway Disease",[92],"2026-12","2027-12","2024-01-15",22,[354],"Common Variable Immunodeficiency",[333],{"trials":357,"activeCount":100},[],{"intervention":359,"totalTrials":118,"cells":360},"Vevye",{"EARLY_PHASE1":361,"PHASE1":363,"PHASE2":365,"PHASE3":367,"PHASE4":369,"NA":381},{"trials":362,"activeCount":100},[],{"trials":364,"activeCount":100},[],{"trials":366,"activeCount":100},[],{"trials":368,"activeCount":100},[],{"trials":370,"activeCount":118,"soonestReadout":375},[371],{"nctId":372,"briefTitle":373,"status":154,"phases":374,"primaryCompletion":375,"completion":375,"start":376,"enrollment":377,"conditions":378,"interventions":380},"NCT07224529","Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction",[92],"2027-02-01","2026-05-01",48,[379],"Meibomian Gland Dysfunction (MGD)",[359],{"trials":382,"activeCount":100},[],{"intervention":384,"totalTrials":118,"cells":385},"Flucelvax",{"EARLY_PHASE1":386,"PHASE1":388,"PHASE2":390,"PHASE3":392,"PHASE4":394,"NA":410},{"trials":387,"activeCount":100},[],{"trials":389,"activeCount":100},[],{"trials":391,"activeCount":100},[],{"trials":393,"activeCount":100},[],{"trials":395,"activeCount":118,"soonestReadout":400},[396],{"nctId":397,"briefTitle":398,"status":108,"phases":399,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":404,"interventions":406},"NCT04101838","B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults",[92],"2026-05-11","2027-05","2021-04-01",50,[405],"Influenza",[407,384,408,409],"Fluzone","Fluzone High-Dose","Fluad",{"trials":411,"activeCount":100},[],{"intervention":408,"totalTrials":118,"cells":413},{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":418,"PHASE3":420,"PHASE4":422,"NA":428},{"trials":415,"activeCount":100},[],{"trials":417,"activeCount":100},[],{"trials":419,"activeCount":100},[],{"trials":421,"activeCount":100},[],{"trials":423,"activeCount":118,"soonestReadout":400},[424],{"nctId":397,"briefTitle":398,"status":108,"phases":425,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":426,"interventions":427},[92],[405],[407,384,408,409],{"trials":429,"activeCount":100},[],{"intervention":409,"totalTrials":118,"cells":431},{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":436,"PHASE3":438,"PHASE4":440,"NA":446},{"trials":433,"activeCount":100},[],{"trials":435,"activeCount":100},[],{"trials":437,"activeCount":100},[],{"trials":439,"activeCount":100},[],{"trials":441,"activeCount":118,"soonestReadout":400},[442],{"nctId":397,"briefTitle":398,"status":108,"phases":443,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":444,"interventions":445},[92],[405],[407,384,408,409],{"trials":447,"activeCount":100},[],{"intervention":449,"totalTrials":118,"cells":450},"Multiple Product PrEP Program",{"EARLY_PHASE1":451,"PHASE1":453,"PHASE2":455,"PHASE3":457,"PHASE4":459,"NA":472},{"trials":452,"activeCount":100},[],{"trials":454,"activeCount":100},[],{"trials":456,"activeCount":100},[],{"trials":458,"activeCount":100},[],{"trials":460,"activeCount":118,"soonestReadout":465},[461],{"nctId":462,"briefTitle":463,"status":124,"phases":464,"primaryCompletion":465,"completion":466,"start":467,"enrollment":468,"conditions":469,"interventions":471},"NCT07076043","Multi-product PrEP Delivery to Young Women Seeking Reproductive Health Services and Coverage of HIV Prevention",[92],"2028-12-30","2029-12-30","2025-06-03",1400,[470],"Hiv",[449],{"trials":473,"activeCount":100},[],{"intervention":212,"totalTrials":118,"cells":475},{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":484,"NA":490},{"trials":477,"activeCount":100},[],{"trials":479,"activeCount":100},[],{"trials":481,"activeCount":100},[],{"trials":483,"activeCount":100},[],{"trials":485,"activeCount":118,"soonestReadout":205},[486],{"nctId":202,"briefTitle":203,"status":154,"phases":487,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":488,"interventions":489},[92],[210],[212,178],{"trials":491,"activeCount":100},[],{"intervention":493,"totalTrials":118,"cells":494},"Methyl Prednisolone",{"EARLY_PHASE1":495,"PHASE1":497,"PHASE2":499,"PHASE3":501,"PHASE4":503,"NA":517},{"trials":496,"activeCount":100},[],{"trials":498,"activeCount":100},[],{"trials":500,"activeCount":100},[],{"trials":502,"activeCount":100},[],{"trials":504,"activeCount":118,"soonestReadout":509},[505],{"nctId":506,"briefTitle":507,"status":154,"phases":508,"primaryCompletion":509,"completion":509,"start":510,"enrollment":511,"conditions":512,"interventions":514},"NCT07605923","Methylprednisolone Addition to Multimodal Pain Regimens After Anterior Cruciate Ligament Reconstruction",[92],"2031-08","2026-09",64,[513],"ACL Reconstruction",[493,515,516],"Standard Post-Operative Pain Control","Surgeon's Standard ACL Postoperative Regimen",{"trials":518,"activeCount":100},[],{"intervention":515,"totalTrials":118,"cells":520},{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":525,"PHASE3":527,"PHASE4":529,"NA":535},{"trials":522,"activeCount":100},[],{"trials":524,"activeCount":100},[],{"trials":526,"activeCount":100},[],{"trials":528,"activeCount":100},[],{"trials":530,"activeCount":118,"soonestReadout":509},[531],{"nctId":506,"briefTitle":507,"status":154,"phases":532,"primaryCompletion":509,"completion":509,"start":510,"enrollment":511,"conditions":533,"interventions":534},[92],[513],[493,515,516],{"trials":536,"activeCount":100},[],{"intervention":516,"totalTrials":118,"cells":538},{"EARLY_PHASE1":539,"PHASE1":541,"PHASE2":543,"PHASE3":545,"PHASE4":547,"NA":553},{"trials":540,"activeCount":100},[],{"trials":542,"activeCount":100},[],{"trials":544,"activeCount":100},[],{"trials":546,"activeCount":100},[],{"trials":548,"activeCount":118,"soonestReadout":509},[549],{"nctId":506,"briefTitle":507,"status":154,"phases":550,"primaryCompletion":509,"completion":509,"start":510,"enrollment":511,"conditions":551,"interventions":552},[92],[513],[493,515,516],{"trials":554,"activeCount":100},[],{"intervention":556,"totalTrials":118,"cells":557},"20-valent pneumococcal conjugate vaccine",{"EARLY_PHASE1":558,"PHASE1":560,"PHASE2":562,"PHASE3":564,"PHASE4":566,"NA":579},{"trials":559,"activeCount":100},[],{"trials":561,"activeCount":100},[],{"trials":563,"activeCount":100},[],{"trials":565,"activeCount":100},[],{"trials":567,"activeCount":118,"soonestReadout":322},[568],{"nctId":569,"briefTitle":570,"status":124,"phases":571,"primaryCompletion":322,"completion":572,"start":573,"enrollment":19,"conditions":574,"interventions":578},"NCT07135427","Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency",[92],"2027-06","2025-09-03",[575,576,577],"Alpha 1-Antitrypsin","COPD","Antibody Deficiency",[556],{"trials":580,"activeCount":100},[],{"intervention":582,"totalTrials":118,"cells":583},"Baricitinib 4 MG Oral",{"EARLY_PHASE1":584,"PHASE1":586,"PHASE2":588,"PHASE3":590,"PHASE4":592,"NA":604},{"trials":585,"activeCount":100},[],{"trials":587,"activeCount":100},[],{"trials":589,"activeCount":100},[],{"trials":591,"activeCount":100},[],{"trials":593,"activeCount":118,"soonestReadout":598},[594],{"nctId":595,"briefTitle":596,"status":108,"phases":597,"primaryCompletion":598,"completion":599,"start":600,"enrollment":271,"conditions":601,"interventions":603},"NCT06240351","A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)",[92],"2026-07-31","2027-07-31","2024-04-22",[602],"Frontal Fibrosing Alopecia",[582],{"trials":605,"activeCount":100},[],{"intervention":607,"totalTrials":96,"cells":608},"fluzone",{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":613,"PHASE3":615,"PHASE4":617,"NA":623},{"trials":610,"activeCount":100},[],{"trials":612,"activeCount":100},[],{"trials":614,"activeCount":100},[],{"trials":616,"activeCount":100},[],{"trials":618,"activeCount":118,"soonestReadout":400},[619],{"nctId":397,"briefTitle":398,"status":108,"phases":620,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":621,"interventions":622},[92],[405],[407,384,408,409],{"trials":624,"activeCount":100},[625],{"nctId":626,"briefTitle":627,"status":166,"phases":628,"primaryCompletion":629,"completion":629,"start":630,"enrollment":631,"conditions":632,"interventions":634},"NCT00611611","BLYS and IFN in SLE",[],"2009-04","2007-10",39,[633],"Systemic Lupus Erythematosus",[607,635],"pneumovax",{"intervention":637,"totalTrials":118,"cells":638},"AZM Group",{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":643,"PHASE3":645,"PHASE4":658,"NA":660},{"trials":640,"activeCount":100},[],{"trials":642,"activeCount":100},[],{"trials":644,"activeCount":100},[],{"trials":646,"activeCount":118,"soonestReadout":651},[647],{"nctId":648,"briefTitle":649,"status":124,"phases":650,"primaryCompletion":651,"completion":652,"start":653,"enrollment":654,"conditions":655,"interventions":657},"NCT05026749","Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children",[91],"2027-07-01","2028-07-31","2022-02-27",370,[656],"Respiratory Syncytial Virus Infections",[637],{"trials":659,"activeCount":100},[],{"trials":661,"activeCount":100},[],{"intervention":663,"totalTrials":118,"cells":664},"LTOWB",{"EARLY_PHASE1":665,"PHASE1":667,"PHASE2":669,"PHASE3":671,"PHASE4":685,"NA":687},{"trials":666,"activeCount":100},[],{"trials":668,"activeCount":100},[],{"trials":670,"activeCount":100},[],{"trials":672,"activeCount":118,"soonestReadout":677},[673],{"nctId":674,"briefTitle":675,"status":124,"phases":676,"primaryCompletion":677,"completion":295,"start":678,"enrollment":679,"conditions":680,"interventions":683},"NCT05638581","Trauma Resuscitation With Low-Titer Group O Whole Blood or Products",[91],"2026-12-31","2023-07-27",1100,[681,682],"Wounds and Injuries","Shock, Hemorrhagic",[663,684],"Components",{"trials":686,"activeCount":100},[],{"trials":688,"activeCount":100},[],{"intervention":684,"totalTrials":118,"cells":690},{"EARLY_PHASE1":691,"PHASE1":693,"PHASE2":695,"PHASE3":697,"PHASE4":703,"NA":705},{"trials":692,"activeCount":100},[],{"trials":694,"activeCount":100},[],{"trials":696,"activeCount":100},[],{"trials":698,"activeCount":118,"soonestReadout":677},[699],{"nctId":674,"briefTitle":675,"status":124,"phases":700,"primaryCompletion":677,"completion":295,"start":678,"enrollment":679,"conditions":701,"interventions":702},[91],[681,682],[663,684],{"trials":704,"activeCount":100},[],{"trials":706,"activeCount":100},[],{"intervention":116,"totalTrials":118,"cells":708},{"EARLY_PHASE1":709,"PHASE1":711,"PHASE2":713,"PHASE3":715,"PHASE4":721,"NA":723},{"trials":710,"activeCount":100},[],{"trials":712,"activeCount":100},[],{"trials":714,"activeCount":100},[],{"trials":716,"activeCount":118,"soonestReadout":60},[717],{"nctId":58,"briefTitle":59,"status":108,"phases":718,"primaryCompletion":60,"completion":110,"start":111,"enrollment":112,"conditions":719,"interventions":720},[91],[114],[61,116,117],{"trials":722,"activeCount":100},[],{"trials":724,"activeCount":100},[],{"intervention":117,"totalTrials":118,"cells":726},{"EARLY_PHASE1":727,"PHASE1":729,"PHASE2":731,"PHASE3":733,"PHASE4":739,"NA":741},{"trials":728,"activeCount":100},[],{"trials":730,"activeCount":100},[],{"trials":732,"activeCount":100},[],{"trials":734,"activeCount":118,"soonestReadout":60},[735],{"nctId":58,"briefTitle":59,"status":108,"phases":736,"primaryCompletion":60,"completion":110,"start":111,"enrollment":112,"conditions":737,"interventions":738},[91],[114],[61,116,117],{"trials":740,"activeCount":100},[],{"trials":742,"activeCount":100},[],{"intervention":744,"totalTrials":118,"cells":745},"oral tranexamic acid",{"EARLY_PHASE1":746,"PHASE1":748,"PHASE2":750,"PHASE3":752,"PHASE4":765,"NA":767},{"trials":747,"activeCount":100},[],{"trials":749,"activeCount":100},[],{"trials":751,"activeCount":100},[],{"trials":753,"activeCount":118,"soonestReadout":758},[754],{"nctId":755,"briefTitle":756,"status":124,"phases":757,"primaryCompletion":758,"completion":759,"start":760,"enrollment":761,"conditions":762,"interventions":764},"NCT06902714","Effects of Oral Tranexamic Acid on Short Term Postoperative Outcomes Following Total Shoulder Arthroplasty",[91],"2028-07","2030-12","2026-04-20",60,[763],"Shoulder Arthroplasty",[744],{"trials":766,"activeCount":100},[],{"trials":768,"activeCount":100},[],{"intervention":770,"totalTrials":118,"cells":771},"Sacubitril-Valsartan 49 Mg-51 Mg Oral",{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":776,"PHASE3":778,"PHASE4":793,"NA":795},{"trials":773,"activeCount":100},[],{"trials":775,"activeCount":100},[],{"trials":777,"activeCount":100},[],{"trials":779,"activeCount":118,"soonestReadout":784},[780],{"nctId":781,"briefTitle":782,"status":124,"phases":783,"primaryCompletion":784,"completion":784,"start":785,"enrollment":158,"conditions":786,"interventions":791},"NCT04971720","PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis",[90,91],"2027-01-01","2022-02-18",[15,787,18,788,789,790],"Cardiovascular Diseases","Nocturnal Blood Pressure","Natriuretic Peptides","Renin-Angiotensin-Aldosterone System",[770,792],"Valsartan 80 mg Oral",{"trials":794,"activeCount":100},[],{"trials":796,"activeCount":100},[],{"intervention":792,"totalTrials":118,"cells":798},{"EARLY_PHASE1":799,"PHASE1":801,"PHASE2":803,"PHASE3":805,"PHASE4":811,"NA":813},{"trials":800,"activeCount":100},[],{"trials":802,"activeCount":100},[],{"trials":804,"activeCount":100},[],{"trials":806,"activeCount":118,"soonestReadout":784},[807],{"nctId":781,"briefTitle":782,"status":124,"phases":808,"primaryCompletion":784,"completion":784,"start":785,"enrollment":158,"conditions":809,"interventions":810},[90,91],[15,787,18,788,789,790],[770,792],{"trials":812,"activeCount":100},[],{"trials":814,"activeCount":100},[],{"intervention":816,"totalTrials":118,"cells":817},"Tenofovir Disoproxil Fumarate",{"EARLY_PHASE1":818,"PHASE1":820,"PHASE2":822,"PHASE3":824,"PHASE4":837,"NA":839},{"trials":819,"activeCount":100},[],{"trials":821,"activeCount":100},[],{"trials":823,"activeCount":100},[],{"trials":825,"activeCount":118,"soonestReadout":830},[826],{"nctId":827,"briefTitle":828,"status":108,"phases":829,"primaryCompletion":830,"completion":677,"start":831,"enrollment":832,"conditions":833,"interventions":835},"NCT04704024","Reducing Vertical Transmission of Hepatitis B in Africa",[91],"2026-08-01","2021-09-03",450,[834],"Hepatitis B Infection",[816,836],"Lamivudine Oral Solution",{"trials":838,"activeCount":100},[],{"trials":840,"activeCount":100},[],{"intervention":836,"totalTrials":118,"cells":842},{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":849,"PHASE4":855,"NA":857},{"trials":844,"activeCount":100},[],{"trials":846,"activeCount":100},[],{"trials":848,"activeCount":100},[],{"trials":850,"activeCount":118,"soonestReadout":830},[851],{"nctId":827,"briefTitle":828,"status":108,"phases":852,"primaryCompletion":830,"completion":677,"start":831,"enrollment":832,"conditions":853,"interventions":854},[91],[834],[816,836],{"trials":856,"activeCount":100},[],{"trials":858,"activeCount":100},[],{"intervention":860,"totalTrials":118,"cells":861},"targeted synthetic DMARD class",{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":868,"PHASE4":882,"NA":884},{"trials":863,"activeCount":100},[],{"trials":865,"activeCount":100},[],{"trials":867,"activeCount":100},[],{"trials":869,"activeCount":118,"soonestReadout":874},[870],{"nctId":871,"briefTitle":872,"status":124,"phases":873,"primaryCompletion":874,"completion":875,"start":876,"enrollment":877,"conditions":878,"interventions":880},"NCT04692493","RA-PRO PRAGMATIC TRIAL",[91],"2027-02-28","2028-12-31","2021-09-22",924,[879],"Rheumatoid Arthritis",[860,881],"non-TNFi-biologic class",{"trials":883,"activeCount":100},[],{"trials":885,"activeCount":100},[],{"intervention":881,"totalTrials":118,"cells":887},{"EARLY_PHASE1":888,"PHASE1":890,"PHASE2":892,"PHASE3":894,"PHASE4":900,"NA":902},{"trials":889,"activeCount":100},[],{"trials":891,"activeCount":100},[],{"trials":893,"activeCount":100},[],{"trials":895,"activeCount":118,"soonestReadout":874},[896],{"nctId":871,"briefTitle":872,"status":124,"phases":897,"primaryCompletion":874,"completion":875,"start":876,"enrollment":877,"conditions":898,"interventions":899},[91],[879],[860,881],{"trials":901,"activeCount":100},[],{"trials":903,"activeCount":100},[],{"intervention":905,"totalTrials":906,"cells":907},"Pembrolizumab",4,{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":912,"PHASE3":964,"PHASE4":966,"NA":968},{"trials":909,"activeCount":100},[],{"trials":911,"activeCount":100},[],{"trials":913,"activeCount":963,"soonestReadout":955},[914,925,935,951],{"nctId":915,"briefTitle":916,"status":917,"phases":918,"primaryCompletion":919,"completion":919,"start":920,"enrollment":921,"conditions":922,"interventions":924},"NCT02837042","Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma","TERMINATED",[90],"2019-10","2016-10",6,[923],"Penile Squamous Cell Carcinoma",[905],{"nctId":926,"briefTitle":927,"status":124,"phases":928,"primaryCompletion":929,"completion":930,"start":931,"enrollment":112,"conditions":932,"interventions":934},"NCT06005818","Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)",[90],"2027-07","2028-09","2024-01-01",[933],"Renal Cell Carcinoma",[905],{"nctId":936,"briefTitle":937,"status":124,"phases":938,"primaryCompletion":939,"completion":940,"start":941,"enrollment":942,"conditions":943,"interventions":945},"NCT06364917","DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC",[90],"2027-04-27","2027-09","2025-05-30",24,[944],"Non Small Cell Lung Cancer",[905,946,947,948,949,950],"Carboplatin","Paclitaxel","Pemetrexed","Nivolumab","Ipilimumab",{"nctId":952,"briefTitle":953,"status":124,"phases":954,"primaryCompletion":955,"completion":956,"start":957,"enrollment":22,"conditions":958,"interventions":962},"NCT05084430","Study of Pembrolizumab and M032 (NSC 733972)",[89,90],"2027-03-01","2028-03-01","2022-02-25",[959,960,961],"Glioblastoma Multiforme","Anaplastic Astrocytoma","Gliosarcoma",[46,905],3,{"trials":965,"activeCount":100},[],{"trials":967,"activeCount":100},[],{"trials":969,"activeCount":100},[],{"intervention":946,"totalTrials":971,"cells":972},5,{"EARLY_PHASE1":973,"PHASE1":975,"PHASE2":977,"PHASE3":1030,"PHASE4":1032,"NA":1034},{"trials":974,"activeCount":100},[],{"trials":976,"activeCount":100},[],{"trials":978,"activeCount":96,"soonestReadout":939},[979,991,1005,1009,1019],{"nctId":980,"briefTitle":981,"status":124,"phases":982,"primaryCompletion":983,"completion":984,"start":985,"enrollment":986,"conditions":987,"interventions":989},"NCT05952453","Newly Diagnosed Stage III\u002FIV Ovarian Cancer, Neoadjuvant Carbo\u002FTaxol\u002FPembro, Maintenance Olaparib\u002FPembro",[90],"2028-10-30","2030-12-30","2025-02-17",20,[988],"Ovarian Cancer",[946,990],"olaparibp, embro",{"nctId":992,"briefTitle":993,"status":166,"phases":994,"primaryCompletion":995,"completion":995,"start":996,"enrollment":997,"conditions":998,"interventions":1000},"NCT00004186","Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer",[89,90],"2004-12","1996-12",55,[999],"Lung Cancer",[1001,1002,1003,1004],"carboplatin","etoposide","ifosfamide","topotecan hydrochloride",{"nctId":936,"briefTitle":937,"status":124,"phases":1006,"primaryCompletion":939,"completion":940,"start":941,"enrollment":942,"conditions":1007,"interventions":1008},[90],[944],[905,946,947,948,949,950],{"nctId":1010,"briefTitle":1011,"status":166,"phases":1012,"primaryCompletion":1013,"completion":1013,"start":1014,"enrollment":1015,"conditions":1016,"interventions":1017},"NCT00096343","Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer",[90],"2005-03","2002-10",31,[21],[1001,1018],"paclitaxel",{"nctId":1020,"briefTitle":1021,"status":166,"phases":1022,"primaryCompletion":1023,"completion":1024,"start":1025,"enrollment":19,"conditions":1026,"interventions":1028},"NCT00581971","Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer",[89,90],"2007-12","2012-03","2002-09",[1027],"Cancer",[1029,946,947],"celecoxib",{"trials":1031,"activeCount":100},[],{"trials":1033,"activeCount":100},[],{"trials":1035,"activeCount":100},[],{"intervention":1037,"totalTrials":906,"cells":1038},"Bevacizumab",{"EARLY_PHASE1":1039,"PHASE1":1041,"PHASE2":1070,"PHASE3":1095,"PHASE4":1097,"NA":1099},{"trials":1040,"activeCount":100},[],{"trials":1042,"activeCount":118,"soonestReadout":929},[1043,1058],{"nctId":1044,"briefTitle":1045,"status":166,"phases":1046,"primaryCompletion":1047,"completion":1048,"start":1049,"enrollment":1050,"conditions":1051,"interventions":1056},"NCT02835833","Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors",[89],"2018-04-14","2018-06-14","2016-06-09",21,[933,1052,1053,1054,1055],"Colorectal Adenocarcinoma","Non-squamous Non-small Cell Lung Cancer","Platinum-refractory Ovarian Carcinoma","Cervical Carcinoma",[1057,1037],"Nintedanib",{"nctId":1059,"briefTitle":1060,"status":124,"phases":1061,"primaryCompletion":929,"completion":758,"start":1062,"enrollment":1063,"conditions":1064,"interventions":1067},"NCT06867822","Trial of ProAgio in Advanced\u002FMetastatic Colorectal Cancer",[89],"2025-07-17",27,[1065,1066],"Advanced Colorectal Cancer","Metastatic Colorectal Cancer",[1068,1069,1037],"ProAgio","FOLFIRI",{"trials":1071,"activeCount":118,"soonestReadout":1087},[1072,1083],{"nctId":1073,"briefTitle":1074,"status":166,"phases":1075,"primaryCompletion":1076,"completion":1077,"start":1078,"enrollment":352,"conditions":1079,"interventions":1082},"NCT01767792","Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas",[90],"2019-01-01","2020-02-01","2013-05-15",[1080,1081],"Neurofibromatosis Type 2","Progressive Vestibular Schwannomas",[1037],{"nctId":1084,"briefTitle":1085,"status":124,"phases":1086,"primaryCompletion":1087,"completion":1088,"start":60,"enrollment":1089,"conditions":1090,"interventions":1092},"NCT06294548","A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC",[89,90],"2028-01-30","2028-08-28",45,[1091],"Hepatocellular Carcinoma",[1093,1094,1037],"Valemetostat","Atezolizumab",{"trials":1096,"activeCount":100},[],{"trials":1098,"activeCount":100},[],{"trials":1100,"activeCount":100},[],{"intervention":46,"totalTrials":96,"cells":1102},{"EARLY_PHASE1":1103,"PHASE1":1105,"PHASE2":1116,"PHASE3":1122,"PHASE4":1124,"NA":1126},{"trials":1104,"activeCount":100},[],{"trials":1106,"activeCount":118,"soonestReadout":45},[1107],{"nctId":43,"briefTitle":44,"status":108,"phases":1108,"primaryCompletion":45,"completion":940,"start":1109,"enrollment":1110,"conditions":1111,"interventions":1115},[89],"2013-11-25",29,[1112,1113,1114],"Recurrent Glioblastoma Multiforme","Progressive Glioblastoma Multiforme","Anaplastic Astrocytoma or Gliosarcoma",[46],{"trials":1117,"activeCount":118,"soonestReadout":955},[1118],{"nctId":952,"briefTitle":953,"status":124,"phases":1119,"primaryCompletion":955,"completion":956,"start":957,"enrollment":22,"conditions":1120,"interventions":1121},[89,90],[959,960,961],[46,905],{"trials":1123,"activeCount":100},[],{"trials":1125,"activeCount":100},[],{"trials":1127,"activeCount":100},[],{"intervention":1129,"totalTrials":96,"cells":1130},"Pirfenidone",{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1135,"PHASE3":1152,"PHASE4":1154,"NA":1156},{"trials":1132,"activeCount":100},[],{"trials":1134,"activeCount":100},[],{"trials":1136,"activeCount":96,"soonestReadout":75},[1137,1146],{"nctId":1138,"briefTitle":1139,"status":124,"phases":1140,"primaryCompletion":1141,"completion":1141,"start":1142,"enrollment":761,"conditions":1143,"interventions":1145},"NCT06253117","Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.",[90],"2028-09-01","2024-06-27",[1144],"Recurrent Acute Pancreatitis",[1129],{"nctId":73,"briefTitle":74,"status":124,"phases":1147,"primaryCompletion":75,"completion":268,"start":1148,"enrollment":761,"conditions":1149,"interventions":1151},[89,90],"2023-08-01",[1150],"Pancreatitis, Acute",[76],{"trials":1153,"activeCount":100},[],{"trials":1155,"activeCount":100},[],{"trials":1157,"activeCount":100},[],{"intervention":1159,"totalTrials":971,"cells":1160},"Dexamethasone",{"EARLY_PHASE1":1161,"PHASE1":1163,"PHASE2":1165,"PHASE3":1191,"PHASE4":1205,"NA":1233},{"trials":1162,"activeCount":100},[],{"trials":1164,"activeCount":100},[],{"trials":1166,"activeCount":118,"soonestReadout":1183},[1167,1179],{"nctId":1168,"briefTitle":1169,"status":166,"phases":1170,"primaryCompletion":1171,"completion":1172,"start":1173,"enrollment":22,"conditions":1174,"interventions":1176},"NCT02047253","Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment",[90],"2017-06-08","2017-07-14","2014-04",[1175],"Metastatic Castration-resistant Prostate Cancer",[1177,1159,1178],"Carfilzomib","Acyclovir",{"nctId":1180,"briefTitle":1181,"status":108,"phases":1182,"primaryCompletion":1183,"completion":1183,"start":1184,"enrollment":1185,"conditions":1186,"interventions":1188},"NCT05434689","COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide",[89,90],"2028-08","2023-01-18",80,[1187],"Multiple Myeloma",[1189,1190,1159,1177],"Iberdomide","Daratumumab",{"trials":1192,"activeCount":100},[1193],{"nctId":1194,"briefTitle":1195,"status":1196,"phases":1197,"primaryCompletion":1198,"completion":1199,"start":1200,"enrollment":100,"conditions":1201,"interventions":1203},"NCT03183596","Optimal Injection Site for Serratus Anterior Plane Block in Reconstructive Breast Surgery","WITHDRAWN",[91],"2020-08","2024-01","2019-12",[1202],"Pain, Postoperative",[1204,1159],"Bupivacaine",{"trials":1206,"activeCount":100},[1207,1218],{"nctId":1208,"briefTitle":1209,"status":166,"phases":1210,"primaryCompletion":1211,"completion":1212,"start":1213,"enrollment":1214,"conditions":1215,"interventions":1217},"NCT03757715","Regional Anesthesia to Reduce Opioid Use Following Functional Endoscopic Sinus Surgery",[92],"2021-03-12","2021-04-12","2019-05-20",46,[1216],"Pain Management",[1204,1159],{"nctId":1219,"briefTitle":1220,"status":166,"phases":1221,"primaryCompletion":1222,"completion":1223,"start":1224,"enrollment":377,"conditions":1225,"interventions":1227},"NCT03859024","Efficacy of Opioid-limiting Pain Management Protocol in Men Undergoing Urethroplasty",[92],"2023-04-30","2023-06-30","2019-03-22",[1202,1226],"Urethral Stricture",[1228,1229,1230,1231,1204,1232,1159],"Oxycodone","Acetaminophen","Gabapentin","celebrex","Ibuprofen 800 mg",{"trials":1234,"activeCount":100},[],{"intervention":947,"totalTrials":921,"cells":1236},{"EARLY_PHASE1":1237,"PHASE1":1239,"PHASE2":1241,"PHASE3":1284,"PHASE4":1286,"NA":1288},{"trials":1238,"activeCount":100},[],{"trials":1240,"activeCount":100},[],{"trials":1242,"activeCount":118,"soonestReadout":939},[1243,1255,1259,1267,1271,1275],{"nctId":1244,"briefTitle":1245,"status":166,"phases":1246,"primaryCompletion":1247,"completion":1248,"start":1249,"enrollment":631,"conditions":1250,"interventions":1252},"NCT00655850","Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer",[90],"2015-09","2016-09","2008-03",[1251],"Non-Small Cell Lung Cancer",[947,1253,1254],"Gemcitabine","Avastin",{"nctId":936,"briefTitle":937,"status":124,"phases":1256,"primaryCompletion":939,"completion":940,"start":941,"enrollment":942,"conditions":1257,"interventions":1258},[90],[944],[905,946,947,948,949,950],{"nctId":1260,"briefTitle":1261,"status":917,"phases":1262,"primaryCompletion":1263,"completion":1263,"start":1263,"enrollment":16,"conditions":1264,"interventions":1265},"NCT00004159","Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor",[89,90],"2000-02",[999],[1266,1018],"gemcitabine hydrochloride",{"nctId":1010,"briefTitle":1011,"status":166,"phases":1268,"primaryCompletion":1013,"completion":1013,"start":1014,"enrollment":1015,"conditions":1269,"interventions":1270},[90],[21],[1001,1018],{"nctId":1020,"briefTitle":1021,"status":166,"phases":1272,"primaryCompletion":1023,"completion":1024,"start":1025,"enrollment":19,"conditions":1273,"interventions":1274},[89,90],[1027],[1029,946,947],{"nctId":1276,"briefTitle":1277,"status":166,"phases":1278,"primaryCompletion":1279,"completion":1279,"start":1263,"enrollment":1280,"conditions":1281,"interventions":1282},"NCT00004160","Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed",[89,90],"2004-05",72,[999],[1283,1266,1018],"cisplatin",{"trials":1285,"activeCount":100},[],{"trials":1287,"activeCount":100},[],{"trials":1289,"activeCount":100},[],{"intervention":1177,"totalTrials":963,"cells":1291},{"EARLY_PHASE1":1292,"PHASE1":1294,"PHASE2":1296,"PHASE3":1315,"PHASE4":1317,"NA":1319},{"trials":1293,"activeCount":100},[],{"trials":1295,"activeCount":100},[],{"trials":1297,"activeCount":118,"soonestReadout":1183},[1298,1307,1311],{"nctId":1299,"briefTitle":1300,"status":166,"phases":1301,"primaryCompletion":1302,"completion":1302,"start":1303,"enrollment":1089,"conditions":1304,"interventions":1305},"NCT01690143","Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation",[89,90],"2017-11-01","2012-05",[1187],[1177,1306],"Melphalan",{"nctId":1168,"briefTitle":1169,"status":166,"phases":1308,"primaryCompletion":1171,"completion":1172,"start":1173,"enrollment":22,"conditions":1309,"interventions":1310},[90],[1175],[1177,1159,1178],{"nctId":1180,"briefTitle":1181,"status":108,"phases":1312,"primaryCompletion":1183,"completion":1183,"start":1184,"enrollment":1185,"conditions":1313,"interventions":1314},[89,90],[1187],[1189,1190,1159,1177],{"trials":1316,"activeCount":100},[],{"trials":1318,"activeCount":100},[],{"trials":1320,"activeCount":100},[],{"intervention":1322,"totalTrials":96,"cells":1323},"Trastuzumab",{"EARLY_PHASE1":1324,"PHASE1":1326,"PHASE2":1328,"PHASE3":1353,"PHASE4":1355,"NA":1357},{"trials":1325,"activeCount":100},[],{"trials":1327,"activeCount":100},[],{"trials":1329,"activeCount":118,"soonestReadout":1346},[1330,1342],{"nctId":1331,"briefTitle":1332,"status":917,"phases":1333,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":33,"conditions":1336,"interventions":1339},"NCT03501979","Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD",[90],"2021-06-22","2019-02-20",[1337,1338],"Metastatic Breast Cancer","Leptomeningeal Disease",[1340,1322,1341],"Tucatinib","Capecitabine",{"nctId":1343,"briefTitle":1344,"status":108,"phases":1345,"primaryCompletion":1346,"completion":1347,"start":1348,"enrollment":1214,"conditions":1349,"interventions":1351},"NCT03368729","Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer",[89,90],"2027-11-01","2027-12-30","2019-09-06",[1337,1350],"HER2 Positive Breast Carcinoma",[1352,1322],"Niraparib",{"trials":1354,"activeCount":100},[],{"trials":1356,"activeCount":100},[],{"trials":1358,"activeCount":100},[],{"intervention":950,"totalTrials":96,"cells":1360},{"EARLY_PHASE1":1361,"PHASE1":1363,"PHASE2":1365,"PHASE3":1382,"PHASE4":1384,"NA":1386},{"trials":1362,"activeCount":100},[],{"trials":1364,"activeCount":100},[],{"trials":1366,"activeCount":118,"soonestReadout":939},[1367,1378],{"nctId":1368,"briefTitle":1369,"status":1196,"phases":1370,"primaryCompletion":1371,"completion":1371,"start":1371,"enrollment":100,"conditions":1372,"interventions":1376},"NCT04149275","Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma",[90],"2021-02",[1373,1374,1375],"Carcinosarcoma of Ovary","Carcinosarcoma of Uterus","Carcinosarcoma of Vagina",[1377,950,949],"Cabozantinib",{"nctId":936,"briefTitle":937,"status":124,"phases":1379,"primaryCompletion":939,"completion":940,"start":941,"enrollment":942,"conditions":1380,"interventions":1381},[90],[944],[905,946,947,948,949,950],{"trials":1383,"activeCount":100},[],{"trials":1385,"activeCount":100},[],{"trials":1387,"activeCount":100},[],{"intervention":949,"totalTrials":96,"cells":1389},{"EARLY_PHASE1":1390,"PHASE1":1392,"PHASE2":1394,"PHASE3":1404,"PHASE4":1406,"NA":1408},{"trials":1391,"activeCount":100},[],{"trials":1393,"activeCount":100},[],{"trials":1395,"activeCount":118,"soonestReadout":939},[1396,1400],{"nctId":1368,"briefTitle":1369,"status":1196,"phases":1397,"primaryCompletion":1371,"completion":1371,"start":1371,"enrollment":100,"conditions":1398,"interventions":1399},[90],[1373,1374,1375],[1377,950,949],{"nctId":936,"briefTitle":937,"status":124,"phases":1401,"primaryCompletion":939,"completion":940,"start":941,"enrollment":942,"conditions":1402,"interventions":1403},[90],[944],[905,946,947,948,949,950],{"trials":1405,"activeCount":100},[],{"trials":1407,"activeCount":100},[],{"trials":1409,"activeCount":100},[],{"intervention":1411,"totalTrials":118,"cells":1412},"Panitumumab-IRDye800",{"EARLY_PHASE1":1413,"PHASE1":1415,"PHASE2":1417,"PHASE3":1429,"PHASE4":1431,"NA":1433},{"trials":1414,"activeCount":100},[],{"trials":1416,"activeCount":100},[],{"trials":1418,"activeCount":118,"soonestReadout":1423},[1419],{"nctId":1420,"briefTitle":1421,"status":124,"phases":1422,"primaryCompletion":1423,"completion":1423,"start":1424,"enrollment":1425,"conditions":1426,"interventions":1428},"NCT04511078","Phase II Panitumumab-IRDye800 in Head & Neck Cancer",[90],"2030-12-31","2021-04-02",25,[1427],"Head and Neck Cancer",[1411],{"trials":1430,"activeCount":100},[],{"trials":1432,"activeCount":100},[],{"trials":1434,"activeCount":100},[],{"intervention":1436,"totalTrials":118,"cells":1437},"ATG Combined with Tacrolimus and Mini Methotrexate",{"EARLY_PHASE1":1438,"PHASE1":1440,"PHASE2":1442,"PHASE3":1455,"PHASE4":1457,"NA":1459},{"trials":1439,"activeCount":100},[],{"trials":1441,"activeCount":100},[],{"trials":1443,"activeCount":118,"soonestReadout":349},[1444],{"nctId":1445,"briefTitle":1446,"status":124,"phases":1447,"primaryCompletion":349,"completion":401,"start":1448,"enrollment":1110,"conditions":1449,"interventions":1454},"NCT06315309","Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant",[90],"2025-04-15",[1450,1451,1452,1453],"GVHD,Acute","Acute Leukemia","Myelodysplastic Syndromes","Myeloproliferative Disorders",[1436],{"trials":1456,"activeCount":100},[],{"trials":1458,"activeCount":100},[],{"trials":1460,"activeCount":100},[],{"intervention":1462,"totalTrials":118,"cells":1463},"Intravenously administered pooled human immunoglobulin",{"EARLY_PHASE1":1464,"PHASE1":1466,"PHASE2":1468,"PHASE3":1480,"PHASE4":1482,"NA":1484},{"trials":1465,"activeCount":100},[],{"trials":1467,"activeCount":100},[],{"trials":1469,"activeCount":118,"soonestReadout":1474},[1470],{"nctId":1471,"briefTitle":1472,"status":124,"phases":1473,"primaryCompletion":1474,"completion":295,"start":1475,"enrollment":1476,"conditions":1477,"interventions":1479},"NCT06599697","The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy",[90],"2026-12-30","2025-10-27",12,[1478],"Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy",[1462],{"trials":1481,"activeCount":100},[],{"trials":1483,"activeCount":100},[],{"trials":1485,"activeCount":100},[],{"intervention":1487,"totalTrials":118,"cells":1488},"mirvetuximab soravtansine",{"EARLY_PHASE1":1489,"PHASE1":1491,"PHASE2":1493,"PHASE3":1506,"PHASE4":1508,"NA":1510},{"trials":1490,"activeCount":100},[],{"trials":1492,"activeCount":100},[],{"trials":1494,"activeCount":118,"soonestReadout":1499},[1495],{"nctId":1496,"briefTitle":1497,"status":124,"phases":1498,"primaryCompletion":1499,"completion":1500,"start":1501,"enrollment":325,"conditions":1502,"interventions":1505},"NCT04606914","Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer",[90],"2026-05-31","2028-05-31","2021-05-27",[988,1503,1504],"Fallopian Tube","Primary Peritoneal Cancer",[1487],{"trials":1507,"activeCount":100},[],{"trials":1509,"activeCount":100},[],{"trials":1511,"activeCount":100},[],{"intervention":1513,"totalTrials":118,"cells":1514},"Selumetinib + ZEN-3694 ± Durvalumab",{"EARLY_PHASE1":1515,"PHASE1":1517,"PHASE2":1519,"PHASE3":1534,"PHASE4":1536,"NA":1538},{"trials":1516,"activeCount":100},[],{"trials":1518,"activeCount":100},[],{"trials":1520,"activeCount":118,"soonestReadout":1525},[1521],{"nctId":1522,"briefTitle":1523,"status":154,"phases":1524,"primaryCompletion":1525,"completion":1526,"start":1527,"enrollment":1528,"conditions":1529,"interventions":1533},"NCT05253131","Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas",[90],"2031-05-15","2032-05-15","2026-05-15",41,[1530,1531,1532],"MPNST","NF1","Sarcoma",[1513],{"trials":1535,"activeCount":100},[],{"trials":1537,"activeCount":100},[],{"trials":1539,"activeCount":100},[],{"intervention":71,"totalTrials":118,"cells":1541},{"EARLY_PHASE1":1542,"PHASE1":1544,"PHASE2":1546,"PHASE3":1560,"PHASE4":1562,"NA":1564},{"trials":1543,"activeCount":100},[],{"trials":1545,"activeCount":100},[],{"trials":1547,"activeCount":118,"soonestReadout":70},[1548],{"nctId":68,"briefTitle":69,"status":108,"phases":1549,"primaryCompletion":70,"completion":1499,"start":1550,"enrollment":1551,"conditions":1552,"interventions":1557},[90],"2022-02-10",120,[1553,1554,1555,1556],"Diabetes Mellitus, Type 2","Preterm Birth","Pregnancy, High Risk","Diabetes, Gestational",[71,1558,1559],"Up-Titration of Home Insulin","Continuous Insulin",{"trials":1561,"activeCount":100},[],{"trials":1563,"activeCount":100},[],{"trials":1565,"activeCount":100},[],{"intervention":1558,"totalTrials":118,"cells":1567},{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1572,"PHASE3":1578,"PHASE4":1580,"NA":1582},{"trials":1569,"activeCount":100},[],{"trials":1571,"activeCount":100},[],{"trials":1573,"activeCount":118,"soonestReadout":70},[1574],{"nctId":68,"briefTitle":69,"status":108,"phases":1575,"primaryCompletion":70,"completion":1499,"start":1550,"enrollment":1551,"conditions":1576,"interventions":1577},[90],[1553,1554,1555,1556],[71,1558,1559],{"trials":1579,"activeCount":100},[],{"trials":1581,"activeCount":100},[],{"trials":1583,"activeCount":100},[],{"intervention":1559,"totalTrials":118,"cells":1585},{"EARLY_PHASE1":1586,"PHASE1":1588,"PHASE2":1590,"PHASE3":1596,"PHASE4":1598,"NA":1600},{"trials":1587,"activeCount":100},[],{"trials":1589,"activeCount":100},[],{"trials":1591,"activeCount":118,"soonestReadout":70},[1592],{"nctId":68,"briefTitle":69,"status":108,"phases":1593,"primaryCompletion":70,"completion":1499,"start":1550,"enrollment":1551,"conditions":1594,"interventions":1595},[90],[1553,1554,1555,1556],[71,1558,1559],{"trials":1597,"activeCount":100},[],{"trials":1599,"activeCount":100},[],{"trials":1601,"activeCount":100},[],{"intervention":1603,"totalTrials":118,"cells":1604},"mirdametinib with radiation",{"EARLY_PHASE1":1605,"PHASE1":1607,"PHASE2":1609,"PHASE3":1621,"PHASE4":1623,"NA":1625},{"trials":1606,"activeCount":100},[],{"trials":1608,"activeCount":100},[],{"trials":1610,"activeCount":118,"soonestReadout":1615},[1611],{"nctId":1612,"briefTitle":1613,"status":154,"phases":1614,"primaryCompletion":1615,"completion":1616,"start":830,"enrollment":997,"conditions":1617,"interventions":1619},"NCT07521657","Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma",[90],"2030-08-01","2031-08-01",[1618],"Neurofibromatosis 1 (NF1)",[1603,1620],"mirdametinib",{"trials":1622,"activeCount":100},[],{"trials":1624,"activeCount":100},[],{"trials":1626,"activeCount":100},[],{"intervention":1620,"totalTrials":118,"cells":1628},{"EARLY_PHASE1":1629,"PHASE1":1631,"PHASE2":1633,"PHASE3":1639,"PHASE4":1641,"NA":1643},{"trials":1630,"activeCount":100},[],{"trials":1632,"activeCount":100},[],{"trials":1634,"activeCount":118,"soonestReadout":1615},[1635],{"nctId":1612,"briefTitle":1613,"status":154,"phases":1636,"primaryCompletion":1615,"completion":1616,"start":830,"enrollment":997,"conditions":1637,"interventions":1638},[90],[1618],[1603,1620],{"trials":1640,"activeCount":100},[],{"trials":1642,"activeCount":100},[],{"trials":1644,"activeCount":100},[],{"intervention":990,"totalTrials":118,"cells":1646},{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1651,"PHASE3":1657,"PHASE4":1659,"NA":1661},{"trials":1648,"activeCount":100},[],{"trials":1650,"activeCount":100},[],{"trials":1652,"activeCount":118,"soonestReadout":983},[1653],{"nctId":980,"briefTitle":981,"status":124,"phases":1654,"primaryCompletion":983,"completion":984,"start":985,"enrollment":986,"conditions":1655,"interventions":1656},[90],[988],[946,990],{"trials":1658,"activeCount":100},[],{"trials":1660,"activeCount":100},[],{"trials":1662,"activeCount":100},[],{"intervention":1664,"totalTrials":118,"cells":1665},"Vericiguat 10 MG",{"EARLY_PHASE1":1666,"PHASE1":1668,"PHASE2":1670,"PHASE3":1686,"PHASE4":1688,"NA":1690},{"trials":1667,"activeCount":100},[],{"trials":1669,"activeCount":100},[],{"trials":1671,"activeCount":118,"soonestReadout":1676},[1672],{"nctId":1673,"briefTitle":1674,"status":154,"phases":1675,"primaryCompletion":1676,"completion":1677,"start":1678,"enrollment":1679,"conditions":1680,"interventions":1685},"NCT06320951","VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway",[90],"2028-04-30","2029-04-30","2026-12-01",200,[787,1681,1682,1683,1684,15],"Insulin Sensitivity\u002FResistance","Metabolic Disease","Metabolism","Energy Expenditure",[1664],{"trials":1687,"activeCount":100},[],{"trials":1689,"activeCount":100},[],{"trials":1691,"activeCount":100},[],{"intervention":1693,"totalTrials":118,"cells":1694},"Cabo + Dostarlimab",{"EARLY_PHASE1":1695,"PHASE1":1697,"PHASE2":1699,"PHASE3":1714,"PHASE4":1716,"NA":1718},{"trials":1696,"activeCount":100},[],{"trials":1698,"activeCount":100},[],{"trials":1700,"activeCount":118,"soonestReadout":1705},[1701],{"nctId":1702,"briefTitle":1703,"status":124,"phases":1704,"primaryCompletion":1705,"completion":1705,"start":1706,"enrollment":1707,"conditions":1708,"interventions":1713},"NCT05559879","Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma",[89,90],"2027-04","2023-08-20",37,[1709,1710,1711,1712],"Gynecologic Cancer","Carcinoma","Uterine Cancer","Endometrial Cancer",[1693],{"trials":1715,"activeCount":100},[],{"trials":1717,"activeCount":100},[],{"trials":1719,"activeCount":100},[],{"intervention":1721,"totalTrials":118,"cells":1722},"DPA-714-PET\u002FMRI",{"EARLY_PHASE1":1723,"PHASE1":1725,"PHASE2":1727,"PHASE3":1741,"PHASE4":1743,"NA":1745},{"trials":1724,"activeCount":100},[],{"trials":1726,"activeCount":100},[],{"trials":1728,"activeCount":118,"soonestReadout":1733},[1729],{"nctId":1730,"briefTitle":1731,"status":124,"phases":1732,"primaryCompletion":1733,"completion":1733,"start":1734,"enrollment":1735,"conditions":1736,"interventions":1738},"NCT03457493","The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy",[89,90],"2028-06","2018-03-22",205,[1737],"Parkinson Disease",[1721,1739,1740],"5-year Follow-up DPA-714-PET\u002FMRI","DPA-714 Metabolite Analysis",{"trials":1742,"activeCount":100},[],{"trials":1744,"activeCount":100},[],{"trials":1746,"activeCount":100},[],{"intervention":1739,"totalTrials":118,"cells":1748},{"EARLY_PHASE1":1749,"PHASE1":1751,"PHASE2":1753,"PHASE3":1759,"PHASE4":1761,"NA":1763},{"trials":1750,"activeCount":100},[],{"trials":1752,"activeCount":100},[],{"trials":1754,"activeCount":118,"soonestReadout":1733},[1755],{"nctId":1730,"briefTitle":1731,"status":124,"phases":1756,"primaryCompletion":1733,"completion":1733,"start":1734,"enrollment":1735,"conditions":1757,"interventions":1758},[89,90],[1737],[1721,1739,1740],{"trials":1760,"activeCount":100},[],{"trials":1762,"activeCount":100},[],{"trials":1764,"activeCount":100},[],{"intervention":1740,"totalTrials":118,"cells":1766},{"EARLY_PHASE1":1767,"PHASE1":1769,"PHASE2":1771,"PHASE3":1777,"PHASE4":1779,"NA":1781},{"trials":1768,"activeCount":100},[],{"trials":1770,"activeCount":100},[],{"trials":1772,"activeCount":118,"soonestReadout":1733},[1773],{"nctId":1730,"briefTitle":1731,"status":124,"phases":1774,"primaryCompletion":1733,"completion":1733,"start":1734,"enrollment":1735,"conditions":1775,"interventions":1776},[89,90],[1737],[1721,1739,1740],{"trials":1778,"activeCount":100},[],{"trials":1780,"activeCount":100},[],{"trials":1782,"activeCount":100},[],{"intervention":41,"totalTrials":118,"cells":1784},{"EARLY_PHASE1":1785,"PHASE1":1787,"PHASE2":1789,"PHASE3":1798,"PHASE4":1800,"NA":1802},{"trials":1786,"activeCount":100},[],{"trials":1788,"activeCount":100},[],{"trials":1790,"activeCount":118,"soonestReadout":40},[1791],{"nctId":38,"briefTitle":39,"status":108,"phases":1792,"primaryCompletion":40,"completion":1793,"start":169,"enrollment":1794,"conditions":1795,"interventions":1796},[90],"2028-12-11",84,[21],[41,1797],"protein expression analysis",{"trials":1799,"activeCount":100},[],{"trials":1801,"activeCount":100},[],{"trials":1803,"activeCount":100},[],{"intervention":1797,"totalTrials":118,"cells":1805},{"EARLY_PHASE1":1806,"PHASE1":1808,"PHASE2":1810,"PHASE3":1816,"PHASE4":1818,"NA":1820},{"trials":1807,"activeCount":100},[],{"trials":1809,"activeCount":100},[],{"trials":1811,"activeCount":118,"soonestReadout":40},[1812],{"nctId":38,"briefTitle":39,"status":108,"phases":1813,"primaryCompletion":40,"completion":1793,"start":169,"enrollment":1794,"conditions":1814,"interventions":1815},[90],[21],[41,1797],{"trials":1817,"activeCount":100},[],{"trials":1819,"activeCount":100},[],{"trials":1821,"activeCount":100},[],{"intervention":948,"totalTrials":118,"cells":1823},{"EARLY_PHASE1":1824,"PHASE1":1826,"PHASE2":1828,"PHASE3":1834,"PHASE4":1836,"NA":1838},{"trials":1825,"activeCount":100},[],{"trials":1827,"activeCount":100},[],{"trials":1829,"activeCount":118,"soonestReadout":939},[1830],{"nctId":936,"briefTitle":937,"status":124,"phases":1831,"primaryCompletion":939,"completion":940,"start":941,"enrollment":942,"conditions":1832,"interventions":1833},[90],[944],[905,946,947,948,949,950],{"trials":1835,"activeCount":100},[],{"trials":1837,"activeCount":100},[],{"trials":1839,"activeCount":100},[],{"intervention":1093,"totalTrials":118,"cells":1841},{"EARLY_PHASE1":1842,"PHASE1":1844,"PHASE2":1846,"PHASE3":1852,"PHASE4":1854,"NA":1856},{"trials":1843,"activeCount":100},[],{"trials":1845,"activeCount":100},[],{"trials":1847,"activeCount":118,"soonestReadout":1087},[1848],{"nctId":1084,"briefTitle":1085,"status":124,"phases":1849,"primaryCompletion":1087,"completion":1088,"start":60,"enrollment":1089,"conditions":1850,"interventions":1851},[89,90],[1091],[1093,1094,1037],{"trials":1853,"activeCount":100},[],{"trials":1855,"activeCount":100},[],{"trials":1857,"activeCount":100},[],{"intervention":1094,"totalTrials":118,"cells":1859},{"EARLY_PHASE1":1860,"PHASE1":1862,"PHASE2":1864,"PHASE3":1870,"PHASE4":1872,"NA":1874},{"trials":1861,"activeCount":100},[],{"trials":1863,"activeCount":100},[],{"trials":1865,"activeCount":118,"soonestReadout":1087},[1866],{"nctId":1084,"briefTitle":1085,"status":124,"phases":1867,"primaryCompletion":1087,"completion":1088,"start":60,"enrollment":1089,"conditions":1868,"interventions":1869},[89,90],[1091],[1093,1094,1037],{"trials":1871,"activeCount":100},[],{"trials":1873,"activeCount":100},[],{"trials":1875,"activeCount":100},[],{"intervention":1189,"totalTrials":118,"cells":1877},{"EARLY_PHASE1":1878,"PHASE1":1880,"PHASE2":1882,"PHASE3":1888,"PHASE4":1890,"NA":1892},{"trials":1879,"activeCount":100},[],{"trials":1881,"activeCount":100},[],{"trials":1883,"activeCount":118,"soonestReadout":1183},[1884],{"nctId":1180,"briefTitle":1181,"status":108,"phases":1885,"primaryCompletion":1183,"completion":1183,"start":1184,"enrollment":1185,"conditions":1886,"interventions":1887},[89,90],[1187],[1189,1190,1159,1177],{"trials":1889,"activeCount":100},[],{"trials":1891,"activeCount":100},[],{"trials":1893,"activeCount":100},[],{"intervention":1190,"totalTrials":118,"cells":1895},{"EARLY_PHASE1":1896,"PHASE1":1898,"PHASE2":1900,"PHASE3":1906,"PHASE4":1908,"NA":1910},{"trials":1897,"activeCount":100},[],{"trials":1899,"activeCount":100},[],{"trials":1901,"activeCount":118,"soonestReadout":1183},[1902],{"nctId":1180,"briefTitle":1181,"status":108,"phases":1903,"primaryCompletion":1183,"completion":1183,"start":1184,"enrollment":1185,"conditions":1904,"interventions":1905},[89,90],[1187],[1189,1190,1159,1177],{"trials":1907,"activeCount":100},[],{"trials":1909,"activeCount":100},[],{"trials":1911,"activeCount":100},[],{"intervention":1913,"totalTrials":118,"cells":1914},"(-)-Epicatechin-rich cocoa supplementation combined with exercise training",{"EARLY_PHASE1":1915,"PHASE1":1917,"PHASE2":1919,"PHASE3":1931,"PHASE4":1933,"NA":1935},{"trials":1916,"activeCount":100},[],{"trials":1918,"activeCount":100},[],{"trials":1920,"activeCount":118,"soonestReadout":1925},[1921],{"nctId":1922,"briefTitle":1923,"status":124,"phases":1924,"primaryCompletion":1925,"completion":1925,"start":1926,"enrollment":1927,"conditions":1928,"interventions":1930},"NCT07161726","Cocoa to Maximize Exercise Training in Older Adults - The COMET Trial",[89,90],"2027-12-31","2026-04-21",36,[1929],"Mobility Disability",[1913],{"trials":1932,"activeCount":100},[],{"trials":1934,"activeCount":100},[],{"trials":1936,"activeCount":100},[],{"intervention":1352,"totalTrials":118,"cells":1938},{"EARLY_PHASE1":1939,"PHASE1":1941,"PHASE2":1943,"PHASE3":1949,"PHASE4":1951,"NA":1953},{"trials":1940,"activeCount":100},[],{"trials":1942,"activeCount":100},[],{"trials":1944,"activeCount":118,"soonestReadout":1346},[1945],{"nctId":1343,"briefTitle":1344,"status":108,"phases":1946,"primaryCompletion":1346,"completion":1347,"start":1348,"enrollment":1214,"conditions":1947,"interventions":1948},[89,90],[1337,1350],[1352,1322],{"trials":1950,"activeCount":100},[],{"trials":1952,"activeCount":100},[],{"trials":1954,"activeCount":100},[],{"intervention":1956,"totalTrials":118,"cells":1957},"DaraVRD\u002FDaraVCD",{"EARLY_PHASE1":1958,"PHASE1":1960,"PHASE2":1962,"PHASE3":1973,"PHASE4":1975,"NA":1977},{"trials":1959,"activeCount":100},[],{"trials":1961,"activeCount":100},[],{"trials":1963,"activeCount":118,"soonestReadout":784},[1964],{"nctId":1965,"briefTitle":1966,"status":124,"phases":1967,"primaryCompletion":784,"completion":1968,"start":876,"enrollment":1969,"conditions":1970,"interventions":1972},"NCT04991103","Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)",[90],"2028-08-27",40,[1187,1971],"Amyloidosis",[1956],{"trials":1974,"activeCount":100},[],{"trials":1976,"activeCount":100},[],{"trials":1978,"activeCount":100},[],{"intervention":1980,"totalTrials":118,"cells":1981},"[C-11]PiB-PET\u002FMRI",{"EARLY_PHASE1":1982,"PHASE1":1984,"PHASE2":1986,"PHASE3":1997,"PHASE4":1999,"NA":2001},{"trials":1983,"activeCount":100},[],{"trials":1985,"activeCount":100},[],{"trials":1987,"activeCount":118,"soonestReadout":1992},[1988],{"nctId":1989,"briefTitle":1990,"status":124,"phases":1991,"primaryCompletion":1992,"completion":1992,"start":1993,"enrollment":158,"conditions":1994,"interventions":1996},"NCT03503331","UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy",[90],"2028-10","2018-04-20",[1995],"Alzheimer Disease",[1980],{"trials":1998,"activeCount":100},[],{"trials":2000,"activeCount":100},[],{"trials":2002,"activeCount":100},[],{"intervention":2004,"totalTrials":118,"cells":2005},"Dara-VRd intensification, Dara-R maintenance",{"EARLY_PHASE1":2006,"PHASE1":2008,"PHASE2":2010,"PHASE3":2025,"PHASE4":2027,"NA":2029},{"trials":2007,"activeCount":100},[],{"trials":2009,"activeCount":100},[],{"trials":2011,"activeCount":118,"soonestReadout":350},[2012],{"nctId":2013,"briefTitle":2014,"status":124,"phases":2015,"primaryCompletion":350,"completion":2016,"start":2017,"enrollment":2018,"conditions":2019,"interventions":2020},"NCT05231629","Sequential Therapy in Multiple Myeloma Guided by MRD Assessments",[90],"2029-12","2023-12-13",300,[1187],[2004,2021,2022,2023,2024],"AHCT intensification, Dara-R maintenance","AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance","AHCT intensification, Dara-R consolidation, Dara-R maintenance","Dara-VRd induction",{"trials":2026,"activeCount":100},[],{"trials":2028,"activeCount":100},[],{"trials":2030,"activeCount":100},[],{"intervention":2021,"totalTrials":118,"cells":2032},{"EARLY_PHASE1":2033,"PHASE1":2035,"PHASE2":2037,"PHASE3":2043,"PHASE4":2045,"NA":2047},{"trials":2034,"activeCount":100},[],{"trials":2036,"activeCount":100},[],{"trials":2038,"activeCount":118,"soonestReadout":350},[2039],{"nctId":2013,"briefTitle":2014,"status":124,"phases":2040,"primaryCompletion":350,"completion":2016,"start":2017,"enrollment":2018,"conditions":2041,"interventions":2042},[90],[1187],[2004,2021,2022,2023,2024],{"trials":2044,"activeCount":100},[],{"trials":2046,"activeCount":100},[],{"trials":2048,"activeCount":100},[],{"intervention":2022,"totalTrials":118,"cells":2050},{"EARLY_PHASE1":2051,"PHASE1":2053,"PHASE2":2055,"PHASE3":2061,"PHASE4":2063,"NA":2065},{"trials":2052,"activeCount":100},[],{"trials":2054,"activeCount":100},[],{"trials":2056,"activeCount":118,"soonestReadout":350},[2057],{"nctId":2013,"briefTitle":2014,"status":124,"phases":2058,"primaryCompletion":350,"completion":2016,"start":2017,"enrollment":2018,"conditions":2059,"interventions":2060},[90],[1187],[2004,2021,2022,2023,2024],{"trials":2062,"activeCount":100},[],{"trials":2064,"activeCount":100},[],{"trials":2066,"activeCount":100},[],{"intervention":2023,"totalTrials":118,"cells":2068},{"EARLY_PHASE1":2069,"PHASE1":2071,"PHASE2":2073,"PHASE3":2079,"PHASE4":2081,"NA":2083},{"trials":2070,"activeCount":100},[],{"trials":2072,"activeCount":100},[],{"trials":2074,"activeCount":118,"soonestReadout":350},[2075],{"nctId":2013,"briefTitle":2014,"status":124,"phases":2076,"primaryCompletion":350,"completion":2016,"start":2017,"enrollment":2018,"conditions":2077,"interventions":2078},[90],[1187],[2004,2021,2022,2023,2024],{"trials":2080,"activeCount":100},[],{"trials":2082,"activeCount":100},[],{"trials":2084,"activeCount":100},[],{"intervention":2024,"totalTrials":118,"cells":2086},{"EARLY_PHASE1":2087,"PHASE1":2089,"PHASE2":2091,"PHASE3":2097,"PHASE4":2099,"NA":2101},{"trials":2088,"activeCount":100},[],{"trials":2090,"activeCount":100},[],{"trials":2092,"activeCount":118,"soonestReadout":350},[2093],{"nctId":2013,"briefTitle":2014,"status":124,"phases":2094,"primaryCompletion":350,"completion":2016,"start":2017,"enrollment":2018,"conditions":2095,"interventions":2096},[90],[1187],[2004,2021,2022,2023,2024],{"trials":2098,"activeCount":100},[],{"trials":2100,"activeCount":100},[],{"trials":2102,"activeCount":100},[],{"intervention":2104,"totalTrials":118,"cells":2105},"Sacubitril, Valsartan 97-103 mg Oral",{"EARLY_PHASE1":2106,"PHASE1":2108,"PHASE2":2110,"PHASE3":2121,"PHASE4":2123,"NA":2125},{"trials":2107,"activeCount":100},[],{"trials":2109,"activeCount":100},[],{"trials":2111,"activeCount":118,"soonestReadout":677},[2112],{"nctId":2113,"briefTitle":2114,"status":124,"phases":2115,"primaryCompletion":677,"completion":294,"start":2116,"enrollment":1679,"conditions":2117,"interventions":2119},"NCT04055428","NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals",[90],"2020-08-15",[2118,787,1681,1682,789,1683,1684],"Diabetes Mellitus",[2104,2120],"Valsartan 160 mg",{"trials":2122,"activeCount":100},[],{"trials":2124,"activeCount":100},[],{"trials":2126,"activeCount":100},[],{"intervention":2120,"totalTrials":118,"cells":2128},{"EARLY_PHASE1":2129,"PHASE1":2131,"PHASE2":2133,"PHASE3":2139,"PHASE4":2141,"NA":2143},{"trials":2130,"activeCount":100},[],{"trials":2132,"activeCount":100},[],{"trials":2134,"activeCount":118,"soonestReadout":677},[2135],{"nctId":2113,"briefTitle":2114,"status":124,"phases":2136,"primaryCompletion":677,"completion":294,"start":2116,"enrollment":1679,"conditions":2137,"interventions":2138},[90],[2118,787,1681,1682,789,1683,1684],[2104,2120],{"trials":2140,"activeCount":100},[],{"trials":2142,"activeCount":100},[],{"trials":2144,"activeCount":100},[],{"intervention":2146,"totalTrials":118,"cells":2147},"Single Agent Asciminib",{"EARLY_PHASE1":2148,"PHASE1":2150,"PHASE2":2152,"PHASE3":2167,"PHASE4":2169,"NA":2171},{"trials":2149,"activeCount":100},[],{"trials":2151,"activeCount":100},[],{"trials":2153,"activeCount":118,"soonestReadout":2158},[2154],{"nctId":2155,"briefTitle":2156,"status":124,"phases":2157,"primaryCompletion":2158,"completion":2158,"start":2159,"enrollment":112,"conditions":2160,"interventions":2165},"NCT05143840","Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase",[90],"2032-02","2022-04-22",[2161,2162,2163,2164],"Chronic Myeloid Leukemia, Chronic Phase","Adult CML","Leukemia, Myeloid","Leukemia,Myeloid, Chronic",[2146,2166],"Low TKI",{"trials":2168,"activeCount":100},[],{"trials":2170,"activeCount":100},[],{"trials":2172,"activeCount":100},[],{"intervention":2166,"totalTrials":118,"cells":2174},{"EARLY_PHASE1":2175,"PHASE1":2177,"PHASE2":2179,"PHASE3":2185,"PHASE4":2187,"NA":2189},{"trials":2176,"activeCount":100},[],{"trials":2178,"activeCount":100},[],{"trials":2180,"activeCount":118,"soonestReadout":2158},[2181],{"nctId":2155,"briefTitle":2156,"status":124,"phases":2182,"primaryCompletion":2158,"completion":2158,"start":2159,"enrollment":112,"conditions":2183,"interventions":2184},[90],[2161,2162,2163,2164],[2146,2166],{"trials":2186,"activeCount":100},[],{"trials":2188,"activeCount":100},[],{"trials":2190,"activeCount":100},[],{"intervention":2192,"totalTrials":118,"cells":2193},"Capecitabine Pill",{"EARLY_PHASE1":2194,"PHASE1":2196,"PHASE2":2198,"PHASE3":2207,"PHASE4":2209,"NA":2211},{"trials":2195,"activeCount":100},[],{"trials":2197,"activeCount":100},[],{"trials":2199,"activeCount":118,"soonestReadout":1733},[2200],{"nctId":2201,"briefTitle":2202,"status":124,"phases":2203,"primaryCompletion":1733,"completion":1733,"start":2204,"enrollment":1969,"conditions":2205,"interventions":2206},"NCT06105684","Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer",[90],"2025-02-14",[1337],[2192],{"trials":2208,"activeCount":100},[],{"trials":2210,"activeCount":100},[],{"trials":2212,"activeCount":100},[],{"intervention":2214,"totalTrials":118,"cells":2215},"Catheter Sclerotherapy",{"EARLY_PHASE1":2216,"PHASE1":2218,"PHASE2":2220,"PHASE3":2230,"PHASE4":2232,"NA":2234},{"trials":2217,"activeCount":100},[],{"trials":2219,"activeCount":100},[],{"trials":2221,"activeCount":118,"soonestReadout":758},[2222],{"nctId":2223,"briefTitle":2224,"status":154,"phases":2225,"primaryCompletion":758,"completion":758,"start":2226,"enrollment":761,"conditions":2227,"interventions":2229},"NCT06906029","Abdominal aBscess Catheter Sclerotherapy (ABCS)",[89,90],"2026-07",[2228],"Abdominal Abscess",[2214],{"trials":2231,"activeCount":100},[],{"trials":2233,"activeCount":100},[],{"trials":2235,"activeCount":100},[],{"intervention":2237,"totalTrials":118,"cells":2238},"Selumetinib",{"EARLY_PHASE1":2239,"PHASE1":2241,"PHASE2":2243,"PHASE3":2256,"PHASE4":2258,"NA":2260},{"trials":2240,"activeCount":100},[],{"trials":2242,"activeCount":100},[],{"trials":2244,"activeCount":118,"soonestReadout":2249},[2245],{"nctId":2246,"briefTitle":2247,"status":124,"phases":2248,"primaryCompletion":2249,"completion":2250,"start":2251,"enrollment":1679,"conditions":2252,"interventions":2255},"NCT06188741","Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1",[90],"2031-09-01","2032-09-01","2025-08-27",[2253,2254],"Neurofibromatosis 1","Plexiform Neurofibroma",[2237],{"trials":2257,"activeCount":100},[],{"trials":2259,"activeCount":100},[],{"trials":2261,"activeCount":100},[],{"intervention":2263,"totalTrials":118,"cells":2264},"Siltuximab",{"EARLY_PHASE1":2265,"PHASE1":2267,"PHASE2":2269,"PHASE3":2282,"PHASE4":2284,"NA":2286},{"trials":2266,"activeCount":100},[],{"trials":2268,"activeCount":100},[],{"trials":2270,"activeCount":118,"soonestReadout":677},[2271],{"nctId":2272,"briefTitle":2273,"status":108,"phases":2274,"primaryCompletion":677,"completion":1925,"start":2275,"enrollment":19,"conditions":2276,"interventions":2281},"NCT04975555","Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy",[90],"2021-11-15",[2277,2278,2279,1187,2280],"Cytokine Release Syndrome","ICANS","Lymphoma, Non-Hodgkin","Acute Lymphoblastic Leukemia",[2263],{"trials":2283,"activeCount":100},[],{"trials":2285,"activeCount":100},[],{"trials":2287,"activeCount":100},[],{"intervention":2289,"totalTrials":118,"cells":2290},"ATG dosing platform when combined with standard tacrolimus and mini methotrexate",{"EARLY_PHASE1":2291,"PHASE1":2293,"PHASE2":2295,"PHASE3":2307,"PHASE4":2309,"NA":2311},{"trials":2292,"activeCount":100},[],{"trials":2294,"activeCount":100},[],{"trials":2296,"activeCount":118,"soonestReadout":1183},[2297],{"nctId":2298,"briefTitle":2299,"status":124,"phases":2300,"primaryCompletion":1183,"completion":2301,"start":2302,"enrollment":2303,"conditions":2304,"interventions":2306},"NCT06265584","Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant",[90],"2028-11","2025-04-08",56,[1451,2305,1453],"Myelodysplastic Syndrome",[2289],{"trials":2308,"activeCount":100},[],{"trials":2310,"activeCount":100},[],{"trials":2312,"activeCount":100},[],{"intervention":2314,"totalTrials":118,"cells":2315},"Beclomethasone Dipropionate\u002FFormoterol Fumarate\u002FGlycopyrrolate pMDI",{"EARLY_PHASE1":2316,"PHASE1":2318,"PHASE2":2320,"PHASE3":2331,"PHASE4":2333,"NA":2335},{"trials":2317,"activeCount":100},[],{"trials":2319,"activeCount":100},[],{"trials":2321,"activeCount":118,"soonestReadout":875},[2322],{"nctId":2323,"briefTitle":2324,"status":124,"phases":2325,"primaryCompletion":875,"completion":1423,"start":2326,"enrollment":986,"conditions":2327,"interventions":2329},"NCT07282886","VENTURI (VENTilation Using Respiratory Imaging)",[90],"2026-03-15",[2328],"Asthma",[2314,2330],"Fluticasone Furoate\u002FUmeclidinium\u002FVilanterol 100 MCG\u002F1 ACTUATION-62.5 MCG\u002F1 ACTUATION-25 MCG\u002F1 ACTUATION Inhalation Powder",{"trials":2332,"activeCount":100},[],{"trials":2334,"activeCount":100},[],{"trials":2336,"activeCount":100},[],{"intervention":2330,"totalTrials":118,"cells":2338},{"EARLY_PHASE1":2339,"PHASE1":2341,"PHASE2":2343,"PHASE3":2349,"PHASE4":2351,"NA":2353},{"trials":2340,"activeCount":100},[],{"trials":2342,"activeCount":100},[],{"trials":2344,"activeCount":118,"soonestReadout":875},[2345],{"nctId":2323,"briefTitle":2324,"status":124,"phases":2346,"primaryCompletion":875,"completion":1423,"start":2326,"enrollment":986,"conditions":2347,"interventions":2348},[90],[2328],[2314,2330],{"trials":2350,"activeCount":100},[],{"trials":2352,"activeCount":100},[],{"trials":2354,"activeCount":100},[],{"intervention":2356,"totalTrials":118,"cells":2357},"Low-Dose Naltrexone, 1.5mg",{"EARLY_PHASE1":2358,"PHASE1":2360,"PHASE2":2362,"PHASE3":2377,"PHASE4":2379,"NA":2381},{"trials":2359,"activeCount":100},[],{"trials":2361,"activeCount":100},[],{"trials":2363,"activeCount":118,"soonestReadout":2368},[2364],{"nctId":2365,"briefTitle":2366,"status":154,"phases":2367,"primaryCompletion":2368,"completion":2368,"start":2369,"enrollment":2370,"conditions":2371,"interventions":2373},"NCT07285473","Low-Dose Naltrexone For ME\u002FCFS: Dose-Finding",[90],"2028-04-01","2026-09-01",75,[2372],"Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome",[2356,2374,2375,2376],"Low-Dose Naltrexone, 3.0mg","Low-Dose Naltrexone, 4.5mg","Low-Dose Naltrexone, 6.0mg",{"trials":2378,"activeCount":100},[],{"trials":2380,"activeCount":100},[],{"trials":2382,"activeCount":100},[],{"intervention":2374,"totalTrials":118,"cells":2384},{"EARLY_PHASE1":2385,"PHASE1":2387,"PHASE2":2389,"PHASE3":2395,"PHASE4":2397,"NA":2399},{"trials":2386,"activeCount":100},[],{"trials":2388,"activeCount":100},[],{"trials":2390,"activeCount":118,"soonestReadout":2368},[2391],{"nctId":2365,"briefTitle":2366,"status":154,"phases":2392,"primaryCompletion":2368,"completion":2368,"start":2369,"enrollment":2370,"conditions":2393,"interventions":2394},[90],[2372],[2356,2374,2375,2376],{"trials":2396,"activeCount":100},[],{"trials":2398,"activeCount":100},[],{"trials":2400,"activeCount":100},[],{"intervention":2375,"totalTrials":118,"cells":2402},{"EARLY_PHASE1":2403,"PHASE1":2405,"PHASE2":2407,"PHASE3":2413,"PHASE4":2415,"NA":2417},{"trials":2404,"activeCount":100},[],{"trials":2406,"activeCount":100},[],{"trials":2408,"activeCount":118,"soonestReadout":2368},[2409],{"nctId":2365,"briefTitle":2366,"status":154,"phases":2410,"primaryCompletion":2368,"completion":2368,"start":2369,"enrollment":2370,"conditions":2411,"interventions":2412},[90],[2372],[2356,2374,2375,2376],{"trials":2414,"activeCount":100},[],{"trials":2416,"activeCount":100},[],{"trials":2418,"activeCount":100},[],{"intervention":2376,"totalTrials":118,"cells":2420},{"EARLY_PHASE1":2421,"PHASE1":2423,"PHASE2":2425,"PHASE3":2431,"PHASE4":2433,"NA":2435},{"trials":2422,"activeCount":100},[],{"trials":2424,"activeCount":100},[],{"trials":2426,"activeCount":118,"soonestReadout":2368},[2427],{"nctId":2365,"briefTitle":2366,"status":154,"phases":2428,"primaryCompletion":2368,"completion":2368,"start":2369,"enrollment":2370,"conditions":2429,"interventions":2430},[90],[2372],[2356,2374,2375,2376],{"trials":2432,"activeCount":100},[],{"trials":2434,"activeCount":100},[],{"trials":2436,"activeCount":100},[],{"intervention":2438,"totalTrials":96,"cells":2439},"DPA-714 PET\u002FMRI",{"EARLY_PHASE1":2440,"PHASE1":2451,"PHASE2":2464,"PHASE3":2466,"PHASE4":2468,"NA":2470},{"trials":2441,"activeCount":118,"soonestReadout":2446},[2442],{"nctId":2443,"briefTitle":2444,"status":124,"phases":2445,"primaryCompletion":2446,"completion":2446,"start":2447,"enrollment":761,"conditions":2448,"interventions":2450},"NCT05656105","Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection",[88],"2028-06-01","2023-11-10",[2449],"SARS CoV-2 Post-Acute Sequelae",[2438],{"trials":2452,"activeCount":118,"soonestReadout":2457},[2453],{"nctId":2454,"briefTitle":2455,"status":124,"phases":2456,"primaryCompletion":2457,"completion":2457,"start":2458,"enrollment":1551,"conditions":2459,"interventions":2463},"NCT03759522","Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.",[89],"2028-04","2019-02-03",[2460,2461,29,2462],"Fibromyalgia","Chronic Fatigue Syndrome","Healthy",[2438],{"trials":2465,"activeCount":100},[],{"trials":2467,"activeCount":100},[],{"trials":2469,"activeCount":100},[],{"trials":2471,"activeCount":100},[],{"intervention":2473,"totalTrials":96,"cells":2474},"Venetoclax",{"EARLY_PHASE1":2475,"PHASE1":2487,"PHASE2":2501,"PHASE3":2503,"PHASE4":2505,"NA":2507},{"trials":2476,"activeCount":100},[2477],{"nctId":2478,"briefTitle":2479,"status":166,"phases":2480,"primaryCompletion":2481,"completion":2482,"start":2483,"enrollment":963,"conditions":2484,"interventions":2486},"NCT05976217","Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis",[88],"2024-03-18","2024-03-20","2023-10-01",[2485],"Idiopathic Pulmonary Fibrosis",[2473],{"trials":2488,"activeCount":118,"soonestReadout":349},[2489],{"nctId":2490,"briefTitle":2491,"status":124,"phases":2492,"primaryCompletion":349,"completion":2493,"start":1062,"enrollment":986,"conditions":2494,"interventions":2498},"NCT07044544","Trial of Novel Anti-leukemia Agents in Flu\u002FMel RIC Transplant for Myeloid Malignancies",[89],"2027-01",[2495,2496,2497,1452],"Myeloid Malignancy","Hematologic Malignancy","Acute Myeloid Leukemia",[2499,2500,2473],"G-CSF","Decitabine",{"trials":2502,"activeCount":100},[],{"trials":2504,"activeCount":100},[],{"trials":2506,"activeCount":100},[],{"trials":2508,"activeCount":100},[],{"intervention":86,"totalTrials":118,"cells":2510},{"EARLY_PHASE1":2511,"PHASE1":2513,"PHASE2":2524,"PHASE3":2526,"PHASE4":2528,"NA":2530},{"trials":2512,"activeCount":100},[],{"trials":2514,"activeCount":118,"soonestReadout":85},[2515],{"nctId":83,"briefTitle":84,"status":124,"phases":2516,"primaryCompletion":85,"completion":598,"start":2517,"enrollment":2518,"conditions":2519,"interventions":2522},[89],"2023-05-01",10,[2520,2521],"Cutaneous T Cell Lymphoma","Mycosis Fungoides",[86,2523],"Brentuximab vedotin",{"trials":2525,"activeCount":100},[],{"trials":2527,"activeCount":100},[],{"trials":2529,"activeCount":100},[],{"trials":2531,"activeCount":100},[],{"intervention":2523,"totalTrials":118,"cells":2533},{"EARLY_PHASE1":2534,"PHASE1":2536,"PHASE2":2542,"PHASE3":2544,"PHASE4":2546,"NA":2548},{"trials":2535,"activeCount":100},[],{"trials":2537,"activeCount":118,"soonestReadout":85},[2538],{"nctId":83,"briefTitle":84,"status":124,"phases":2539,"primaryCompletion":85,"completion":598,"start":2517,"enrollment":2518,"conditions":2540,"interventions":2541},[89],[2520,2521],[86,2523],{"trials":2543,"activeCount":100},[],{"trials":2545,"activeCount":100},[],{"trials":2547,"activeCount":100},[],{"trials":2549,"activeCount":100},[],{"intervention":2551,"totalTrials":118,"cells":2552},"PET\u002FCT using PET ligands [F-18]FDG and [F-18]DPA-714",{"EARLY_PHASE1":2553,"PHASE1":2555,"PHASE2":2564,"PHASE3":2566,"PHASE4":2568,"NA":2570},{"trials":2554,"activeCount":100},[],{"trials":2556,"activeCount":118,"soonestReadout":572},[2557],{"nctId":2558,"briefTitle":2559,"status":124,"phases":2560,"primaryCompletion":572,"completion":572,"start":2561,"enrollment":2518,"conditions":2562,"interventions":2563},"NCT04362644","Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis",[89],"2020-12-08",[2485],[2551],{"trials":2565,"activeCount":100},[],{"trials":2567,"activeCount":100},[],{"trials":2569,"activeCount":100},[],{"trials":2571,"activeCount":100},[],{"intervention":2573,"totalTrials":118,"cells":2574},"pNGVL4aCRTE6E7L2",{"EARLY_PHASE1":2575,"PHASE1":2577,"PHASE2":2589,"PHASE3":2591,"PHASE4":2593,"NA":2595},{"trials":2576,"activeCount":100},[],{"trials":2578,"activeCount":118,"soonestReadout":350},[2579],{"nctId":2580,"briefTitle":2581,"status":124,"phases":2582,"primaryCompletion":350,"completion":350,"start":2583,"enrollment":19,"conditions":2584,"interventions":2587},"NCT03913117","Study of Treatment for HPV16+ ASC-US or LSIL",[89],"2023-07-10",[2585,2586],"ASC-US","LSIL",[2573,2588],"TA-CIN",{"trials":2590,"activeCount":100},[],{"trials":2592,"activeCount":100},[],{"trials":2594,"activeCount":100},[],{"trials":2596,"activeCount":100},[],{"intervention":2588,"totalTrials":118,"cells":2598},{"EARLY_PHASE1":2599,"PHASE1":2601,"PHASE2":2607,"PHASE3":2609,"PHASE4":2611,"NA":2613},{"trials":2600,"activeCount":100},[],{"trials":2602,"activeCount":118,"soonestReadout":350},[2603],{"nctId":2580,"briefTitle":2581,"status":124,"phases":2604,"primaryCompletion":350,"completion":350,"start":2583,"enrollment":19,"conditions":2605,"interventions":2606},[89],[2585,2586],[2573,2588],{"trials":2608,"activeCount":100},[],{"trials":2610,"activeCount":100},[],{"trials":2612,"activeCount":100},[],{"trials":2614,"activeCount":100},[],{"intervention":2616,"totalTrials":118,"cells":2617},"[18F]FMISO PET\u002FMRI imaging",{"EARLY_PHASE1":2618,"PHASE1":2620,"PHASE2":2630,"PHASE3":2632,"PHASE4":2634,"NA":2636},{"trials":2619,"activeCount":100},[],{"trials":2621,"activeCount":118,"soonestReadout":323},[2622],{"nctId":2623,"briefTitle":2624,"status":124,"phases":2625,"primaryCompletion":323,"completion":323,"start":2626,"enrollment":1425,"conditions":2627,"interventions":2629},"NCT04332588","Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET\u002FMRI",[89],"2022-03-25",[2628],"HER2-positive Breast Cancer",[2616],{"trials":2631,"activeCount":100},[],{"trials":2633,"activeCount":100},[],{"trials":2635,"activeCount":100},[],{"trials":2637,"activeCount":100},[],{"intervention":2639,"totalTrials":118,"cells":2640},"[18F]DPA-714-PET\u002FMRI",{"EARLY_PHASE1":2641,"PHASE1":2643,"PHASE2":2653,"PHASE3":2655,"PHASE4":2657,"NA":2659},{"trials":2642,"activeCount":100},[],{"trials":2644,"activeCount":118,"soonestReadout":1992},[2645],{"nctId":2646,"briefTitle":2647,"status":108,"phases":2648,"primaryCompletion":1992,"completion":1992,"start":2649,"enrollment":921,"conditions":2650,"interventions":2652},"NCT03968445","Neuroinflammation After Myocardial Infarction - Imaging Substudy",[89],"2019-10-17",[2651],"Myocardial Infarction",[2639],{"trials":2654,"activeCount":100},[],{"trials":2656,"activeCount":100},[],{"trials":2658,"activeCount":100},[],{"trials":2660,"activeCount":100},[],{"intervention":56,"totalTrials":118,"cells":2662},{"EARLY_PHASE1":2663,"PHASE1":2665,"PHASE2":2675,"PHASE3":2677,"PHASE4":2679,"NA":2681},{"trials":2664,"activeCount":100},[],{"trials":2666,"activeCount":118,"soonestReadout":55},[2667],{"nctId":53,"briefTitle":54,"status":108,"phases":2668,"primaryCompletion":55,"completion":510,"start":2669,"enrollment":30,"conditions":2670,"interventions":2674},[89],"2019-09-23",[2671,2672,2673],"Glioblastoma Multiforme of Brain","Anaplastic Astrocytoma of Brain","Gliosarcoma of Brain",[56],{"trials":2676,"activeCount":100},[],{"trials":2678,"activeCount":100},[],{"trials":2680,"activeCount":100},[],{"trials":2682,"activeCount":100},[],{"intervention":2684,"totalTrials":118,"cells":2685},"Octreotide",{"EARLY_PHASE1":2686,"PHASE1":2688,"PHASE2":2698,"PHASE3":2700,"PHASE4":2702,"NA":2704},{"trials":2687,"activeCount":100},[],{"trials":2689,"activeCount":118,"soonestReadout":350},[2690],{"nctId":2691,"briefTitle":2692,"status":154,"phases":2693,"primaryCompletion":350,"completion":350,"start":2694,"enrollment":761,"conditions":2695,"interventions":2697},"NCT06881888","Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema",[89],"2026-08-31",[2696],"Diabetic Macular Edema",[2684],{"trials":2699,"activeCount":100},[],{"trials":2701,"activeCount":100},[],{"trials":2703,"activeCount":100},[],{"trials":2705,"activeCount":100},[],{"intervention":1068,"totalTrials":118,"cells":2707},{"EARLY_PHASE1":2708,"PHASE1":2710,"PHASE2":2716,"PHASE3":2718,"PHASE4":2720,"NA":2722},{"trials":2709,"activeCount":100},[],{"trials":2711,"activeCount":118,"soonestReadout":929},[2712],{"nctId":1059,"briefTitle":1060,"status":124,"phases":2713,"primaryCompletion":929,"completion":758,"start":1062,"enrollment":1063,"conditions":2714,"interventions":2715},[89],[1065,1066],[1068,1069,1037],{"trials":2717,"activeCount":100},[],{"trials":2719,"activeCount":100},[],{"trials":2721,"activeCount":100},[],{"trials":2723,"activeCount":100},[],{"intervention":1069,"totalTrials":118,"cells":2725},{"EARLY_PHASE1":2726,"PHASE1":2728,"PHASE2":2734,"PHASE3":2736,"PHASE4":2738,"NA":2740},{"trials":2727,"activeCount":100},[],{"trials":2729,"activeCount":118,"soonestReadout":929},[2730],{"nctId":1059,"briefTitle":1060,"status":124,"phases":2731,"primaryCompletion":929,"completion":758,"start":1062,"enrollment":1063,"conditions":2732,"interventions":2733},[89],[1065,1066],[1068,1069,1037],{"trials":2735,"activeCount":100},[],{"trials":2737,"activeCount":100},[],{"trials":2739,"activeCount":100},[],{"trials":2741,"activeCount":100},[],{"intervention":2743,"totalTrials":118,"cells":2744},"DRI cell therapy",{"EARLY_PHASE1":2745,"PHASE1":2747,"PHASE2":2757,"PHASE3":2759,"PHASE4":2761,"NA":2763},{"trials":2746,"activeCount":100},[],{"trials":2748,"activeCount":118,"soonestReadout":677},[2749],{"nctId":2750,"briefTitle":2751,"status":108,"phases":2752,"primaryCompletion":677,"completion":677,"start":2753,"enrollment":352,"conditions":2754,"interventions":2756},"NCT04165941","Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma",[89],"2020-02-11",[2755],"Brain Tumor Adult",[2743],{"trials":2758,"activeCount":100},[],{"trials":2760,"activeCount":100},[],{"trials":2762,"activeCount":100},[],{"trials":2764,"activeCount":100},[],{"intervention":2766,"totalTrials":118,"cells":2767},"Labetalol or Nifedipine",{"EARLY_PHASE1":2768,"PHASE1":2770,"PHASE2":2781,"PHASE3":2783,"PHASE4":2785,"NA":2787},{"trials":2769,"activeCount":100},[],{"trials":2771,"activeCount":118,"soonestReadout":677},[2772],{"nctId":2773,"briefTitle":2774,"status":124,"phases":2775,"primaryCompletion":677,"completion":677,"start":2776,"enrollment":2777,"conditions":2778,"interventions":2780},"NCT05989581","Chronic Hypertension and Pregnancy 2 (CHAP2) Pilot Project",[89],"2024-04-24",74,[2779],"Hypertension in Pregnancy",[2766],{"trials":2782,"activeCount":100},[],{"trials":2784,"activeCount":100},[],{"trials":2786,"activeCount":100},[],{"trials":2788,"activeCount":100},[],{"intervention":2499,"totalTrials":118,"cells":2790},{"EARLY_PHASE1":2791,"PHASE1":2793,"PHASE2":2799,"PHASE3":2801,"PHASE4":2803,"NA":2805},{"trials":2792,"activeCount":100},[],{"trials":2794,"activeCount":118,"soonestReadout":349},[2795],{"nctId":2490,"briefTitle":2491,"status":124,"phases":2796,"primaryCompletion":349,"completion":2493,"start":1062,"enrollment":986,"conditions":2797,"interventions":2798},[89],[2495,2496,2497,1452],[2499,2500,2473],{"trials":2800,"activeCount":100},[],{"trials":2802,"activeCount":100},[],{"trials":2804,"activeCount":100},[],{"trials":2806,"activeCount":100},[],{"intervention":2500,"totalTrials":118,"cells":2808},{"EARLY_PHASE1":2809,"PHASE1":2811,"PHASE2":2817,"PHASE3":2819,"PHASE4":2821,"NA":2823},{"trials":2810,"activeCount":100},[],{"trials":2812,"activeCount":118,"soonestReadout":349},[2813],{"nctId":2490,"briefTitle":2491,"status":124,"phases":2814,"primaryCompletion":349,"completion":2493,"start":1062,"enrollment":986,"conditions":2815,"interventions":2816},[89],[2495,2496,2497,1452],[2499,2500,2473],{"trials":2818,"activeCount":100},[],{"trials":2820,"activeCount":100},[],{"trials":2822,"activeCount":100},[],{"trials":2824,"activeCount":100},[],{"intervention":2826,"totalTrials":118,"cells":2827},"Infusion of CD34 selected hematopoietic stem cells",{"EARLY_PHASE1":2828,"PHASE1":2830,"PHASE2":2845,"PHASE3":2847,"PHASE4":2849,"NA":2851},{"trials":2829,"activeCount":100},[],{"trials":2831,"activeCount":118,"soonestReadout":2836},[2832],{"nctId":2833,"briefTitle":2834,"status":124,"phases":2835,"primaryCompletion":2836,"completion":2016,"start":2837,"enrollment":403,"conditions":2838,"interventions":2844},"NCT06047886","UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy",[89],"2029-10","2025-04-22",[2839,2840,2841,1452,2842,2843],"AML","ALL","Lymphoid Malignancies","CML","Primary Myelofibrosis",[2826],{"trials":2846,"activeCount":100},[],{"trials":2848,"activeCount":100},[],{"trials":2850,"activeCount":100},[],{"trials":2852,"activeCount":100},[],{"intervention":2854,"totalTrials":118,"cells":2855},"Loncastuximab Tesirine and Acalabrutinib",{"EARLY_PHASE1":2856,"PHASE1":2858,"PHASE2":2868,"PHASE3":2870,"PHASE4":2872,"NA":2874},{"trials":2857,"activeCount":100},[],{"trials":2859,"activeCount":118,"soonestReadout":677},[2860],{"nctId":2861,"briefTitle":2862,"status":108,"phases":2863,"primaryCompletion":677,"completion":875,"start":2864,"enrollment":942,"conditions":2865,"interventions":2867},"NCT05971251","Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia",[89],"2023-12-18",[2866],"Chronic Lymphocytic Leukemia",[2854],{"trials":2869,"activeCount":100},[],{"trials":2871,"activeCount":100},[],{"trials":2873,"activeCount":100},[],{"trials":2875,"activeCount":100},[],{"intervention":2877,"totalTrials":118,"cells":2878},"[F-18]AV-1451-PET",{"EARLY_PHASE1":2879,"PHASE1":2881,"PHASE2":2890,"PHASE3":2892,"PHASE4":2894,"NA":2896},{"trials":2880,"activeCount":100},[],{"trials":2882,"activeCount":118,"soonestReadout":758},[2883],{"nctId":2884,"briefTitle":2885,"status":124,"phases":2886,"primaryCompletion":758,"completion":758,"start":2887,"enrollment":158,"conditions":2888,"interventions":2889},"NCT03809351","UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy",[89],"2020-07-08",[1995],[2877],{"trials":2891,"activeCount":100},[],{"trials":2893,"activeCount":100},[],{"trials":2895,"activeCount":100},[],{"trials":2897,"activeCount":100},[],{"intervention":2899,"totalTrials":906,"cells":2900},"Ivacaftor",{"EARLY_PHASE1":2901,"PHASE1":2923,"PHASE2":2925,"PHASE3":2935,"PHASE4":2937,"NA":2948},{"trials":2902,"activeCount":118,"soonestReadout":1705},[2903,2913],{"nctId":2904,"briefTitle":2905,"status":166,"phases":2906,"primaryCompletion":2907,"completion":2908,"start":2909,"enrollment":1476,"conditions":2910,"interventions":2912},"NCT02135432","TOPIC Trial for COPD",[88],"2015-10","2015-11","2015-05",[2911],"Chronic Obstructive Pulmonary Disease",[2899],{"nctId":2914,"briefTitle":2915,"status":124,"phases":2916,"primaryCompletion":1705,"completion":2917,"start":2918,"enrollment":986,"conditions":2919,"interventions":2921},"NCT03439865","Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis",[88],"2027-05-01","2019-05-02",[2920],"Chronic Rhinosinusitis (Diagnosis)",[2899,2922],"standard of care treatment",{"trials":2924,"activeCount":100},[],{"trials":2926,"activeCount":100},[2927],{"nctId":2928,"briefTitle":2929,"status":1196,"phases":2930,"primaryCompletion":2931,"completion":2931,"start":2932,"enrollment":100,"conditions":2933,"interventions":2934},"NCT04066751","The Multicenter Topic Trial",[90],"2024-10-31","2021-12-01",[2911],[2899],{"trials":2936,"activeCount":100},[],{"trials":2938,"activeCount":100},[2939],{"nctId":2940,"briefTitle":2941,"status":1196,"phases":2942,"primaryCompletion":2943,"completion":2943,"start":2944,"enrollment":100,"conditions":2945,"interventions":2947},"NCT03251911","VX-770 for the Treatment of Chronic Bronchitis",[92],"2022-02-01","2020-01-01",[2946],"Chronic Bronchitis",[2899],{"trials":2949,"activeCount":100},[],{"intervention":2951,"totalTrials":96,"cells":2952},"Indocyanine green",{"EARLY_PHASE1":2953,"PHASE1":2967,"PHASE2":2969,"PHASE3":2971,"PHASE4":2973,"NA":2986},{"trials":2954,"activeCount":118,"soonestReadout":322},[2955],{"nctId":2956,"briefTitle":2957,"status":124,"phases":2958,"primaryCompletion":322,"completion":322,"start":2959,"enrollment":271,"conditions":2960,"interventions":2965},"NCT07250854","The Use of Near-Infrared Fluorescence Cholangiography With Indocyanine Green (ICG) in the Work Up of Neonatal Cholestasis",[88],"2026-01-23",[2961,2962,2963,2964],"Biliary Atresia","Kasai","Cholestasis in Newborn","Cholestasis in Newborn Infant",[2966],"Indocyanine Green",{"trials":2968,"activeCount":100},[],{"trials":2970,"activeCount":100},[],{"trials":2972,"activeCount":100},[],{"trials":2974,"activeCount":100},[2975],{"nctId":2976,"briefTitle":2977,"status":917,"phases":2978,"primaryCompletion":2979,"completion":2979,"start":2980,"enrollment":2981,"conditions":2982,"interventions":2985},"NCT06169735","Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation",[92],"2026-05-05","2024-04-11",417,[2983,2984],"Parathyroid Dysfunction","Adenoma",[2951],{"trials":2987,"activeCount":100},[],{"intervention":2989,"totalTrials":963,"cells":2990},"Psilocybin",{"EARLY_PHASE1":2991,"PHASE1":3010,"PHASE2":3012,"PHASE3":3023,"PHASE4":3025,"NA":3027},{"trials":2992,"activeCount":118,"soonestReadout":677},[2993,3002],{"nctId":2994,"briefTitle":2995,"status":1196,"phases":2996,"primaryCompletion":2997,"completion":2997,"start":2998,"enrollment":100,"conditions":2999,"interventions":3001},"NCT05227742","Exploratory Study of Low Dose Psilocybin",[88],"2026-03","2023-08-15",[3000],"Demoralization",[2989],{"nctId":3003,"briefTitle":3004,"status":124,"phases":3005,"primaryCompletion":677,"completion":677,"start":270,"enrollment":19,"conditions":3006,"interventions":3008},"NCT05068791","Psilocybin-facilitated Treatment for Chronic Pain",[88],[3007],"Fibromyalgia, Primary",[2989,3009],"Dextromethorphan",{"trials":3011,"activeCount":100},[],{"trials":3013,"activeCount":100},[3014],{"nctId":3015,"briefTitle":3016,"status":166,"phases":3017,"primaryCompletion":3018,"completion":3018,"start":2909,"enrollment":1969,"conditions":3019,"interventions":3021},"NCT02037126","Psilocybin-facilitated Treatment for Cocaine Use",[90],"2024-05",[3020],"Cocaine-Related Disorders",[2989,3022],"Diphenhydramine",{"trials":3024,"activeCount":100},[],{"trials":3026,"activeCount":100},[],{"trials":3028,"activeCount":100},[],{"intervention":3009,"totalTrials":96,"cells":3030},{"EARLY_PHASE1":3031,"PHASE1":3037,"PHASE2":3039,"PHASE3":3049,"PHASE4":3051,"NA":3053},{"trials":3032,"activeCount":118,"soonestReadout":677},[3033],{"nctId":3003,"briefTitle":3004,"status":124,"phases":3034,"primaryCompletion":677,"completion":677,"start":270,"enrollment":19,"conditions":3035,"interventions":3036},[88],[3007],[2989,3009],{"trials":3038,"activeCount":100},[],{"trials":3040,"activeCount":100},[3041],{"nctId":3042,"briefTitle":3043,"status":166,"phases":3044,"primaryCompletion":3045,"completion":3045,"start":3046,"enrollment":1063,"conditions":3047,"interventions":3048},"NCT03538054","Dextromethorphan in Fibromyalgia",[90],"2020-03-18","2018-06-26",[2460],[3009],{"trials":3050,"activeCount":100},[],{"trials":3052,"activeCount":100},[],{"trials":3054,"activeCount":100},[],{"intervention":3056,"totalTrials":118,"cells":3057},"Diphenylcyclopropenone",{"EARLY_PHASE1":3058,"PHASE1":3070,"PHASE2":3072,"PHASE3":3074,"PHASE4":3076,"NA":3078},{"trials":3059,"activeCount":118,"soonestReadout":3064},[3060],{"nctId":3061,"briefTitle":3062,"status":108,"phases":3063,"primaryCompletion":3064,"completion":3065,"start":3066,"enrollment":325,"conditions":3067,"interventions":3069},"NCT05020496","Trem-1 and Ultraviolet Radiation-induced Immune Suppression",[88],"2026-06-30","2026-10-01","2022-03-21",[3068],"Skin Diseases",[3056],{"trials":3071,"activeCount":100},[],{"trials":3073,"activeCount":100},[],{"trials":3075,"activeCount":100},[],{"trials":3077,"activeCount":100},[],{"trials":3079,"activeCount":100},[],{"intervention":3081,"totalTrials":118,"cells":3082},"Siplizumab",{"EARLY_PHASE1":3083,"PHASE1":3093,"PHASE2":3095,"PHASE3":3097,"PHASE4":3099,"NA":3101},{"trials":3084,"activeCount":118,"soonestReadout":1925},[3085],{"nctId":3086,"briefTitle":3087,"status":124,"phases":3088,"primaryCompletion":1925,"completion":652,"start":3089,"enrollment":1476,"conditions":3090,"interventions":3092},"NCT06326476","Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.",[88],"2025-05-09",[3091],"Hidradenitis Suppurativa",[3081],{"trials":3094,"activeCount":100},[],{"trials":3096,"activeCount":100},[],{"trials":3098,"activeCount":100},[],{"trials":3100,"activeCount":100},[],{"trials":3102,"activeCount":100},[],{"intervention":3104,"totalTrials":118,"cells":3105},"[89Zr]Panitumumab Tracer",{"EARLY_PHASE1":3106,"PHASE1":3117,"PHASE2":3119,"PHASE3":3121,"PHASE4":3123,"NA":3125},{"trials":3107,"activeCount":118,"soonestReadout":269},[3108],{"nctId":3109,"briefTitle":3110,"status":124,"phases":3111,"primaryCompletion":269,"completion":269,"start":3112,"enrollment":3113,"conditions":3114,"interventions":3116},"NCT05183048","Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma",[88],"2023-02-20",14,[3115],"Head and Neck Squamous Cell Carcinoma",[3104],{"trials":3118,"activeCount":100},[],{"trials":3120,"activeCount":100},[],{"trials":3122,"activeCount":100},[],{"trials":3124,"activeCount":100},[],{"trials":3126,"activeCount":100},[],{"intervention":3128,"totalTrials":118,"cells":3129},"[F-18]MeFAMP PET",{"EARLY_PHASE1":3130,"PHASE1":3143,"PHASE2":3145,"PHASE3":3147,"PHASE4":3149,"NA":3151},{"trials":3131,"activeCount":118,"soonestReadout":3136},[3132],{"nctId":3133,"briefTitle":3134,"status":154,"phases":3135,"primaryCompletion":3136,"completion":3136,"start":3137,"enrollment":22,"conditions":3138,"interventions":3142},"NCT05676489","MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors",[88],"2029-08-30","2027-04-01",[3139,3140,3141],"Healthy Volunteers","Recurrent Glioma","Brain Metastases From Extra-cranial Solid Tumors",[3128],{"trials":3144,"activeCount":100},[],{"trials":3146,"activeCount":100},[],{"trials":3148,"activeCount":100},[],{"trials":3150,"activeCount":100},[],{"trials":3152,"activeCount":100},[],{"intervention":3154,"totalTrials":118,"cells":3155},"[F-18]DPA714 administration IV",{"EARLY_PHASE1":3156,"PHASE1":3165,"PHASE2":3167,"PHASE3":3169,"PHASE4":3171,"NA":3173},{"trials":3157,"activeCount":118,"soonestReadout":1733},[3158],{"nctId":3159,"briefTitle":3160,"status":124,"phases":3161,"primaryCompletion":1733,"completion":1733,"start":3162,"enrollment":761,"conditions":3163,"interventions":3164},"NCT06289582","Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)",[88],"2024-08-14",[1737],[3154],{"trials":3166,"activeCount":100},[],{"trials":3168,"activeCount":100},[],{"trials":3170,"activeCount":100},[],{"trials":3172,"activeCount":100},[],{"trials":3174,"activeCount":100},[],{"intervention":2922,"totalTrials":118,"cells":3176},{"EARLY_PHASE1":3177,"PHASE1":3183,"PHASE2":3185,"PHASE3":3187,"PHASE4":3189,"NA":3191},{"trials":3178,"activeCount":118,"soonestReadout":1705},[3179],{"nctId":2914,"briefTitle":2915,"status":124,"phases":3180,"primaryCompletion":1705,"completion":2917,"start":2918,"enrollment":986,"conditions":3181,"interventions":3182},[88],[2920],[2899,2922],{"trials":3184,"activeCount":100},[],{"trials":3186,"activeCount":100},[],{"trials":3188,"activeCount":100},[],{"trials":3190,"activeCount":100},[],{"trials":3192,"activeCount":100},[],{"intervention":3194,"totalTrials":118,"cells":3195},"[89Zr]-Df-Trastuzumab",{"EARLY_PHASE1":3196,"PHASE1":3205,"PHASE2":3207,"PHASE3":3209,"PHASE4":3211,"NA":3213},{"trials":3197,"activeCount":118,"soonestReadout":1992},[3198],{"nctId":3199,"briefTitle":3200,"status":124,"phases":3201,"primaryCompletion":1992,"completion":1992,"start":3202,"enrollment":2518,"conditions":3203,"interventions":3204},"NCT03321045","Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness",[88],"2017-11-21",[21],[3194],{"trials":3206,"activeCount":100},[],{"trials":3208,"activeCount":100},[],{"trials":3210,"activeCount":100},[],{"trials":3212,"activeCount":100},[],{"trials":3214,"activeCount":100},[],{"intervention":3216,"totalTrials":118,"cells":3217},"[18F]FMISO-PET with contrast-enhanced MRI",{"EARLY_PHASE1":3218,"PHASE1":3228,"PHASE2":3230,"PHASE3":3232,"PHASE4":3234,"NA":3236},{"trials":3219,"activeCount":118,"soonestReadout":1183},[3220],{"nctId":3221,"briefTitle":3222,"status":124,"phases":3223,"primaryCompletion":1183,"completion":1183,"start":3224,"enrollment":986,"conditions":3225,"interventions":3227},"NCT04861077","Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET\u002FMRI)",[88],"2026-06",[3226],"Triple Negative Breast Cancer",[3216],{"trials":3229,"activeCount":100},[],{"trials":3231,"activeCount":100},[],{"trials":3233,"activeCount":100},[],{"trials":3235,"activeCount":100},[],{"trials":3237,"activeCount":100},[],{"intervention":3239,"totalTrials":118,"cells":3240},"O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET\u002FMRI",{"EARLY_PHASE1":3241,"PHASE1":3252,"PHASE2":3254,"PHASE3":3256,"PHASE4":3258,"NA":3260},{"trials":3242,"activeCount":118,"soonestReadout":3247},[3243],{"nctId":3244,"briefTitle":3245,"status":124,"phases":3246,"primaryCompletion":3247,"completion":3247,"start":3248,"enrollment":986,"conditions":3249,"interventions":3251},"NCT05632562","Multiparametic Metabolic and Hypoxic PET\u002FMRI for Disease Assessment in High Grade Glioma",[88],"2028-02-01","2024-03-07",[3250],"High Grade Glioma",[3239],{"trials":3253,"activeCount":100},[],{"trials":3255,"activeCount":100},[],{"trials":3257,"activeCount":100},[],{"trials":3259,"activeCount":100},[],{"trials":3261,"activeCount":100},[],{"intervention":3263,"totalTrials":96,"cells":3264},"Etonogestrel (ETG) implant",{"EARLY_PHASE1":3265,"PHASE1":3267,"PHASE2":3269,"PHASE3":3271,"PHASE4":3273,"NA":3288},{"trials":3266,"activeCount":100},[],{"trials":3268,"activeCount":100},[],{"trials":3270,"activeCount":100},[],{"trials":3272,"activeCount":100},[],{"trials":3274,"activeCount":100},[3275],{"nctId":3276,"briefTitle":3277,"status":166,"phases":3278,"primaryCompletion":3279,"completion":3279,"start":3280,"enrollment":3281,"conditions":3282,"interventions":3285},"NCT04669678","Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa",[92],"2024-02-05","2021-11-17",110,[32,3283,3284],"Contraception","Drug-drug Interaction",[3263,3286,3287],"Intramuscular depo-medroxyprogesterone acetate","Sub-cutaneous medroxyprogesterone acetate",{"trials":3289,"activeCount":118,"soonestReadout":3294},[3290],{"nctId":3291,"briefTitle":3292,"status":124,"phases":3293,"primaryCompletion":3294,"completion":3294,"start":3295,"enrollment":3296,"conditions":3297,"interventions":3298},"NCT05044962","Kuwa Free! - Live Free!",[93],"2027-03-31","2021-11-26",700,[32,3283,3284],[3299,3263,3286,3300,3301],"Cabotegravir\u002F Rilpivirine","Levonorgestrel","NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens",{"intervention":3286,"totalTrials":96,"cells":3303},{"EARLY_PHASE1":3304,"PHASE1":3306,"PHASE2":3308,"PHASE3":3310,"PHASE4":3312,"NA":3318},{"trials":3305,"activeCount":100},[],{"trials":3307,"activeCount":100},[],{"trials":3309,"activeCount":100},[],{"trials":3311,"activeCount":100},[],{"trials":3313,"activeCount":100},[3314],{"nctId":3276,"briefTitle":3277,"status":166,"phases":3315,"primaryCompletion":3279,"completion":3279,"start":3280,"enrollment":3281,"conditions":3316,"interventions":3317},[92],[32,3283,3284],[3263,3286,3287],{"trials":3319,"activeCount":118,"soonestReadout":3294},[3320],{"nctId":3291,"briefTitle":3292,"status":124,"phases":3321,"primaryCompletion":3294,"completion":3294,"start":3295,"enrollment":3296,"conditions":3322,"interventions":3323},[93],[32,3283,3284],[3299,3263,3286,3300,3301],{"intervention":3325,"totalTrials":118,"cells":3326},"Long-acting injectable cabotegravir",{"EARLY_PHASE1":3327,"PHASE1":3329,"PHASE2":3331,"PHASE3":3333,"PHASE4":3335,"NA":3337},{"trials":3328,"activeCount":100},[],{"trials":3330,"activeCount":100},[],{"trials":3332,"activeCount":100},[],{"trials":3334,"activeCount":100},[],{"trials":3336,"activeCount":100},[],{"trials":3338,"activeCount":118,"soonestReadout":677},[3339],{"nctId":3340,"briefTitle":3341,"status":154,"phases":3342,"primaryCompletion":677,"completion":677,"start":296,"enrollment":3343,"conditions":3344,"interventions":3347},"NCT07516548","Pharmacokinetic Study of Long-acting Antiretrovirals and Contraceptives in HIV",[],105,[32,3283,3284,3345,3346],"PrEP","Long-acting Injectable Cabotegravir for PrEP",[3325],{"intervention":3349,"totalTrials":118,"cells":3350},"Patients with psychosis will be treated with known antipsychotic medication",{"EARLY_PHASE1":3351,"PHASE1":3353,"PHASE2":3355,"PHASE3":3357,"PHASE4":3359,"NA":3361},{"trials":3352,"activeCount":100},[],{"trials":3354,"activeCount":100},[],{"trials":3356,"activeCount":100},[],{"trials":3358,"activeCount":100},[],{"trials":3360,"activeCount":100},[],{"trials":3362,"activeCount":118,"soonestReadout":1474},[3363],{"nctId":3364,"briefTitle":3365,"status":108,"phases":3366,"primaryCompletion":1474,"completion":677,"start":3367,"enrollment":3368,"conditions":3369,"interventions":3371},"NCT03442101","Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study",[],"2018-04-01",156,[3370],"Psychosis",[3349],{"intervention":3373,"totalTrials":118,"cells":3374},"CYP2C19 Genotype Guided DAPT",{"EARLY_PHASE1":3375,"PHASE1":3377,"PHASE2":3379,"PHASE3":3381,"PHASE4":3383,"NA":3385},{"trials":3376,"activeCount":100},[],{"trials":3378,"activeCount":100},[],{"trials":3380,"activeCount":100},[],{"trials":3382,"activeCount":100},[],{"trials":3384,"activeCount":100},[],{"trials":3386,"activeCount":118,"soonestReadout":2368},[3387],{"nctId":3388,"briefTitle":3389,"status":124,"phases":3390,"primaryCompletion":2368,"completion":3391,"start":3392,"enrollment":1679,"conditions":3393,"interventions":3395},"NCT06943586","Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing",[93],"2029-04-01","2025-04-09",[24,3394],"Transient Ischemic Attack (TIA)",[3373],{"intervention":3299,"totalTrials":118,"cells":3397},{"EARLY_PHASE1":3398,"PHASE1":3400,"PHASE2":3402,"PHASE3":3404,"PHASE4":3406,"NA":3408},{"trials":3399,"activeCount":100},[],{"trials":3401,"activeCount":100},[],{"trials":3403,"activeCount":100},[],{"trials":3405,"activeCount":100},[],{"trials":3407,"activeCount":100},[],{"trials":3409,"activeCount":118,"soonestReadout":3294},[3410],{"nctId":3291,"briefTitle":3292,"status":124,"phases":3411,"primaryCompletion":3294,"completion":3294,"start":3295,"enrollment":3296,"conditions":3412,"interventions":3413},[93],[32,3283,3284],[3299,3263,3286,3300,3301],{"intervention":3300,"totalTrials":118,"cells":3415},{"EARLY_PHASE1":3416,"PHASE1":3418,"PHASE2":3420,"PHASE3":3422,"PHASE4":3424,"NA":3426},{"trials":3417,"activeCount":100},[],{"trials":3419,"activeCount":100},[],{"trials":3421,"activeCount":100},[],{"trials":3423,"activeCount":100},[],{"trials":3425,"activeCount":100},[],{"trials":3427,"activeCount":118,"soonestReadout":3294},[3428],{"nctId":3291,"briefTitle":3292,"status":124,"phases":3429,"primaryCompletion":3294,"completion":3294,"start":3295,"enrollment":3296,"conditions":3430,"interventions":3431},[93],[32,3283,3284],[3299,3263,3286,3300,3301],{"intervention":3301,"totalTrials":118,"cells":3433},{"EARLY_PHASE1":3434,"PHASE1":3436,"PHASE2":3438,"PHASE3":3440,"PHASE4":3442,"NA":3444},{"trials":3435,"activeCount":100},[],{"trials":3437,"activeCount":100},[],{"trials":3439,"activeCount":100},[],{"trials":3441,"activeCount":100},[],{"trials":3443,"activeCount":100},[],{"trials":3445,"activeCount":118,"soonestReadout":3294},[3446],{"nctId":3291,"briefTitle":3292,"status":124,"phases":3447,"primaryCompletion":3294,"completion":3294,"start":3295,"enrollment":3296,"conditions":3448,"interventions":3449},[93],[32,3283,3284],[3299,3263,3286,3300,3301],{"intervention":3451,"totalTrials":118,"cells":3452},"Antihypertensive treatment",{"EARLY_PHASE1":3453,"PHASE1":3455,"PHASE2":3457,"PHASE3":3459,"PHASE4":3461,"NA":3463},{"trials":3454,"activeCount":100},[],{"trials":3456,"activeCount":100},[],{"trials":3458,"activeCount":100},[],{"trials":3460,"activeCount":100},[],{"trials":3462,"activeCount":100},[],{"trials":3464,"activeCount":118,"soonestReadout":349},[3465],{"nctId":3466,"briefTitle":3467,"status":124,"phases":3468,"primaryCompletion":349,"completion":572,"start":3469,"enrollment":3470,"conditions":3471,"interventions":3475},"NCT05676476","The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.",[93],"2023-02-14",132,[3472,3473,3474],"Preeclampsia","Gestational Hypertension","Hypertensive Disorder of Pregnancy",[3451],{"intervention":3477,"totalTrials":118,"cells":3478},"blood draw",{"EARLY_PHASE1":3479,"PHASE1":3481,"PHASE2":3483,"PHASE3":3485,"PHASE4":3487,"NA":3489},{"trials":3480,"activeCount":100},[],{"trials":3482,"activeCount":100},[],{"trials":3484,"activeCount":100},[],{"trials":3486,"activeCount":100},[],{"trials":3488,"activeCount":100},[],{"trials":3490,"activeCount":118,"soonestReadout":677},[3491],{"nctId":3492,"briefTitle":3493,"status":124,"phases":3494,"primaryCompletion":677,"completion":677,"start":3495,"enrollment":3496,"conditions":3497,"interventions":3499},"NCT03403686","Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)",[],"2018-01-11",104,[3498],"Diabetic Retinopathy",[3477],{"intervention":3501,"totalTrials":118,"cells":3502},"Genetic testing",{"EARLY_PHASE1":3503,"PHASE1":3505,"PHASE2":3507,"PHASE3":3509,"PHASE4":3511,"NA":3513},{"trials":3504,"activeCount":100},[],{"trials":3506,"activeCount":100},[],{"trials":3508,"activeCount":100},[],{"trials":3510,"activeCount":100},[],{"trials":3512,"activeCount":100},[],{"trials":3514,"activeCount":118,"soonestReadout":3519},[3515],{"nctId":3516,"briefTitle":3517,"status":124,"phases":3518,"primaryCompletion":3519,"completion":295,"start":3520,"enrollment":3521,"conditions":3522,"interventions":3532},"NCT05437588","Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents",[93],"2027-06-29","2022-10-01",240,[3523,3524,3525,3526,3527,3528,3529,3530,3531],"Major Depressive Disorder","Suicidal Ideas","Suicide, Attempted","MDD","Depression","Depression, Teen","Depression and Suicide","Depression in Adolescence","Suicide",[3501],{"intervention":81,"totalTrials":118,"cells":3534},{"EARLY_PHASE1":3535,"PHASE1":3537,"PHASE2":3539,"PHASE3":3541,"PHASE4":3543,"NA":3545},{"trials":3536,"activeCount":100},[],{"trials":3538,"activeCount":100},[],{"trials":3540,"activeCount":100},[],{"trials":3542,"activeCount":100},[],{"trials":3544,"activeCount":100},[],{"trials":3546,"activeCount":118,"soonestReadout":80},[3547],{"nctId":78,"briefTitle":79,"status":108,"phases":3548,"primaryCompletion":80,"completion":80,"start":2907,"enrollment":3549,"conditions":3550,"interventions":3557},[],303,[3551,3552,3553,3554,1091,3555,3556],"Human Immunodeficiency Virus","HBV","Fibrosis, Liver","Cirrhosis, Liver","Hepatitis Delta Virus","Alcoholic Hepatitis",[81],{"intervention":51,"totalTrials":118,"cells":3559},{"EARLY_PHASE1":3560,"PHASE1":3562,"PHASE2":3564,"PHASE3":3566,"PHASE4":3568,"NA":3570},{"trials":3561,"activeCount":100},[],{"trials":3563,"activeCount":100},[],{"trials":3565,"activeCount":100},[],{"trials":3567,"activeCount":100},[],{"trials":3569,"activeCount":100},[],{"trials":3571,"activeCount":118,"soonestReadout":50},[3572],{"nctId":48,"briefTitle":49,"status":108,"phases":3573,"primaryCompletion":50,"completion":349,"start":3574,"enrollment":971,"conditions":3575,"interventions":3577},[],"2021-08-31",[3576],"Bone Loss",[51,3578,3579,3580],"Amount of PDGF-BB available in PRF + bone substitutes vs. rhPDGF-BB+ bone substitutes following preparation","Release kinetics of PDGF-BB in PRF + bone substitutes vs. rhPDGF-BB + bone substitutes","Release kinetics of PDGF-BB in rhPDGF-BB + PRF + bone substitutes",{"intervention":3578,"totalTrials":118,"cells":3582},{"EARLY_PHASE1":3583,"PHASE1":3585,"PHASE2":3587,"PHASE3":3589,"PHASE4":3591,"NA":3593},{"trials":3584,"activeCount":100},[],{"trials":3586,"activeCount":100},[],{"trials":3588,"activeCount":100},[],{"trials":3590,"activeCount":100},[],{"trials":3592,"activeCount":100},[],{"trials":3594,"activeCount":118,"soonestReadout":50},[3595],{"nctId":48,"briefTitle":49,"status":108,"phases":3596,"primaryCompletion":50,"completion":349,"start":3574,"enrollment":971,"conditions":3597,"interventions":3598},[],[3576],[51,3578,3579,3580],{"intervention":3579,"totalTrials":118,"cells":3600},{"EARLY_PHASE1":3601,"PHASE1":3603,"PHASE2":3605,"PHASE3":3607,"PHASE4":3609,"NA":3611},{"trials":3602,"activeCount":100},[],{"trials":3604,"activeCount":100},[],{"trials":3606,"activeCount":100},[],{"trials":3608,"activeCount":100},[],{"trials":3610,"activeCount":100},[],{"trials":3612,"activeCount":118,"soonestReadout":50},[3613],{"nctId":48,"briefTitle":49,"status":108,"phases":3614,"primaryCompletion":50,"completion":349,"start":3574,"enrollment":971,"conditions":3615,"interventions":3616},[],[3576],[51,3578,3579,3580],{"intervention":3580,"totalTrials":118,"cells":3618},{"EARLY_PHASE1":3619,"PHASE1":3621,"PHASE2":3623,"PHASE3":3625,"PHASE4":3627,"NA":3629},{"trials":3620,"activeCount":100},[],{"trials":3622,"activeCount":100},[],{"trials":3624,"activeCount":100},[],{"trials":3626,"activeCount":100},[],{"trials":3628,"activeCount":100},[],{"trials":3630,"activeCount":118,"soonestReadout":50},[3631],{"nctId":48,"briefTitle":49,"status":108,"phases":3632,"primaryCompletion":50,"completion":349,"start":3574,"enrollment":971,"conditions":3633,"interventions":3634},[],[3576],[51,3578,3579,3580],{"intervention":3636,"totalTrials":118,"cells":3637},"superior laryngeal nerve block",{"EARLY_PHASE1":3638,"PHASE1":3640,"PHASE2":3642,"PHASE3":3644,"PHASE4":3646,"NA":3648},{"trials":3639,"activeCount":100},[],{"trials":3641,"activeCount":100},[],{"trials":3643,"activeCount":100},[],{"trials":3645,"activeCount":100},[],{"trials":3647,"activeCount":100},[],{"trials":3649,"activeCount":118,"soonestReadout":3654},[3650],{"nctId":3651,"briefTitle":3652,"status":124,"phases":3653,"primaryCompletion":3654,"completion":3654,"start":3655,"enrollment":403,"conditions":3656,"interventions":3658},"NCT04642352","Office-Based Superior Laryngeal Nerve Block for Treatment of Neurogenic Cough",[],"2026-10","2022-01-03",[3657],"Cough",[3636],{"intervention":3660,"totalTrials":118,"cells":3661},"Allograft particles hydrated with rhPDGF",{"EARLY_PHASE1":3662,"PHASE1":3664,"PHASE2":3666,"PHASE3":3668,"PHASE4":3670,"NA":3672},{"trials":3663,"activeCount":100},[],{"trials":3665,"activeCount":100},[],{"trials":3667,"activeCount":100},[],{"trials":3669,"activeCount":100},[],{"trials":3671,"activeCount":100},[],{"trials":3673,"activeCount":118,"soonestReadout":349},[3674],{"nctId":3675,"briefTitle":3676,"status":124,"phases":3677,"primaryCompletion":349,"completion":350,"start":3678,"enrollment":171,"conditions":3679,"interventions":3681},"NCT04954664","Ridge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor",[93],"2021-08-11",[3680,3576],"Dental Implant",[3660,3682],"Allograft particles hydrated in a conventional way with saline.",{"intervention":3682,"totalTrials":118,"cells":3684},{"EARLY_PHASE1":3685,"PHASE1":3687,"PHASE2":3689,"PHASE3":3691,"PHASE4":3693,"NA":3695},{"trials":3686,"activeCount":100},[],{"trials":3688,"activeCount":100},[],{"trials":3690,"activeCount":100},[],{"trials":3692,"activeCount":100},[],{"trials":3694,"activeCount":100},[],{"trials":3696,"activeCount":118,"soonestReadout":349},[3697],{"nctId":3675,"briefTitle":3676,"status":124,"phases":3698,"primaryCompletion":349,"completion":350,"start":3678,"enrollment":171,"conditions":3699,"interventions":3700},[93],[3680,3576],[3660,3682],{"intervention":3702,"totalTrials":118,"cells":3703},"Misoprostol",{"EARLY_PHASE1":3704,"PHASE1":3706,"PHASE2":3708,"PHASE3":3710,"PHASE4":3712,"NA":3714},{"trials":3705,"activeCount":100},[],{"trials":3707,"activeCount":100},[],{"trials":3709,"activeCount":100},[],{"trials":3711,"activeCount":100},[],{"trials":3713,"activeCount":100},[],{"trials":3715,"activeCount":118,"soonestReadout":3720},[3716],{"nctId":3717,"briefTitle":3718,"status":124,"phases":3719,"primaryCompletion":3720,"completion":3721,"start":3722,"enrollment":3723,"conditions":3724,"interventions":3726},"NCT06669533","Use Misoprostol to Optimize Prevention of Cervical Cancer",[93],"2026-11-04","2027-11-04","2025-02-25",420,[3725],"Cervical Cancers",[3702],{"intervention":3728,"totalTrials":118,"cells":3729},"E-PRF\u002FrhBMP-2",{"EARLY_PHASE1":3730,"PHASE1":3732,"PHASE2":3734,"PHASE3":3736,"PHASE4":3738,"NA":3740},{"trials":3731,"activeCount":100},[],{"trials":3733,"activeCount":100},[],{"trials":3735,"activeCount":100},[],{"trials":3737,"activeCount":100},[],{"trials":3739,"activeCount":100},[],{"trials":3741,"activeCount":118,"soonestReadout":350},[3742],{"nctId":3743,"briefTitle":3744,"status":154,"phases":3745,"primaryCompletion":350,"completion":758,"start":510,"enrollment":986,"conditions":3746,"interventions":3747},"NCT04670965","Release Kinetics of rhBMP-2 Using E-PRF as an Autologous Carrier: An In Vitro Analysis",[],[3576],[3728,3748,3749,3750],"E-PRF\u002FACS\u002FrhBMP-2","rhBMP-2\u002FE-PRF","E-PRF only",{"intervention":3748,"totalTrials":118,"cells":3752},{"EARLY_PHASE1":3753,"PHASE1":3755,"PHASE2":3757,"PHASE3":3759,"PHASE4":3761,"NA":3763},{"trials":3754,"activeCount":100},[],{"trials":3756,"activeCount":100},[],{"trials":3758,"activeCount":100},[],{"trials":3760,"activeCount":100},[],{"trials":3762,"activeCount":100},[],{"trials":3764,"activeCount":118,"soonestReadout":350},[3765],{"nctId":3743,"briefTitle":3744,"status":154,"phases":3766,"primaryCompletion":350,"completion":758,"start":510,"enrollment":986,"conditions":3767,"interventions":3768},[],[3576],[3728,3748,3749,3750],{"intervention":3749,"totalTrials":118,"cells":3770},{"EARLY_PHASE1":3771,"PHASE1":3773,"PHASE2":3775,"PHASE3":3777,"PHASE4":3779,"NA":3781},{"trials":3772,"activeCount":100},[],{"trials":3774,"activeCount":100},[],{"trials":3776,"activeCount":100},[],{"trials":3778,"activeCount":100},[],{"trials":3780,"activeCount":100},[],{"trials":3782,"activeCount":118,"soonestReadout":350},[3783],{"nctId":3743,"briefTitle":3744,"status":154,"phases":3784,"primaryCompletion":350,"completion":758,"start":510,"enrollment":986,"conditions":3785,"interventions":3786},[],[3576],[3728,3748,3749,3750],{"intervention":3750,"totalTrials":118,"cells":3788},{"EARLY_PHASE1":3789,"PHASE1":3791,"PHASE2":3793,"PHASE3":3795,"PHASE4":3797,"NA":3799},{"trials":3790,"activeCount":100},[],{"trials":3792,"activeCount":100},[],{"trials":3794,"activeCount":100},[],{"trials":3796,"activeCount":100},[],{"trials":3798,"activeCount":100},[],{"trials":3800,"activeCount":118,"soonestReadout":350},[3801],{"nctId":3743,"briefTitle":3744,"status":154,"phases":3802,"primaryCompletion":350,"completion":758,"start":510,"enrollment":986,"conditions":3803,"interventions":3804},[],[3576],[3728,3748,3749,3750],{"intervention":66,"totalTrials":118,"cells":3806},{"EARLY_PHASE1":3807,"PHASE1":3809,"PHASE2":3811,"PHASE3":3813,"PHASE4":3815,"NA":3817},{"trials":3808,"activeCount":100},[],{"trials":3810,"activeCount":100},[],{"trials":3812,"activeCount":100},[],{"trials":3814,"activeCount":100},[],{"trials":3816,"activeCount":100},[],{"trials":3818,"activeCount":118,"soonestReadout":65},[3819],{"nctId":63,"briefTitle":64,"status":108,"phases":3820,"primaryCompletion":65,"completion":3224,"start":3821,"enrollment":3822,"conditions":3823,"interventions":3825},[],"2022-11-01",2500,[3824],"Urinary Incontinence",[66],{"intervention":3827,"totalTrials":118,"cells":3828},"octafluropropane",{"EARLY_PHASE1":3829,"PHASE1":3831,"PHASE2":3833,"PHASE3":3835,"PHASE4":3837,"NA":3839},{"trials":3830,"activeCount":100},[],{"trials":3832,"activeCount":100},[],{"trials":3834,"activeCount":100},[],{"trials":3836,"activeCount":100},[],{"trials":3838,"activeCount":100},[],{"trials":3840,"activeCount":118,"soonestReadout":1925},[3841],{"nctId":3842,"briefTitle":3843,"status":124,"phases":3844,"primaryCompletion":1925,"completion":1925,"start":3845,"enrollment":1969,"conditions":3846,"interventions":3848},"NCT02370199","Peripheral Blood Flow Responses to Electromagnetic Energy",[93],"2014-11",[3847],"Exposure to Man-made Visible Light",[3827],{"intervention":3850,"totalTrials":118,"cells":3851},"Generation of inducible pluripotent stem cells",{"EARLY_PHASE1":3852,"PHASE1":3854,"PHASE2":3856,"PHASE3":3858,"PHASE4":3860,"NA":3862},{"trials":3853,"activeCount":100},[],{"trials":3855,"activeCount":100},[],{"trials":3857,"activeCount":100},[],{"trials":3859,"activeCount":100},[],{"trials":3861,"activeCount":100},[],{"trials":3863,"activeCount":118,"soonestReadout":677},[3864],{"nctId":3865,"briefTitle":3866,"status":124,"phases":3867,"primaryCompletion":677,"completion":1925,"start":3495,"enrollment":986,"conditions":3868,"interventions":3870},"NCT03403699","Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy",[],[3869,3498],"Diabetes Complications",[3850],{"intervention":3872,"totalTrials":118,"cells":3873},"Octafluoropropane",{"EARLY_PHASE1":3874,"PHASE1":3876,"PHASE2":3878,"PHASE3":3880,"PHASE4":3882,"NA":3884},{"trials":3875,"activeCount":100},[],{"trials":3877,"activeCount":100},[],{"trials":3879,"activeCount":100},[],{"trials":3881,"activeCount":100},[],{"trials":3883,"activeCount":100},[],{"trials":3885,"activeCount":118,"soonestReadout":875},[3886],{"nctId":3887,"briefTitle":3888,"status":124,"phases":3889,"primaryCompletion":875,"completion":875,"start":3890,"enrollment":1969,"conditions":3891,"interventions":3895},"NCT03203239","Red Light Treatment in Peripheral Artery Disease",[93],"2018-01-17",[3892,3893,3894],"Peripheral Artery Disease","Claudication, Intermittent","Vasodilation",[3872],{"intervention":1204,"totalTrials":906,"cells":3897},{"EARLY_PHASE1":3898,"PHASE1":3900,"PHASE2":3902,"PHASE3":3913,"PHASE4":3919,"NA":3929},{"trials":3899,"activeCount":100},[],{"trials":3901,"activeCount":100},[],{"trials":3903,"activeCount":100},[3904],{"nctId":3905,"briefTitle":3906,"status":917,"phases":3907,"primaryCompletion":3908,"completion":3908,"start":3909,"enrollment":271,"conditions":3910,"interventions":3911},"NCT03993314","Optimizing Anesthesia for Post Partum Tubal Ligations",[90],"2020-12-03","2019-08-13",[193],[3912,1204],"Chloroprocaine",{"trials":3914,"activeCount":100},[3915],{"nctId":1194,"briefTitle":1195,"status":1196,"phases":3916,"primaryCompletion":1198,"completion":1199,"start":1200,"enrollment":100,"conditions":3917,"interventions":3918},[91],[1202],[1204,1159],{"trials":3920,"activeCount":100},[3921,3925],{"nctId":1208,"briefTitle":1209,"status":166,"phases":3922,"primaryCompletion":1211,"completion":1212,"start":1213,"enrollment":1214,"conditions":3923,"interventions":3924},[92],[1216],[1204,1159],{"nctId":1219,"briefTitle":1220,"status":166,"phases":3926,"primaryCompletion":1222,"completion":1223,"start":1224,"enrollment":377,"conditions":3927,"interventions":3928},[92],[1202,1226],[1228,1229,1230,1231,1204,1232,1159],{"trials":3930,"activeCount":100},[],{"intervention":3932,"totalTrials":906,"cells":3933},"Ropivacaine",{"EARLY_PHASE1":3934,"PHASE1":3936,"PHASE2":3938,"PHASE3":3951,"PHASE4":3979,"NA":3991},{"trials":3935,"activeCount":100},[],{"trials":3937,"activeCount":100},[],{"trials":3939,"activeCount":100},[3940],{"nctId":3941,"briefTitle":3942,"status":917,"phases":3943,"primaryCompletion":3944,"completion":3944,"start":3945,"enrollment":3113,"conditions":3946,"interventions":3948},"NCT01986751","Effectiveness of Perineural Clonidine as an Adjuvant With Ropivacaine for Popliteal Nerve Block in Patients Undergoing Foot and Ankle Surgery",[89,90],"2015-12","2014-01",[3947],"Pain",[3949,3950],"Clonidine","ropivacaine",{"trials":3952,"activeCount":100},[3953,3968],{"nctId":3954,"briefTitle":3955,"status":917,"phases":3956,"primaryCompletion":3957,"completion":3957,"start":3958,"enrollment":1110,"conditions":3959,"interventions":3961},"NCT03098420","Dose Escalation of Dexamethasone to Increase Duration of Transversus Abdominal Plane Block Following Cesarean Section",[90,91],"2021-05-20","2016-07",[3960],"Post Surgical Pain",[3962,3963,3932,3964,3965,3966,3967],"2mg Dexamethasone","4mg Dexamethasone","Morphine","Bupivacaine Hydrochloride","Normal saline 1ml","Normal saline 0.5ml",{"nctId":3969,"briefTitle":3970,"status":1196,"phases":3971,"primaryCompletion":3972,"completion":3973,"start":3974,"enrollment":100,"conditions":3975,"interventions":3977},"NCT03187899","Superficial Cervical Plexus Blockade for Clavicle Fracture Analgesia",[91],"2018-07","2018-12","2018-04",[1202,3976],"Satisfaction",[3932,3978],"Normal saline",{"trials":3980,"activeCount":100},[3981],{"nctId":3982,"briefTitle":3983,"status":166,"phases":3984,"primaryCompletion":3985,"completion":3985,"start":3986,"enrollment":511,"conditions":3987,"interventions":3989},"NCT03738696","Liposomal Bupivacaine in Rotator Cuff Repair",[92],"2022-01-01","2019-12-15",[3988],"Rotator Cuff Injury",[3990,3932],"Exparel",{"trials":3992,"activeCount":100},[],{"intervention":3994,"totalTrials":963,"cells":3995},"methotrexate",{"EARLY_PHASE1":3996,"PHASE1":3998,"PHASE2":4012,"PHASE3":4024,"PHASE4":4026,"NA":4039},{"trials":3997,"activeCount":100},[],{"trials":3999,"activeCount":100},[4000],{"nctId":4001,"briefTitle":4002,"status":166,"phases":4003,"primaryCompletion":4004,"completion":4004,"start":4005,"enrollment":377,"conditions":4006,"interventions":4008},"NCT00004162","Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma",[89],"2001-01","1997-06",[4007],"Lymphoma",[4009,3994,4010,4011],"sargramostim","pegylated liposomal doxorubicin hydrochloride","vincristine sulfate",{"trials":4013,"activeCount":100},[4014],{"nctId":4015,"briefTitle":4016,"status":166,"phases":4017,"primaryCompletion":4018,"completion":4018,"start":4019,"enrollment":1969,"conditions":4020,"interventions":4022},"NCT00000395","Antifolate Effectiveness in Arthritis",[90],"2002-08","1996-09",[879,4021],"Adjuvant Arthritis",[4023],"Methotrexate",{"trials":4025,"activeCount":100},[],{"trials":4027,"activeCount":100},[4028],{"nctId":4029,"briefTitle":4030,"status":166,"phases":4031,"primaryCompletion":4032,"completion":4032,"start":1279,"enrollment":4033,"conditions":4034,"interventions":4035},"NCT00259610","Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)",[92],"2009-06",755,[879],[3994,4036,4037,4038],"sulfasalazine","hydroxychloroquine","etanercept",{"trials":4040,"activeCount":100},[],{"intervention":1229,"totalTrials":963,"cells":4042},{"EARLY_PHASE1":4043,"PHASE1":4045,"PHASE2":4047,"PHASE3":4049,"PHASE4":4051,"NA":4076},{"trials":4044,"activeCount":100},[],{"trials":4046,"activeCount":100},[],{"trials":4048,"activeCount":100},[],{"trials":4050,"activeCount":100},[],{"trials":4052,"activeCount":100},[4053,4064,4068],{"nctId":4054,"briefTitle":4055,"status":1196,"phases":4056,"primaryCompletion":4057,"completion":4058,"start":4059,"enrollment":100,"conditions":4060,"interventions":4061},"NCT03121963","Pain Management in Head and Neck Surgery Patients",[92],"2020-11-06","2021-11-06","2017-11-10",[1216],[1228,1229,1230,4062,4063],"Celecoxib","Hydrocodone-Acetaminophen",{"nctId":1219,"briefTitle":1220,"status":166,"phases":4065,"primaryCompletion":1222,"completion":1223,"start":1224,"enrollment":377,"conditions":4066,"interventions":4067},[92],[1202,1226],[1228,1229,1230,1231,1204,1232,1159],{"nctId":4069,"briefTitle":4070,"status":166,"phases":4071,"primaryCompletion":3958,"completion":3958,"start":4072,"enrollment":4073,"conditions":4074,"interventions":4075},"NCT02418182","A Randomized Controlled Trial of Oral Acetaminophen for Analgesic Control After Transvaginal Oocyte Retrieval",[92],"2015-01",99,[3947],[1229],{"trials":4077,"activeCount":100},[],{"intervention":4079,"totalTrials":96,"cells":4080},"Systane Complete",{"EARLY_PHASE1":4081,"PHASE1":4083,"PHASE2":4085,"PHASE3":4087,"PHASE4":4089,"NA":4112},{"trials":4082,"activeCount":100},[],{"trials":4084,"activeCount":100},[],{"trials":4086,"activeCount":100},[],{"trials":4088,"activeCount":100},[],{"trials":4090,"activeCount":100},[4091,4101],{"nctId":4092,"briefTitle":4093,"status":166,"phases":4094,"primaryCompletion":4095,"completion":4095,"start":4096,"enrollment":1214,"conditions":4097,"interventions":4100},"NCT03682809","Evaluation of Systane Complete for the Treatment of Contact Lens Discomfort",[92],"2019-03-23","2018-11-19",[4098,4099],"Contact Lens Discomfort","Dry Eye",[4079],{"nctId":4102,"briefTitle":4103,"status":166,"phases":4104,"primaryCompletion":4105,"completion":4105,"start":4106,"enrollment":4107,"conditions":4108,"interventions":4110},"NCT03848221","Direct Application of Systane Complete to Contact Lenses",[92],"2019-10-20","2019-05-28",73,[4099,4109],"Contact Lens Complication",[4079,4111],"Sensitive Eyes Rewetting Drops",{"trials":4113,"activeCount":100},[],{"intervention":4115,"totalTrials":96,"cells":4116},"Oxytocin",{"EARLY_PHASE1":4117,"PHASE1":4119,"PHASE2":4121,"PHASE3":4123,"PHASE4":4125,"NA":4145},{"trials":4118,"activeCount":100},[],{"trials":4120,"activeCount":100},[],{"trials":4122,"activeCount":100},[],{"trials":4124,"activeCount":100},[],{"trials":4126,"activeCount":100},[4127,4138],{"nctId":4128,"briefTitle":4129,"status":166,"phases":4130,"primaryCompletion":4131,"completion":4131,"start":4132,"enrollment":4133,"conditions":4134,"interventions":4137},"NCT00790062","Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT",[92],"2010-06","2008-11",1798,[4135,4136],"Uterine Atony","Postpartum Hemorrhage",[4115],{"nctId":4139,"briefTitle":4140,"status":166,"phases":4141,"primaryCompletion":1247,"completion":1247,"start":4131,"enrollment":1425,"conditions":4142,"interventions":4144},"NCT00919802","Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis",[92],[4143],"Interstitial Cystitis",[4115],{"trials":4146,"activeCount":100},[],{"intervention":4148,"totalTrials":96,"cells":4149},"inhaled Nitric Oxide",{"EARLY_PHASE1":4150,"PHASE1":4152,"PHASE2":4154,"PHASE3":4156,"PHASE4":4171,"NA":4186},{"trials":4151,"activeCount":100},[],{"trials":4153,"activeCount":100},[],{"trials":4155,"activeCount":100},[],{"trials":4157,"activeCount":100},[4158],{"nctId":4159,"briefTitle":4160,"status":166,"phases":4161,"primaryCompletion":4162,"completion":4163,"start":4164,"enrollment":1185,"conditions":4165,"interventions":4168},"NCT00582010","Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation",[90,91],"2009-03","2012-10","2008-04",[4166,4167],"Reperfusion Injury","Liver Injury",[4169,4170],"inhaled nitric oxide","nitrogen gas",{"trials":4172,"activeCount":100},[4173],{"nctId":4174,"briefTitle":4175,"status":166,"phases":4176,"primaryCompletion":4177,"completion":4177,"start":4178,"enrollment":4179,"conditions":4180,"interventions":4184},"NCT00732537","Inhaled Nitric Oxide by Oxygen Hood in Neonates",[92],"2005-06","1999-03",8,[4181,4182,4183],"Respiratory Failure","Infant","Persistent Fetal Circulation",[4148,4185],"Oxygen (>90% by hood) - standard therapy",{"trials":4187,"activeCount":100},[],{"intervention":1228,"totalTrials":96,"cells":4189},{"EARLY_PHASE1":4190,"PHASE1":4192,"PHASE2":4194,"PHASE3":4196,"PHASE4":4198,"NA":4208},{"trials":4191,"activeCount":100},[],{"trials":4193,"activeCount":100},[],{"trials":4195,"activeCount":100},[],{"trials":4197,"activeCount":100},[],{"trials":4199,"activeCount":100},[4200,4204],{"nctId":4054,"briefTitle":4055,"status":1196,"phases":4201,"primaryCompletion":4057,"completion":4058,"start":4059,"enrollment":100,"conditions":4202,"interventions":4203},[92],[1216],[1228,1229,1230,4062,4063],{"nctId":1219,"briefTitle":1220,"status":166,"phases":4205,"primaryCompletion":1222,"completion":1223,"start":1224,"enrollment":377,"conditions":4206,"interventions":4207},[92],[1202,1226],[1228,1229,1230,1231,1204,1232,1159],{"trials":4209,"activeCount":100},[],{"intervention":1230,"totalTrials":96,"cells":4211},{"EARLY_PHASE1":4212,"PHASE1":4214,"PHASE2":4216,"PHASE3":4218,"PHASE4":4220,"NA":4230},{"trials":4213,"activeCount":100},[],{"trials":4215,"activeCount":100},[],{"trials":4217,"activeCount":100},[],{"trials":4219,"activeCount":100},[],{"trials":4221,"activeCount":100},[4222,4226],{"nctId":4054,"briefTitle":4055,"status":1196,"phases":4223,"primaryCompletion":4057,"completion":4058,"start":4059,"enrollment":100,"conditions":4224,"interventions":4225},[92],[1216],[1228,1229,1230,4062,4063],{"nctId":1219,"briefTitle":1220,"status":166,"phases":4227,"primaryCompletion":1222,"completion":1223,"start":1224,"enrollment":377,"conditions":4228,"interventions":4229},[92],[1202,1226],[1228,1229,1230,1231,1204,1232,1159],{"trials":4231,"activeCount":100},[],{"intervention":4233,"totalTrials":96,"cells":4234},"Lifitegrast",{"EARLY_PHASE1":4235,"PHASE1":4237,"PHASE2":4239,"PHASE3":4241,"PHASE4":4243,"NA":4266},{"trials":4236,"activeCount":100},[],{"trials":4238,"activeCount":100},[],{"trials":4240,"activeCount":100},[],{"trials":4242,"activeCount":100},[],{"trials":4244,"activeCount":100},[4245,4255],{"nctId":4246,"briefTitle":4247,"status":1196,"phases":4248,"primaryCompletion":4249,"completion":4250,"start":4251,"enrollment":100,"conditions":4252,"interventions":4254},"NCT03431272","Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers",[92],"2018-12-31","2019-12-31","2018-11-01",[4253],"Contact Lens Dry Eye",[4233],{"nctId":4256,"briefTitle":4257,"status":1196,"phases":4258,"primaryCompletion":4259,"completion":4259,"start":4260,"enrollment":100,"conditions":4261,"interventions":4265},"NCT03408015","Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease",[92],"2019-01-30","2019-01",[4262,4263,4099,4109,4264],"Ocular Discomfort","Ocular Inflammation","Keratoconjunctivitis Sicca",[4233],{"trials":4267,"activeCount":100},[],{"intervention":4269,"totalTrials":96,"cells":4270},"Baclofen 10mg",{"EARLY_PHASE1":4271,"PHASE1":4273,"PHASE2":4275,"PHASE3":4277,"PHASE4":4291,"NA":4302},{"trials":4272,"activeCount":100},[],{"trials":4274,"activeCount":100},[],{"trials":4276,"activeCount":100},[],{"trials":4278,"activeCount":100},[4279],{"nctId":4280,"briefTitle":4281,"status":917,"phases":4282,"primaryCompletion":4283,"completion":4283,"start":4284,"enrollment":30,"conditions":4285,"interventions":4288},"NCT04251819","Buprenorphine Plus Baclofen to Increase Analgesia in Healthy Volunteers",[90,91],"2024-06-15","2021-01-21",[4286,4287],"Acute Pain","Analgesia",[4289,4290,4269],"Placebos","Baclofen 5 mg",{"trials":4292,"activeCount":100},[4293],{"nctId":4294,"briefTitle":4295,"status":917,"phases":4296,"primaryCompletion":4297,"completion":4297,"start":4298,"enrollment":4299,"conditions":4300,"interventions":4301},"NCT03720717","Baclofen as a Perioperative Analgesic Adjuvant",[92],"2022-10-28","2020-10-27",34,[3947],[4269],{"trials":4303,"activeCount":100},[],{"intervention":4305,"totalTrials":96,"cells":4306},"Saline",{"EARLY_PHASE1":4307,"PHASE1":4309,"PHASE2":4311,"PHASE3":4313,"PHASE4":4326,"NA":4339},{"trials":4308,"activeCount":100},[],{"trials":4310,"activeCount":100},[],{"trials":4312,"activeCount":100},[],{"trials":4314,"activeCount":100},[4315],{"nctId":4316,"briefTitle":4317,"status":1196,"phases":4318,"primaryCompletion":4319,"completion":4320,"start":4321,"enrollment":100,"conditions":4322,"interventions":4324},"NCT03331146","Nitrite Infusion in High Risk Patients Undergoing Cardiopulmonary Bypass",[91],"2019-06-01","2020-12-01","2018-10-01",[4323],"Acute Kidney Injury",[4305,4325],"Sodium Nitrite",{"trials":4327,"activeCount":100},[4328],{"nctId":4329,"briefTitle":4330,"status":917,"phases":4331,"primaryCompletion":4332,"completion":4332,"start":4333,"enrollment":3113,"conditions":4334,"interventions":4337},"NCT01381926","Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist",[92],"2015-08","2011-02",[4335,4336],"Type 2 Diabetes Mellitus","Bone Remodeling",[4338,4305],"exenatide",{"trials":4340,"activeCount":100},[],{"intervention":4038,"totalTrials":96,"cells":4342},{"EARLY_PHASE1":4343,"PHASE1":4345,"PHASE2":4347,"PHASE3":4349,"PHASE4":4351,"NA":4368},{"trials":4344,"activeCount":100},[],{"trials":4346,"activeCount":100},[],{"trials":4348,"activeCount":100},[],{"trials":4350,"activeCount":100},[],{"trials":4352,"activeCount":100},[4353,4357],{"nctId":4029,"briefTitle":4030,"status":166,"phases":4354,"primaryCompletion":4032,"completion":4032,"start":1279,"enrollment":4033,"conditions":4355,"interventions":4356},[92],[879],[3994,4036,4037,4038],{"nctId":4358,"briefTitle":4359,"status":166,"phases":4360,"primaryCompletion":4361,"completion":4361,"start":4362,"enrollment":921,"conditions":4363,"interventions":4367},"NCT01053819","Can We Miss Pigmented Lesions in Psoriasis Patients?",[92],"2012-04","2007-09",[4364,4365,4366],"Psoriasis","Melanoma","Non-melanoma Skin Cancer",[4038],{"trials":4369,"activeCount":100},[],{"intervention":4371,"totalTrials":118,"cells":4372},"Jublia",{"EARLY_PHASE1":4373,"PHASE1":4375,"PHASE2":4377,"PHASE3":4379,"PHASE4":4381,"NA":4392},{"trials":4374,"activeCount":100},[],{"trials":4376,"activeCount":100},[],{"trials":4378,"activeCount":100},[],{"trials":4380,"activeCount":100},[],{"trials":4382,"activeCount":100},[4383],{"nctId":4384,"briefTitle":4385,"status":166,"phases":4386,"primaryCompletion":4387,"completion":3972,"start":1247,"enrollment":30,"conditions":4388,"interventions":4391},"NCT03098615","Study Evaluating the Effect of Jublia on Dermatophytomas",[92],"2017-05",[4389,4390],"Onychomycosis","Dermatophytosis",[4371],{"trials":4393,"activeCount":100},[],{"intervention":4395,"totalTrials":118,"cells":4396},"Chlorhexidine Gluconate 2% Wipe",{"EARLY_PHASE1":4397,"PHASE1":4399,"PHASE2":4401,"PHASE3":4403,"PHASE4":4405,"NA":4415},{"trials":4398,"activeCount":100},[],{"trials":4400,"activeCount":100},[],{"trials":4402,"activeCount":100},[],{"trials":4404,"activeCount":100},[],{"trials":4406,"activeCount":100},[4407],{"nctId":4408,"briefTitle":4409,"status":917,"phases":4410,"primaryCompletion":4320,"completion":4320,"start":4251,"enrollment":4411,"conditions":4412,"interventions":4414},"NCT03401749","Preadmission Skin Wipe Use for Surgical Site Infection Prophylaxis in Adult Orthopaedic Surgery Patients",[92],203,[4413],"Surgical Site Infection",[4395],{"trials":4416,"activeCount":100},[],{"intervention":4418,"totalTrials":118,"cells":4419},"Symdeko",{"EARLY_PHASE1":4420,"PHASE1":4422,"PHASE2":4424,"PHASE3":4426,"PHASE4":4428,"NA":4439},{"trials":4421,"activeCount":100},[],{"trials":4423,"activeCount":100},[],{"trials":4425,"activeCount":100},[],{"trials":4427,"activeCount":100},[],{"trials":4429,"activeCount":100},[4430],{"nctId":4431,"briefTitle":4432,"status":917,"phases":4433,"primaryCompletion":4434,"completion":4434,"start":4435,"enrollment":118,"conditions":4436,"interventions":4437},"NCT03624101","Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations",[92],"2019-10-03","2018-12-01",[35],[4418,4438],"Ivacaftor and Symdeko",{"trials":4440,"activeCount":100},[],{"intervention":4438,"totalTrials":118,"cells":4442},{"EARLY_PHASE1":4443,"PHASE1":4445,"PHASE2":4447,"PHASE3":4449,"PHASE4":4451,"NA":4457},{"trials":4444,"activeCount":100},[],{"trials":4446,"activeCount":100},[],{"trials":4448,"activeCount":100},[],{"trials":4450,"activeCount":100},[],{"trials":4452,"activeCount":100},[4453],{"nctId":4431,"briefTitle":4432,"status":917,"phases":4454,"primaryCompletion":4434,"completion":4434,"start":4435,"enrollment":118,"conditions":4455,"interventions":4456},[92],[35],[4418,4438],{"trials":4458,"activeCount":100},[],{"intervention":4460,"totalTrials":118,"cells":4461},"Ivacaftor\u002FAtaluren",{"EARLY_PHASE1":4462,"PHASE1":4464,"PHASE2":4466,"PHASE3":4468,"PHASE4":4470,"NA":4481},{"trials":4463,"activeCount":100},[],{"trials":4465,"activeCount":100},[],{"trials":4467,"activeCount":100},[],{"trials":4469,"activeCount":100},[],{"trials":4471,"activeCount":100},[4472],{"nctId":4473,"briefTitle":4474,"status":166,"phases":4475,"primaryCompletion":4476,"completion":4477,"start":4478,"enrollment":118,"conditions":4479,"interventions":4480},"NCT03256799","Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations",[92],"2017-07-10","2018-02-16","2017-03-17",[35],[4460],{"trials":4482,"activeCount":100},[],{"intervention":4484,"totalTrials":118,"cells":4485},"Systane Hydration PF",{"EARLY_PHASE1":4486,"PHASE1":4488,"PHASE2":4490,"PHASE3":4492,"PHASE4":4494,"NA":4504},{"trials":4487,"activeCount":100},[],{"trials":4489,"activeCount":100},[],{"trials":4491,"activeCount":100},[],{"trials":4493,"activeCount":100},[],{"trials":4495,"activeCount":100},[4496],{"nctId":4497,"briefTitle":4498,"status":166,"phases":4499,"primaryCompletion":4500,"completion":4500,"start":4501,"enrollment":19,"conditions":4502,"interventions":4503},"NCT04837807","Digital Device Users Who Are Treated With Systane Hydration PF",[92],"2021-11-19","2021-08-18",[4099],[4484],{"trials":4505,"activeCount":100},[],{"intervention":4111,"totalTrials":118,"cells":4507},{"EARLY_PHASE1":4508,"PHASE1":4510,"PHASE2":4512,"PHASE3":4514,"PHASE4":4516,"NA":4522},{"trials":4509,"activeCount":100},[],{"trials":4511,"activeCount":100},[],{"trials":4513,"activeCount":100},[],{"trials":4515,"activeCount":100},[],{"trials":4517,"activeCount":100},[4518],{"nctId":4102,"briefTitle":4103,"status":166,"phases":4519,"primaryCompletion":4105,"completion":4105,"start":4106,"enrollment":4107,"conditions":4520,"interventions":4521},[92],[4099,4109],[4079,4111],{"trials":4523,"activeCount":100},[],{"intervention":4525,"totalTrials":118,"cells":4526},"tenofovir",{"EARLY_PHASE1":4527,"PHASE1":4529,"PHASE2":4531,"PHASE3":4533,"PHASE4":4535,"NA":4547},{"trials":4528,"activeCount":100},[],{"trials":4530,"activeCount":100},[],{"trials":4532,"activeCount":100},[],{"trials":4534,"activeCount":100},[],{"trials":4536,"activeCount":100},[4537],{"nctId":4538,"briefTitle":4539,"status":166,"phases":4540,"primaryCompletion":4541,"completion":4541,"start":4162,"enrollment":942,"conditions":4542,"interventions":4543},"NCT00869960","Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women",[92],"2010-12",[2462],[4525,4544,4545,4546],"emtricitabine","atazanavir","ritonavir",{"trials":4548,"activeCount":100},[],{"intervention":4544,"totalTrials":118,"cells":4550},{"EARLY_PHASE1":4551,"PHASE1":4553,"PHASE2":4555,"PHASE3":4557,"PHASE4":4559,"NA":4565},{"trials":4552,"activeCount":100},[],{"trials":4554,"activeCount":100},[],{"trials":4556,"activeCount":100},[],{"trials":4558,"activeCount":100},[],{"trials":4560,"activeCount":100},[4561],{"nctId":4538,"briefTitle":4539,"status":166,"phases":4562,"primaryCompletion":4541,"completion":4541,"start":4162,"enrollment":942,"conditions":4563,"interventions":4564},[92],[2462],[4525,4544,4545,4546],{"trials":4566,"activeCount":100},[],{"intervention":4545,"totalTrials":118,"cells":4568},{"EARLY_PHASE1":4569,"PHASE1":4571,"PHASE2":4573,"PHASE3":4575,"PHASE4":4577,"NA":4583},{"trials":4570,"activeCount":100},[],{"trials":4572,"activeCount":100},[],{"trials":4574,"activeCount":100},[],{"trials":4576,"activeCount":100},[],{"trials":4578,"activeCount":100},[4579],{"nctId":4538,"briefTitle":4539,"status":166,"phases":4580,"primaryCompletion":4541,"completion":4541,"start":4162,"enrollment":942,"conditions":4581,"interventions":4582},[92],[2462],[4525,4544,4545,4546],{"trials":4584,"activeCount":100},[],{"intervention":4546,"totalTrials":118,"cells":4586},{"EARLY_PHASE1":4587,"PHASE1":4589,"PHASE2":4591,"PHASE3":4593,"PHASE4":4595,"NA":4601},{"trials":4588,"activeCount":100},[],{"trials":4590,"activeCount":100},[],{"trials":4592,"activeCount":100},[],{"trials":4594,"activeCount":100},[],{"trials":4596,"activeCount":100},[4597],{"nctId":4538,"briefTitle":4539,"status":166,"phases":4598,"primaryCompletion":4541,"completion":4541,"start":4162,"enrollment":942,"conditions":4599,"interventions":4600},[92],[2462],[4525,4544,4545,4546],{"trials":4602,"activeCount":100},[],{"intervention":4604,"totalTrials":118,"cells":4605},"HydroEye®",{"EARLY_PHASE1":4606,"PHASE1":4608,"PHASE2":4610,"PHASE3":4612,"PHASE4":4614,"NA":4624},{"trials":4607,"activeCount":100},[],{"trials":4609,"activeCount":100},[],{"trials":4611,"activeCount":100},[],{"trials":4613,"activeCount":100},[],{"trials":4615,"activeCount":100},[4616],{"nctId":4617,"briefTitle":4618,"status":917,"phases":4619,"primaryCompletion":4620,"completion":4620,"start":4621,"enrollment":1015,"conditions":4622,"interventions":4623},"NCT04163328","Effects of Supplementation With PUFAs and Antioxidants for Contact Lens Discomfort",[92],"2024-08-21","2022-09-16",[4099,4109],[4604],{"trials":4625,"activeCount":100},[],{"intervention":4627,"totalTrials":118,"cells":4628},"tinidazole, metronidazole",{"EARLY_PHASE1":4629,"PHASE1":4631,"PHASE2":4633,"PHASE3":4635,"PHASE4":4637,"NA":4649},{"trials":4630,"activeCount":100},[],{"trials":4632,"activeCount":100},[],{"trials":4634,"activeCount":100},[],{"trials":4636,"activeCount":100},[],{"trials":4638,"activeCount":100},[4639],{"nctId":4640,"briefTitle":4641,"status":166,"phases":4642,"primaryCompletion":4643,"completion":4643,"start":4644,"enrollment":4645,"conditions":4646,"interventions":4648},"NCT00334633","Treatment of Bacterial Vaginosis (BV) With Tinidazole",[92],"2009-12","2004-11",593,[4647],"Bacterial Vaginosis",[4627],{"trials":4650,"activeCount":100},[],{"intervention":4652,"totalTrials":118,"cells":4653},"Microcyn",{"EARLY_PHASE1":4654,"PHASE1":4656,"PHASE2":4658,"PHASE3":4660,"PHASE4":4662,"NA":4675},{"trials":4655,"activeCount":100},[],{"trials":4657,"activeCount":100},[],{"trials":4659,"activeCount":100},[],{"trials":4661,"activeCount":100},[],{"trials":4663,"activeCount":100},[4664],{"nctId":4665,"briefTitle":4666,"status":166,"phases":4667,"primaryCompletion":4668,"completion":4668,"start":4669,"enrollment":4670,"conditions":4671,"interventions":4674},"NCT02001558","Pressure Ulcer Healing With Microcyn",[92],"2017-08","2013-03",65,[4672,4673],"Pressure Ulcer","Spinal Cord Injuries",[4652],{"trials":4676,"activeCount":100},[],{"intervention":4678,"totalTrials":118,"cells":4679},"Gardasil9",{"EARLY_PHASE1":4680,"PHASE1":4682,"PHASE2":4684,"PHASE3":4686,"PHASE4":4688,"NA":4701},{"trials":4681,"activeCount":100},[],{"trials":4683,"activeCount":100},[],{"trials":4685,"activeCount":100},[],{"trials":4687,"activeCount":100},[],{"trials":4689,"activeCount":100},[4690],{"nctId":4691,"briefTitle":4692,"status":166,"phases":4693,"primaryCompletion":4694,"completion":4695,"start":4696,"enrollment":4697,"conditions":4698,"interventions":4700},"NCT03451071","Postpartum HPV Vaccination",[92],"2020-06-01","2020-12-30","2019-04-29",195,[4699],"HPV-Related Malignancy",[4678],{"trials":4702,"activeCount":100},[],{"intervention":4704,"totalTrials":118,"cells":4705},"Venlafaxine",{"EARLY_PHASE1":4706,"PHASE1":4708,"PHASE2":4710,"PHASE3":4712,"PHASE4":4714,"NA":4725},{"trials":4707,"activeCount":100},[],{"trials":4709,"activeCount":100},[],{"trials":4711,"activeCount":100},[],{"trials":4713,"activeCount":100},[],{"trials":4715,"activeCount":100},[4716],{"nctId":4717,"briefTitle":4718,"status":1196,"phases":4719,"primaryCompletion":4720,"completion":4720,"start":4721,"enrollment":100,"conditions":4722,"interventions":4724},"NCT04977271","Mood Disorders in Head and Neck Cancer Patients",[92],"2024-10-01","2024-01-05",[4723,1427],"Depressive Disorder",[4704],{"trials":4726,"activeCount":100},[],{"intervention":4728,"totalTrials":118,"cells":4729},"Crysvita (burosumab-twza) Treatment",{"EARLY_PHASE1":4730,"PHASE1":4732,"PHASE2":4734,"PHASE3":4736,"PHASE4":4738,"NA":4749},{"trials":4731,"activeCount":100},[],{"trials":4733,"activeCount":100},[],{"trials":4735,"activeCount":100},[],{"trials":4737,"activeCount":100},[],{"trials":4739,"activeCount":100},[4740],{"nctId":4741,"briefTitle":4742,"status":166,"phases":4743,"primaryCompletion":4744,"completion":3574,"start":4745,"enrollment":118,"conditions":4746,"interventions":4748},"NCT04320316","A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)",[92],"2021-07-31","2020-07-31",[4747],"Epidermal Nevus Syndrome",[4728],{"trials":4750,"activeCount":100},[],{"intervention":4185,"totalTrials":118,"cells":4752},{"EARLY_PHASE1":4753,"PHASE1":4755,"PHASE2":4757,"PHASE3":4759,"PHASE4":4761,"NA":4767},{"trials":4754,"activeCount":100},[],{"trials":4756,"activeCount":100},[],{"trials":4758,"activeCount":100},[],{"trials":4760,"activeCount":100},[],{"trials":4762,"activeCount":100},[4763],{"nctId":4174,"briefTitle":4175,"status":166,"phases":4764,"primaryCompletion":4177,"completion":4177,"start":4178,"enrollment":4179,"conditions":4765,"interventions":4766},[92],[4181,4182,4183],[4148,4185],{"trials":4768,"activeCount":100},[],{"intervention":4770,"totalTrials":118,"cells":4771},"Ataluren",{"EARLY_PHASE1":4772,"PHASE1":4774,"PHASE2":4776,"PHASE3":4778,"PHASE4":4780,"NA":4789},{"trials":4773,"activeCount":100},[],{"trials":4775,"activeCount":100},[],{"trials":4777,"activeCount":100},[],{"trials":4779,"activeCount":100},[],{"trials":4781,"activeCount":100},[4782],{"nctId":4783,"briefTitle":4784,"status":166,"phases":4785,"primaryCompletion":4435,"completion":4249,"start":4786,"enrollment":118,"conditions":4787,"interventions":4788},"NCT03256968","PTC Study to Evaluate Ataluren in Combination With Ivacaftor",[92],"2017-01-27",[35],[4770],{"trials":4790,"activeCount":100},[],{"intervention":4792,"totalTrials":118,"cells":4793},"Recommendation and Counseling for Alcohol Pharmacotherapy",{"EARLY_PHASE1":4794,"PHASE1":4796,"PHASE2":4798,"PHASE3":4800,"PHASE4":4802,"NA":4814},{"trials":4795,"activeCount":100},[],{"trials":4797,"activeCount":100},[],{"trials":4799,"activeCount":100},[],{"trials":4801,"activeCount":100},[],{"trials":4803,"activeCount":100},[4804],{"nctId":4805,"briefTitle":4806,"status":166,"phases":4807,"primaryCompletion":3821,"completion":270,"start":4808,"enrollment":4809,"conditions":4810,"interventions":4813},"NCT02938377","Alcohol Research Consortium in HIV-Intervention Research Arm",[92],"2017-11-06",4985,[4811,4812],"HIV Positive","Alcohol Use",[4792],{"trials":4815,"activeCount":100},[],{"intervention":4817,"totalTrials":118,"cells":4818},"Algorithm Treatment",{"EARLY_PHASE1":4819,"PHASE1":4821,"PHASE2":4823,"PHASE3":4825,"PHASE4":4827,"NA":4839},{"trials":4820,"activeCount":100},[],{"trials":4822,"activeCount":100},[],{"trials":4824,"activeCount":100},[],{"trials":4826,"activeCount":100},[],{"trials":4828,"activeCount":100},[4829],{"nctId":4830,"briefTitle":4831,"status":166,"phases":4832,"primaryCompletion":189,"completion":189,"start":4833,"enrollment":4834,"conditions":4835,"interventions":4838},"NCT03670316","Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care",[92],"2020-08-17",371,[27,4836,4837],"AIDS","Smoking Cessation",[4817],{"trials":4840,"activeCount":100},[],{"intervention":4842,"totalTrials":118,"cells":4843},"aliskiren 300 mg once daily",{"EARLY_PHASE1":4844,"PHASE1":4846,"PHASE2":4848,"PHASE3":4850,"PHASE4":4852,"NA":4864},{"trials":4845,"activeCount":100},[],{"trials":4847,"activeCount":100},[],{"trials":4849,"activeCount":100},[],{"trials":4851,"activeCount":100},[],{"trials":4853,"activeCount":100},[4854],{"nctId":4855,"briefTitle":4856,"status":917,"phases":4857,"primaryCompletion":4858,"completion":4858,"start":4859,"enrollment":1050,"conditions":4860,"interventions":4863},"NCT01349114","Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects",[92],"2012-01","2011-06",[4861,4862,18],"Diabetes","Pre-hypertension",[4842],{"trials":4865,"activeCount":100},[],{"intervention":4867,"totalTrials":118,"cells":4868},"Opioid Overdose Education with Naloxone Distribution",{"EARLY_PHASE1":4869,"PHASE1":4871,"PHASE2":4873,"PHASE3":4875,"PHASE4":4877,"NA":4890},{"trials":4870,"activeCount":100},[],{"trials":4872,"activeCount":100},[],{"trials":4874,"activeCount":100},[],{"trials":4876,"activeCount":100},[],{"trials":4878,"activeCount":100},[4879],{"nctId":4880,"briefTitle":4881,"status":166,"phases":4882,"primaryCompletion":4883,"completion":4883,"start":4884,"enrollment":4885,"conditions":4886,"interventions":4888},"NCT04303000","Increasing Naloxone Access for Persons Who Use Opioids",[92],"2022-01-13","2021-07-11",111,[4887],"Naloxone",[4867,4889],"Opioid Overdose Education",{"trials":4891,"activeCount":100},[],{"intervention":4889,"totalTrials":118,"cells":4893},{"EARLY_PHASE1":4894,"PHASE1":4896,"PHASE2":4898,"PHASE3":4900,"PHASE4":4902,"NA":4908},{"trials":4895,"activeCount":100},[],{"trials":4897,"activeCount":100},[],{"trials":4899,"activeCount":100},[],{"trials":4901,"activeCount":100},[],{"trials":4903,"activeCount":100},[4904],{"nctId":4880,"briefTitle":4881,"status":166,"phases":4905,"primaryCompletion":4883,"completion":4883,"start":4884,"enrollment":4885,"conditions":4906,"interventions":4907},[92],[4887],[4867,4889],{"trials":4909,"activeCount":100},[],{"intervention":4911,"totalTrials":118,"cells":4912},"Intravenous Ketamine",{"EARLY_PHASE1":4913,"PHASE1":4915,"PHASE2":4917,"PHASE3":4919,"PHASE4":4921,"NA":4938},{"trials":4914,"activeCount":100},[],{"trials":4916,"activeCount":100},[],{"trials":4918,"activeCount":100},[],{"trials":4920,"activeCount":100},[],{"trials":4922,"activeCount":100},[4923],{"nctId":4924,"briefTitle":4925,"status":917,"phases":4926,"primaryCompletion":4927,"completion":4928,"start":4929,"enrollment":1969,"conditions":4930,"interventions":4936},"NCT03781817","Intranasal Versus Intravenous Ketamine for Procedural Sedation in Children With Non-operative Fractures",[92],"2022-01-21","2022-04-30","2019-09-09",[4931,4932,4933,4934,4935],"Trauma","Fractures, Closed","Children, Only","Deep Sedation","Ketamine",[4911,4937],"Intranasal Ketamine",{"trials":4939,"activeCount":100},[],{"intervention":4937,"totalTrials":118,"cells":4941},{"EARLY_PHASE1":4942,"PHASE1":4944,"PHASE2":4946,"PHASE3":4948,"PHASE4":4950,"NA":4956},{"trials":4943,"activeCount":100},[],{"trials":4945,"activeCount":100},[],{"trials":4947,"activeCount":100},[],{"trials":4949,"activeCount":100},[],{"trials":4951,"activeCount":100},[4952],{"nctId":4924,"briefTitle":4925,"status":917,"phases":4953,"primaryCompletion":4927,"completion":4928,"start":4929,"enrollment":1969,"conditions":4954,"interventions":4955},[92],[4931,4932,4933,4934,4935],[4911,4937],{"trials":4957,"activeCount":100},[],{"intervention":4959,"totalTrials":118,"cells":4960},"TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION",{"EARLY_PHASE1":4961,"PHASE1":4963,"PHASE2":4965,"PHASE3":4967,"PHASE4":4969,"NA":4983},{"trials":4962,"activeCount":100},[],{"trials":4964,"activeCount":100},[],{"trials":4966,"activeCount":100},[],{"trials":4968,"activeCount":100},[],{"trials":4970,"activeCount":100},[4971],{"nctId":4972,"briefTitle":4973,"status":166,"phases":4974,"primaryCompletion":4975,"completion":4976,"start":4977,"enrollment":4978,"conditions":4979,"interventions":4982},"NCT05474027","Reducing Hypotensive Anesthesia Use With TXA During Orthognathic Surgery",[92],"2025-11-11","2025-12-01","2022-11-11",115,[4980,4981],"Hypotension During Surgery","Blood Loss, Surgical",[4959],{"trials":4984,"activeCount":100},[],{"intervention":4986,"totalTrials":118,"cells":4987},"metronidazole and azithromycin",{"EARLY_PHASE1":4988,"PHASE1":4990,"PHASE2":4992,"PHASE3":4994,"PHASE4":4996,"NA":5007},{"trials":4989,"activeCount":100},[],{"trials":4991,"activeCount":100},[],{"trials":4993,"activeCount":100},[],{"trials":4995,"activeCount":100},[],{"trials":4997,"activeCount":100},[4998],{"nctId":4999,"briefTitle":5000,"status":166,"phases":5001,"primaryCompletion":5002,"completion":5002,"start":5003,"enrollment":5004,"conditions":5005,"interventions":5006},"NCT00324818","Treatment of Bacterial Vaginosis",[92],"2006-05","2002-07",600,[4647],[4986],{"trials":5008,"activeCount":100},[],{"intervention":3990,"totalTrials":118,"cells":5010},{"EARLY_PHASE1":5011,"PHASE1":5013,"PHASE2":5015,"PHASE3":5017,"PHASE4":5019,"NA":5025},{"trials":5012,"activeCount":100},[],{"trials":5014,"activeCount":100},[],{"trials":5016,"activeCount":100},[],{"trials":5018,"activeCount":100},[],{"trials":5020,"activeCount":100},[5021],{"nctId":3982,"briefTitle":3983,"status":166,"phases":5022,"primaryCompletion":3985,"completion":3985,"start":3986,"enrollment":511,"conditions":5023,"interventions":5024},[92],[3988],[3990,3932],{"trials":5026,"activeCount":100},[],{"intervention":5028,"totalTrials":118,"cells":5029},"combination NRT",{"EARLY_PHASE1":5030,"PHASE1":5032,"PHASE2":5034,"PHASE3":5036,"PHASE4":5038,"NA":5049},{"trials":5031,"activeCount":100},[],{"trials":5033,"activeCount":100},[],{"trials":5035,"activeCount":100},[],{"trials":5037,"activeCount":100},[],{"trials":5039,"activeCount":100},[5040],{"nctId":5041,"briefTitle":5042,"status":166,"phases":5043,"primaryCompletion":5044,"completion":5045,"start":5046,"enrollment":1185,"conditions":5047,"interventions":5048},"NCT03276780","Nicotine Replacement Therapy (NRT) Sampling and Selection to Increase Medication Adherence",[92],"2020-05-31","2020-10-31","2018-05-03",[4837],[5028],{"trials":5050,"activeCount":100},[],{"intervention":5052,"totalTrials":118,"cells":5053},"DMAB Discontinuation and Switching",{"EARLY_PHASE1":5054,"PHASE1":5056,"PHASE2":5058,"PHASE3":5060,"PHASE4":5062,"NA":5073},{"trials":5055,"activeCount":100},[],{"trials":5057,"activeCount":100},[],{"trials":5059,"activeCount":100},[],{"trials":5061,"activeCount":100},[],{"trials":5063,"activeCount":100},[5064],{"nctId":5065,"briefTitle":5066,"status":166,"phases":5067,"primaryCompletion":5068,"completion":5069,"start":4833,"enrollment":1089,"conditions":5070,"interventions":5072},"NCT04177940","Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study",[92],"2024-07-22","2025-01-14",[5071],"Osteoporosis",[5052],{"trials":5074,"activeCount":100},[],{"intervention":5076,"totalTrials":118,"cells":5077},"sitagliptin",{"EARLY_PHASE1":5078,"PHASE1":5080,"PHASE2":5082,"PHASE3":5084,"PHASE4":5086,"NA":5096},{"trials":5079,"activeCount":100},[],{"trials":5081,"activeCount":100},[],{"trials":5083,"activeCount":100},[],{"trials":5085,"activeCount":100},[],{"trials":5087,"activeCount":100},[5088],{"nctId":5089,"briefTitle":5090,"status":917,"phases":5091,"primaryCompletion":5092,"completion":1247,"start":5093,"enrollment":921,"conditions":5094,"interventions":5095},"NCT01374568","Changes in Bone Turnover With Increased Incretin Hormone Exposure",[92],"2012-07-06","2010-07",[4335],[5076],{"trials":5097,"activeCount":100},[],{"intervention":5099,"totalTrials":118,"cells":5100},"repository corticotropin",{"EARLY_PHASE1":5101,"PHASE1":5103,"PHASE2":5105,"PHASE3":5107,"PHASE4":5109,"NA":5117},{"trials":5102,"activeCount":100},[],{"trials":5104,"activeCount":100},[],{"trials":5106,"activeCount":100},[],{"trials":5108,"activeCount":100},[],{"trials":5110,"activeCount":100},[5111],{"nctId":5112,"briefTitle":5113,"status":1196,"phases":5114,"primaryCompletion":4251,"completion":4251,"start":4251,"enrollment":100,"conditions":5115,"interventions":5116},"NCT03398018","Repository Corticotropin Injection in Keratoconjunctivitis Sicca",[92],[4264],[5099],{"trials":5118,"activeCount":100},[],{"intervention":5120,"totalTrials":118,"cells":5121},"Azithromycin and amoxicillin",{"EARLY_PHASE1":5122,"PHASE1":5124,"PHASE2":5126,"PHASE3":5128,"PHASE4":5130,"NA":5146},{"trials":5123,"activeCount":100},[],{"trials":5125,"activeCount":100},[],{"trials":5127,"activeCount":100},[],{"trials":5129,"activeCount":100},[],{"trials":5131,"activeCount":100},[5132],{"nctId":5133,"briefTitle":5134,"status":166,"phases":5135,"primaryCompletion":5136,"completion":5137,"start":5138,"enrollment":5139,"conditions":5140,"interventions":5144},"NCT03248297","Antibiotic Prophlaxis for High-risk Laboring Women in Low Income Countries",[92],"2020-05-15","2020-10-01","2018-01-12",756,[5141,5142,5143],"Postpartum Sepsis","Postpartum Endometritis","Postpartum Fever",[5145,5120],"Azithromycin",{"trials":5147,"activeCount":100},[],{"intervention":5149,"totalTrials":118,"cells":5150},"Anti-hypertensive therapy",{"EARLY_PHASE1":5151,"PHASE1":5153,"PHASE2":5155,"PHASE3":5157,"PHASE4":5159,"NA":5171},{"trials":5152,"activeCount":100},[],{"trials":5154,"activeCount":100},[],{"trials":5156,"activeCount":100},[],{"trials":5158,"activeCount":100},[],{"trials":5160,"activeCount":100},[5161],{"nctId":5162,"briefTitle":5163,"status":166,"phases":5164,"primaryCompletion":5165,"completion":5166,"start":5167,"enrollment":5168,"conditions":5169,"interventions":5170},"NCT02299414","Chronic Hypertension and Pregnancy (CHAP) Project",[92],"2022-04-01","2022-12-16","2015-06",2408,[18],[5149],{"trials":5172,"activeCount":100},[],{"intervention":5174,"totalTrials":118,"cells":5175},"Varenicline",{"EARLY_PHASE1":5176,"PHASE1":5178,"PHASE2":5180,"PHASE3":5182,"PHASE4":5184,"NA":5195},{"trials":5177,"activeCount":100},[],{"trials":5179,"activeCount":100},[],{"trials":5181,"activeCount":100},[],{"trials":5183,"activeCount":100},[],{"trials":5185,"activeCount":100},[5186],{"nctId":5187,"briefTitle":5188,"status":166,"phases":5189,"primaryCompletion":5190,"completion":5190,"start":5191,"enrollment":1185,"conditions":5192,"interventions":5194},"NCT03538808","Balanced Placebo Design With Varenicline: Pharmacological and Expectancy Effects on Medication Adherence",[92],"2019-10-29","2018-11-06",[5193],"Medication Adherence",[5174],{"trials":5196,"activeCount":100},[],{"intervention":5198,"totalTrials":118,"cells":5199},"Adderall",{"EARLY_PHASE1":5200,"PHASE1":5202,"PHASE2":5204,"PHASE3":5206,"PHASE4":5208,"NA":5219},{"trials":5201,"activeCount":100},[],{"trials":5203,"activeCount":100},[],{"trials":5205,"activeCount":100},[],{"trials":5207,"activeCount":100},[],{"trials":5209,"activeCount":100},[5210],{"nctId":5211,"briefTitle":5212,"status":166,"phases":5213,"primaryCompletion":5214,"completion":5214,"start":5215,"enrollment":906,"conditions":5216,"interventions":5218},"NCT03530631","Neuroimaging the Expectancy Versus Pharmacotherapy Effect of Adderall on Cognitive Performance",[92],"2018-12-18","2018-11-10",[5217],"Expectancy Versus Pharmacotherapy Effect of Adderall",[5198],{"trials":5220,"activeCount":100},[],{"intervention":4063,"totalTrials":118,"cells":5222},{"EARLY_PHASE1":5223,"PHASE1":5225,"PHASE2":5227,"PHASE3":5229,"PHASE4":5231,"NA":5237},{"trials":5224,"activeCount":100},[],{"trials":5226,"activeCount":100},[],{"trials":5228,"activeCount":100},[],{"trials":5230,"activeCount":100},[],{"trials":5232,"activeCount":100},[5233],{"nctId":4054,"briefTitle":4055,"status":1196,"phases":5234,"primaryCompletion":4057,"completion":4058,"start":4059,"enrollment":100,"conditions":5235,"interventions":5236},[92],[1216],[1228,1229,1230,4062,4063],{"trials":5238,"activeCount":100},[],{"intervention":5240,"totalTrials":118,"cells":5241},"Crisaborole",{"EARLY_PHASE1":5242,"PHASE1":5244,"PHASE2":5246,"PHASE3":5248,"PHASE4":5250,"NA":5262},{"trials":5243,"activeCount":100},[],{"trials":5245,"activeCount":100},[],{"trials":5247,"activeCount":100},[],{"trials":5249,"activeCount":100},[],{"trials":5251,"activeCount":100},[5252],{"nctId":5253,"briefTitle":5254,"status":166,"phases":5255,"primaryCompletion":5256,"completion":5257,"start":5258,"enrollment":19,"conditions":5259,"interventions":5261},"NCT03567980","A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis",[92],"2020-04-30","2021-05-12","2018-09-01",[5260],"Seborrheic Dermatitis",[5240],{"trials":5263,"activeCount":100},[],{"intervention":5265,"totalTrials":118,"cells":5266},"paliperidone",{"EARLY_PHASE1":5267,"PHASE1":5269,"PHASE2":5271,"PHASE3":5273,"PHASE4":5275,"NA":5287},{"trials":5268,"activeCount":100},[],{"trials":5270,"activeCount":100},[],{"trials":5272,"activeCount":100},[],{"trials":5274,"activeCount":100},[],{"trials":5276,"activeCount":100},[5277],{"nctId":5278,"briefTitle":5279,"status":166,"phases":5280,"primaryCompletion":5281,"completion":5281,"start":5282,"enrollment":16,"conditions":5283,"interventions":5285},"NCT01134731","Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation",[92],"2014-02","2010-05",[3523,5284],"Suicidal Ideation",[5265,5286],"lithium",{"trials":5288,"activeCount":100},[],{"intervention":5286,"totalTrials":118,"cells":5290},{"EARLY_PHASE1":5291,"PHASE1":5293,"PHASE2":5295,"PHASE3":5297,"PHASE4":5299,"NA":5305},{"trials":5292,"activeCount":100},[],{"trials":5294,"activeCount":100},[],{"trials":5296,"activeCount":100},[],{"trials":5298,"activeCount":100},[],{"trials":5300,"activeCount":100},[5301],{"nctId":5278,"briefTitle":5279,"status":166,"phases":5302,"primaryCompletion":5281,"completion":5281,"start":5282,"enrollment":16,"conditions":5303,"interventions":5304},[92],[3523,5284],[5265,5286],{"trials":5306,"activeCount":100},[],{"intervention":3287,"totalTrials":118,"cells":5308},{"EARLY_PHASE1":5309,"PHASE1":5311,"PHASE2":5313,"PHASE3":5315,"PHASE4":5317,"NA":5323},{"trials":5310,"activeCount":100},[],{"trials":5312,"activeCount":100},[],{"trials":5314,"activeCount":100},[],{"trials":5316,"activeCount":100},[],{"trials":5318,"activeCount":100},[5319],{"nctId":3276,"briefTitle":3277,"status":166,"phases":5320,"primaryCompletion":3279,"completion":3279,"start":3280,"enrollment":3281,"conditions":5321,"interventions":5322},[92],[32,3283,3284],[3263,3286,3287],{"trials":5324,"activeCount":100},[],{"intervention":5326,"totalTrials":118,"cells":5327},"tenofovir, emtricitabine and efavirenz fixed dose",{"EARLY_PHASE1":5328,"PHASE1":5330,"PHASE2":5332,"PHASE3":5334,"PHASE4":5336,"NA":5347},{"trials":5329,"activeCount":100},[],{"trials":5331,"activeCount":100},[],{"trials":5333,"activeCount":100},[],{"trials":5335,"activeCount":100},[],{"trials":5337,"activeCount":100},[5338],{"nctId":5339,"briefTitle":5340,"status":166,"phases":5341,"primaryCompletion":5342,"completion":5282,"start":5343,"enrollment":3113,"conditions":5344,"interventions":5345},"NCT00862823","The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers",[92],"2010-02","2009-02",[2462],[5326,5346],"tenofovir, emtricitabine and efavirenz tablet added to solution",{"trials":5348,"activeCount":100},[],{"intervention":5346,"totalTrials":118,"cells":5350},{"EARLY_PHASE1":5351,"PHASE1":5353,"PHASE2":5355,"PHASE3":5357,"PHASE4":5359,"NA":5365},{"trials":5352,"activeCount":100},[],{"trials":5354,"activeCount":100},[],{"trials":5356,"activeCount":100},[],{"trials":5358,"activeCount":100},[],{"trials":5360,"activeCount":100},[5361],{"nctId":5339,"briefTitle":5340,"status":166,"phases":5362,"primaryCompletion":5342,"completion":5282,"start":5343,"enrollment":3113,"conditions":5363,"interventions":5364},[92],[2462],[5326,5346],{"trials":5366,"activeCount":100},[],{"intervention":5368,"totalTrials":118,"cells":5369},"Apremilast",{"EARLY_PHASE1":5370,"PHASE1":5372,"PHASE2":5374,"PHASE3":5376,"PHASE4":5378,"NA":5391},{"trials":5371,"activeCount":100},[],{"trials":5373,"activeCount":100},[],{"trials":5375,"activeCount":100},[],{"trials":5377,"activeCount":100},[],{"trials":5379,"activeCount":100},[5380],{"nctId":5381,"briefTitle":5382,"status":166,"phases":5383,"primaryCompletion":5384,"completion":5385,"start":5386,"enrollment":1476,"conditions":5387,"interventions":5390},"NCT03022617","A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis",[92],"2020-09-01","2022-09-29","2017-01",[5388,5389,4364],"Psoriatic Nail","Psoriasis Vulgaris",[5368],{"trials":5392,"activeCount":100},[],{"intervention":1231,"totalTrials":118,"cells":5394},{"EARLY_PHASE1":5395,"PHASE1":5397,"PHASE2":5399,"PHASE3":5401,"PHASE4":5403,"NA":5409},{"trials":5396,"activeCount":100},[],{"trials":5398,"activeCount":100},[],{"trials":5400,"activeCount":100},[],{"trials":5402,"activeCount":100},[],{"trials":5404,"activeCount":100},[5405],{"nctId":1219,"briefTitle":1220,"status":166,"phases":5406,"primaryCompletion":1222,"completion":1223,"start":1224,"enrollment":377,"conditions":5407,"interventions":5408},[92],[1202,1226],[1228,1229,1230,1231,1204,1232,1159],{"trials":5410,"activeCount":100},[],{"intervention":1232,"totalTrials":118,"cells":5412},{"EARLY_PHASE1":5413,"PHASE1":5415,"PHASE2":5417,"PHASE3":5419,"PHASE4":5421,"NA":5427},{"trials":5414,"activeCount":100},[],{"trials":5416,"activeCount":100},[],{"trials":5418,"activeCount":100},[],{"trials":5420,"activeCount":100},[],{"trials":5422,"activeCount":100},[5423],{"nctId":1219,"briefTitle":1220,"status":166,"phases":5424,"primaryCompletion":1222,"completion":1223,"start":1224,"enrollment":377,"conditions":5425,"interventions":5426},[92],[1202,1226],[1228,1229,1230,1231,1204,1232,1159],{"trials":5428,"activeCount":100},[],{"intervention":5430,"totalTrials":118,"cells":5431},"Apraclonidine",{"EARLY_PHASE1":5432,"PHASE1":5434,"PHASE2":5436,"PHASE3":5438,"PHASE4":5440,"NA":5452},{"trials":5433,"activeCount":100},[],{"trials":5435,"activeCount":100},[],{"trials":5437,"activeCount":100},[],{"trials":5439,"activeCount":100},[],{"trials":5441,"activeCount":100},[5442],{"nctId":5443,"briefTitle":5444,"status":1196,"phases":5445,"primaryCompletion":5446,"completion":2301,"start":5447,"enrollment":100,"conditions":5448,"interventions":5451},"NCT05167760","Efficacy of Topical Apraclonidine for the Treatment of Ocular Synkinesis",[92],"2027-11","2025-12",[5449,5450],"Synkinesis","Facial Nerve Palsy",[5430],{"trials":5453,"activeCount":100},[],{"intervention":5455,"totalTrials":118,"cells":5456},"Conjugated Estrogens Cream",{"EARLY_PHASE1":5457,"PHASE1":5459,"PHASE2":5461,"PHASE3":5463,"PHASE4":5465,"NA":5480},{"trials":5458,"activeCount":100},[],{"trials":5460,"activeCount":100},[],{"trials":5462,"activeCount":100},[],{"trials":5464,"activeCount":100},[],{"trials":5466,"activeCount":100},[5467],{"nctId":5468,"briefTitle":5469,"status":166,"phases":5470,"primaryCompletion":5471,"completion":5471,"start":5472,"enrollment":1425,"conditions":5473,"interventions":5479},"NCT03996603","Investigation of Microbiomes of Postmenopausal Women Looking for Outcomes and Response to Estrogen Therapy",[92],"2021-01-14","2019-08-01",[5474,5475,5476,5477,5478],"Female Urogenital Diseases","Vaginal Atrophy","Postmenopausal Atrophic Vaginitis","Genitourinary Disease","Postmenopausal Symptoms",[5455],{"trials":5481,"activeCount":100},[],{"intervention":5483,"totalTrials":118,"cells":5484},"ropivicaine 0.2%",{"EARLY_PHASE1":5485,"PHASE1":5487,"PHASE2":5489,"PHASE3":5491,"PHASE4":5493,"NA":5503},{"trials":5486,"activeCount":100},[],{"trials":5488,"activeCount":100},[],{"trials":5490,"activeCount":100},[],{"trials":5492,"activeCount":100},[],{"trials":5494,"activeCount":100},[5495],{"nctId":5496,"briefTitle":5497,"status":166,"phases":5498,"primaryCompletion":5499,"completion":5499,"start":5500,"enrollment":112,"conditions":5501,"interventions":5502},"NCT04080739","Regional Block for Postoperative Free Flap Care",[92],"2022-03-01","2020-01-13",[1216],[5483],{"trials":5504,"activeCount":100},[],{"intervention":5506,"totalTrials":118,"cells":5507},"ambrisentan",{"EARLY_PHASE1":5508,"PHASE1":5510,"PHASE2":5512,"PHASE3":5514,"PHASE4":5516,"NA":5528},{"trials":5509,"activeCount":100},[],{"trials":5511,"activeCount":100},[],{"trials":5513,"activeCount":100},[],{"trials":5515,"activeCount":100},[],{"trials":5517,"activeCount":100},[5518],{"nctId":5519,"briefTitle":5520,"status":166,"phases":5521,"primaryCompletion":5522,"completion":5522,"start":5523,"enrollment":5524,"conditions":5525,"interventions":5527},"NCT01330108","Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension",[92],"2012-06","2011-05",32,[5526],"Pulmonary Arterial Hypertension",[5506],{"trials":5529,"activeCount":100},[],{"intervention":4037,"totalTrials":118,"cells":5531},{"EARLY_PHASE1":5532,"PHASE1":5534,"PHASE2":5536,"PHASE3":5538,"PHASE4":5540,"NA":5546},{"trials":5533,"activeCount":100},[],{"trials":5535,"activeCount":100},[],{"trials":5537,"activeCount":100},[],{"trials":5539,"activeCount":100},[],{"trials":5541,"activeCount":100},[5542],{"nctId":4029,"briefTitle":4030,"status":166,"phases":5543,"primaryCompletion":4032,"completion":4032,"start":1279,"enrollment":4033,"conditions":5544,"interventions":5545},[92],[879],[3994,4036,4037,4038],{"trials":5547,"activeCount":100},[],{"intervention":5549,"totalTrials":118,"cells":5550},"Adderall 10Mg",{"EARLY_PHASE1":5551,"PHASE1":5553,"PHASE2":5555,"PHASE3":5557,"PHASE4":5559,"NA":5573},{"trials":5552,"activeCount":100},[],{"trials":5554,"activeCount":100},[],{"trials":5556,"activeCount":100},[],{"trials":5558,"activeCount":100},[],{"trials":5560,"activeCount":100},[5561],{"nctId":5562,"briefTitle":5563,"status":1196,"phases":5564,"primaryCompletion":5565,"completion":5566,"start":5567,"enrollment":100,"conditions":5568,"interventions":5572},"NCT04635826","The Role of Expectancy for Cognitive Enhancement in College Students Using Prescription Stimulants Nonmedically",[92],"2029-07-31","2030-07-31","2025-07-01",[5569,5570,5571],"Prescription Stimulants","Expectations","Deception",[5549],{"trials":5574,"activeCount":100},[],{"intervention":5576,"totalTrials":118,"cells":5577},"Ergocalciferol 50000 UNT",{"EARLY_PHASE1":5578,"PHASE1":5580,"PHASE2":5582,"PHASE3":5584,"PHASE4":5586,"NA":5602},{"trials":5579,"activeCount":100},[],{"trials":5581,"activeCount":100},[],{"trials":5583,"activeCount":100},[],{"trials":5585,"activeCount":100},[],{"trials":5587,"activeCount":100},[5588],{"nctId":5589,"briefTitle":5590,"status":1196,"phases":5591,"primaryCompletion":3973,"completion":3973,"start":5592,"enrollment":100,"conditions":5593,"interventions":5601},"NCT03073369","Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease",[92],"2018-01-01",[5594,5595,5596,5597,5598,5599,5600],"CKD","Chronic Kidney Diseases","Hepcidin","Ergocalciferol","Vitamin D","Iron-deficiency","Anemia",[5576],{"trials":5603,"activeCount":100},[],{"intervention":5605,"totalTrials":118,"cells":5606},"Metaderm",{"EARLY_PHASE1":5607,"PHASE1":5609,"PHASE2":5611,"PHASE3":5613,"PHASE4":5615,"NA":5626},{"trials":5608,"activeCount":100},[],{"trials":5610,"activeCount":100},[],{"trials":5612,"activeCount":100},[],{"trials":5614,"activeCount":100},[],{"trials":5616,"activeCount":100},[5617],{"nctId":5618,"briefTitle":5619,"status":166,"phases":5620,"primaryCompletion":5045,"completion":5621,"start":5622,"enrollment":5623,"conditions":5624,"interventions":5625},"NCT03597620","Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis",[92],"2022-12-13","2018-11-07",11,[4364],[5605],{"trials":5627,"activeCount":100},[],{"intervention":5629,"totalTrials":118,"cells":5630},"Active study drug",{"EARLY_PHASE1":5631,"PHASE1":5633,"PHASE2":5635,"PHASE3":5637,"PHASE4":5639,"NA":5650},{"trials":5632,"activeCount":100},[],{"trials":5634,"activeCount":100},[],{"trials":5636,"activeCount":100},[],{"trials":5638,"activeCount":100},[],{"trials":5640,"activeCount":100},[5641],{"nctId":5642,"briefTitle":5643,"status":1196,"phases":5644,"primaryCompletion":5645,"completion":5645,"start":5646,"enrollment":100,"conditions":5647,"interventions":5649},"NCT04732169","Cannabidiol for Treatment Resistant Depression",[92],"2021-07-09","2021-07-01",[5648],"Treatment Resistant Depression",[5629],{"trials":5651,"activeCount":100},[],{"intervention":5653,"totalTrials":118,"cells":5654},"Alendronate",{"EARLY_PHASE1":5655,"PHASE1":5657,"PHASE2":5659,"PHASE3":5661,"PHASE4":5663,"NA":5673},{"trials":5656,"activeCount":100},[],{"trials":5658,"activeCount":100},[],{"trials":5660,"activeCount":100},[],{"trials":5662,"activeCount":100},[],{"trials":5664,"activeCount":100},[5665],{"nctId":5666,"briefTitle":5667,"status":166,"phases":5668,"primaryCompletion":5669,"completion":3958,"start":5670,"enrollment":1063,"conditions":5671,"interventions":5672},"NCT02139007","Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study",[92],"2016-06","2014-06",[5071],[5653],{"trials":5674,"activeCount":100},[],{"intervention":5676,"totalTrials":118,"cells":5677},"Efinaconazole 10% Topical Application Solution [JUBLIA]",{"EARLY_PHASE1":5678,"PHASE1":5680,"PHASE2":5682,"PHASE3":5684,"PHASE4":5686,"NA":5695},{"trials":5679,"activeCount":100},[],{"trials":5681,"activeCount":100},[],{"trials":5683,"activeCount":100},[],{"trials":5685,"activeCount":100},[],{"trials":5687,"activeCount":100},[5688],{"nctId":5689,"briefTitle":5690,"status":166,"phases":5691,"primaryCompletion":4387,"completion":3972,"start":1247,"enrollment":191,"conditions":5692,"interventions":5694},"NCT03110029","Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish",[92],[5693],"Onychomycosis of Toenail",[5676],{"trials":5696,"activeCount":100},[],{"intervention":5698,"totalTrials":118,"cells":5699},"Flumist Quadrivalent Nasal Product",{"EARLY_PHASE1":5700,"PHASE1":5702,"PHASE2":5704,"PHASE3":5706,"PHASE4":5708,"NA":5718},{"trials":5701,"activeCount":100},[],{"trials":5703,"activeCount":100},[],{"trials":5705,"activeCount":100},[],{"trials":5707,"activeCount":100},[],{"trials":5709,"activeCount":100},[5710],{"nctId":5711,"briefTitle":5712,"status":166,"phases":5713,"primaryCompletion":5714,"completion":5714,"start":5384,"enrollment":5715,"conditions":5716,"interventions":5717},"NCT04164212","Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection",[92],"2026-01-22",33,[405],[5698],{"trials":5719,"activeCount":100},[],{"intervention":5721,"totalTrials":118,"cells":5722},"Omnipaque",{"EARLY_PHASE1":5723,"PHASE1":5725,"PHASE2":5727,"PHASE3":5729,"PHASE4":5731,"NA":5741},{"trials":5724,"activeCount":100},[],{"trials":5726,"activeCount":100},[],{"trials":5728,"activeCount":100},[],{"trials":5730,"activeCount":100},[],{"trials":5732,"activeCount":100},[5733],{"nctId":5734,"briefTitle":5735,"status":166,"phases":5736,"primaryCompletion":4162,"completion":4162,"start":5737,"enrollment":2018,"conditions":5738,"interventions":5739},"NCT00478556","Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT",[92],"2007-08",[2462],[5721,5740],"Gastroview",{"trials":5742,"activeCount":100},[],{"intervention":5740,"totalTrials":118,"cells":5744},{"EARLY_PHASE1":5745,"PHASE1":5747,"PHASE2":5749,"PHASE3":5751,"PHASE4":5753,"NA":5759},{"trials":5746,"activeCount":100},[],{"trials":5748,"activeCount":100},[],{"trials":5750,"activeCount":100},[],{"trials":5752,"activeCount":100},[],{"trials":5754,"activeCount":100},[5755],{"nctId":5734,"briefTitle":5735,"status":166,"phases":5756,"primaryCompletion":4162,"completion":4162,"start":5737,"enrollment":2018,"conditions":5757,"interventions":5758},[92],[2462],[5721,5740],{"trials":5760,"activeCount":100},[],{"intervention":4338,"totalTrials":118,"cells":5762},{"EARLY_PHASE1":5763,"PHASE1":5765,"PHASE2":5767,"PHASE3":5769,"PHASE4":5771,"NA":5777},{"trials":5764,"activeCount":100},[],{"trials":5766,"activeCount":100},[],{"trials":5768,"activeCount":100},[],{"trials":5770,"activeCount":100},[],{"trials":5772,"activeCount":100},[5773],{"nctId":4329,"briefTitle":4330,"status":917,"phases":5774,"primaryCompletion":4332,"completion":4332,"start":4333,"enrollment":3113,"conditions":5775,"interventions":5776},[92],[4335,4336],[4338,4305],{"trials":5778,"activeCount":100},[],{"intervention":5780,"totalTrials":118,"cells":5781},"Estradiol 0.01% Vag Cream",{"EARLY_PHASE1":5782,"PHASE1":5784,"PHASE2":5786,"PHASE3":5788,"PHASE4":5790,"NA":5804},{"trials":5783,"activeCount":100},[],{"trials":5785,"activeCount":100},[],{"trials":5787,"activeCount":100},[],{"trials":5789,"activeCount":100},[],{"trials":5791,"activeCount":100},[5792],{"nctId":5793,"briefTitle":5794,"status":917,"phases":5795,"primaryCompletion":5796,"completion":5796,"start":5797,"enrollment":5798,"conditions":5799,"interventions":5803},"NCT05317364","Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery",[92],"2026-02-13","2022-07-14",38,[5800,5801,5802,3824],"Obstetric; Injury Pelvic Floor","Sexual Dysfunction","Anal Incontinence",[5780],{"trials":5805,"activeCount":100},[],{"intervention":5807,"totalTrials":118,"cells":5808},"Ramelteon",{"EARLY_PHASE1":5809,"PHASE1":5811,"PHASE2":5813,"PHASE3":5815,"PHASE4":5817,"NA":5827},{"trials":5810,"activeCount":100},[],{"trials":5812,"activeCount":100},[],{"trials":5814,"activeCount":100},[],{"trials":5816,"activeCount":100},[],{"trials":5818,"activeCount":100},[5819],{"nctId":5820,"briefTitle":5821,"status":166,"phases":5822,"primaryCompletion":5342,"completion":4541,"start":5823,"enrollment":5524,"conditions":5824,"interventions":5826},"NCT00622427","Ramelteon for Treatment of Adult Patients With ADHD-Related Insomnia",[92],"2008-02",[5825],"ADHD With Sleep Onset Insomnia",[5807],{"trials":5828,"activeCount":100},[],{"intervention":5830,"totalTrials":118,"cells":5831},"Enstilar Foam",{"EARLY_PHASE1":5832,"PHASE1":5834,"PHASE2":5836,"PHASE3":5838,"PHASE4":5840,"NA":5851},{"trials":5833,"activeCount":100},[],{"trials":5835,"activeCount":100},[],{"trials":5837,"activeCount":100},[],{"trials":5839,"activeCount":100},[],{"trials":5841,"activeCount":100},[5842],{"nctId":5843,"briefTitle":5844,"status":166,"phases":5845,"primaryCompletion":5846,"completion":5846,"start":5847,"enrollment":921,"conditions":5848,"interventions":5850},"NCT04227288","A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis",[92],"2023-10-31","2021-11-01",[5849],"Nail Psoriasis",[5830],{"trials":5852,"activeCount":100},[],{"intervention":5854,"totalTrials":118,"cells":5855},"MI Varnish",{"EARLY_PHASE1":5856,"PHASE1":5858,"PHASE2":5860,"PHASE3":5862,"PHASE4":5864,"NA":5878},{"trials":5857,"activeCount":100},[],{"trials":5859,"activeCount":100},[],{"trials":5861,"activeCount":100},[],{"trials":5863,"activeCount":100},[],{"trials":5865,"activeCount":100},[5866],{"nctId":5867,"briefTitle":5868,"status":166,"phases":5869,"primaryCompletion":5870,"completion":5871,"start":5872,"enrollment":5873,"conditions":5874,"interventions":5877},"NCT03446690","MI Varnish for the Prevention of White Spot Lesions",[92],"2015-11-01","2016-01-01","2015-01-01",62,[5875,5876],"White Spot Lesion","Orthodontic Treatment",[5854],{"trials":5879,"activeCount":100},[],{"intervention":5881,"totalTrials":118,"cells":5882},"Mirabegron 50 MG",{"EARLY_PHASE1":5883,"PHASE1":5885,"PHASE2":5887,"PHASE3":5889,"PHASE4":5891,"NA":5903},{"trials":5884,"activeCount":100},[],{"trials":5886,"activeCount":100},[],{"trials":5888,"activeCount":100},[],{"trials":5890,"activeCount":100},[],{"trials":5892,"activeCount":100},[5893],{"nctId":5894,"briefTitle":5895,"status":166,"phases":5896,"primaryCompletion":5897,"completion":5898,"start":5899,"enrollment":16,"conditions":5900,"interventions":5902},"NCT04907032","Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)",[92],"2023-04-01","2023-04-15","2021-10-01",[5901],"Overactive Bladder",[5881],{"trials":5904,"activeCount":100},[],{"intervention":5906,"totalTrials":118,"cells":5907},"Occipital Nerve Block",{"EARLY_PHASE1":5908,"PHASE1":5910,"PHASE2":5912,"PHASE3":5914,"PHASE4":5916,"NA":5927},{"trials":5909,"activeCount":100},[],{"trials":5911,"activeCount":100},[],{"trials":5913,"activeCount":100},[],{"trials":5915,"activeCount":100},[],{"trials":5917,"activeCount":100},[5918],{"nctId":5919,"briefTitle":5920,"status":166,"phases":5921,"primaryCompletion":5922,"completion":5922,"start":5923,"enrollment":5873,"conditions":5924,"interventions":5926},"NCT03951649","Acute Headache Treatment in Pregnancy: Occipital Nerve Block vs PO Acetaminophen With Caffeine",[92],"2022-12-31","2020-02-10",[5925,193,5906],"Headache",[5906],{"trials":5928,"activeCount":100},[],{"intervention":5930,"totalTrials":963,"cells":5931},"cetuximab",{"EARLY_PHASE1":5932,"PHASE1":5934,"PHASE2":5936,"PHASE3":5956,"PHASE4":5966,"NA":5968},{"trials":5933,"activeCount":100},[],{"trials":5935,"activeCount":100},[],{"trials":5937,"activeCount":100},[5938,5948],{"nctId":5939,"briefTitle":5940,"status":166,"phases":5941,"primaryCompletion":5942,"completion":5942,"start":5943,"enrollment":3281,"conditions":5944,"interventions":5946},"NCT00005076","Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer",[90],"2005-07","1999-10",[5945],"Colorectal Cancer",[5930,5947],"irinotecan hydrochloride",{"nctId":5949,"briefTitle":5950,"status":1196,"phases":5951,"primaryCompletion":5952,"completion":5952,"start":5943,"enrollment":100,"conditions":5953,"interventions":5955},"NCT00005591","Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas",[90],"2003-04",[5954],"Pancreatic Cancer",[5930,1266],{"trials":5957,"activeCount":100},[5958],{"nctId":5959,"briefTitle":5960,"status":917,"phases":5961,"primaryCompletion":5962,"completion":170,"start":5963,"enrollment":5524,"conditions":5964,"interventions":5965},"NCT00004227","Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx",[91],"2007-03","1999-04",[1427],[5930],{"trials":5967,"activeCount":100},[],{"trials":5969,"activeCount":100},[],{"intervention":5971,"totalTrials":963,"cells":5972},"Tranexamic acid",{"EARLY_PHASE1":5973,"PHASE1":5975,"PHASE2":5977,"PHASE3":5997,"PHASE4":6007,"NA":6009},{"trials":5974,"activeCount":100},[],{"trials":5976,"activeCount":100},[],{"trials":5978,"activeCount":100},[5979,5987],{"nctId":5980,"briefTitle":5981,"status":917,"phases":5982,"primaryCompletion":5983,"completion":5983,"start":4694,"enrollment":971,"conditions":5984,"interventions":5986},"NCT04338074","TXA and Corona Virus 2019 (COVID19) in Outpatients",[90],"2021-04-21",[5985],"COVID-19",[5971],{"nctId":5988,"briefTitle":5989,"status":1196,"phases":5990,"primaryCompletion":5991,"completion":5992,"start":5993,"enrollment":100,"conditions":5994,"interventions":5996},"NCT04338126","Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients",[90],"2021-12-15","2021-12-31","2021-09-30",[5995],"COVID19",[5971],{"trials":5998,"activeCount":100},[5999],{"nctId":6000,"briefTitle":6001,"status":1196,"phases":6002,"primaryCompletion":5922,"completion":6003,"start":6004,"enrollment":100,"conditions":6005,"interventions":6006},"NCT04550338","Antiviral Effects of TXA as a Preventative Treatment Following COVID-19 Exposure",[91],"2023-03-31","2021-08-01",[5985],[5971],{"trials":6008,"activeCount":100},[],{"trials":6010,"activeCount":100},[],{"intervention":3964,"totalTrials":96,"cells":6012},{"EARLY_PHASE1":6013,"PHASE1":6015,"PHASE2":6017,"PHASE3":6019,"PHASE4":6038,"NA":6040},{"trials":6014,"activeCount":100},[],{"trials":6016,"activeCount":100},[],{"trials":6018,"activeCount":100},[],{"trials":6020,"activeCount":100},[6021,6034],{"nctId":6022,"briefTitle":6023,"status":1196,"phases":6024,"primaryCompletion":6025,"completion":6026,"start":6027,"enrollment":100,"conditions":6028,"interventions":6031},"NCT03678792","Comparison of Three Opioid Detoxification Treatment Regimens",[91],"2020-09","2020-10-25","2019-11-15",[6029,6030],"Opioid-Related Disorders","Opioid Withdrawal",[6032,3964,6033],"Buprenorphine\u002Fnaloxone","Tramadol",{"nctId":3954,"briefTitle":3955,"status":917,"phases":6035,"primaryCompletion":3957,"completion":3957,"start":3958,"enrollment":1110,"conditions":6036,"interventions":6037},[90,91],[3960],[3962,3963,3932,3964,3965,3966,3967],{"trials":6039,"activeCount":100},[],{"trials":6041,"activeCount":100},[],{"intervention":6043,"totalTrials":96,"cells":6044},"Sildenafil 50 mg Oral",{"EARLY_PHASE1":6045,"PHASE1":6047,"PHASE2":6049,"PHASE3":6051,"PHASE4":6072,"NA":6074},{"trials":6046,"activeCount":100},[],{"trials":6048,"activeCount":100},[],{"trials":6050,"activeCount":100},[],{"trials":6052,"activeCount":100},[6053,6065],{"nctId":6054,"briefTitle":6055,"status":1196,"phases":6056,"primaryCompletion":1499,"completion":6057,"start":6058,"enrollment":100,"conditions":6059,"interventions":6064},"NCT06522854","Oral Sildenafil Citrate to Improve Maternal and Neonatal Outcomes in Low-resource Settings",[91],"2026-11-30","2025-05-01",[6060,6061,6062,6063],"Intrapartum Fetal Distress","Neonatal Asphyxia","Intrapartum Asphyxia","Instrumental Delivery; Affecting Fetus",[6043],{"nctId":6066,"briefTitle":6067,"status":1196,"phases":6068,"primaryCompletion":2694,"completion":6069,"start":6058,"enrollment":100,"conditions":6070,"interventions":6071},"NCT06377098","Intrapartum Sildenafil in Laboring Mothers",[91],"2028-09-30",[6061,6060,301,6062],[6043],{"trials":6073,"activeCount":100},[],{"trials":6075,"activeCount":100},[],{"intervention":6077,"totalTrials":96,"cells":6078},"Allopurinol",{"EARLY_PHASE1":6079,"PHASE1":6081,"PHASE2":6083,"PHASE3":6085,"PHASE4":6105,"NA":6107},{"trials":6080,"activeCount":100},[],{"trials":6082,"activeCount":100},[],{"trials":6084,"activeCount":100},[],{"trials":6086,"activeCount":100},[6087,6096],{"nctId":6088,"briefTitle":6089,"status":166,"phases":6090,"primaryCompletion":6091,"completion":6091,"start":6092,"enrollment":4073,"conditions":6093,"interventions":6095},"NCT02038179","Center of Research Translation (CORT) Project 2",[90,91],"2018-08","2014-07",[4862,6094],"JNC 7 Stage I Hypertension",[6077],{"nctId":6097,"briefTitle":6098,"status":166,"phases":6099,"primaryCompletion":6100,"completion":6100,"start":5942,"enrollment":1280,"conditions":6101,"interventions":6102},"NCT01052272","Impact of Diabetes on Left Ventricular Remodeling",[90,91],"2010-11",[4861],[6103,6104,6077],"Ramipril","Candesartan cilexetil",{"trials":6106,"activeCount":100},[],{"trials":6108,"activeCount":100},[],{"intervention":6110,"totalTrials":96,"cells":6111},"Fludarabine",{"EARLY_PHASE1":6112,"PHASE1":6114,"PHASE2":6116,"PHASE3":6128,"PHASE4":6142,"NA":6144},{"trials":6113,"activeCount":100},[],{"trials":6115,"activeCount":100},[],{"trials":6117,"activeCount":100},[6118],{"nctId":6119,"briefTitle":6120,"status":166,"phases":6121,"primaryCompletion":6122,"completion":6123,"start":6124,"enrollment":30,"conditions":6125,"interventions":6127},"NCT01991457","Fludarabine \u002F Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia",[90],"2020-01-30","2022-08-23","2013-08-27",[6126],"Adult Lymphoblastic Lymphoma",[6110],{"trials":6129,"activeCount":100},[6130],{"nctId":6131,"briefTitle":6132,"status":917,"phases":6133,"primaryCompletion":6134,"completion":6134,"start":6135,"enrollment":971,"conditions":6136,"interventions":6141},"NCT00714259","Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies",[90,91],"2013-02","2008-07",[1187,6137,6138,6139,6140],"CLL \u002F SLL","Non Hodgkin's Lymphoma","Waldenstroms","Mantle Cell Lymphoma",[6110],{"trials":6143,"activeCount":100},[],{"trials":6145,"activeCount":100},[],{"intervention":6032,"totalTrials":118,"cells":6147},{"EARLY_PHASE1":6148,"PHASE1":6150,"PHASE2":6152,"PHASE3":6154,"PHASE4":6160,"NA":6162},{"trials":6149,"activeCount":100},[],{"trials":6151,"activeCount":100},[],{"trials":6153,"activeCount":100},[],{"trials":6155,"activeCount":100},[6156],{"nctId":6022,"briefTitle":6023,"status":1196,"phases":6157,"primaryCompletion":6025,"completion":6026,"start":6027,"enrollment":100,"conditions":6158,"interventions":6159},[91],[6029,6030],[6032,3964,6033],{"trials":6161,"activeCount":100},[],{"trials":6163,"activeCount":100},[],{"intervention":6033,"totalTrials":118,"cells":6165},{"EARLY_PHASE1":6166,"PHASE1":6168,"PHASE2":6170,"PHASE3":6172,"PHASE4":6178,"NA":6180},{"trials":6167,"activeCount":100},[],{"trials":6169,"activeCount":100},[],{"trials":6171,"activeCount":100},[],{"trials":6173,"activeCount":100},[6174],{"nctId":6022,"briefTitle":6023,"status":1196,"phases":6175,"primaryCompletion":6025,"completion":6026,"start":6027,"enrollment":100,"conditions":6176,"interventions":6177},[91],[6029,6030],[6032,3964,6033],{"trials":6179,"activeCount":100},[],{"trials":6181,"activeCount":100},[],{"intervention":6183,"totalTrials":118,"cells":6184},"Amlodipine",{"EARLY_PHASE1":6185,"PHASE1":6187,"PHASE2":6189,"PHASE3":6191,"PHASE4":6202,"NA":6204},{"trials":6186,"activeCount":100},[],{"trials":6188,"activeCount":100},[],{"trials":6190,"activeCount":100},[],{"trials":6192,"activeCount":100},[6193],{"nctId":6194,"briefTitle":6195,"status":1196,"phases":6196,"primaryCompletion":3224,"completion":3224,"start":6197,"enrollment":100,"conditions":6198,"interventions":6200},"NCT04121299","Mechanism of Masked Hypertension - Intervention",[91],"2021-07",[6199],"Masked Hypertension",[6201,6183],"Carvedilol",{"trials":6203,"activeCount":100},[],{"trials":6205,"activeCount":100},[],{"intervention":6207,"totalTrials":118,"cells":6208},"10 mg Bupivacaine",{"EARLY_PHASE1":6209,"PHASE1":6211,"PHASE2":6213,"PHASE3":6215,"PHASE4":6229,"NA":6231},{"trials":6210,"activeCount":100},[],{"trials":6212,"activeCount":100},[],{"trials":6214,"activeCount":100},[],{"trials":6216,"activeCount":100},[6217],{"nctId":6218,"briefTitle":6219,"status":166,"phases":6220,"primaryCompletion":6221,"completion":6222,"start":6223,"enrollment":1089,"conditions":6224,"interventions":6227},"NCT03110003","Bupivacaine With Epidural Volume Extension",[91],"2017-12-01","2018-09-30","2016-06-27",[6225,6226],"Spinal Anesthesia","Epidural; Anesthesia",[6207,6228],"5 mg Bupivacaine",{"trials":6230,"activeCount":100},[],{"trials":6232,"activeCount":100},[],{"intervention":6228,"totalTrials":118,"cells":6234},{"EARLY_PHASE1":6235,"PHASE1":6237,"PHASE2":6239,"PHASE3":6241,"PHASE4":6247,"NA":6249},{"trials":6236,"activeCount":100},[],{"trials":6238,"activeCount":100},[],{"trials":6240,"activeCount":100},[],{"trials":6242,"activeCount":100},[6243],{"nctId":6218,"briefTitle":6219,"status":166,"phases":6244,"primaryCompletion":6221,"completion":6222,"start":6223,"enrollment":1089,"conditions":6245,"interventions":6246},[91],[6225,6226],[6207,6228],{"trials":6248,"activeCount":100},[],{"trials":6250,"activeCount":100},[],{"intervention":6252,"totalTrials":118,"cells":6253},"Quadratus Lumborum Block",{"EARLY_PHASE1":6254,"PHASE1":6256,"PHASE2":6258,"PHASE3":6260,"PHASE4":6272,"NA":6274},{"trials":6255,"activeCount":100},[],{"trials":6257,"activeCount":100},[],{"trials":6259,"activeCount":100},[],{"trials":6261,"activeCount":100},[6262],{"nctId":6263,"briefTitle":6264,"status":166,"phases":6265,"primaryCompletion":6266,"completion":6267,"start":3367,"enrollment":1185,"conditions":6268,"interventions":6270},"NCT03408483","Quadratus Lumborum Block Versus Control for Total Hip Arthroplasty",[90,91],"2019-05-10","2020-08-22",[6269],"Total Hip Arthroplasty",[6252,6271],"Standard of Care",{"trials":6273,"activeCount":100},[],{"trials":6275,"activeCount":100},[],{"intervention":6271,"totalTrials":118,"cells":6277},{"EARLY_PHASE1":6278,"PHASE1":6280,"PHASE2":6282,"PHASE3":6284,"PHASE4":6290,"NA":6292},{"trials":6279,"activeCount":100},[],{"trials":6281,"activeCount":100},[],{"trials":6283,"activeCount":100},[],{"trials":6285,"activeCount":100},[6286],{"nctId":6263,"briefTitle":6264,"status":166,"phases":6287,"primaryCompletion":6266,"completion":6267,"start":3367,"enrollment":1185,"conditions":6288,"interventions":6289},[90,91],[6269],[6252,6271],{"trials":6291,"activeCount":100},[],{"trials":6293,"activeCount":100},[],{"intervention":6295,"totalTrials":118,"cells":6296},"metoprolol succinate",{"EARLY_PHASE1":6297,"PHASE1":6299,"PHASE2":6301,"PHASE3":6303,"PHASE4":6313,"NA":6315},{"trials":6298,"activeCount":100},[],{"trials":6300,"activeCount":100},[],{"trials":6302,"activeCount":100},[],{"trials":6304,"activeCount":100},[6305],{"nctId":6306,"briefTitle":6307,"status":166,"phases":6308,"primaryCompletion":5093,"completion":5093,"start":6309,"enrollment":5798,"conditions":6310,"interventions":6312},"NCT01052428","Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)",[90,91],"2004-08",[6311],"Mitral Regurgitation",[6295],{"trials":6314,"activeCount":100},[],{"trials":6316,"activeCount":100},[],{"intervention":6318,"totalTrials":118,"cells":6319},"PENG Block",{"EARLY_PHASE1":6320,"PHASE1":6322,"PHASE2":6324,"PHASE3":6326,"PHASE4":6338,"NA":6340},{"trials":6321,"activeCount":100},[],{"trials":6323,"activeCount":100},[],{"trials":6325,"activeCount":100},[],{"trials":6327,"activeCount":100},[6328],{"nctId":6329,"briefTitle":6330,"status":166,"phases":6331,"primaryCompletion":6332,"completion":3821,"start":6333,"enrollment":6334,"conditions":6335,"interventions":6336},"NCT04591353","Trial Comparing Impact of PENG Block on Quality of Recovery Compared to No-block for Primary Total Hip Arthroplasty",[91],"2022-09-15","2021-02-01",122,[6269],[6318,6337],"Lidocaine",{"trials":6339,"activeCount":100},[],{"trials":6341,"activeCount":100},[],{"intervention":6343,"totalTrials":118,"cells":6344},"1% Lidocaine",{"EARLY_PHASE1":6345,"PHASE1":6347,"PHASE2":6349,"PHASE3":6351,"PHASE4":6364,"NA":6366},{"trials":6346,"activeCount":100},[],{"trials":6348,"activeCount":100},[],{"trials":6350,"activeCount":100},[],{"trials":6352,"activeCount":100},[6353],{"nctId":6354,"briefTitle":6355,"status":166,"phases":6356,"primaryCompletion":6357,"completion":4929,"start":6358,"enrollment":2370,"conditions":6359,"interventions":6361},"NCT03103100","Comparing Bupivacaine, Lidocaine, and a Combination of Bupivacaine and Lidocaine for Labor Epidural Activation",[91],"2019-07-01","2015-10-08",[6360],"Labor Pain",[6343,6362,6363],"0.25% Bupivacaine","Bupivacaine plus Lidocaine",{"trials":6365,"activeCount":100},[],{"trials":6367,"activeCount":100},[],{"intervention":6362,"totalTrials":118,"cells":6369},{"EARLY_PHASE1":6370,"PHASE1":6372,"PHASE2":6374,"PHASE3":6376,"PHASE4":6382,"NA":6384},{"trials":6371,"activeCount":100},[],{"trials":6373,"activeCount":100},[],{"trials":6375,"activeCount":100},[],{"trials":6377,"activeCount":100},[6378],{"nctId":6354,"briefTitle":6355,"status":166,"phases":6379,"primaryCompletion":6357,"completion":4929,"start":6358,"enrollment":2370,"conditions":6380,"interventions":6381},[91],[6360],[6343,6362,6363],{"trials":6383,"activeCount":100},[],{"trials":6385,"activeCount":100},[],{"intervention":6363,"totalTrials":118,"cells":6387},{"EARLY_PHASE1":6388,"PHASE1":6390,"PHASE2":6392,"PHASE3":6394,"PHASE4":6400,"NA":6402},{"trials":6389,"activeCount":100},[],{"trials":6391,"activeCount":100},[],{"trials":6393,"activeCount":100},[],{"trials":6395,"activeCount":100},[6396],{"nctId":6354,"briefTitle":6355,"status":166,"phases":6397,"primaryCompletion":6357,"completion":4929,"start":6358,"enrollment":2370,"conditions":6398,"interventions":6399},[91],[6360],[6343,6362,6363],{"trials":6401,"activeCount":100},[],{"trials":6403,"activeCount":100},[],{"intervention":6405,"totalTrials":118,"cells":6406},"Saw Palmetto - first 24 weeks",{"EARLY_PHASE1":6407,"PHASE1":6409,"PHASE2":6411,"PHASE3":6413,"PHASE4":6425,"NA":6427},{"trials":6408,"activeCount":100},[],{"trials":6410,"activeCount":100},[],{"trials":6412,"activeCount":100},[],{"trials":6414,"activeCount":100},[6415],{"nctId":6416,"briefTitle":6417,"status":166,"phases":6418,"primaryCompletion":4541,"completion":4541,"start":5823,"enrollment":6419,"conditions":6420,"interventions":6422},"NCT00603304","Complementary and Alternative Medicine for Urological Symptoms(CAMUS)",[91],369,[6421],"Urological",[6405,6423,6424],"Saw Palmetto - weeks 24 - 48","Saw Palmetto - weeks 48 - 72",{"trials":6426,"activeCount":100},[],{"trials":6428,"activeCount":100},[],{"intervention":6423,"totalTrials":118,"cells":6430},{"EARLY_PHASE1":6431,"PHASE1":6433,"PHASE2":6435,"PHASE3":6437,"PHASE4":6443,"NA":6445},{"trials":6432,"activeCount":100},[],{"trials":6434,"activeCount":100},[],{"trials":6436,"activeCount":100},[],{"trials":6438,"activeCount":100},[6439],{"nctId":6416,"briefTitle":6417,"status":166,"phases":6440,"primaryCompletion":4541,"completion":4541,"start":5823,"enrollment":6419,"conditions":6441,"interventions":6442},[91],[6421],[6405,6423,6424],{"trials":6444,"activeCount":100},[],{"trials":6446,"activeCount":100},[],{"intervention":6424,"totalTrials":118,"cells":6448},{"EARLY_PHASE1":6449,"PHASE1":6451,"PHASE2":6453,"PHASE3":6455,"PHASE4":6461,"NA":6463},{"trials":6450,"activeCount":100},[],{"trials":6452,"activeCount":100},[],{"trials":6454,"activeCount":100},[],{"trials":6456,"activeCount":100},[6457],{"nctId":6416,"briefTitle":6417,"status":166,"phases":6458,"primaryCompletion":4541,"completion":4541,"start":5823,"enrollment":6419,"conditions":6459,"interventions":6460},[91],[6421],[6405,6423,6424],{"trials":6462,"activeCount":100},[],{"trials":6464,"activeCount":100},[],{"intervention":6466,"totalTrials":118,"cells":6467},"Hormonal Contraception",{"EARLY_PHASE1":6468,"PHASE1":6470,"PHASE2":6472,"PHASE3":6474,"PHASE4":6486,"NA":6488},{"trials":6469,"activeCount":100},[],{"trials":6471,"activeCount":100},[],{"trials":6473,"activeCount":100},[],{"trials":6475,"activeCount":100},[6476],{"nctId":6477,"briefTitle":6478,"status":166,"phases":6479,"primaryCompletion":6480,"completion":6480,"start":6481,"enrollment":5004,"conditions":6482,"interventions":6485},"NCT00336245","A Randomized Trial of IUD Versus Hormonal Contraception in HIV-infected Women in Zambia",[91],"2005-10","2002-06",[6483,6484],"Pregnancy","HIV Infection",[6466],{"trials":6487,"activeCount":100},[],{"trials":6489,"activeCount":100},[],{"intervention":6491,"totalTrials":118,"cells":6492},"Metronidazole",{"EARLY_PHASE1":6493,"PHASE1":6495,"PHASE2":6497,"PHASE3":6499,"PHASE4":6511,"NA":6513},{"trials":6494,"activeCount":100},[],{"trials":6496,"activeCount":100},[],{"trials":6498,"activeCount":100},[],{"trials":6500,"activeCount":100},[6501],{"nctId":6502,"briefTitle":6503,"status":166,"phases":6504,"primaryCompletion":6505,"completion":6505,"start":6506,"enrollment":6507,"conditions":6508,"interventions":6510},"NCT02209519","Randomized Controlled Trial of Treatment of Male Partners of Women With BV",[91],"2019-03","2015-02",214,[6509],"Recurrent Bacterial Vaginosis",[6491],{"trials":6512,"activeCount":100},[],{"trials":6514,"activeCount":100},[],{"intervention":6516,"totalTrials":118,"cells":6517},"prednisone alone",{"EARLY_PHASE1":6518,"PHASE1":6520,"PHASE2":6522,"PHASE3":6524,"PHASE4":6535,"NA":6537},{"trials":6519,"activeCount":100},[],{"trials":6521,"activeCount":100},[],{"trials":6523,"activeCount":100},[],{"trials":6525,"activeCount":100},[6526],{"nctId":6527,"briefTitle":6528,"status":166,"phases":6529,"primaryCompletion":2908,"completion":3944,"start":6530,"enrollment":6531,"conditions":6532,"interventions":6534},"NCT00294658","Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy",[91],"2006-06",126,[6533],"Myasthenia Gravis",[6516],{"trials":6536,"activeCount":100},[],{"trials":6538,"activeCount":100},[],{"intervention":4170,"totalTrials":118,"cells":6540},{"EARLY_PHASE1":6541,"PHASE1":6543,"PHASE2":6545,"PHASE3":6547,"PHASE4":6553,"NA":6555},{"trials":6542,"activeCount":100},[],{"trials":6544,"activeCount":100},[],{"trials":6546,"activeCount":100},[],{"trials":6548,"activeCount":100},[6549],{"nctId":4159,"briefTitle":4160,"status":166,"phases":6550,"primaryCompletion":4162,"completion":4163,"start":4164,"enrollment":1185,"conditions":6551,"interventions":6552},[90,91],[4166,4167],[4169,4170],{"trials":6554,"activeCount":100},[],{"trials":6556,"activeCount":100},[],{"intervention":6558,"totalTrials":118,"cells":6559},"Tolterodine + tamsulosin",{"EARLY_PHASE1":6560,"PHASE1":6562,"PHASE2":6564,"PHASE3":6566,"PHASE4":6577,"NA":6579},{"trials":6561,"activeCount":100},[],{"trials":6563,"activeCount":100},[],{"trials":6565,"activeCount":100},[],{"trials":6567,"activeCount":100},[6568],{"nctId":6569,"briefTitle":6570,"status":166,"phases":6571,"primaryCompletion":6572,"completion":6572,"start":5093,"enrollment":6573,"conditions":6574,"interventions":6576},"NCT01175382","Combined Behavioral and Drug Treatment of Overactive Bladder in Men",[90,91],"2015-07",204,[5901,6575],"Lower Urinary Tract Symptoms",[6558],{"trials":6578,"activeCount":100},[],{"trials":6580,"activeCount":100},[],{"intervention":3962,"totalTrials":118,"cells":6582},{"EARLY_PHASE1":6583,"PHASE1":6585,"PHASE2":6587,"PHASE3":6589,"PHASE4":6595,"NA":6597},{"trials":6584,"activeCount":100},[],{"trials":6586,"activeCount":100},[],{"trials":6588,"activeCount":100},[],{"trials":6590,"activeCount":100},[6591],{"nctId":3954,"briefTitle":3955,"status":917,"phases":6592,"primaryCompletion":3957,"completion":3957,"start":3958,"enrollment":1110,"conditions":6593,"interventions":6594},[90,91],[3960],[3962,3963,3932,3964,3965,3966,3967],{"trials":6596,"activeCount":100},[],{"trials":6598,"activeCount":100},[],{"intervention":3963,"totalTrials":118,"cells":6600},{"EARLY_PHASE1":6601,"PHASE1":6603,"PHASE2":6605,"PHASE3":6607,"PHASE4":6613,"NA":6615},{"trials":6602,"activeCount":100},[],{"trials":6604,"activeCount":100},[],{"trials":6606,"activeCount":100},[],{"trials":6608,"activeCount":100},[6609],{"nctId":3954,"briefTitle":3955,"status":917,"phases":6610,"primaryCompletion":3957,"completion":3957,"start":3958,"enrollment":1110,"conditions":6611,"interventions":6612},[90,91],[3960],[3962,3963,3932,3964,3965,3966,3967],{"trials":6614,"activeCount":100},[],{"trials":6616,"activeCount":100},[],{"intervention":3965,"totalTrials":118,"cells":6618},{"EARLY_PHASE1":6619,"PHASE1":6621,"PHASE2":6623,"PHASE3":6625,"PHASE4":6631,"NA":6633},{"trials":6620,"activeCount":100},[],{"trials":6622,"activeCount":100},[],{"trials":6624,"activeCount":100},[],{"trials":6626,"activeCount":100},[6627],{"nctId":3954,"briefTitle":3955,"status":917,"phases":6628,"primaryCompletion":3957,"completion":3957,"start":3958,"enrollment":1110,"conditions":6629,"interventions":6630},[90,91],[3960],[3962,3963,3932,3964,3965,3966,3967],{"trials":6632,"activeCount":100},[],{"trials":6634,"activeCount":100},[],{"intervention":3966,"totalTrials":118,"cells":6636},{"EARLY_PHASE1":6637,"PHASE1":6639,"PHASE2":6641,"PHASE3":6643,"PHASE4":6649,"NA":6651},{"trials":6638,"activeCount":100},[],{"trials":6640,"activeCount":100},[],{"trials":6642,"activeCount":100},[],{"trials":6644,"activeCount":100},[6645],{"nctId":3954,"briefTitle":3955,"status":917,"phases":6646,"primaryCompletion":3957,"completion":3957,"start":3958,"enrollment":1110,"conditions":6647,"interventions":6648},[90,91],[3960],[3962,3963,3932,3964,3965,3966,3967],{"trials":6650,"activeCount":100},[],{"trials":6652,"activeCount":100},[],{"intervention":3967,"totalTrials":118,"cells":6654},{"EARLY_PHASE1":6655,"PHASE1":6657,"PHASE2":6659,"PHASE3":6661,"PHASE4":6667,"NA":6669},{"trials":6656,"activeCount":100},[],{"trials":6658,"activeCount":100},[],{"trials":6660,"activeCount":100},[],{"trials":6662,"activeCount":100},[6663],{"nctId":3954,"briefTitle":3955,"status":917,"phases":6664,"primaryCompletion":3957,"completion":3957,"start":3958,"enrollment":1110,"conditions":6665,"interventions":6666},[90,91],[3960],[3962,3963,3932,3964,3965,3966,3967],{"trials":6668,"activeCount":100},[],{"trials":6670,"activeCount":100},[],{"intervention":4325,"totalTrials":118,"cells":6672},{"EARLY_PHASE1":6673,"PHASE1":6675,"PHASE2":6677,"PHASE3":6679,"PHASE4":6685,"NA":6687},{"trials":6674,"activeCount":100},[],{"trials":6676,"activeCount":100},[],{"trials":6678,"activeCount":100},[],{"trials":6680,"activeCount":100},[6681],{"nctId":4316,"briefTitle":4317,"status":1196,"phases":6682,"primaryCompletion":4319,"completion":4320,"start":4321,"enrollment":100,"conditions":6683,"interventions":6684},[91],[4323],[4305,4325],{"trials":6686,"activeCount":100},[],{"trials":6688,"activeCount":100},[],{"intervention":6690,"totalTrials":118,"cells":6691},"Anakinra",{"EARLY_PHASE1":6692,"PHASE1":6694,"PHASE2":6696,"PHASE3":6698,"PHASE4":6709,"NA":6711},{"trials":6693,"activeCount":100},[],{"trials":6695,"activeCount":100},[],{"trials":6697,"activeCount":100},[],{"trials":6699,"activeCount":100},[6700],{"nctId":6701,"briefTitle":6702,"status":166,"phases":6703,"primaryCompletion":5992,"completion":6704,"start":6705,"enrollment":5524,"conditions":6706,"interventions":6708},"NCT04362111","Early Treatment of Cytokine Storm Syndrome in Covid-19",[91],"2023-06-01","2020-08-01",[6707,5985],"Cytokine Storm",[6690,3978],{"trials":6710,"activeCount":100},[],{"trials":6712,"activeCount":100},[],{"intervention":6103,"totalTrials":118,"cells":6714},{"EARLY_PHASE1":6715,"PHASE1":6717,"PHASE2":6719,"PHASE3":6721,"PHASE4":6727,"NA":6729},{"trials":6716,"activeCount":100},[],{"trials":6718,"activeCount":100},[],{"trials":6720,"activeCount":100},[],{"trials":6722,"activeCount":100},[6723],{"nctId":6097,"briefTitle":6098,"status":166,"phases":6724,"primaryCompletion":6100,"completion":6100,"start":5942,"enrollment":1280,"conditions":6725,"interventions":6726},[90,91],[4861],[6103,6104,6077],{"trials":6728,"activeCount":100},[],{"trials":6730,"activeCount":100},[],{"intervention":6104,"totalTrials":118,"cells":6732},{"EARLY_PHASE1":6733,"PHASE1":6735,"PHASE2":6737,"PHASE3":6739,"PHASE4":6745,"NA":6747},{"trials":6734,"activeCount":100},[],{"trials":6736,"activeCount":100},[],{"trials":6738,"activeCount":100},[],{"trials":6740,"activeCount":100},[6741],{"nctId":6097,"briefTitle":6098,"status":166,"phases":6742,"primaryCompletion":6100,"completion":6100,"start":5942,"enrollment":1280,"conditions":6743,"interventions":6744},[90,91],[4861],[6103,6104,6077],{"trials":6746,"activeCount":100},[],{"trials":6748,"activeCount":100},[],{"intervention":4289,"totalTrials":118,"cells":6750},{"EARLY_PHASE1":6751,"PHASE1":6753,"PHASE2":6755,"PHASE3":6757,"PHASE4":6763,"NA":6765},{"trials":6752,"activeCount":100},[],{"trials":6754,"activeCount":100},[],{"trials":6756,"activeCount":100},[],{"trials":6758,"activeCount":100},[6759],{"nctId":4280,"briefTitle":4281,"status":917,"phases":6760,"primaryCompletion":4283,"completion":4283,"start":4284,"enrollment":30,"conditions":6761,"interventions":6762},[90,91],[4286,4287],[4289,4290,4269],{"trials":6764,"activeCount":100},[],{"trials":6766,"activeCount":100},[],{"intervention":4290,"totalTrials":118,"cells":6768},{"EARLY_PHASE1":6769,"PHASE1":6771,"PHASE2":6773,"PHASE3":6775,"PHASE4":6781,"NA":6783},{"trials":6770,"activeCount":100},[],{"trials":6772,"activeCount":100},[],{"trials":6774,"activeCount":100},[],{"trials":6776,"activeCount":100},[6777],{"nctId":4280,"briefTitle":4281,"status":917,"phases":6778,"primaryCompletion":4283,"completion":4283,"start":4284,"enrollment":30,"conditions":6779,"interventions":6780},[90,91],[4286,4287],[4289,4290,4269],{"trials":6782,"activeCount":100},[],{"trials":6784,"activeCount":100},[],{"intervention":6786,"totalTrials":118,"cells":6787},"recombinant interferon alfa",{"EARLY_PHASE1":6788,"PHASE1":6790,"PHASE2":6792,"PHASE3":6794,"PHASE4":6807,"NA":6809},{"trials":6789,"activeCount":100},[],{"trials":6791,"activeCount":100},[],{"trials":6793,"activeCount":100},[],{"trials":6795,"activeCount":100},[6796],{"nctId":6797,"briefTitle":6798,"status":166,"phases":6799,"primaryCompletion":6800,"completion":6801,"start":5943,"enrollment":6802,"conditions":6803,"interventions":6805},"NCT00004196","Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis",[91],"2004-10","2007-11",3000,[6804],"Melanoma (Skin)",[6786,6806],"Observation",{"trials":6808,"activeCount":100},[],{"trials":6810,"activeCount":100},[],{"intervention":6806,"totalTrials":118,"cells":6812},{"EARLY_PHASE1":6813,"PHASE1":6815,"PHASE2":6817,"PHASE3":6819,"PHASE4":6825,"NA":6827},{"trials":6814,"activeCount":100},[],{"trials":6816,"activeCount":100},[],{"trials":6818,"activeCount":100},[],{"trials":6820,"activeCount":100},[6821],{"nctId":6797,"briefTitle":6798,"status":166,"phases":6822,"primaryCompletion":6800,"completion":6801,"start":5943,"enrollment":6802,"conditions":6823,"interventions":6824},[91],[6804],[6786,6806],{"trials":6826,"activeCount":100},[],{"trials":6828,"activeCount":100},[],{"intervention":6830,"totalTrials":118,"cells":6831},"Endotoxin, Escherichia Coli",{"EARLY_PHASE1":6832,"PHASE1":6834,"PHASE2":6836,"PHASE3":6838,"PHASE4":6848,"NA":6850},{"trials":6833,"activeCount":100},[],{"trials":6835,"activeCount":100},[],{"trials":6837,"activeCount":100},[],{"trials":6839,"activeCount":100},[6840],{"nctId":6841,"briefTitle":6842,"status":166,"phases":6843,"primaryCompletion":6844,"completion":6844,"start":6845,"enrollment":1927,"conditions":6846,"interventions":6847},"NCT04263454","The Innate Central Nervous System Immune Response to an Experimental Immune Challenge in People With Fibromyalgia",[90,91],"2021-12-22","2020-03-11",[2460],[6830],{"trials":6849,"activeCount":100},[],{"trials":6851,"activeCount":100},[],{"intervention":6853,"totalTrials":118,"cells":6854},"Guanfacine",{"EARLY_PHASE1":6855,"PHASE1":6857,"PHASE2":6859,"PHASE3":6861,"PHASE4":6871,"NA":6873},{"trials":6856,"activeCount":100},[],{"trials":6858,"activeCount":100},[],{"trials":6860,"activeCount":100},[],{"trials":6862,"activeCount":100},[6863],{"nctId":6864,"briefTitle":6865,"status":166,"phases":6866,"primaryCompletion":3112,"completion":5897,"start":6867,"enrollment":112,"conditions":6868,"interventions":6870},"NCT04578886","The Effect of Guanfacine on Delirium in Critically Ill Patients",[91],"2020-11-23",[6869],"Delirium",[6853],{"trials":6872,"activeCount":100},[],{"trials":6874,"activeCount":100},[],{"intervention":6876,"totalTrials":118,"cells":6877},"Arixtra",{"EARLY_PHASE1":6878,"PHASE1":6880,"PHASE2":6882,"PHASE3":6884,"PHASE4":6895,"NA":6897},{"trials":6879,"activeCount":100},[],{"trials":6881,"activeCount":100},[],{"trials":6883,"activeCount":100},[],{"trials":6885,"activeCount":100},[6886],{"nctId":6887,"briefTitle":6888,"status":917,"phases":6889,"primaryCompletion":4131,"completion":4131,"start":6890,"enrollment":6891,"conditions":6892,"interventions":6894},"NCT00539942","Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy",[91],"2007-04",7,[6893],"Venous Thrombosis",[6876],{"trials":6896,"activeCount":100},[],{"trials":6898,"activeCount":100},[],{"intervention":6900,"totalTrials":118,"cells":6901},"Olanzapine",{"EARLY_PHASE1":6902,"PHASE1":6904,"PHASE2":6906,"PHASE3":6908,"PHASE4":6920,"NA":6922},{"trials":6903,"activeCount":100},[],{"trials":6905,"activeCount":100},[],{"trials":6907,"activeCount":100},[],{"trials":6909,"activeCount":100},[6910],{"nctId":6911,"briefTitle":6912,"status":166,"phases":6913,"primaryCompletion":6914,"completion":6915,"start":6916,"enrollment":19,"conditions":6917,"interventions":6919},"NCT03137121","Olanzapine for the Treatment of Chronic Nausea and\u002For Vomiting in Advanced Cancer Patients",[90,91],"2019-07-12","2020-09-15","2017-07-12",[6918],"Advanced Cancer",[6900],{"trials":6921,"activeCount":100},[],{"trials":6923,"activeCount":100},[],{"intervention":6925,"totalTrials":118,"cells":6926},"Traditional Treatment",{"EARLY_PHASE1":6927,"PHASE1":6929,"PHASE2":6931,"PHASE3":6933,"PHASE4":6944,"NA":6946},{"trials":6928,"activeCount":100},[],{"trials":6930,"activeCount":100},[],{"trials":6932,"activeCount":100},[],{"trials":6934,"activeCount":100},[6935],{"nctId":6936,"briefTitle":6937,"status":1196,"phases":6938,"primaryCompletion":4250,"completion":6939,"start":6940,"enrollment":100,"conditions":6941,"interventions":6943},"NCT03115489","Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus",[90,91],"2021-05-18","2017-05-04",[6942],"Refractory Epilepsy",[6925,4935],{"trials":6945,"activeCount":100},[],{"trials":6947,"activeCount":100},[],{"intervention":6949,"totalTrials":118,"cells":6950},"Femoral Nerve Block",{"EARLY_PHASE1":6951,"PHASE1":6953,"PHASE2":6955,"PHASE3":6957,"PHASE4":6969,"NA":6971},{"trials":6952,"activeCount":100},[],{"trials":6954,"activeCount":100},[],{"trials":6956,"activeCount":100},[],{"trials":6958,"activeCount":100},[6959],{"nctId":6960,"briefTitle":6961,"status":166,"phases":6962,"primaryCompletion":6963,"completion":4260,"start":6964,"enrollment":6965,"conditions":6966,"interventions":6968},"NCT03133481","Adductor Canal Block Versus Femoral Nerve Block for Total Knee Arthroplasty",[91],"2017-10","2014-10-22",94,[6967],"Arthropathy of Knee",[6949],{"trials":6970,"activeCount":100},[],{"trials":6972,"activeCount":100},[],{"intervention":6974,"totalTrials":118,"cells":6975},"NicoBloc",{"EARLY_PHASE1":6976,"PHASE1":6978,"PHASE2":6980,"PHASE3":6982,"PHASE4":6995,"NA":6997},{"trials":6977,"activeCount":100},[],{"trials":6979,"activeCount":100},[],{"trials":6981,"activeCount":100},[],{"trials":6983,"activeCount":100},[6984],{"nctId":6985,"briefTitle":6986,"status":166,"phases":6987,"primaryCompletion":6988,"completion":6989,"start":6990,"enrollment":1089,"conditions":6991,"interventions":6993},"NCT03720899","Comparing NicoBloc to Nicotine Lozenges",[90,91],"2021-01-03","2021-03-03","2019-03-21",[4837,6992],"Nicotine Dependence",[6974,6994],"Nicotine Lozenge",{"trials":6996,"activeCount":100},[],{"trials":6998,"activeCount":100},[],{"intervention":6994,"totalTrials":118,"cells":7000},{"EARLY_PHASE1":7001,"PHASE1":7003,"PHASE2":7005,"PHASE3":7007,"PHASE4":7013,"NA":7015},{"trials":7002,"activeCount":100},[],{"trials":7004,"activeCount":100},[],{"trials":7006,"activeCount":100},[],{"trials":7008,"activeCount":100},[7009],{"nctId":6985,"briefTitle":6986,"status":166,"phases":7010,"primaryCompletion":6988,"completion":6989,"start":6990,"enrollment":1089,"conditions":7011,"interventions":7012},[90,91],[4837,6992],[6974,6994],{"trials":7014,"activeCount":100},[],{"trials":7016,"activeCount":100},[],{"intervention":7018,"totalTrials":118,"cells":7019},"SUBA itraconazole",{"EARLY_PHASE1":7020,"PHASE1":7022,"PHASE2":7024,"PHASE3":7026,"PHASE4":7040,"NA":7042},{"trials":7021,"activeCount":100},[],{"trials":7023,"activeCount":100},[],{"trials":7025,"activeCount":100},[],{"trials":7027,"activeCount":100},[7028],{"nctId":7029,"briefTitle":7030,"status":166,"phases":7031,"primaryCompletion":7032,"completion":7033,"start":7034,"enrollment":7035,"conditions":7036,"interventions":7038},"NCT03572049","Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole",[90,91],"2021-05-31","2022-04-29","2018-09-17",88,[7037],"Invasive Fungal Infections",[7018,7039],"Conventional itraconazole",{"trials":7041,"activeCount":100},[],{"trials":7043,"activeCount":100},[],{"intervention":7039,"totalTrials":118,"cells":7045},{"EARLY_PHASE1":7046,"PHASE1":7048,"PHASE2":7050,"PHASE3":7052,"PHASE4":7058,"NA":7060},{"trials":7047,"activeCount":100},[],{"trials":7049,"activeCount":100},[],{"trials":7051,"activeCount":100},[],{"trials":7053,"activeCount":100},[7054],{"nctId":7029,"briefTitle":7030,"status":166,"phases":7055,"primaryCompletion":7032,"completion":7033,"start":7034,"enrollment":7035,"conditions":7056,"interventions":7057},[90,91],[7037],[7018,7039],{"trials":7059,"activeCount":100},[],{"trials":7061,"activeCount":100},[],{"intervention":7063,"totalTrials":921,"cells":7064},"Cisplatin",{"EARLY_PHASE1":7065,"PHASE1":7067,"PHASE2":7085,"PHASE3":7122,"PHASE4":7124,"NA":7126},{"trials":7066,"activeCount":100},[],{"trials":7068,"activeCount":100},[7069,7077],{"nctId":7070,"briefTitle":7071,"status":917,"phases":7072,"start":5942,"enrollment":19,"conditions":7073,"interventions":7075},"NCT00322920","Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurrent Cervical Cancer",[89],[7074],"Cervix Cancer",[7076,7063],"Topotecan",{"nctId":7078,"briefTitle":7079,"status":1196,"phases":7080,"enrollment":100,"conditions":7081,"interventions":7083},"NCT00137358","Radiation With Chemotherapy and a Study Drug to the Para-Aortic Nodes in Cervical Cancer",[89],[7082],"Cervical Cancer",[7063,7084],"Amifostine",{"trials":7086,"activeCount":100},[7087,7097,7108,7118],{"nctId":7088,"briefTitle":7089,"status":166,"phases":7090,"primaryCompletion":7091,"completion":7091,"start":7092,"conditions":7093,"interventions":7094},"NCT00062270","Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer",[89,90],"2004-09","2003-05",[999],[1283,7095,7096,1266],"docetaxel","gefitinib",{"nctId":7098,"briefTitle":7099,"status":166,"phases":7100,"primaryCompletion":6890,"completion":1023,"start":1014,"enrollment":377,"conditions":7101,"interventions":7106},"NCT00318890","Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck",[89,90],[7102,7103,1427,7104,7105],"Cancer of Head and Neck","Head Cancer","Neck Cancer","Neck Neoplasms",[7063,7107,7084],"Docetaxel",{"nctId":7109,"briefTitle":7110,"status":1196,"phases":7111,"primaryCompletion":7112,"completion":7113,"start":401,"enrollment":100,"conditions":7114,"interventions":7117},"NCT04595981","Chemo-embolization for Head and Neck Cancer",[90],"2029-05","2030-05",[7115,7116],"SCCHN","Squamous Cell Carcinoma",[7063],{"nctId":1276,"briefTitle":1277,"status":166,"phases":7119,"primaryCompletion":1279,"completion":1279,"start":1263,"enrollment":1280,"conditions":7120,"interventions":7121},[89,90],[999],[1283,1266,1018],{"trials":7123,"activeCount":100},[],{"trials":7125,"activeCount":100},[],{"trials":7127,"activeCount":100},[],{"intervention":7129,"totalTrials":971,"cells":7130},"rituximab",{"EARLY_PHASE1":7131,"PHASE1":7133,"PHASE2":7144,"PHASE3":7185,"PHASE4":7187,"NA":7189},{"trials":7132,"activeCount":100},[],{"trials":7134,"activeCount":100},[7135],{"nctId":7136,"briefTitle":7137,"status":917,"phases":7138,"primaryCompletion":7139,"completion":7139,"start":7140,"enrollment":7141,"conditions":7142,"interventions":7143},"NCT00033423","Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",[89],"2009-05","2001-08",18,[4007],[7129],{"trials":7145,"activeCount":100},[7146,7154,7165,7175],{"nctId":7147,"briefTitle":7148,"status":166,"phases":7149,"primaryCompletion":5737,"start":7150,"enrollment":986,"conditions":7151,"interventions":7153},"NCT00005652","Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura",[90],"2000-12",[7152],"Purpura, Thrombocytopenic, Idiopathic",[7129],{"nctId":7155,"briefTitle":7156,"status":166,"phases":7157,"primaryCompletion":7158,"completion":7159,"start":7160,"enrollment":963,"conditions":7161,"interventions":7163},"NCT00584935","Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid",[89,90],"2010-01","2026-01-01","2006-01",[7162],"Ocular Cicatricial Pemphigoid",[7164],"Rituximab",{"nctId":7166,"briefTitle":7167,"status":166,"phases":7168,"primaryCompletion":7169,"completion":7170,"start":7171,"enrollment":25,"conditions":7172,"interventions":7173},"NCT00005592","Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",[90],"2002-03","2005-11","1999-11",[4007],[7174,7129],"90-Y-ibritumomab tiuxetan",{"nctId":7176,"briefTitle":7177,"status":166,"phases":7178,"primaryCompletion":7179,"completion":7180,"start":3945,"enrollment":7181,"conditions":7182,"interventions":7184},"NCT01969409","Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis",[90],"2019-01-31","2020-11-30",58,[7183],"Ambulatory IPF",[7164],{"trials":7186,"activeCount":100},[],{"trials":7188,"activeCount":100},[],{"trials":7190,"activeCount":100},[],{"intervention":1266,"totalTrials":906,"cells":7192},{"EARLY_PHASE1":7193,"PHASE1":7195,"PHASE2":7197,"PHASE3":7215,"PHASE4":7217,"NA":7219},{"trials":7194,"activeCount":100},[],{"trials":7196,"activeCount":100},[],{"trials":7198,"activeCount":100},[7199,7203,7207,7211],{"nctId":7088,"briefTitle":7089,"status":166,"phases":7200,"primaryCompletion":7091,"completion":7091,"start":7092,"conditions":7201,"interventions":7202},[89,90],[999],[1283,7095,7096,1266],{"nctId":5949,"briefTitle":5950,"status":1196,"phases":7204,"primaryCompletion":5952,"completion":5952,"start":5943,"enrollment":100,"conditions":7205,"interventions":7206},[90],[5954],[5930,1266],{"nctId":1260,"briefTitle":1261,"status":917,"phases":7208,"primaryCompletion":1263,"completion":1263,"start":1263,"enrollment":16,"conditions":7209,"interventions":7210},[89,90],[999],[1266,1018],{"nctId":1276,"briefTitle":1277,"status":166,"phases":7212,"primaryCompletion":1279,"completion":1279,"start":1263,"enrollment":1280,"conditions":7213,"interventions":7214},[89,90],[999],[1283,1266,1018],{"trials":7216,"activeCount":100},[],{"trials":7218,"activeCount":100},[],{"trials":7220,"activeCount":100},[],{"intervention":7222,"totalTrials":963,"cells":7223},"Erlotinib",{"EARLY_PHASE1":7224,"PHASE1":7226,"PHASE2":7228,"PHASE3":7254,"PHASE4":7256,"NA":7258},{"trials":7225,"activeCount":100},[],{"trials":7227,"activeCount":100},[],{"trials":7229,"activeCount":100},[7230,7238,7246],{"nctId":7231,"briefTitle":7232,"status":917,"phases":7233,"primaryCompletion":7234,"completion":7234,"start":5343,"enrollment":921,"conditions":7235,"interventions":7236},"NCT00841035","7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients",[90],"2011-07",[5954],[7237],"erlotinib",{"nctId":7239,"briefTitle":7240,"status":166,"phases":7241,"primaryCompletion":4858,"completion":7242,"start":7243,"enrollment":271,"conditions":7244,"interventions":7245},"NCT00369512","A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma",[90],"2012-09","2006-08",[1027],[7222],{"nctId":7247,"briefTitle":7248,"status":166,"phases":7249,"primaryCompletion":7250,"completion":7251,"start":1023,"enrollment":1015,"conditions":7252,"interventions":7253},"NCT00570232","UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer",[90],"2014-12","2015-03",[1427],[7222],{"trials":7255,"activeCount":100},[],{"trials":7257,"activeCount":100},[],{"trials":7259,"activeCount":100},[],{"intervention":4009,"totalTrials":96,"cells":7261},{"EARLY_PHASE1":7262,"PHASE1":7264,"PHASE2":7270,"PHASE3":7282,"PHASE4":7284,"NA":7286},{"trials":7263,"activeCount":100},[],{"trials":7265,"activeCount":100},[7266],{"nctId":4001,"briefTitle":4002,"status":166,"phases":7267,"primaryCompletion":4004,"completion":4004,"start":4005,"enrollment":377,"conditions":7268,"interventions":7269},[89],[4007],[4009,3994,4010,4011],{"trials":7271,"activeCount":100},[7272],{"nctId":7273,"briefTitle":7274,"status":166,"phases":7275,"primaryCompletion":7276,"completion":7276,"start":7277,"enrollment":403,"conditions":7278,"interventions":7279},"NCT00004184","Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma",[89,90],"2001-06","1998-08",[6804],[7280,4009,7281],"monoclonal antibody 4B5 anti-idiotype vaccine","alum adjuvant",{"trials":7283,"activeCount":100},[],{"trials":7285,"activeCount":100},[],{"trials":7287,"activeCount":100},[],{"intervention":1377,"totalTrials":96,"cells":7289},{"EARLY_PHASE1":7290,"PHASE1":7292,"PHASE2":7294,"PHASE3":7309,"PHASE4":7311,"NA":7313},{"trials":7291,"activeCount":100},[],{"trials":7293,"activeCount":100},[],{"trials":7295,"activeCount":100},[7296,7305],{"nctId":7297,"briefTitle":7298,"status":166,"phases":7299,"primaryCompletion":7300,"completion":7300,"start":5670,"enrollment":1089,"conditions":7301,"interventions":7304},"NCT02101736","Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults",[90],"2022-02-16",[1531,7302,7303],"Neurofibromatosis","Plexiform Neurofibromas",[1377],{"nctId":1368,"briefTitle":1369,"status":1196,"phases":7306,"primaryCompletion":1371,"completion":1371,"start":1371,"enrollment":100,"conditions":7307,"interventions":7308},[90],[1373,1374,1375],[1377,950,949],{"trials":7310,"activeCount":100},[],{"trials":7312,"activeCount":100},[],{"trials":7314,"activeCount":100},[],{"intervention":7316,"totalTrials":96,"cells":7317},"Alvelestat",{"EARLY_PHASE1":7318,"PHASE1":7320,"PHASE2":7322,"PHASE3":7346,"PHASE4":7348,"NA":7350},{"trials":7319,"activeCount":100},[],{"trials":7321,"activeCount":100},[],{"trials":7323,"activeCount":100},[7324,7333],{"nctId":7325,"briefTitle":7326,"status":166,"phases":7327,"primaryCompletion":7328,"completion":7328,"start":7329,"enrollment":271,"conditions":7330,"interventions":7332},"NCT04539795","COVID-19 Study of Safety and Tolerability of Alvelestat",[89,90],"2021-10-29","2021-01-25",[7331],"Covid19",[7316],{"nctId":7334,"briefTitle":7335,"status":166,"phases":7336,"primaryCompletion":7337,"completion":7338,"start":7339,"enrollment":7340,"conditions":7341,"interventions":7345},"NCT03679598","Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency",[90],"2023-11-30","2023-12-01","2019-04-08",63,[7342,7343,7344],"Alpha-1 Antitrypsin Deficiency (AATD)","Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype\u002FGenotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations","Emphysema or COPD",[7316],{"trials":7347,"activeCount":100},[],{"trials":7349,"activeCount":100},[],{"trials":7351,"activeCount":100},[],{"intervention":1254,"totalTrials":96,"cells":7353},{"EARLY_PHASE1":7354,"PHASE1":7356,"PHASE2":7358,"PHASE3":7372,"PHASE4":7374,"NA":7376},{"trials":7355,"activeCount":100},[],{"trials":7357,"activeCount":100},[],{"trials":7359,"activeCount":100},[7360,7364],{"nctId":1244,"briefTitle":1245,"status":166,"phases":7361,"primaryCompletion":1247,"completion":1248,"start":1249,"enrollment":631,"conditions":7362,"interventions":7363},[90],[1251],[947,1253,1254],{"nctId":7365,"briefTitle":7366,"status":166,"phases":7367,"primaryCompletion":4162,"completion":7368,"start":6480,"enrollment":19,"conditions":7369,"interventions":7370},"NCT00240071","Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.",[90],"2011-04",[1337],[1254,7371],"Hormonal therapy",{"trials":7373,"activeCount":100},[],{"trials":7375,"activeCount":100},[],{"trials":7377,"activeCount":100},[],{"intervention":7379,"totalTrials":96,"cells":7380},"Irinotecan",{"EARLY_PHASE1":7381,"PHASE1":7383,"PHASE2":7385,"PHASE3":7410,"PHASE4":7412,"NA":7414},{"trials":7382,"activeCount":100},[],{"trials":7384,"activeCount":100},[],{"trials":7386,"activeCount":100},[7387,7396],{"nctId":7388,"briefTitle":7389,"status":917,"phases":7390,"primaryCompletion":5942,"completion":5942,"start":7391,"enrollment":96,"conditions":7392,"interventions":7393},"NCT00033306","BMS-247550 in Treating Patients With Metastatic Colorectal Cancer",[90],"2002-02",[5945],[7394,7395,7379],"ixabepilone","Fluoropyrimidine",{"nctId":7397,"briefTitle":7398,"status":166,"phases":7399,"completion":7400,"start":7401,"enrollment":1425,"conditions":7402,"interventions":7408},"NCT00318903","Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer",[90],"2006-04","2002-01",[7403,7404,7405,7406,7407],"Esophageal Cancer","Cancer of the Esophagus","Esophagus Cancer","Esophageal Neoplasm","Cancer of Esophagus",[7379,7409],"Taxotere",{"trials":7411,"activeCount":100},[],{"trials":7413,"activeCount":100},[],{"trials":7415,"activeCount":100},[],{"intervention":7417,"totalTrials":96,"cells":7418},"Ticagrelor",{"EARLY_PHASE1":7419,"PHASE1":7421,"PHASE2":7423,"PHASE3":7443,"PHASE4":7445,"NA":7447},{"trials":7420,"activeCount":100},[],{"trials":7422,"activeCount":100},[],{"trials":7424,"activeCount":100},[7425,7437],{"nctId":7426,"briefTitle":7427,"status":166,"phases":7428,"primaryCompletion":7429,"completion":4435,"start":7430,"enrollment":112,"conditions":7431,"interventions":7434},"NCT02925923","Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel",[90],"2018-01-30","2016-11-01",[7432,7433],"Acute Coronary Syndrome","Angina, Unstable",[7417,7435,7436],"Eptifibatide","Clopidogrel",{"nctId":7438,"briefTitle":7439,"status":166,"phases":7440,"primaryCompletion":3944,"completion":3944,"start":5281,"enrollment":325,"conditions":7441,"interventions":7442},"NCT01919723","Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion",[90],[7432],[7417,7435],{"trials":7444,"activeCount":100},[],{"trials":7446,"activeCount":100},[],{"trials":7448,"activeCount":100},[],{"intervention":7435,"totalTrials":96,"cells":7450},{"EARLY_PHASE1":7451,"PHASE1":7453,"PHASE2":7455,"PHASE3":7465,"PHASE4":7467,"NA":7469},{"trials":7452,"activeCount":100},[],{"trials":7454,"activeCount":100},[],{"trials":7456,"activeCount":100},[7457,7461],{"nctId":7426,"briefTitle":7427,"status":166,"phases":7458,"primaryCompletion":7429,"completion":4435,"start":7430,"enrollment":112,"conditions":7459,"interventions":7460},[90],[7432,7433],[7417,7435,7436],{"nctId":7438,"briefTitle":7439,"status":166,"phases":7462,"primaryCompletion":3944,"completion":3944,"start":5281,"enrollment":325,"conditions":7463,"interventions":7464},[90],[7432],[7417,7435],{"trials":7466,"activeCount":100},[],{"trials":7468,"activeCount":100},[],{"trials":7470,"activeCount":100},[],{"intervention":7095,"totalTrials":96,"cells":7472},{"EARLY_PHASE1":7473,"PHASE1":7475,"PHASE2":7477,"PHASE3":7487,"PHASE4":7489,"NA":7491},{"trials":7474,"activeCount":100},[],{"trials":7476,"activeCount":100},[],{"trials":7478,"activeCount":100},[7479,7483],{"nctId":7088,"briefTitle":7089,"status":166,"phases":7480,"primaryCompletion":7091,"completion":7091,"start":7092,"conditions":7481,"interventions":7482},[89,90],[999],[1283,7095,7096,1266],{"nctId":7098,"briefTitle":7099,"status":166,"phases":7484,"primaryCompletion":6890,"completion":1023,"start":1014,"enrollment":377,"conditions":7485,"interventions":7486},[89,90],[7102,7103,1427,7104,7105],[7063,7107,7084],{"trials":7488,"activeCount":100},[],{"trials":7490,"activeCount":100},[],{"trials":7492,"activeCount":100},[],{"intervention":7084,"totalTrials":96,"cells":7494},{"EARLY_PHASE1":7495,"PHASE1":7497,"PHASE2":7503,"PHASE3":7509,"PHASE4":7511,"NA":7513},{"trials":7496,"activeCount":100},[],{"trials":7498,"activeCount":100},[7499],{"nctId":7078,"briefTitle":7079,"status":1196,"phases":7500,"enrollment":100,"conditions":7501,"interventions":7502},[89],[7082],[7063,7084],{"trials":7504,"activeCount":100},[7505],{"nctId":7098,"briefTitle":7099,"status":166,"phases":7506,"primaryCompletion":6890,"completion":1023,"start":1014,"enrollment":377,"conditions":7507,"interventions":7508},[89,90],[7102,7103,1427,7104,7105],[7063,7107,7084],{"trials":7510,"activeCount":100},[],{"trials":7512,"activeCount":100},[],{"trials":7514,"activeCount":100},[],{"intervention":7516,"totalTrials":96,"cells":7517},"ISIS 2503",{"EARLY_PHASE1":7518,"PHASE1":7520,"PHASE2":7522,"PHASE3":7539,"PHASE4":7541,"NA":7543},{"trials":7519,"activeCount":100},[],{"trials":7521,"activeCount":100},[],{"trials":7523,"activeCount":100},[7524,7531],{"nctId":7525,"briefTitle":7526,"status":166,"phases":7527,"primaryCompletion":7150,"start":7528,"enrollment":906,"conditions":7529,"interventions":7530},"NCT00005594","ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas",[90],"2000-07",[5954],[7516],{"nctId":7532,"briefTitle":7533,"status":917,"phases":7534,"primaryCompletion":7535,"completion":7535,"start":7536,"enrollment":1425,"conditions":7537,"interventions":7538},"NCT00004193","ISIS 2503 in Treating Patients With Metastatic and\u002For Locally Recurrent Colorectal Cancer",[90],"2000-11","1999-01",[5945],[7516],{"trials":7540,"activeCount":100},[],{"trials":7542,"activeCount":100},[],{"trials":7544,"activeCount":100},[],{"intervention":7546,"totalTrials":96,"cells":7547},"TRC105",{"EARLY_PHASE1":7548,"PHASE1":7550,"PHASE2":7560,"PHASE3":7572,"PHASE4":7574,"NA":7576},{"trials":7549,"activeCount":100},[],{"trials":7551,"activeCount":100},[7552],{"nctId":7553,"briefTitle":7554,"status":166,"phases":7555,"primaryCompletion":3973,"completion":1200,"start":7556,"enrollment":7557,"conditions":7558,"interventions":7559},"NCT02429843","A Study of TRC105 in Combination With Paclitaxel\u002FCarboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer",[89],"2015-11-02",16,[999],[7546],{"trials":7561,"activeCount":100},[7562],{"nctId":7563,"briefTitle":7564,"status":166,"phases":7565,"primaryCompletion":7566,"completion":7566,"start":7567,"enrollment":271,"conditions":7568,"interventions":7569},"NCT02520063","Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer",[89,90],"2022-12-01","2015-02-01",[21],[7570,7571,7546],"Letrozole","Everolimus",{"trials":7573,"activeCount":100},[],{"trials":7575,"activeCount":100},[],{"trials":7577,"activeCount":100},[],{"intervention":7579,"totalTrials":96,"cells":7580},"Losartan",{"EARLY_PHASE1":7581,"PHASE1":7583,"PHASE2":7585,"PHASE3":7611,"PHASE4":7613,"NA":7615},{"trials":7582,"activeCount":100},[],{"trials":7584,"activeCount":100},[],{"trials":7586,"activeCount":100},[7587,7598],{"nctId":7588,"briefTitle":7589,"status":917,"phases":7590,"primaryCompletion":1371,"completion":6197,"start":7591,"enrollment":118,"conditions":7592,"interventions":7597},"NCT02373241","Preventing Sickle Cell Kidney Disease",[90],"2015-04",[7593,7594,7595,18,7596],"Anemia, Sickle Cell","Sickle Cell Disease","Kidney Disease","Proteinuria",[7579,7579],{"nctId":7599,"briefTitle":7600,"status":166,"phases":7601,"primaryCompletion":7602,"completion":7602,"start":7603,"enrollment":7604,"conditions":7605,"interventions":7608},"NCT03295734","ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension",[90],"2024-09-19","2018-05-29",223,[18,7606,7607],"Aging","Sedentary Lifestyle",[7609,7579,7610],"Perindopril","HCTZ",{"trials":7612,"activeCount":100},[],{"trials":7614,"activeCount":100},[],{"trials":7616,"activeCount":100},[],{"intervention":7618,"totalTrials":118,"cells":7619},"Paclitaxel and carboplatin combination",{"EARLY_PHASE1":7620,"PHASE1":7622,"PHASE2":7624,"PHASE3":7634,"PHASE4":7636,"NA":7638},{"trials":7621,"activeCount":100},[],{"trials":7623,"activeCount":100},[],{"trials":7625,"activeCount":100},[7626],{"nctId":7627,"briefTitle":7628,"status":917,"phases":7629,"primaryCompletion":169,"completion":7630,"start":7631,"enrollment":191,"conditions":7632,"interventions":7633},"NCT00584909","A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus",[90],"2011-09","2006-03",[1711],[7618],{"trials":7635,"activeCount":100},[],{"trials":7637,"activeCount":100},[],{"trials":7639,"activeCount":100},[],{"intervention":7641,"totalTrials":118,"cells":7642},"Cabazitaxel-XRP6258",{"EARLY_PHASE1":7643,"PHASE1":7645,"PHASE2":7647,"PHASE3":7659,"PHASE4":7661,"NA":7663},{"trials":7644,"activeCount":100},[],{"trials":7646,"activeCount":100},[],{"trials":7648,"activeCount":100},[7649],{"nctId":7650,"briefTitle":7651,"status":166,"phases":7652,"primaryCompletion":7653,"completion":1247,"start":7630,"enrollment":22,"conditions":7654,"interventions":7658},"NCT01438307","Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer",[90],"2014-09",[7655,7656,7657],"Non-small Cell Lung Cancer (NSCLC)","Stage IV NSCLC","Metastatic NSCLC",[7641,7641],{"trials":7660,"activeCount":100},[],{"trials":7662,"activeCount":100},[],{"trials":7664,"activeCount":100},[],{"intervention":7280,"totalTrials":118,"cells":7666},{"EARLY_PHASE1":7667,"PHASE1":7669,"PHASE2":7671,"PHASE3":7677,"PHASE4":7679,"NA":7681},{"trials":7668,"activeCount":100},[],{"trials":7670,"activeCount":100},[],{"trials":7672,"activeCount":100},[7673],{"nctId":7273,"briefTitle":7274,"status":166,"phases":7674,"primaryCompletion":7276,"completion":7276,"start":7277,"enrollment":403,"conditions":7675,"interventions":7676},[89,90],[6804],[7280,4009,7281],{"trials":7678,"activeCount":100},[],{"trials":7680,"activeCount":100},[],{"trials":7682,"activeCount":100},[],{"intervention":7281,"totalTrials":118,"cells":7684},{"EARLY_PHASE1":7685,"PHASE1":7687,"PHASE2":7689,"PHASE3":7695,"PHASE4":7697,"NA":7699},{"trials":7686,"activeCount":100},[],{"trials":7688,"activeCount":100},[],{"trials":7690,"activeCount":100},[7691],{"nctId":7273,"briefTitle":7274,"status":166,"phases":7692,"primaryCompletion":7276,"completion":7276,"start":7277,"enrollment":403,"conditions":7693,"interventions":7694},[89,90],[6804],[7280,4009,7281],{"trials":7696,"activeCount":100},[],{"trials":7698,"activeCount":100},[],{"trials":7700,"activeCount":100},[],{"intervention":7702,"totalTrials":118,"cells":7703},"Novel Drug Combination",{"EARLY_PHASE1":7704,"PHASE1":7706,"PHASE2":7708,"PHASE3":7720,"PHASE4":7722,"NA":7724},{"trials":7705,"activeCount":100},[],{"trials":7707,"activeCount":100},[],{"trials":7709,"activeCount":100},[7710],{"nctId":7711,"briefTitle":7712,"status":166,"phases":7713,"primaryCompletion":2909,"completion":7714,"start":629,"enrollment":19,"conditions":7715,"interventions":7719},"NCT00856830","Bendamustine With Irinotecan Followed by Etoposide\u002FCarboplatin for Patients With Extensive Stage Small Cell Lung Cancer",[89,90],"2016-05",[7716,7717,7718],"Small Cell Lung Cancer","Extensive Stage Lung Cancer","Chemonaive",[7702],{"trials":7721,"activeCount":100},[],{"trials":7723,"activeCount":100},[],{"trials":7725,"activeCount":100},[],{"intervention":7727,"totalTrials":118,"cells":7728},"quadrivalent human papillomavirus",{"EARLY_PHASE1":7729,"PHASE1":7731,"PHASE2":7733,"PHASE3":7747,"PHASE4":7749,"NA":7751},{"trials":7730,"activeCount":100},[],{"trials":7732,"activeCount":100},[],{"trials":7734,"activeCount":100},[7735],{"nctId":7736,"briefTitle":7737,"status":166,"phases":7738,"primaryCompletion":7739,"completion":7740,"start":7741,"enrollment":7742,"conditions":7743,"interventions":7746},"NCT01492582","Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors",[90],"2019-02-08","2020-07-20","2012-07",1499,[7744,7745],"Cancer Survivor","Prevention of Human Papillomavirus Infection",[7727],{"trials":7748,"activeCount":100},[],{"trials":7750,"activeCount":100},[],{"trials":7752,"activeCount":100},[],{"intervention":7754,"totalTrials":118,"cells":7755},"Reserpine",{"EARLY_PHASE1":7756,"PHASE1":7758,"PHASE2":7760,"PHASE3":7771,"PHASE4":7773,"NA":7775},{"trials":7757,"activeCount":100},[],{"trials":7759,"activeCount":100},[],{"trials":7761,"activeCount":100},[7762],{"nctId":7763,"briefTitle":7764,"status":166,"phases":7765,"primaryCompletion":7766,"completion":7766,"start":7767,"enrollment":6891,"conditions":7768,"interventions":7770},"NCT03223272","Mechanisms of Refractory Hypertension (Reserpine)",[90],"2020-01-31","2015-07-23",[7769],"Refractory Hypertension",[7754],{"trials":7772,"activeCount":100},[],{"trials":7774,"activeCount":100},[],{"trials":7776,"activeCount":100},[],{"intervention":7778,"totalTrials":118,"cells":7779},"GKT137831",{"EARLY_PHASE1":7780,"PHASE1":7782,"PHASE2":7784,"PHASE3":7794,"PHASE4":7796,"NA":7798},{"trials":7781,"activeCount":100},[],{"trials":7783,"activeCount":100},[],{"trials":7785,"activeCount":100},[7786],{"nctId":7787,"briefTitle":7788,"status":166,"phases":7789,"primaryCompletion":7790,"completion":7790,"start":7791,"enrollment":7181,"conditions":7792,"interventions":7793},"NCT03865927","GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis",[90],"2024-11-30","2020-09-07",[2485],[7778],{"trials":7795,"activeCount":100},[],{"trials":7797,"activeCount":100},[],{"trials":7799,"activeCount":100},[],{"intervention":7801,"totalTrials":118,"cells":7802},"[18F] fluciclovine",{"EARLY_PHASE1":7803,"PHASE1":7805,"PHASE2":7807,"PHASE3":7818,"PHASE4":7820,"NA":7822},{"trials":7804,"activeCount":100},[],{"trials":7806,"activeCount":100},[],{"trials":7808,"activeCount":100},[7809],{"nctId":7810,"briefTitle":7811,"status":166,"phases":7812,"primaryCompletion":4259,"completion":7813,"start":7814,"enrollment":7141,"conditions":7815,"interventions":7817},"NCT03264456","Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET\u002FMRI",[89,90],"2020-02-13","2017-11-08",[7816],"Prostate Cancer",[7801],{"trials":7819,"activeCount":100},[],{"trials":7821,"activeCount":100},[],{"trials":7823,"activeCount":100},[],{"intervention":1306,"totalTrials":118,"cells":7825},{"EARLY_PHASE1":7826,"PHASE1":7828,"PHASE2":7830,"PHASE3":7836,"PHASE4":7838,"NA":7840},{"trials":7827,"activeCount":100},[],{"trials":7829,"activeCount":100},[],{"trials":7831,"activeCount":100},[7832],{"nctId":1299,"briefTitle":1300,"status":166,"phases":7833,"primaryCompletion":1302,"completion":1302,"start":1303,"enrollment":1089,"conditions":7834,"interventions":7835},[89,90],[1187],[1177,1306],{"trials":7837,"activeCount":100},[],{"trials":7839,"activeCount":100},[],{"trials":7841,"activeCount":100},[],{"intervention":7843,"totalTrials":118,"cells":7844},"Gilotrif",{"EARLY_PHASE1":7845,"PHASE1":7847,"PHASE2":7849,"PHASE3":7860,"PHASE4":7862,"NA":7864},{"trials":7846,"activeCount":100},[],{"trials":7848,"activeCount":100},[],{"trials":7850,"activeCount":100},[7851],{"nctId":7852,"briefTitle":7853,"status":917,"phases":7854,"primaryCompletion":7855,"completion":7856,"start":2907,"enrollment":4179,"conditions":7857,"interventions":7859},"NCT02541903","Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma",[90],"2019-01-26","2020-04",[7858],"Penile Squamous Cell Carcinoma (PSCC)",[7843],{"trials":7861,"activeCount":100},[],{"trials":7863,"activeCount":100},[],{"trials":7865,"activeCount":100},[],{"intervention":7867,"totalTrials":118,"cells":7868},"Regorafenib",{"EARLY_PHASE1":7869,"PHASE1":7871,"PHASE2":7873,"PHASE3":7883,"PHASE4":7885,"NA":7887},{"trials":7870,"activeCount":100},[],{"trials":7872,"activeCount":100},[],{"trials":7874,"activeCount":100},[7875],{"nctId":7876,"briefTitle":7877,"status":166,"phases":7878,"primaryCompletion":7879,"completion":7856,"start":2909,"enrollment":33,"conditions":7880,"interventions":7882},"NCT02459119","Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)",[90],"2019-02",[7881],"Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)",[7867],{"trials":7884,"activeCount":100},[],{"trials":7886,"activeCount":100},[],{"trials":7888,"activeCount":100},[],{"intervention":7890,"totalTrials":118,"cells":7891},"Ivacaftor 150 MG",{"EARLY_PHASE1":7892,"PHASE1":7894,"PHASE2":7896,"PHASE3":7906,"PHASE4":7908,"NA":7910},{"trials":7893,"activeCount":100},[],{"trials":7895,"activeCount":100},[],{"trials":7897,"activeCount":100},[7898],{"nctId":7899,"briefTitle":7900,"status":166,"phases":7901,"primaryCompletion":7902,"completion":7902,"start":7903,"enrollment":1969,"conditions":7904,"interventions":7905},"NCT03085485","The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor",[90],"2022-09-30","2017-03-16",[2911,2946],[7890],{"trials":7907,"activeCount":100},[],{"trials":7909,"activeCount":100},[],{"trials":7911,"activeCount":100},[],{"intervention":7913,"totalTrials":118,"cells":7914},"Verapamil",{"EARLY_PHASE1":7915,"PHASE1":7917,"PHASE2":7919,"PHASE3":7929,"PHASE4":7931,"NA":7933},{"trials":7916,"activeCount":100},[],{"trials":7918,"activeCount":100},[],{"trials":7920,"activeCount":100},[7921],{"nctId":7922,"briefTitle":7923,"status":166,"phases":7924,"primaryCompletion":7925,"completion":1200,"start":6506,"enrollment":5524,"conditions":7926,"interventions":7928},"NCT02372253","Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes",[90],"2017-12",[7927],"Type 1 Diabetes Mellitus",[7913],{"trials":7930,"activeCount":100},[],{"trials":7932,"activeCount":100},[],{"trials":7934,"activeCount":100},[],{"intervention":1340,"totalTrials":118,"cells":7936},{"EARLY_PHASE1":7937,"PHASE1":7939,"PHASE2":7941,"PHASE3":7947,"PHASE4":7949,"NA":7951},{"trials":7938,"activeCount":100},[],{"trials":7940,"activeCount":100},[],{"trials":7942,"activeCount":100},[7943],{"nctId":1331,"briefTitle":1332,"status":917,"phases":7944,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":33,"conditions":7945,"interventions":7946},[90],[1337,1338],[1340,1322,1341],{"trials":7948,"activeCount":100},[],{"trials":7950,"activeCount":100},[],{"trials":7952,"activeCount":100},[],{"intervention":1341,"totalTrials":118,"cells":7954},{"EARLY_PHASE1":7955,"PHASE1":7957,"PHASE2":7959,"PHASE3":7965,"PHASE4":7967,"NA":7969},{"trials":7956,"activeCount":100},[],{"trials":7958,"activeCount":100},[],{"trials":7960,"activeCount":100},[7961],{"nctId":1331,"briefTitle":1332,"status":917,"phases":7962,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":33,"conditions":7963,"interventions":7964},[90],[1337,1338],[1340,1322,1341],{"trials":7966,"activeCount":100},[],{"trials":7968,"activeCount":100},[],{"trials":7970,"activeCount":100},[],{"intervention":7972,"totalTrials":118,"cells":7973},"Binimetinib",{"EARLY_PHASE1":7974,"PHASE1":7976,"PHASE2":7978,"PHASE3":7989,"PHASE4":7991,"NA":7993},{"trials":7975,"activeCount":100},[],{"trials":7977,"activeCount":100},[],{"trials":7979,"activeCount":100},[7980],{"nctId":7981,"briefTitle":7982,"status":166,"phases":7983,"primaryCompletion":7984,"completion":7984,"start":7985,"enrollment":1089,"conditions":7986,"interventions":7988},"NCT03231306","Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas",[90],"2024-04-17","2017-11-28",[7987,2254],"Neurofibromatosis Type 1",[7972],{"trials":7990,"activeCount":100},[],{"trials":7992,"activeCount":100},[],{"trials":7994,"activeCount":100},[],{"intervention":7996,"totalTrials":118,"cells":7997},"Abemaciclib 150 MG by mouth twice daily",{"EARLY_PHASE1":7998,"PHASE1":8000,"PHASE2":8002,"PHASE3":8015,"PHASE4":8017,"NA":8019},{"trials":7999,"activeCount":100},[],{"trials":8001,"activeCount":100},[],{"trials":8003,"activeCount":100},[8004],{"nctId":8005,"briefTitle":8006,"status":917,"phases":8007,"primaryCompletion":8008,"completion":8009,"start":8010,"enrollment":8011,"conditions":8012,"interventions":8013},"NCT04298983","Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer",[90],"2024-07-18","2024-09-04","2021-02-25",9,[7816],[7996,8014],"Androgen deprivation therapy",{"trials":8016,"activeCount":100},[],{"trials":8018,"activeCount":100},[],{"trials":8020,"activeCount":100},[],{"intervention":8014,"totalTrials":118,"cells":8022},{"EARLY_PHASE1":8023,"PHASE1":8025,"PHASE2":8027,"PHASE3":8033,"PHASE4":8035,"NA":8037},{"trials":8024,"activeCount":100},[],{"trials":8026,"activeCount":100},[],{"trials":8028,"activeCount":100},[8029],{"nctId":8005,"briefTitle":8006,"status":917,"phases":8030,"primaryCompletion":8008,"completion":8009,"start":8010,"enrollment":8011,"conditions":8031,"interventions":8032},[90],[7816],[7996,8014],{"trials":8034,"activeCount":100},[],{"trials":8036,"activeCount":100},[],{"trials":8038,"activeCount":100},[],{"intervention":8040,"totalTrials":118,"cells":8041},"oral metronidazole",{"EARLY_PHASE1":8042,"PHASE1":8044,"PHASE2":8046,"PHASE3":8060,"PHASE4":8062,"NA":8064},{"trials":8043,"activeCount":100},[],{"trials":8045,"activeCount":100},[],{"trials":8047,"activeCount":100},[8048],{"nctId":8049,"briefTitle":8050,"status":166,"phases":8051,"primaryCompletion":8052,"completion":8053,"start":8054,"enrollment":1969,"conditions":8055,"interventions":8057},"NCT01361048","Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis",[90],"2012-08","2013-01","2011-12",[8056],"Trichomonas Vaginitis",[8040,8058,8059],"neo penotran forte","neo penotran forte once a day",{"trials":8061,"activeCount":100},[],{"trials":8063,"activeCount":100},[],{"trials":8065,"activeCount":100},[],{"intervention":8058,"totalTrials":118,"cells":8067},{"EARLY_PHASE1":8068,"PHASE1":8070,"PHASE2":8072,"PHASE3":8078,"PHASE4":8080,"NA":8082},{"trials":8069,"activeCount":100},[],{"trials":8071,"activeCount":100},[],{"trials":8073,"activeCount":100},[8074],{"nctId":8049,"briefTitle":8050,"status":166,"phases":8075,"primaryCompletion":8052,"completion":8053,"start":8054,"enrollment":1969,"conditions":8076,"interventions":8077},[90],[8056],[8040,8058,8059],{"trials":8079,"activeCount":100},[],{"trials":8081,"activeCount":100},[],{"trials":8083,"activeCount":100},[],{"intervention":8059,"totalTrials":118,"cells":8085},{"EARLY_PHASE1":8086,"PHASE1":8088,"PHASE2":8090,"PHASE3":8096,"PHASE4":8098,"NA":8100},{"trials":8087,"activeCount":100},[],{"trials":8089,"activeCount":100},[],{"trials":8091,"activeCount":100},[8092],{"nctId":8049,"briefTitle":8050,"status":166,"phases":8093,"primaryCompletion":8052,"completion":8053,"start":8054,"enrollment":1969,"conditions":8094,"interventions":8095},[90],[8056],[8040,8058,8059],{"trials":8097,"activeCount":100},[],{"trials":8099,"activeCount":100},[],{"trials":8101,"activeCount":100},[],{"intervention":8103,"totalTrials":118,"cells":8104},"Paclitaxel ,Carboplatin , Megesterol Acetate",{"EARLY_PHASE1":8105,"PHASE1":8107,"PHASE2":8109,"PHASE3":8120,"PHASE4":8122,"NA":8124},{"trials":8106,"activeCount":100},[],{"trials":8108,"activeCount":100},[],{"trials":8110,"activeCount":100},[8111],{"nctId":8112,"briefTitle":8113,"status":166,"phases":8114,"primaryCompletion":8115,"completion":8116,"start":8117,"enrollment":19,"conditions":8118,"interventions":8119},"NCT00584857","A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer",[90],"2010-10","2011-10","2004-07",[1711],[8103],{"trials":8121,"activeCount":100},[],{"trials":8123,"activeCount":100},[],{"trials":8125,"activeCount":100},[],{"intervention":8127,"totalTrials":118,"cells":8128},"Abraxane alone",{"EARLY_PHASE1":8129,"PHASE1":8131,"PHASE2":8133,"PHASE3":8145,"PHASE4":8147,"NA":8149},{"trials":8130,"activeCount":100},[],{"trials":8132,"activeCount":100},[],{"trials":8134,"activeCount":100},[8135],{"nctId":8136,"briefTitle":8137,"status":166,"phases":8138,"primaryCompletion":5669,"completion":8139,"start":8140,"enrollment":511,"conditions":8141,"interventions":8143},"NCT01307891","Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer",[90],"2017-06","2011-03",[21,3226,8142,1337],"Stage IV Breast Cancer",[8127,8144],"Abraxane + Tigatuzumab",{"trials":8146,"activeCount":100},[],{"trials":8148,"activeCount":100},[],{"trials":8150,"activeCount":100},[],{"intervention":8144,"totalTrials":118,"cells":8152},{"EARLY_PHASE1":8153,"PHASE1":8155,"PHASE2":8157,"PHASE3":8163,"PHASE4":8165,"NA":8167},{"trials":8154,"activeCount":100},[],{"trials":8156,"activeCount":100},[],{"trials":8158,"activeCount":100},[8159],{"nctId":8136,"briefTitle":8137,"status":166,"phases":8160,"primaryCompletion":5669,"completion":8139,"start":8140,"enrollment":511,"conditions":8161,"interventions":8162},[90],[21,3226,8142,1337],[8127,8144],{"trials":8164,"activeCount":100},[],{"trials":8166,"activeCount":100},[],{"trials":8168,"activeCount":100},[],{"intervention":1253,"totalTrials":118,"cells":8170},{"EARLY_PHASE1":8171,"PHASE1":8173,"PHASE2":8175,"PHASE3":8181,"PHASE4":8183,"NA":8185},{"trials":8172,"activeCount":100},[],{"trials":8174,"activeCount":100},[],{"trials":8176,"activeCount":100},[8177],{"nctId":1244,"briefTitle":1245,"status":166,"phases":8178,"primaryCompletion":1247,"completion":1248,"start":1249,"enrollment":631,"conditions":8179,"interventions":8180},[90],[1251],[947,1253,1254],{"trials":8182,"activeCount":100},[],{"trials":8184,"activeCount":100},[],{"trials":8186,"activeCount":100},[],{"intervention":8188,"totalTrials":118,"cells":8189},"Letrozole; Avastin",{"EARLY_PHASE1":8190,"PHASE1":8192,"PHASE2":8194,"PHASE3":8206,"PHASE4":8208,"NA":8210},{"trials":8191,"activeCount":100},[],{"trials":8193,"activeCount":100},[],{"trials":8195,"activeCount":100},[8196],{"nctId":8197,"briefTitle":8198,"status":166,"phases":8199,"primaryCompletion":5499,"completion":8200,"start":8201,"enrollment":2370,"conditions":8202,"interventions":8205},"NCT00530868","Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer",[90],"2022-03-31","2007-10-08",[21,8203,8204],"Cancer of the Breast","Breast Neoplasm",[8188],{"trials":8207,"activeCount":100},[],{"trials":8209,"activeCount":100},[],{"trials":8211,"activeCount":100},[],{"intervention":5947,"totalTrials":118,"cells":8213},{"EARLY_PHASE1":8214,"PHASE1":8216,"PHASE2":8218,"PHASE3":8224,"PHASE4":8226,"NA":8228},{"trials":8215,"activeCount":100},[],{"trials":8217,"activeCount":100},[],{"trials":8219,"activeCount":100},[8220],{"nctId":5939,"briefTitle":5940,"status":166,"phases":8221,"primaryCompletion":5942,"completion":5942,"start":5943,"enrollment":3281,"conditions":8222,"interventions":8223},[90],[5945],[5930,5947],{"trials":8225,"activeCount":100},[],{"trials":8227,"activeCount":100},[],{"trials":8229,"activeCount":100},[],{"intervention":8231,"totalTrials":118,"cells":8232},"Metoprolol Succinate ER",{"EARLY_PHASE1":8233,"PHASE1":8235,"PHASE2":8237,"PHASE3":8249,"PHASE4":8251,"NA":8253},{"trials":8234,"activeCount":100},[],{"trials":8236,"activeCount":100},[],{"trials":8238,"activeCount":100},[8239],{"nctId":8240,"briefTitle":8241,"status":166,"phases":8242,"primaryCompletion":8243,"completion":8244,"start":8245,"enrollment":1185,"conditions":8246,"interventions":8248},"NCT03070184","Race, Natriuretic Peptides and Physiological Perturbations",[90],"2023-12-31","2024-04-30","2017-04-30",[2462,8247],"Pre Hypertension",[8231],{"trials":8250,"activeCount":100},[],{"trials":8252,"activeCount":100},[],{"trials":8254,"activeCount":100},[],{"intervention":7394,"totalTrials":118,"cells":8256},{"EARLY_PHASE1":8257,"PHASE1":8259,"PHASE2":8261,"PHASE3":8267,"PHASE4":8269,"NA":8271},{"trials":8258,"activeCount":100},[],{"trials":8260,"activeCount":100},[],{"trials":8262,"activeCount":100},[8263],{"nctId":7388,"briefTitle":7389,"status":917,"phases":8264,"primaryCompletion":5942,"completion":5942,"start":7391,"enrollment":96,"conditions":8265,"interventions":8266},[90],[5945],[7394,7395,7379],{"trials":8268,"activeCount":100},[],{"trials":8270,"activeCount":100},[],{"trials":8272,"activeCount":100},[],{"intervention":7395,"totalTrials":118,"cells":8274},{"EARLY_PHASE1":8275,"PHASE1":8277,"PHASE2":8279,"PHASE3":8285,"PHASE4":8287,"NA":8289},{"trials":8276,"activeCount":100},[],{"trials":8278,"activeCount":100},[],{"trials":8280,"activeCount":100},[8281],{"nctId":7388,"briefTitle":7389,"status":917,"phases":8282,"primaryCompletion":5942,"completion":5942,"start":7391,"enrollment":96,"conditions":8283,"interventions":8284},[90],[5945],[7394,7395,7379],{"trials":8286,"activeCount":100},[],{"trials":8288,"activeCount":100},[],{"trials":8290,"activeCount":100},[],{"intervention":8292,"totalTrials":118,"cells":8293},"KRdD followed by auto-HCT",{"EARLY_PHASE1":8294,"PHASE1":8296,"PHASE2":8298,"PHASE3":8309,"PHASE4":8311,"NA":8313},{"trials":8295,"activeCount":100},[],{"trials":8297,"activeCount":100},[],{"trials":8299,"activeCount":100},[8300],{"nctId":8301,"briefTitle":8302,"status":166,"phases":8303,"primaryCompletion":2517,"completion":1223,"start":8304,"enrollment":8305,"conditions":8306,"interventions":8307},"NCT03224507","Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma",[90],"2018-03-14",123,[1187],[8292,8308],"KRdD only",{"trials":8310,"activeCount":100},[],{"trials":8312,"activeCount":100},[],{"trials":8314,"activeCount":100},[],{"intervention":8308,"totalTrials":118,"cells":8316},{"EARLY_PHASE1":8317,"PHASE1":8319,"PHASE2":8321,"PHASE3":8327,"PHASE4":8329,"NA":8331},{"trials":8318,"activeCount":100},[],{"trials":8320,"activeCount":100},[],{"trials":8322,"activeCount":100},[8323],{"nctId":8301,"briefTitle":8302,"status":166,"phases":8324,"primaryCompletion":2517,"completion":1223,"start":8304,"enrollment":8305,"conditions":8325,"interventions":8326},[90],[1187],[8292,8308],{"trials":8328,"activeCount":100},[],{"trials":8330,"activeCount":100},[],{"trials":8332,"activeCount":100},[],{"intervention":8334,"totalTrials":118,"cells":8335},"Study Group",{"EARLY_PHASE1":8336,"PHASE1":8338,"PHASE2":8340,"PHASE3":8353,"PHASE4":8355,"NA":8357},{"trials":8337,"activeCount":100},[],{"trials":8339,"activeCount":100},[],{"trials":8341,"activeCount":100},[8342],{"nctId":8343,"briefTitle":8344,"status":166,"phases":8345,"primaryCompletion":8346,"completion":8346,"start":8347,"enrollment":8348,"conditions":8349,"interventions":8351},"NCT03762473","Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection",[90],"2022-03-16","2019-05-09",89,[8350],"Renal Transplant Infection",[8334,8352],"Control Group",{"trials":8354,"activeCount":100},[],{"trials":8356,"activeCount":100},[],{"trials":8358,"activeCount":100},[],{"intervention":8352,"totalTrials":118,"cells":8360},{"EARLY_PHASE1":8361,"PHASE1":8363,"PHASE2":8365,"PHASE3":8371,"PHASE4":8373,"NA":8375},{"trials":8362,"activeCount":100},[],{"trials":8364,"activeCount":100},[],{"trials":8366,"activeCount":100},[8367],{"nctId":8343,"briefTitle":8344,"status":166,"phases":8368,"primaryCompletion":8346,"completion":8346,"start":8347,"enrollment":8348,"conditions":8369,"interventions":8370},[90],[8350],[8334,8352],{"trials":8372,"activeCount":100},[],{"trials":8374,"activeCount":100},[],{"trials":8376,"activeCount":100},[],{"intervention":8378,"totalTrials":118,"cells":8379},"Solaraze and Vaniqa",{"EARLY_PHASE1":8380,"PHASE1":8382,"PHASE2":8384,"PHASE3":8394,"PHASE4":8396,"NA":8398},{"trials":8381,"activeCount":100},[],{"trials":8383,"activeCount":100},[],{"trials":8385,"activeCount":100},[8386],{"nctId":8387,"briefTitle":8388,"status":166,"phases":8389,"primaryCompletion":8390,"completion":8390,"start":8391,"enrollment":511,"conditions":8392,"interventions":8393},"NCT04091022","Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer",[90],"2025-12-11","2021-01-18",[4366],[8378],{"trials":8395,"activeCount":100},[],{"trials":8397,"activeCount":100},[],{"trials":8399,"activeCount":100},[],{"intervention":8401,"totalTrials":118,"cells":8402},"AZ compound",{"EARLY_PHASE1":8403,"PHASE1":8405,"PHASE2":8407,"PHASE3":8419,"PHASE4":8421,"NA":8423},{"trials":8404,"activeCount":100},[],{"trials":8406,"activeCount":100},[],{"trials":8408,"activeCount":100},[8409],{"nctId":8410,"briefTitle":8411,"status":917,"phases":8412,"primaryCompletion":8413,"completion":8413,"start":2908,"enrollment":8414,"conditions":8415,"interventions":8418},"NCT02605616","Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)",[90],"2019-09",93,[8416,8417],"Non-alcoholic Fatty Liver Disease (NAFLD)","Non-alcoholic Steatohepatitis (NASH)",[8401],{"trials":8420,"activeCount":100},[],{"trials":8422,"activeCount":100},[],{"trials":8424,"activeCount":100},[],{"intervention":8426,"totalTrials":118,"cells":8427},"Pre-Isolation",{"EARLY_PHASE1":8428,"PHASE1":8430,"PHASE2":8432,"PHASE3":8443,"PHASE4":8445,"NA":8447},{"trials":8429,"activeCount":100},[],{"trials":8431,"activeCount":100},[],{"trials":8433,"activeCount":100},[8434],{"nctId":8435,"briefTitle":8436,"status":917,"phases":8437,"primaryCompletion":8438,"completion":8438,"start":8439,"enrollment":906,"conditions":8440,"interventions":8441},"NCT03544242","Nitrite Infusion in Islet Cell Transplantation",[90],"2019-06-27","2017-05-07",[4861],[8426,8442],"Post-Isolation",{"trials":8444,"activeCount":100},[],{"trials":8446,"activeCount":100},[],{"trials":8448,"activeCount":100},[],{"intervention":8442,"totalTrials":118,"cells":8450},{"EARLY_PHASE1":8451,"PHASE1":8453,"PHASE2":8455,"PHASE3":8461,"PHASE4":8463,"NA":8465},{"trials":8452,"activeCount":100},[],{"trials":8454,"activeCount":100},[],{"trials":8456,"activeCount":100},[8457],{"nctId":8435,"briefTitle":8436,"status":917,"phases":8458,"primaryCompletion":8438,"completion":8438,"start":8439,"enrollment":906,"conditions":8459,"interventions":8460},[90],[4861],[8426,8442],{"trials":8462,"activeCount":100},[],{"trials":8464,"activeCount":100},[],{"trials":8466,"activeCount":100},[],{"intervention":8468,"totalTrials":118,"cells":8469},"FMISO",{"EARLY_PHASE1":8470,"PHASE1":8472,"PHASE2":8474,"PHASE3":8484,"PHASE4":8486,"NA":8488},{"trials":8471,"activeCount":100},[],{"trials":8473,"activeCount":100},[],{"trials":8475,"activeCount":100},[8476],{"nctId":8477,"briefTitle":8478,"status":917,"phases":8479,"primaryCompletion":8480,"completion":8480,"start":8481,"enrollment":963,"conditions":8482,"interventions":8483},"NCT03303469","Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging",[90],"2021-01-06","2017-10-30",[1091],[8468,8468,8468],{"trials":8485,"activeCount":100},[],{"trials":8487,"activeCount":100},[],{"trials":8489,"activeCount":100},[],{"intervention":8491,"totalTrials":118,"cells":8492},"[68Ga]DOTATATE-PET\u002FMRI",{"EARLY_PHASE1":8493,"PHASE1":8495,"PHASE2":8497,"PHASE3":8506,"PHASE4":8508,"NA":8510},{"trials":8494,"activeCount":100},[],{"trials":8496,"activeCount":100},[],{"trials":8498,"activeCount":100},[8499],{"nctId":8500,"briefTitle":8501,"status":166,"phases":8502,"primaryCompletion":8503,"completion":8503,"start":4259,"enrollment":1476,"conditions":8504,"interventions":8505},"NCT03648073","[68Ga]DOTATATE-PET\u002FMRI in Hepatocellular Carcinoma",[89,90],"2022-02-03",[1091],[8491],{"trials":8507,"activeCount":100},[],{"trials":8509,"activeCount":100},[],{"trials":8511,"activeCount":100},[],{"intervention":8513,"totalTrials":118,"cells":8514},"Zometa",{"EARLY_PHASE1":8515,"PHASE1":8517,"PHASE2":8519,"PHASE3":8529,"PHASE4":8531,"NA":8533},{"trials":8516,"activeCount":100},[],{"trials":8518,"activeCount":100},[],{"trials":8520,"activeCount":100},[8521],{"nctId":8522,"briefTitle":8523,"status":166,"phases":8524,"primaryCompletion":7591,"completion":8525,"start":4032,"enrollment":4179,"conditions":8526,"interventions":8528},"NCT01204203","Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)",[90],"2016-04",[8527],"Mesothelioma",[8513],{"trials":8530,"activeCount":100},[],{"trials":8532,"activeCount":100},[],{"trials":8534,"activeCount":100},[],{"intervention":1002,"totalTrials":118,"cells":8536},{"EARLY_PHASE1":8537,"PHASE1":8539,"PHASE2":8541,"PHASE3":8547,"PHASE4":8549,"NA":8551},{"trials":8538,"activeCount":100},[],{"trials":8540,"activeCount":100},[],{"trials":8542,"activeCount":100},[8543],{"nctId":992,"briefTitle":993,"status":166,"phases":8544,"primaryCompletion":995,"completion":995,"start":996,"enrollment":997,"conditions":8545,"interventions":8546},[89,90],[999],[1001,1002,1003,1004],{"trials":8548,"activeCount":100},[],{"trials":8550,"activeCount":100},[],{"trials":8552,"activeCount":100},[],{"intervention":1003,"totalTrials":118,"cells":8554},{"EARLY_PHASE1":8555,"PHASE1":8557,"PHASE2":8559,"PHASE3":8565,"PHASE4":8567,"NA":8569},{"trials":8556,"activeCount":100},[],{"trials":8558,"activeCount":100},[],{"trials":8560,"activeCount":100},[8561],{"nctId":992,"briefTitle":993,"status":166,"phases":8562,"primaryCompletion":995,"completion":995,"start":996,"enrollment":997,"conditions":8563,"interventions":8564},[89,90],[999],[1001,1002,1003,1004],{"trials":8566,"activeCount":100},[],{"trials":8568,"activeCount":100},[],{"trials":8570,"activeCount":100},[],{"intervention":1004,"totalTrials":118,"cells":8572},{"EARLY_PHASE1":8573,"PHASE1":8575,"PHASE2":8577,"PHASE3":8583,"PHASE4":8585,"NA":8587},{"trials":8574,"activeCount":100},[],{"trials":8576,"activeCount":100},[],{"trials":8578,"activeCount":100},[8579],{"nctId":992,"briefTitle":993,"status":166,"phases":8580,"primaryCompletion":995,"completion":995,"start":996,"enrollment":997,"conditions":8581,"interventions":8582},[89,90],[999],[1001,1002,1003,1004],{"trials":8584,"activeCount":100},[],{"trials":8586,"activeCount":100},[],{"trials":8588,"activeCount":100},[],{"intervention":8590,"totalTrials":118,"cells":8591},"Fluoxetine",{"EARLY_PHASE1":8592,"PHASE1":8594,"PHASE2":8596,"PHASE3":8608,"PHASE4":8610,"NA":8612},{"trials":8593,"activeCount":100},[],{"trials":8595,"activeCount":100},[],{"trials":8597,"activeCount":100},[8598],{"nctId":8599,"briefTitle":8600,"status":1196,"phases":8601,"primaryCompletion":8602,"completion":8603,"start":8604,"enrollment":100,"conditions":8605,"interventions":8607},"NCT01963832","RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke",[90],"2020-11","2021-11","2016-11",[8606],"Severe Stroke With Affected Arm Motor Function",[8590],{"trials":8609,"activeCount":100},[],{"trials":8611,"activeCount":100},[],{"trials":8613,"activeCount":100},[],{"intervention":7436,"totalTrials":118,"cells":8615},{"EARLY_PHASE1":8616,"PHASE1":8618,"PHASE2":8620,"PHASE3":8626,"PHASE4":8628,"NA":8630},{"trials":8617,"activeCount":100},[],{"trials":8619,"activeCount":100},[],{"trials":8621,"activeCount":100},[8622],{"nctId":7426,"briefTitle":7427,"status":166,"phases":8623,"primaryCompletion":7429,"completion":4435,"start":7430,"enrollment":112,"conditions":8624,"interventions":8625},[90],[7432,7433],[7417,7435,7436],{"trials":8627,"activeCount":100},[],{"trials":8629,"activeCount":100},[],{"trials":8631,"activeCount":100},[],{"intervention":8633,"totalTrials":118,"cells":8634},"fenretinide",{"EARLY_PHASE1":8635,"PHASE1":8637,"PHASE2":8639,"PHASE3":8648,"PHASE4":8650,"NA":8652},{"trials":8636,"activeCount":100},[],{"trials":8638,"activeCount":100},[],{"trials":8640,"activeCount":100},[8641],{"nctId":8642,"briefTitle":8643,"status":166,"phases":8644,"primaryCompletion":8645,"completion":8645,"start":4005,"enrollment":19,"conditions":8646,"interventions":8647},"NCT00004161","Fenretinide in Treating Patients With Leukoplakia of the Mouth",[90],"2004-01",[1427],[8633],{"trials":8649,"activeCount":100},[],{"trials":8651,"activeCount":100},[],{"trials":8653,"activeCount":100},[],{"intervention":8655,"totalTrials":118,"cells":8656},"Denosumab",{"EARLY_PHASE1":8657,"PHASE1":8659,"PHASE2":8661,"PHASE3":8672,"PHASE4":8674,"NA":8676},{"trials":8658,"activeCount":100},[],{"trials":8660,"activeCount":100},[],{"trials":8662,"activeCount":100},[8663],{"nctId":8664,"briefTitle":8665,"status":166,"phases":8666,"primaryCompletion":8667,"completion":8667,"start":8668,"enrollment":986,"conditions":8669,"interventions":8671},"NCT02903446","Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions",[90],"2020-03-01","2017-02-01",[8670],"Gout",[8655],{"trials":8673,"activeCount":100},[],{"trials":8675,"activeCount":100},[],{"trials":8677,"activeCount":100},[],{"intervention":7096,"totalTrials":118,"cells":8679},{"EARLY_PHASE1":8680,"PHASE1":8682,"PHASE2":8684,"PHASE3":8690,"PHASE4":8692,"NA":8694},{"trials":8681,"activeCount":100},[],{"trials":8683,"activeCount":100},[],{"trials":8685,"activeCount":100},[8686],{"nctId":7088,"briefTitle":7089,"status":166,"phases":8687,"primaryCompletion":7091,"completion":7091,"start":7092,"conditions":8688,"interventions":8689},[89,90],[999],[1283,7095,7096,1266],{"trials":8691,"activeCount":100},[],{"trials":8693,"activeCount":100},[],{"trials":8695,"activeCount":100},[],{"intervention":8697,"totalTrials":118,"cells":8698},"Intervention A: Irinotecan; Oxaliplatin; Neulasta",{"EARLY_PHASE1":8699,"PHASE1":8701,"PHASE2":8703,"PHASE3":8712,"PHASE4":8714,"NA":8716},{"trials":8700,"activeCount":100},[],{"trials":8702,"activeCount":100},[],{"trials":8704,"activeCount":100},[8705],{"nctId":8706,"briefTitle":8707,"status":166,"phases":8708,"primaryCompletion":4131,"completion":4131,"start":4177,"enrollment":19,"conditions":8709,"interventions":8710},"NCT00240097","Study of Sequential Topoisomerase, Irinotecan\u002FOxaliplatin - Etoposide \u002FCarboplatin in Extensive Small Cell Lung Cancer (SCLC)",[90],[1251],[8697,8711],"Intervention B: Etoposide; Carboplatin; Neulasta",{"trials":8713,"activeCount":100},[],{"trials":8715,"activeCount":100},[],{"trials":8717,"activeCount":100},[],{"intervention":8711,"totalTrials":118,"cells":8719},{"EARLY_PHASE1":8720,"PHASE1":8722,"PHASE2":8724,"PHASE3":8730,"PHASE4":8732,"NA":8734},{"trials":8721,"activeCount":100},[],{"trials":8723,"activeCount":100},[],{"trials":8725,"activeCount":100},[8726],{"nctId":8706,"briefTitle":8707,"status":166,"phases":8727,"primaryCompletion":4131,"completion":4131,"start":4177,"enrollment":19,"conditions":8728,"interventions":8729},[90],[1251],[8697,8711],{"trials":8731,"activeCount":100},[],{"trials":8733,"activeCount":100},[],{"trials":8735,"activeCount":100},[],{"intervention":8737,"totalTrials":118,"cells":8738},"Collagen-hydroxyapatite scaffold",{"EARLY_PHASE1":8739,"PHASE1":8741,"PHASE2":8743,"PHASE3":8754,"PHASE4":8756,"NA":8758},{"trials":8740,"activeCount":100},[],{"trials":8742,"activeCount":100},[],{"trials":8744,"activeCount":100},[8745],{"nctId":8746,"briefTitle":8747,"status":1196,"phases":8748,"primaryCompletion":8749,"completion":8749,"start":8749,"enrollment":100,"conditions":8750,"interventions":8752},"NCT03613090","Novel Collagen Scaffold vs Conventional Scaffold in Regeneration of Human Dental Pulp Tissue",[90],"2019-04-01",[8751],"Root Canal Therapy",[8737,8753],"Collagen Scaffold",{"trials":8755,"activeCount":100},[],{"trials":8757,"activeCount":100},[],{"trials":8759,"activeCount":100},[],{"intervention":8753,"totalTrials":118,"cells":8761},{"EARLY_PHASE1":8762,"PHASE1":8764,"PHASE2":8766,"PHASE3":8772,"PHASE4":8774,"NA":8776},{"trials":8763,"activeCount":100},[],{"trials":8765,"activeCount":100},[],{"trials":8767,"activeCount":100},[8768],{"nctId":8746,"briefTitle":8747,"status":1196,"phases":8769,"primaryCompletion":8749,"completion":8749,"start":8749,"enrollment":100,"conditions":8770,"interventions":8771},[90],[8751],[8737,8753],{"trials":8773,"activeCount":100},[],{"trials":8775,"activeCount":100},[],{"trials":8777,"activeCount":100},[],{"intervention":8779,"totalTrials":118,"cells":8780},"bicalutamide",{"EARLY_PHASE1":8781,"PHASE1":8783,"PHASE2":8785,"PHASE3":8798,"PHASE4":8800,"NA":8802},{"trials":8782,"activeCount":100},[],{"trials":8784,"activeCount":100},[],{"trials":8786,"activeCount":100},[8787],{"nctId":8788,"briefTitle":8789,"status":166,"phases":8790,"primaryCompletion":8791,"completion":8791,"start":8792,"enrollment":4299,"conditions":8793,"interventions":8794},"NCT00086736","Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy",[90],"2003-11","2001-11",[7816],[8779,8795,8796,8797],"eflornithine","oral eflornithine placebo","oral bicalutamide placebo",{"trials":8799,"activeCount":100},[],{"trials":8801,"activeCount":100},[],{"trials":8803,"activeCount":100},[],{"intervention":8795,"totalTrials":118,"cells":8805},{"EARLY_PHASE1":8806,"PHASE1":8808,"PHASE2":8810,"PHASE3":8816,"PHASE4":8818,"NA":8820},{"trials":8807,"activeCount":100},[],{"trials":8809,"activeCount":100},[],{"trials":8811,"activeCount":100},[8812],{"nctId":8788,"briefTitle":8789,"status":166,"phases":8813,"primaryCompletion":8791,"completion":8791,"start":8792,"enrollment":4299,"conditions":8814,"interventions":8815},[90],[7816],[8779,8795,8796,8797],{"trials":8817,"activeCount":100},[],{"trials":8819,"activeCount":100},[],{"trials":8821,"activeCount":100},[],{"intervention":8796,"totalTrials":118,"cells":8823},{"EARLY_PHASE1":8824,"PHASE1":8826,"PHASE2":8828,"PHASE3":8834,"PHASE4":8836,"NA":8838},{"trials":8825,"activeCount":100},[],{"trials":8827,"activeCount":100},[],{"trials":8829,"activeCount":100},[8830],{"nctId":8788,"briefTitle":8789,"status":166,"phases":8831,"primaryCompletion":8791,"completion":8791,"start":8792,"enrollment":4299,"conditions":8832,"interventions":8833},[90],[7816],[8779,8795,8796,8797],{"trials":8835,"activeCount":100},[],{"trials":8837,"activeCount":100},[],{"trials":8839,"activeCount":100},[],{"intervention":8797,"totalTrials":118,"cells":8841},{"EARLY_PHASE1":8842,"PHASE1":8844,"PHASE2":8846,"PHASE3":8852,"PHASE4":8854,"NA":8856},{"trials":8843,"activeCount":100},[],{"trials":8845,"activeCount":100},[],{"trials":8847,"activeCount":100},[8848],{"nctId":8788,"briefTitle":8789,"status":166,"phases":8849,"primaryCompletion":8791,"completion":8791,"start":8792,"enrollment":4299,"conditions":8850,"interventions":8851},[90],[7816],[8779,8795,8796,8797],{"trials":8853,"activeCount":100},[],{"trials":8855,"activeCount":100},[],{"trials":8857,"activeCount":100},[],{"intervention":1178,"totalTrials":118,"cells":8859},{"EARLY_PHASE1":8860,"PHASE1":8862,"PHASE2":8864,"PHASE3":8870,"PHASE4":8872,"NA":8874},{"trials":8861,"activeCount":100},[],{"trials":8863,"activeCount":100},[],{"trials":8865,"activeCount":100},[8866],{"nctId":1168,"briefTitle":1169,"status":166,"phases":8867,"primaryCompletion":1171,"completion":1172,"start":1173,"enrollment":22,"conditions":8868,"interventions":8869},[90],[1175],[1177,1159,1178],{"trials":8871,"activeCount":100},[],{"trials":8873,"activeCount":100},[],{"trials":8875,"activeCount":100},[],{"intervention":3949,"totalTrials":118,"cells":8877},{"EARLY_PHASE1":8878,"PHASE1":8880,"PHASE2":8882,"PHASE3":8888,"PHASE4":8890,"NA":8892},{"trials":8879,"activeCount":100},[],{"trials":8881,"activeCount":100},[],{"trials":8883,"activeCount":100},[8884],{"nctId":3941,"briefTitle":3942,"status":917,"phases":8885,"primaryCompletion":3944,"completion":3944,"start":3945,"enrollment":3113,"conditions":8886,"interventions":8887},[89,90],[3947],[3949,3950],{"trials":8889,"activeCount":100},[],{"trials":8891,"activeCount":100},[],{"trials":8893,"activeCount":100},[],{"intervention":8895,"totalTrials":118,"cells":8896},"RAD001",{"EARLY_PHASE1":8897,"PHASE1":8899,"PHASE2":8901,"PHASE3":8913,"PHASE4":8915,"NA":8917},{"trials":8898,"activeCount":100},[],{"trials":8900,"activeCount":100},[],{"trials":8902,"activeCount":100},[8903],{"nctId":8904,"briefTitle":8905,"status":166,"phases":8906,"primaryCompletion":8907,"completion":8908,"start":8909,"enrollment":25,"conditions":8910,"interventions":8912},"NCT01158651","Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas",[90],"2014-09-04","2017-10-26","2010-07-10",[8911],"Glioma",[8895],{"trials":8914,"activeCount":100},[],{"trials":8916,"activeCount":100},[],{"trials":8918,"activeCount":100},[],{"intervention":8920,"totalTrials":118,"cells":8921},"Novel combination of chemotherapy and immunotherapy",{"EARLY_PHASE1":8922,"PHASE1":8924,"PHASE2":8926,"PHASE3":8937,"PHASE4":8939,"NA":8941},{"trials":8923,"activeCount":100},[],{"trials":8925,"activeCount":100},[],{"trials":8927,"activeCount":100},[8928],{"nctId":8929,"briefTitle":8930,"status":917,"phases":8931,"primaryCompletion":2482,"completion":8932,"start":8933,"enrollment":118,"conditions":8934,"interventions":8936},"NCT04989218","Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)",[89,90],"2024-05-01","2023-01-30",[8935],"Cholangiocarcinoma",[8920],{"trials":8938,"activeCount":100},[],{"trials":8940,"activeCount":100},[],{"trials":8942,"activeCount":100},[],{"intervention":8944,"totalTrials":118,"cells":8945},"Letrozole in combination with Bevacizumab",{"EARLY_PHASE1":8946,"PHASE1":8948,"PHASE2":8950,"PHASE3":8959,"PHASE4":8961,"NA":8963},{"trials":8947,"activeCount":100},[],{"trials":8949,"activeCount":100},[],{"trials":8951,"activeCount":100},[8952],{"nctId":8953,"briefTitle":8954,"status":166,"phases":8955,"primaryCompletion":8956,"completion":8956,"start":4177,"enrollment":22,"conditions":8957,"interventions":8958},"NCT00161291","Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer",[90],"2006-11",[21],[8944],{"trials":8960,"activeCount":100},[],{"trials":8962,"activeCount":100},[],{"trials":8964,"activeCount":100},[],{"intervention":8966,"totalTrials":118,"cells":8967},"gamma-amino-butyric acid",{"EARLY_PHASE1":8968,"PHASE1":8970,"PHASE2":8972,"PHASE3":8981,"PHASE4":8983,"NA":8985},{"trials":8969,"activeCount":100},[],{"trials":8971,"activeCount":100},[],{"trials":8973,"activeCount":100},[8974],{"nctId":8975,"briefTitle":8976,"status":1196,"phases":8977,"primaryCompletion":8978,"start":5522,"enrollment":100,"conditions":8979,"interventions":8980},"NCT01561508","Effect of GABA Supplementation in the Progression of Type 1 Diabetes in Children",[90],"2013-04",[2118],[8966],{"trials":8982,"activeCount":100},[],{"trials":8984,"activeCount":100},[],{"trials":8986,"activeCount":100},[],{"intervention":8988,"totalTrials":118,"cells":8989},"Poly ICLC",{"EARLY_PHASE1":8990,"PHASE1":8992,"PHASE2":8994,"PHASE3":9006,"PHASE4":9008,"NA":9010},{"trials":8991,"activeCount":100},[],{"trials":8993,"activeCount":100},[],{"trials":8995,"activeCount":100},[8996],{"nctId":8997,"briefTitle":8998,"status":917,"phases":8999,"primaryCompletion":9000,"completion":9001,"start":9002,"enrollment":963,"conditions":9003,"interventions":9005},"NCT04544007","A Phase II Trial of Poly-ICLC for Low-Grade Gliomas",[90],"2024-01-04","2024-11-15","2022-02-08",[1531,9004],"Low-grade Glioma",[8988],{"trials":9007,"activeCount":100},[],{"trials":9009,"activeCount":100},[],{"trials":9011,"activeCount":100},[],{"intervention":9013,"totalTrials":118,"cells":9014},"Amiloride",{"EARLY_PHASE1":9015,"PHASE1":9017,"PHASE2":9019,"PHASE3":9030,"PHASE4":9032,"NA":9034},{"trials":9016,"activeCount":100},[],{"trials":9018,"activeCount":100},[],{"trials":9020,"activeCount":100},[9021],{"nctId":9022,"briefTitle":9023,"status":166,"phases":9024,"primaryCompletion":6197,"completion":6197,"start":7251,"enrollment":1050,"conditions":9025,"interventions":9028},"NCT02497300","Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease",[90],[9026,9027],"Chronic Kidney Disease","Albuminuria",[9029,9013],"Spironolactone",{"trials":9031,"activeCount":100},[],{"trials":9033,"activeCount":100},[],{"trials":9035,"activeCount":100},[],{"intervention":9037,"totalTrials":118,"cells":9038},"Acarbose",{"EARLY_PHASE1":9039,"PHASE1":9041,"PHASE2":9043,"PHASE3":9053,"PHASE4":9055,"NA":9057},{"trials":9040,"activeCount":100},[],{"trials":9042,"activeCount":100},[],{"trials":9044,"activeCount":100},[9045],{"nctId":9046,"briefTitle":9047,"status":1196,"phases":9048,"primaryCompletion":3654,"completion":349,"start":9049,"enrollment":100,"conditions":9050,"interventions":9052},"NCT05487859","Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)",[90],"2025-12-31",[9051],"Kidney Cancer",[9037],{"trials":9054,"activeCount":100},[],{"trials":9056,"activeCount":100},[],{"trials":9058,"activeCount":100},[],{"intervention":9060,"totalTrials":118,"cells":9061},"Lovastatin ™",{"EARLY_PHASE1":9062,"PHASE1":9064,"PHASE2":9066,"PHASE3":9078,"PHASE4":9080,"NA":9082},{"trials":9063,"activeCount":100},[],{"trials":9065,"activeCount":100},[],{"trials":9067,"activeCount":100},[9068],{"nctId":9069,"briefTitle":9070,"status":166,"phases":9071,"primaryCompletion":9072,"completion":9073,"start":9074,"enrollment":9075,"conditions":9076,"interventions":9077},"NCT00853580","A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1",[90],"2014-05","2016-12","2009-07",146,[7987],[9060],{"trials":9079,"activeCount":100},[],{"trials":9081,"activeCount":100},[],{"trials":9083,"activeCount":100},[],{"intervention":3912,"totalTrials":118,"cells":9085},{"EARLY_PHASE1":9086,"PHASE1":9088,"PHASE2":9090,"PHASE3":9096,"PHASE4":9098,"NA":9100},{"trials":9087,"activeCount":100},[],{"trials":9089,"activeCount":100},[],{"trials":9091,"activeCount":100},[9092],{"nctId":3905,"briefTitle":3906,"status":917,"phases":9093,"primaryCompletion":3908,"completion":3908,"start":3909,"enrollment":271,"conditions":9094,"interventions":9095},[90],[193],[3912,1204],{"trials":9097,"activeCount":100},[],{"trials":9099,"activeCount":100},[],{"trials":9101,"activeCount":100},[],{"intervention":9103,"totalTrials":118,"cells":9104},"Depo Provera",{"EARLY_PHASE1":9105,"PHASE1":9107,"PHASE2":9109,"PHASE3":9118,"PHASE4":9120,"NA":9122},{"trials":9106,"activeCount":100},[],{"trials":9108,"activeCount":100},[],{"trials":9110,"activeCount":100},[9111],{"nctId":9112,"briefTitle":9113,"status":166,"phases":9114,"primaryCompletion":5093,"completion":5093,"start":4132,"enrollment":9115,"conditions":9116,"interventions":9117},"NCT00807625","Impact of Different Contraceptives on the Immune System of HIV Infected Women in Zambia",[90],66,[27,3283,32],[9103],{"trials":9119,"activeCount":100},[],{"trials":9121,"activeCount":100},[],{"trials":9123,"activeCount":100},[],{"intervention":9125,"totalTrials":118,"cells":9126},"Glyburide",{"EARLY_PHASE1":9127,"PHASE1":9129,"PHASE2":9131,"PHASE3":9143,"PHASE4":9145,"NA":9147},{"trials":9128,"activeCount":100},[],{"trials":9130,"activeCount":100},[],{"trials":9132,"activeCount":100},[9133],{"nctId":9134,"briefTitle":9135,"status":917,"phases":9136,"primaryCompletion":9137,"completion":9137,"start":9138,"enrollment":118,"conditions":9139,"interventions":9142},"NCT02460874","Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502\u002FUAB 1593)",[89,90],"2021-05-19","2017-08-16",[9140,9141],"Cerebral Edema","Brain Metastases",[9125],{"trials":9144,"activeCount":100},[],{"trials":9146,"activeCount":100},[],{"trials":9148,"activeCount":100},[],{"intervention":9150,"totalTrials":118,"cells":9151},"Cyclophosphamide",{"EARLY_PHASE1":9152,"PHASE1":9154,"PHASE2":9156,"PHASE3":9169,"PHASE4":9171,"NA":9173},{"trials":9153,"activeCount":100},[],{"trials":9155,"activeCount":100},[],{"trials":9157,"activeCount":100},[9158],{"nctId":9159,"briefTitle":9160,"status":166,"phases":9161,"primaryCompletion":9162,"completion":9162,"start":6124,"enrollment":631,"conditions":9163,"interventions":9168},"NCT02065154","Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis",[90],"2022-04",[9164,4007,2305,9165,9166,9167],"Leukemia","Myelofibrosis","Severe Aplastic Anemia","Allogeneic Transplant",[9150],{"trials":9170,"activeCount":100},[],{"trials":9172,"activeCount":100},[],{"trials":9174,"activeCount":100},[],{"intervention":9176,"totalTrials":118,"cells":9177},"Sirolimus",{"EARLY_PHASE1":9178,"PHASE1":9180,"PHASE2":9182,"PHASE3":9190,"PHASE4":9192,"NA":9194},{"trials":9179,"activeCount":100},[],{"trials":9181,"activeCount":100},[],{"trials":9183,"activeCount":100},[9184],{"nctId":9185,"briefTitle":9186,"status":166,"phases":9187,"primaryCompletion":3845,"completion":3944,"start":4164,"enrollment":7181,"conditions":9188,"interventions":9189},"NCT00634270","A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas",[90],[7987],[9176],{"trials":9191,"activeCount":100},[],{"trials":9193,"activeCount":100},[],{"trials":9195,"activeCount":100},[],{"intervention":9197,"totalTrials":118,"cells":9198},"Cetuximab in combination with Carboplatin\u002FGemcitabine",{"EARLY_PHASE1":9199,"PHASE1":9201,"PHASE2":9203,"PHASE3":9212,"PHASE4":9214,"NA":9216},{"trials":9200,"activeCount":100},[],{"trials":9202,"activeCount":100},[],{"trials":9204,"activeCount":100},[9205],{"nctId":9206,"briefTitle":9207,"status":166,"phases":9208,"primaryCompletion":7401,"completion":7160,"start":7276,"enrollment":6891,"conditions":9209,"interventions":9211},"NCT01004731","Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine\u002FCarboplatin in Patients With Stage IV Lung Cancer",[89,90],[9210],"Stage IV Non-Small Cell Lung Cancer",[9197],{"trials":9213,"activeCount":100},[],{"trials":9215,"activeCount":100},[],{"trials":9217,"activeCount":100},[],{"intervention":7174,"totalTrials":118,"cells":9219},{"EARLY_PHASE1":9220,"PHASE1":9222,"PHASE2":9224,"PHASE3":9230,"PHASE4":9232,"NA":9234},{"trials":9221,"activeCount":100},[],{"trials":9223,"activeCount":100},[],{"trials":9225,"activeCount":100},[9226],{"nctId":7166,"briefTitle":7167,"status":166,"phases":9227,"primaryCompletion":7169,"completion":7170,"start":7171,"enrollment":25,"conditions":9228,"interventions":9229},[90],[4007],[7174,7129],{"trials":9231,"activeCount":100},[],{"trials":9233,"activeCount":100},[],{"trials":9235,"activeCount":100},[],{"intervention":9237,"totalTrials":118,"cells":9238},"topical diclofenac daily",{"EARLY_PHASE1":9239,"PHASE1":9241,"PHASE2":9243,"PHASE3":9252,"PHASE4":9254,"NA":9256},{"trials":9240,"activeCount":100},[],{"trials":9242,"activeCount":100},[],{"trials":9244,"activeCount":100},[9245],{"nctId":9246,"briefTitle":9247,"status":166,"phases":9248,"primaryCompletion":4976,"completion":9049,"start":9249,"enrollment":942,"conditions":9250,"interventions":9251},"NCT02636569","Topical Chemoprevention of Skin Cancer Biomarkers",[90],"2017-10-25",[4366],[9237],{"trials":9253,"activeCount":100},[],{"trials":9255,"activeCount":100},[],{"trials":9257,"activeCount":100},[],{"intervention":9259,"totalTrials":118,"cells":9260},"Crizotinib",{"EARLY_PHASE1":9261,"PHASE1":9263,"PHASE2":9265,"PHASE3":9276,"PHASE4":9278,"NA":9280},{"trials":9262,"activeCount":100},[],{"trials":9264,"activeCount":100},[],{"trials":9266,"activeCount":100},[9267],{"nctId":9268,"briefTitle":9269,"status":166,"phases":9270,"primaryCompletion":3722,"completion":3722,"start":9271,"enrollment":1476,"conditions":9272,"interventions":9275},"NCT04283669","Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas",[90],"2020-02-18",[9273,9274],"Neurofibromatosis 2","Progressive Vestibular Schwannoma (VS)",[9259],{"trials":9277,"activeCount":100},[],{"trials":9279,"activeCount":100},[],{"trials":9281,"activeCount":100},[],{"intervention":9283,"totalTrials":118,"cells":9284},"Belimumab",{"EARLY_PHASE1":9285,"PHASE1":9287,"PHASE2":9289,"PHASE3":9299,"PHASE4":9301,"NA":9303},{"trials":9286,"activeCount":100},[],{"trials":9288,"activeCount":100},[],{"trials":9290,"activeCount":100},[9291],{"nctId":9292,"briefTitle":9293,"status":166,"phases":9294,"primaryCompletion":5165,"completion":5165,"start":9295,"enrollment":33,"conditions":9296,"interventions":9298},"NCT03244059","Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies",[90],"2018-08-09",[2911,9297],"Emphysema",[9283],{"trials":9300,"activeCount":100},[],{"trials":9302,"activeCount":100},[],{"trials":9304,"activeCount":100},[],{"intervention":9306,"totalTrials":118,"cells":9307},"local injection of bevacizumab",{"EARLY_PHASE1":9308,"PHASE1":9310,"PHASE2":9312,"PHASE3":9322,"PHASE4":9324,"NA":9326},{"trials":9309,"activeCount":100},[],{"trials":9311,"activeCount":100},[],{"trials":9313,"activeCount":100},[9314],{"nctId":9315,"briefTitle":9316,"status":166,"phases":9317,"primaryCompletion":9318,"completion":9318,"start":5737,"enrollment":971,"conditions":9319,"interventions":9321},"NCT00592176","The Effect of Bevacizumab (Avastin) on Pterygium",[90],"2010-03",[9320],"Pterygium",[9306],{"trials":9323,"activeCount":100},[],{"trials":9325,"activeCount":100},[],{"trials":9327,"activeCount":100},[],{"intervention":9329,"totalTrials":118,"cells":9330},"GRANISETRON EXTENDED RELEASE",{"EARLY_PHASE1":9331,"PHASE1":9333,"PHASE2":9335,"PHASE3":9344,"PHASE4":9346,"NA":9348},{"trials":9332,"activeCount":100},[],{"trials":9334,"activeCount":100},[],{"trials":9336,"activeCount":100},[9337],{"nctId":9338,"briefTitle":9339,"status":1196,"phases":9340,"primaryCompletion":2116,"completion":7566,"start":2116,"enrollment":100,"conditions":9341,"interventions":9343},"NCT04085393","Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting",[90],[9342],"Chemotherapy-induced Nausea and Vomiting",[9329],{"trials":9345,"activeCount":100},[],{"trials":9347,"activeCount":100},[],{"trials":9349,"activeCount":100},[],{"intervention":9351,"totalTrials":118,"cells":9352},"L-377202",{"EARLY_PHASE1":9353,"PHASE1":9355,"PHASE2":9357,"PHASE3":9367,"PHASE4":9369,"NA":9371},{"trials":9354,"activeCount":100},[],{"trials":9356,"activeCount":100},[],{"trials":9358,"activeCount":100},[9359],{"nctId":9360,"briefTitle":9361,"status":166,"phases":9362,"primaryCompletion":9363,"completion":8792,"start":4178,"enrollment":191,"conditions":9364,"interventions":9366},"NCT00987753","Study Evaluating the Safety and Tolerability of L-377202",[89,90],"2000-09",[9365,7816],"Hormone Refractory Prostate Cancer",[9351],{"trials":9368,"activeCount":100},[],{"trials":9370,"activeCount":100},[],{"trials":9372,"activeCount":100},[],{"intervention":9374,"totalTrials":118,"cells":9375},"Novel Antiviral Drug",{"EARLY_PHASE1":9376,"PHASE1":9378,"PHASE2":9380,"PHASE3":9390,"PHASE4":9392,"NA":9394},{"trials":9377,"activeCount":100},[],{"trials":9379,"activeCount":100},[],{"trials":9381,"activeCount":100},[9382],{"nctId":9383,"briefTitle":9384,"status":1196,"phases":9385,"primaryCompletion":8139,"completion":8139,"start":9386,"enrollment":100,"conditions":9387,"interventions":9389},"NCT01610765","A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)",[89,90],"2016-01",[9388],"Herpes Simplex Virus",[9374],{"trials":9391,"activeCount":100},[],{"trials":9393,"activeCount":100},[],{"trials":9395,"activeCount":100},[],{"intervention":7570,"totalTrials":118,"cells":9397},{"EARLY_PHASE1":9398,"PHASE1":9400,"PHASE2":9402,"PHASE3":9408,"PHASE4":9410,"NA":9412},{"trials":9399,"activeCount":100},[],{"trials":9401,"activeCount":100},[],{"trials":9403,"activeCount":100},[9404],{"nctId":7563,"briefTitle":7564,"status":166,"phases":9405,"primaryCompletion":7566,"completion":7566,"start":7567,"enrollment":271,"conditions":9406,"interventions":9407},[89,90],[21],[7570,7571,7546],{"trials":9409,"activeCount":100},[],{"trials":9411,"activeCount":100},[],{"trials":9413,"activeCount":100},[],{"intervention":7571,"totalTrials":118,"cells":9415},{"EARLY_PHASE1":9416,"PHASE1":9418,"PHASE2":9420,"PHASE3":9426,"PHASE4":9428,"NA":9430},{"trials":9417,"activeCount":100},[],{"trials":9419,"activeCount":100},[],{"trials":9421,"activeCount":100},[9422],{"nctId":7563,"briefTitle":7564,"status":166,"phases":9423,"primaryCompletion":7566,"completion":7566,"start":7567,"enrollment":271,"conditions":9424,"interventions":9425},[89,90],[21],[7570,7571,7546],{"trials":9427,"activeCount":100},[],{"trials":9429,"activeCount":100},[],{"trials":9431,"activeCount":100},[],{"intervention":9433,"totalTrials":118,"cells":9434},"UAB30",{"EARLY_PHASE1":9435,"PHASE1":9437,"PHASE2":9439,"PHASE3":9448,"PHASE4":9450,"NA":9452},{"trials":9436,"activeCount":100},[],{"trials":9438,"activeCount":100},[],{"trials":9440,"activeCount":100},[9441],{"nctId":9442,"briefTitle":9443,"status":1196,"phases":9444,"primaryCompletion":9445,"completion":9445,"start":5137,"enrollment":100,"conditions":9446,"interventions":9447},"NCT03327064","A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer",[89,90],"2023-08-31",[4366],[9433],{"trials":9449,"activeCount":100},[],{"trials":9451,"activeCount":100},[],{"trials":9453,"activeCount":100},[],{"intervention":9455,"totalTrials":118,"cells":9456},"CI-1040",{"EARLY_PHASE1":9457,"PHASE1":9459,"PHASE2":9461,"PHASE3":9469,"PHASE4":9471,"NA":9473},{"trials":9458,"activeCount":100},[],{"trials":9460,"activeCount":100},[],{"trials":9462,"activeCount":100},[9463],{"nctId":9464,"briefTitle":9465,"status":166,"phases":9466,"primaryCompletion":8791,"completion":8791,"start":7391,"conditions":9467,"interventions":9468},"NCT00033384","CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer",[90],[21,5945,999,5954],[9455],{"trials":9470,"activeCount":100},[],{"trials":9472,"activeCount":100},[],{"trials":9474,"activeCount":100},[],{"intervention":9476,"totalTrials":118,"cells":9477},"Pegloticase 8 MG\u002FML [Krystexxa]",{"EARLY_PHASE1":9478,"PHASE1":9480,"PHASE2":9482,"PHASE3":9495,"PHASE4":9497,"NA":9499},{"trials":9479,"activeCount":100},[],{"trials":9481,"activeCount":100},[],{"trials":9483,"activeCount":100},[9484],{"nctId":9485,"briefTitle":9486,"status":166,"phases":9487,"primaryCompletion":9488,"completion":9489,"start":1048,"enrollment":9490,"conditions":9491,"interventions":9493},"NCT03303989","REduCing Immunogenicity to PegloticasE (RECIPE) Study",[90],"2020-04-27","2021-03-31",35,[9492],"Gout Chronic",[9476,9494,9476],"MMF",{"trials":9496,"activeCount":100},[],{"trials":9498,"activeCount":100},[],{"trials":9500,"activeCount":100},[],{"intervention":9494,"totalTrials":118,"cells":9502},{"EARLY_PHASE1":9503,"PHASE1":9505,"PHASE2":9507,"PHASE3":9513,"PHASE4":9515,"NA":9517},{"trials":9504,"activeCount":100},[],{"trials":9506,"activeCount":100},[],{"trials":9508,"activeCount":100},[9509],{"nctId":9485,"briefTitle":9486,"status":166,"phases":9510,"primaryCompletion":9488,"completion":9489,"start":1048,"enrollment":9490,"conditions":9511,"interventions":9512},[90],[9492],[9476,9494,9476],{"trials":9514,"activeCount":100},[],{"trials":9516,"activeCount":100},[],{"trials":9518,"activeCount":100},[],{"intervention":9520,"totalTrials":118,"cells":9521},"[89Zr]Panitumumab PET-MRI",{"EARLY_PHASE1":9522,"PHASE1":9524,"PHASE2":9526,"PHASE3":9538,"PHASE4":9540,"NA":9542},{"trials":9523,"activeCount":100},[],{"trials":9525,"activeCount":100},[],{"trials":9527,"activeCount":100},[9528],{"nctId":9529,"briefTitle":9530,"status":1196,"phases":9531,"primaryCompletion":9532,"completion":9533,"start":9534,"enrollment":100,"conditions":9535,"interventions":9537},"NCT03764137","Imaging with [89Zr]Panitumumab-PET\u002FMRI in Patients with Newly Diagnosed Colorectal Cancer",[89,90],"2025-01","2026-01","2019-03-14",[9536],"Metastatic Colon Cancer",[9520],{"trials":9539,"activeCount":100},[],{"trials":9541,"activeCount":100},[],{"trials":9543,"activeCount":100},[],{"intervention":7409,"totalTrials":118,"cells":9545},{"EARLY_PHASE1":9546,"PHASE1":9548,"PHASE2":9550,"PHASE3":9556,"PHASE4":9558,"NA":9560},{"trials":9547,"activeCount":100},[],{"trials":9549,"activeCount":100},[],{"trials":9551,"activeCount":100},[9552],{"nctId":7397,"briefTitle":7398,"status":166,"phases":9553,"completion":7400,"start":7401,"enrollment":1425,"conditions":9554,"interventions":9555},[90],[7403,7404,7405,7406,7407],[7379,7409],{"trials":9557,"activeCount":100},[],{"trials":9559,"activeCount":100},[],{"trials":9561,"activeCount":100},[],{"intervention":9563,"totalTrials":118,"cells":9564},"Thawed plasma",{"EARLY_PHASE1":9565,"PHASE1":9567,"PHASE2":9569,"PHASE3":9578,"PHASE4":9580,"NA":9582},{"trials":9566,"activeCount":100},[],{"trials":9568,"activeCount":100},[],{"trials":9570,"activeCount":100},[9571],{"nctId":9572,"briefTitle":9573,"status":1196,"phases":9574,"primaryCompletion":9575,"completion":9575,"start":9575,"enrollment":100,"conditions":9576,"interventions":9577},"NCT04723589","Restoration of Endothelial Integrity in Patients With COVID-19 (RELIC)",[90],"2021-04-30",[5985],[9563],{"trials":9579,"activeCount":100},[],{"trials":9581,"activeCount":100},[],{"trials":9583,"activeCount":100},[],{"intervention":9585,"totalTrials":118,"cells":9586},"Azithromycin 10 mg",{"EARLY_PHASE1":9587,"PHASE1":9589,"PHASE2":9591,"PHASE3":9603,"PHASE4":9605,"NA":9607},{"trials":9588,"activeCount":100},[],{"trials":9590,"activeCount":100},[],{"trials":9592,"activeCount":100},[9593],{"nctId":9594,"briefTitle":9595,"status":166,"phases":9596,"primaryCompletion":9597,"completion":9598,"start":5871,"enrollment":377,"conditions":9599,"interventions":9601},"NCT02707523","Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children",[90],"2019-02-06","2020-06-20",[9600],"Respiratory Syncytial Virus",[9585,9602],"Azithromycin 20mg",{"trials":9604,"activeCount":100},[],{"trials":9606,"activeCount":100},[],{"trials":9608,"activeCount":100},[],{"intervention":9602,"totalTrials":118,"cells":9610},{"EARLY_PHASE1":9611,"PHASE1":9613,"PHASE2":9615,"PHASE3":9621,"PHASE4":9623,"NA":9625},{"trials":9612,"activeCount":100},[],{"trials":9614,"activeCount":100},[],{"trials":9616,"activeCount":100},[9617],{"nctId":9594,"briefTitle":9595,"status":166,"phases":9618,"primaryCompletion":9597,"completion":9598,"start":5871,"enrollment":377,"conditions":9619,"interventions":9620},[90],[9600],[9585,9602],{"trials":9622,"activeCount":100},[],{"trials":9624,"activeCount":100},[],{"trials":9626,"activeCount":100},[],{"intervention":9628,"totalTrials":118,"cells":9629},"[18F]-FDG",{"EARLY_PHASE1":9630,"PHASE1":9632,"PHASE2":9634,"PHASE3":9644,"PHASE4":9646,"NA":9648},{"trials":9631,"activeCount":100},[],{"trials":9633,"activeCount":100},[],{"trials":9635,"activeCount":100},[9636],{"nctId":9637,"briefTitle":9638,"status":1196,"phases":9639,"primaryCompletion":9640,"completion":9640,"start":9641,"enrollment":100,"conditions":9642,"interventions":9643},"NCT04273555","Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET\u002FMR Imaging",[89,90],"2028-06-30","2026-03-01",[2628],[9628],{"trials":9645,"activeCount":100},[],{"trials":9647,"activeCount":100},[],{"trials":9649,"activeCount":100},[],{"intervention":3022,"totalTrials":118,"cells":9651},{"EARLY_PHASE1":9652,"PHASE1":9654,"PHASE2":9656,"PHASE3":9662,"PHASE4":9664,"NA":9666},{"trials":9653,"activeCount":100},[],{"trials":9655,"activeCount":100},[],{"trials":9657,"activeCount":100},[9658],{"nctId":3015,"briefTitle":3016,"status":166,"phases":9659,"primaryCompletion":3018,"completion":3018,"start":2909,"enrollment":1969,"conditions":9660,"interventions":9661},[90],[3020],[2989,3022],{"trials":9663,"activeCount":100},[],{"trials":9665,"activeCount":100},[],{"trials":9667,"activeCount":100},[],{"intervention":9669,"totalTrials":118,"cells":9670},"Azithromycin\u002FTMPS",{"EARLY_PHASE1":9671,"PHASE1":9673,"PHASE2":9675,"PHASE3":9688,"PHASE4":9690,"NA":9692},{"trials":9672,"activeCount":100},[],{"trials":9674,"activeCount":100},[],{"trials":9676,"activeCount":100},[9677],{"nctId":9678,"briefTitle":9679,"status":166,"phases":9680,"primaryCompletion":9681,"completion":3985,"start":9682,"enrollment":9683,"conditions":9684,"interventions":9687},"NCT03431168","A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV",[90],"2021-01-01","2018-03-07",308,[27,9685,9686],"Pregnancy Malaria","Sexually Transmitted Infection",[9669],{"trials":9689,"activeCount":100},[],{"trials":9691,"activeCount":100},[],{"trials":9693,"activeCount":100},[],{"intervention":9695,"totalTrials":118,"cells":9696},"Ublituximab",{"EARLY_PHASE1":9697,"PHASE1":9699,"PHASE2":9701,"PHASE3":9711,"PHASE4":9713,"NA":9715},{"trials":9698,"activeCount":100},[],{"trials":9700,"activeCount":100},[],{"trials":9702,"activeCount":100},[9703],{"nctId":9704,"briefTitle":9705,"status":917,"phases":9706,"primaryCompletion":9707,"completion":9707,"start":3574,"enrollment":118,"conditions":9708,"interventions":9709},"NCT04692155","Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)",[89,90],"2022-06-30",[6140],[9695,9710],"Umbralisib",{"trials":9712,"activeCount":100},[],{"trials":9714,"activeCount":100},[],{"trials":9716,"activeCount":100},[],{"intervention":9710,"totalTrials":118,"cells":9718},{"EARLY_PHASE1":9719,"PHASE1":9721,"PHASE2":9723,"PHASE3":9729,"PHASE4":9731,"NA":9733},{"trials":9720,"activeCount":100},[],{"trials":9722,"activeCount":100},[],{"trials":9724,"activeCount":100},[9725],{"nctId":9704,"briefTitle":9705,"status":917,"phases":9726,"primaryCompletion":9707,"completion":9707,"start":3574,"enrollment":118,"conditions":9727,"interventions":9728},[89,90],[6140],[9695,9710],{"trials":9730,"activeCount":100},[],{"trials":9732,"activeCount":100},[],{"trials":9734,"activeCount":100},[],{"intervention":9736,"totalTrials":118,"cells":9737},"eniluracil",{"EARLY_PHASE1":9738,"PHASE1":9740,"PHASE2":9742,"PHASE3":9752,"PHASE4":9754,"NA":9756},{"trials":9739,"activeCount":100},[],{"trials":9741,"activeCount":100},[],{"trials":9743,"activeCount":100},[9744],{"nctId":9745,"briefTitle":9746,"status":166,"phases":9747,"primaryCompletion":5943,"completion":9748,"start":9749,"enrollment":22,"conditions":9750,"interventions":9751},"NCT00004195","Eniluracil and Surgery in Treating Patients With Primary or Metastatic Colorectal Cancer",[90],"2001-05","1998-09",[5945],[9736],{"trials":9753,"activeCount":100},[],{"trials":9755,"activeCount":100},[],{"trials":9757,"activeCount":100},[],{"intervention":9759,"totalTrials":118,"cells":9760},"Empagliflozin Arm",{"EARLY_PHASE1":9761,"PHASE1":9763,"PHASE2":9765,"PHASE3":9776,"PHASE4":9778,"NA":9780},{"trials":9762,"activeCount":100},[],{"trials":9764,"activeCount":100},[],{"trials":9766,"activeCount":100},[9767],{"nctId":9768,"briefTitle":9769,"status":1196,"phases":9770,"primaryCompletion":9771,"completion":295,"start":9772,"enrollment":100,"conditions":9773,"interventions":9775},"NCT05885074","Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors",[90],"2026-01-30","2025-01-30",[15,9774],"Weight Loss",[9759],{"trials":9777,"activeCount":100},[],{"trials":9779,"activeCount":100},[],{"trials":9781,"activeCount":100},[],{"intervention":7371,"totalTrials":118,"cells":9783},{"EARLY_PHASE1":9784,"PHASE1":9786,"PHASE2":9788,"PHASE3":9794,"PHASE4":9796,"NA":9798},{"trials":9785,"activeCount":100},[],{"trials":9787,"activeCount":100},[],{"trials":9789,"activeCount":100},[9790],{"nctId":7365,"briefTitle":7366,"status":166,"phases":9791,"primaryCompletion":4162,"completion":7368,"start":6480,"enrollment":19,"conditions":9792,"interventions":9793},[90],[1337],[1254,7371],{"trials":9795,"activeCount":100},[],{"trials":9797,"activeCount":100},[],{"trials":9799,"activeCount":100},[],{"intervention":9801,"totalTrials":118,"cells":9802},"PD-0325901",{"EARLY_PHASE1":9803,"PHASE1":9805,"PHASE2":9807,"PHASE3":9818,"PHASE4":9820,"NA":9822},{"trials":9804,"activeCount":100},[],{"trials":9806,"activeCount":100},[],{"trials":9808,"activeCount":100},[9809],{"nctId":9810,"briefTitle":9811,"status":166,"phases":9812,"primaryCompletion":9813,"completion":9814,"start":5670,"enrollment":30,"conditions":9815,"interventions":9817},"NCT02096471","MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1",[90],"2017-08-09","2018-08-01",[9816],"Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN",[9801],{"trials":9819,"activeCount":100},[],{"trials":9821,"activeCount":100},[],{"trials":9823,"activeCount":100},[],{"intervention":7609,"totalTrials":118,"cells":9825},{"EARLY_PHASE1":9826,"PHASE1":9828,"PHASE2":9830,"PHASE3":9836,"PHASE4":9838,"NA":9840},{"trials":9827,"activeCount":100},[],{"trials":9829,"activeCount":100},[],{"trials":9831,"activeCount":100},[9832],{"nctId":7599,"briefTitle":7600,"status":166,"phases":9833,"primaryCompletion":7602,"completion":7602,"start":7603,"enrollment":7604,"conditions":9834,"interventions":9835},[90],[18,7606,7607],[7609,7579,7610],{"trials":9837,"activeCount":100},[],{"trials":9839,"activeCount":100},[],{"trials":9841,"activeCount":100},[],{"intervention":7610,"totalTrials":118,"cells":9843},{"EARLY_PHASE1":9844,"PHASE1":9846,"PHASE2":9848,"PHASE3":9854,"PHASE4":9856,"NA":9858},{"trials":9845,"activeCount":100},[],{"trials":9847,"activeCount":100},[],{"trials":9849,"activeCount":100},[9850],{"nctId":7599,"briefTitle":7600,"status":166,"phases":9851,"primaryCompletion":7602,"completion":7602,"start":7603,"enrollment":7604,"conditions":9852,"interventions":9853},[90],[18,7606,7607],[7609,7579,7610],{"trials":9855,"activeCount":100},[],{"trials":9857,"activeCount":100},[],{"trials":9859,"activeCount":100},[],{"intervention":9861,"totalTrials":118,"cells":9862},"Doxil, Paclitaxel, Cyclophosphamide, Avastin",{"EARLY_PHASE1":9863,"PHASE1":9865,"PHASE2":9867,"PHASE3":9876,"PHASE4":9878,"NA":9880},{"trials":9864,"activeCount":100},[],{"trials":9866,"activeCount":100},[],{"trials":9868,"activeCount":100},[9869],{"nctId":9870,"briefTitle":9871,"status":166,"phases":9872,"primaryCompletion":7250,"completion":5167,"start":1249,"enrollment":5524,"conditions":9873,"interventions":9875},"NCT00635050","Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin",[90],[9874],"Invasive Breast Cancer",[9861],{"trials":9877,"activeCount":100},[],{"trials":9879,"activeCount":100},[],{"trials":9881,"activeCount":100},[],{"intervention":9883,"totalTrials":118,"cells":9884},"Cohort 1 Not Previously Treated",{"EARLY_PHASE1":9885,"PHASE1":9887,"PHASE2":9889,"PHASE3":9900,"PHASE4":9902,"NA":9904},{"trials":9886,"activeCount":100},[],{"trials":9888,"activeCount":100},[],{"trials":9890,"activeCount":100},[9891],{"nctId":9892,"briefTitle":9893,"status":917,"phases":9894,"primaryCompletion":9895,"completion":9895,"start":9896,"enrollment":118,"conditions":9897,"interventions":9898},"NCT03938337","Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer",[90],"2020-04-03","2019-10-08",[1427],[9883,9899],"Cohort 2 Treated Previously",{"trials":9901,"activeCount":100},[],{"trials":9903,"activeCount":100},[],{"trials":9905,"activeCount":100},[],{"intervention":9899,"totalTrials":118,"cells":9907},{"EARLY_PHASE1":9908,"PHASE1":9910,"PHASE2":9912,"PHASE3":9918,"PHASE4":9920,"NA":9922},{"trials":9909,"activeCount":100},[],{"trials":9911,"activeCount":100},[],{"trials":9913,"activeCount":100},[9914],{"nctId":9892,"briefTitle":9893,"status":917,"phases":9915,"primaryCompletion":9895,"completion":9895,"start":9896,"enrollment":118,"conditions":9916,"interventions":9917},[90],[1427],[9883,9899],{"trials":9919,"activeCount":100},[],{"trials":9921,"activeCount":100},[],{"trials":9923,"activeCount":100},[],{"intervention":9925,"totalTrials":118,"cells":9926},"Herpes Zoster (HZ) Vaccine",{"EARLY_PHASE1":9927,"PHASE1":9929,"PHASE2":9931,"PHASE3":9947,"PHASE4":9949,"NA":9951},{"trials":9928,"activeCount":100},[],{"trials":9930,"activeCount":100},[],{"trials":9932,"activeCount":100},[9933],{"nctId":9934,"briefTitle":9935,"status":166,"phases":9936,"primaryCompletion":1200,"completion":9937,"start":7714,"enrollment":9938,"conditions":9939,"interventions":9946},"NCT02538341","Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)",[90],"2020-12",617,[879,9940,9941,9942,4364,9943,9944,9945],"Inflammatory Arthritis","Arthritis","Psoriatic Arthritis","Ankylosing Spondylitis","Enteropathic Arthritis","Crohn's Disease",[9925],{"trials":9948,"activeCount":100},[],{"trials":9950,"activeCount":100},[],{"trials":9952,"activeCount":100},[],{"intervention":9954,"totalTrials":118,"cells":9955},"Autoantibody Reductive Therapy",{"EARLY_PHASE1":9956,"PHASE1":9958,"PHASE2":9960,"PHASE3":9973,"PHASE4":9975,"NA":9977},{"trials":9957,"activeCount":100},[],{"trials":9959,"activeCount":100},[],{"trials":9961,"activeCount":100},[9962],{"nctId":9963,"briefTitle":9964,"status":166,"phases":9965,"primaryCompletion":9966,"completion":9966,"start":9967,"enrollment":9968,"conditions":9969,"interventions":9971},"NCT03286556","Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis",[90],"2024-08-01","2018-09-04",82,[9970],"Idiopathic Pulmonary Fibrosis, Acute Fatal Form",[9954,9972],"Treatment as Usual",{"trials":9974,"activeCount":100},[],{"trials":9976,"activeCount":100},[],{"trials":9978,"activeCount":100},[],{"intervention":9972,"totalTrials":118,"cells":9980},{"EARLY_PHASE1":9981,"PHASE1":9983,"PHASE2":9985,"PHASE3":9991,"PHASE4":9993,"NA":9995},{"trials":9982,"activeCount":100},[],{"trials":9984,"activeCount":100},[],{"trials":9986,"activeCount":100},[9987],{"nctId":9963,"briefTitle":9964,"status":166,"phases":9988,"primaryCompletion":9966,"completion":9966,"start":9967,"enrollment":9968,"conditions":9989,"interventions":9990},[90],[9970],[9954,9972],{"trials":9992,"activeCount":100},[],{"trials":9994,"activeCount":100},[],{"trials":9996,"activeCount":100},[],{"intervention":9998,"totalTrials":96,"cells":9999},"Epidiolex",{"EARLY_PHASE1":10000,"PHASE1":10002,"PHASE2":10020,"PHASE3":10022,"PHASE4":10024,"NA":10026},{"trials":10001,"activeCount":100},[],{"trials":10003,"activeCount":100},[10004,10013],{"nctId":10005,"briefTitle":10006,"status":166,"phases":10007,"primaryCompletion":10008,"completion":10008,"start":7591,"enrollment":8348,"conditions":10009,"interventions":10012},"NCT02695537","University of Alabama at Birmingham (UAB) Pediatric CBD Program",[89],"2019-02-27",[10010,10011],"Epilepsy","Seizures",[9998],{"nctId":10014,"briefTitle":10015,"status":166,"phases":10016,"primaryCompletion":10017,"completion":10017,"start":7591,"enrollment":1185,"conditions":10018,"interventions":10019},"NCT02700412","University of Alabama at Birmingham (UAB) Adult CBD Program",[89],"2019-08-08",[10010,10011],[9998],{"trials":10021,"activeCount":100},[],{"trials":10023,"activeCount":100},[],{"trials":10025,"activeCount":100},[],{"trials":10027,"activeCount":100},[],{"intervention":10029,"totalTrials":118,"cells":10030},"[Zr-89]Oxine-labeled leukocytes PET\u002FMRI",{"EARLY_PHASE1":10031,"PHASE1":10033,"PHASE2":10043,"PHASE3":10045,"PHASE4":10047,"NA":10049},{"trials":10032,"activeCount":100},[],{"trials":10034,"activeCount":100},[10035],{"nctId":10036,"briefTitle":10037,"status":10038,"phases":10039,"primaryCompletion":1992,"completion":1992,"start":10040,"enrollment":1551,"conditions":10041,"interventions":10042},"NCT03807973","Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.","SUSPENDED",[89],"2021-10-05",[2460,2461,29,2462],[10029],{"trials":10044,"activeCount":100},[],{"trials":10046,"activeCount":100},[],{"trials":10048,"activeCount":100},[],{"trials":10050,"activeCount":100},[],{"intervention":10052,"totalTrials":118,"cells":10053},"PACE with Cabazitaxel",{"EARLY_PHASE1":10054,"PHASE1":10056,"PHASE2":10067,"PHASE3":10069,"PHASE4":10071,"NA":10073},{"trials":10055,"activeCount":100},[],{"trials":10057,"activeCount":100},[10058],{"nctId":10059,"briefTitle":10060,"status":1196,"phases":10061,"primaryCompletion":10062,"completion":10062,"start":10063,"enrollment":100,"conditions":10064,"interventions":10066},"NCT03110588","Phase I Trial of PACE for Metastatic Prostate Cancer",[89],"2019-12-18","2018-05-09",[10065],"Metastatic Prostate Cancer",[10052,10052],{"trials":10068,"activeCount":100},[],{"trials":10070,"activeCount":100},[],{"trials":10072,"activeCount":100},[],{"trials":10074,"activeCount":100},[],{"intervention":10076,"totalTrials":118,"cells":10077},"pGT-1 gene lipid complex",{"EARLY_PHASE1":10078,"PHASE1":10080,"PHASE2":10089,"PHASE3":10091,"PHASE4":10093,"NA":10095},{"trials":10079,"activeCount":100},[],{"trials":10081,"activeCount":100},[10082],{"nctId":10083,"briefTitle":10084,"status":166,"phases":10085,"primaryCompletion":9748,"start":10086,"enrollment":8011,"conditions":10087,"interventions":10088},"NCT00004471","Phase I Pilot Study of Gene Therapy for Cystic Fibrosis Using Cationic Liposome Mediated Gene Transfer",[89],"1995-08",[35],[10076],{"trials":10090,"activeCount":100},[],{"trials":10092,"activeCount":100},[],{"trials":10094,"activeCount":100},[],{"trials":10096,"activeCount":100},[],{"intervention":10098,"totalTrials":118,"cells":10099},"Ad5-delta24RGD",{"EARLY_PHASE1":10100,"PHASE1":10102,"PHASE2":10112,"PHASE3":10114,"PHASE4":10116,"NA":10118},{"trials":10101,"activeCount":100},[],{"trials":10103,"activeCount":100},[10104],{"nctId":10105,"briefTitle":10106,"status":166,"phases":10107,"primaryCompletion":7139,"completion":4131,"start":10108,"enrollment":10109,"conditions":10110,"interventions":10111},"NCT00562003","Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients",[89],"2007-06",26,[988,1504],[10098],{"trials":10113,"activeCount":100},[],{"trials":10115,"activeCount":100},[],{"trials":10117,"activeCount":100},[],{"trials":10119,"activeCount":100},[],{"intervention":10121,"totalTrials":118,"cells":10122},"[11C]PiB and 18F-labeled DPA-714 PET scan",{"EARLY_PHASE1":10123,"PHASE1":10125,"PHASE2":10135,"PHASE3":10137,"PHASE4":10139,"NA":10141},{"trials":10124,"activeCount":100},[],{"trials":10126,"activeCount":100},[10127],{"nctId":10128,"briefTitle":10129,"status":1196,"phases":10130,"primaryCompletion":10131,"completion":10131,"start":10132,"enrollment":100,"conditions":10133,"interventions":10134},"NCT04542603","Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer",[89],"2026-08","2025-06",[988],[10121],{"trials":10136,"activeCount":100},[],{"trials":10138,"activeCount":100},[],{"trials":10140,"activeCount":100},[],{"trials":10142,"activeCount":100},[],{"intervention":10144,"totalTrials":118,"cells":10145},"18F-labeled DPA-714 PET scan",{"EARLY_PHASE1":10146,"PHASE1":10148,"PHASE2":10158,"PHASE3":10160,"PHASE4":10162,"NA":10164},{"trials":10147,"activeCount":100},[],{"trials":10149,"activeCount":100},[10150],{"nctId":10151,"briefTitle":10152,"status":1196,"phases":10153,"primaryCompletion":10154,"completion":10154,"start":10155,"enrollment":100,"conditions":10156,"interventions":10157},"NCT04364672","Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive Impairment in Breast Cancer",[89],"2026-07-01","2025-06-01",[21],[10144],{"trials":10159,"activeCount":100},[],{"trials":10161,"activeCount":100},[],{"trials":10163,"activeCount":100},[],{"trials":10165,"activeCount":100},[],{"intervention":10167,"totalTrials":118,"cells":10168},"NTX-301",{"EARLY_PHASE1":10169,"PHASE1":10171,"PHASE2":10181,"PHASE3":10183,"PHASE4":10185,"NA":10187},{"trials":10170,"activeCount":100},[],{"trials":10172,"activeCount":100},[10173],{"nctId":10174,"briefTitle":10175,"status":166,"phases":10176,"primaryCompletion":10177,"completion":10177,"start":8480,"enrollment":352,"conditions":10178,"interventions":10180},"NCT04167917","NTX-301 in MDS\u002FAML",[89],"2025-04-24",[2497,1452,10179],"Chronic Myelomonocytic Leukemia",[10167],{"trials":10182,"activeCount":100},[],{"trials":10184,"activeCount":100},[],{"trials":10186,"activeCount":100},[],{"trials":10188,"activeCount":100},[],{"intervention":10190,"totalTrials":118,"cells":10191},"[68Ga]PSMA-PET\u002FMRI or PET\u002FCT",{"EARLY_PHASE1":10192,"PHASE1":10194,"PHASE2":10204,"PHASE3":10206,"PHASE4":10208,"NA":10210},{"trials":10193,"activeCount":100},[],{"trials":10195,"activeCount":100},[10196],{"nctId":10197,"briefTitle":10198,"status":166,"phases":10199,"primaryCompletion":10200,"completion":10200,"start":10201,"enrollment":2518,"conditions":10202,"interventions":10203},"NCT04086966","PSMA-PET\u002FMRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study",[89],"2022-02-23","2020-08-20",[10065],[10190],{"trials":10205,"activeCount":100},[],{"trials":10207,"activeCount":100},[],{"trials":10209,"activeCount":100},[],{"trials":10211,"activeCount":100},[],{"intervention":10213,"totalTrials":118,"cells":10214},"Cystic fibrosis transmembrane conductance regulator",{"EARLY_PHASE1":10215,"PHASE1":10217,"PHASE2":10227,"PHASE3":10229,"PHASE4":10231,"NA":10233},{"trials":10216,"activeCount":100},[],{"trials":10218,"activeCount":100},[10219],{"nctId":10220,"briefTitle":10221,"status":166,"phases":10222,"primaryCompletion":10223,"completion":10223,"start":10224,"enrollment":8011,"conditions":10225,"interventions":10226},"NCT00004806","Phase I Study of Liposome-Mediated Gene Transfer in Patients With Cystic Fibrosis",[89],"2002-11","1995-06",[35],[10213],{"trials":10228,"activeCount":100},[],{"trials":10230,"activeCount":100},[],{"trials":10232,"activeCount":100},[],{"trials":10234,"activeCount":100},[],{"intervention":4010,"totalTrials":118,"cells":10236},{"EARLY_PHASE1":10237,"PHASE1":10239,"PHASE2":10245,"PHASE3":10247,"PHASE4":10249,"NA":10251},{"trials":10238,"activeCount":100},[],{"trials":10240,"activeCount":100},[10241],{"nctId":4001,"briefTitle":4002,"status":166,"phases":10242,"primaryCompletion":4004,"completion":4004,"start":4005,"enrollment":377,"conditions":10243,"interventions":10244},[89],[4007],[4009,3994,4010,4011],{"trials":10246,"activeCount":100},[],{"trials":10248,"activeCount":100},[],{"trials":10250,"activeCount":100},[],{"trials":10252,"activeCount":100},[],{"intervention":4011,"totalTrials":118,"cells":10254},{"EARLY_PHASE1":10255,"PHASE1":10257,"PHASE2":10263,"PHASE3":10265,"PHASE4":10267,"NA":10269},{"trials":10256,"activeCount":100},[],{"trials":10258,"activeCount":100},[10259],{"nctId":4001,"briefTitle":4002,"status":166,"phases":10260,"primaryCompletion":4004,"completion":4004,"start":4005,"enrollment":377,"conditions":10261,"interventions":10262},[89],[4007],[4009,3994,4010,4011],{"trials":10264,"activeCount":100},[],{"trials":10266,"activeCount":100},[],{"trials":10268,"activeCount":100},[],{"trials":10270,"activeCount":100},[],{"intervention":10272,"totalTrials":118,"cells":10273},"LDE225",{"EARLY_PHASE1":10274,"PHASE1":10276,"PHASE2":10287,"PHASE3":10289,"PHASE4":10291,"NA":10293},{"trials":10275,"activeCount":100},[],{"trials":10277,"activeCount":100},[10278],{"nctId":10279,"briefTitle":10280,"status":166,"phases":10281,"primaryCompletion":10282,"completion":10283,"start":7653,"enrollment":271,"conditions":10284,"interventions":10286},"NCT02195973","Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer",[89],"2016-12-10","2017-09-30",[10285],"Recurrent Ovarian Cancer",[10272],{"trials":10288,"activeCount":100},[],{"trials":10290,"activeCount":100},[],{"trials":10292,"activeCount":100},[],{"trials":10294,"activeCount":100},[],{"intervention":10296,"totalTrials":118,"cells":10297},"Ad5.SSTR\u002FTK.RGD",{"EARLY_PHASE1":10298,"PHASE1":10300,"PHASE2":10310,"PHASE3":10312,"PHASE4":10314,"NA":10316},{"trials":10299,"activeCount":100},[],{"trials":10301,"activeCount":100},[10302],{"nctId":10303,"briefTitle":10304,"status":166,"phases":10305,"primaryCompletion":4541,"completion":4361,"start":10306,"enrollment":5623,"conditions":10307,"interventions":10308},"NCT00964756","A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers",[89],"2009-08",[988],[10296,10309],"Ganciclovir",{"trials":10311,"activeCount":100},[],{"trials":10313,"activeCount":100},[],{"trials":10315,"activeCount":100},[],{"trials":10317,"activeCount":100},[],{"intervention":10309,"totalTrials":118,"cells":10319},{"EARLY_PHASE1":10320,"PHASE1":10322,"PHASE2":10328,"PHASE3":10330,"PHASE4":10332,"NA":10334},{"trials":10321,"activeCount":100},[],{"trials":10323,"activeCount":100},[10324],{"nctId":10303,"briefTitle":10304,"status":166,"phases":10325,"primaryCompletion":4541,"completion":4361,"start":10306,"enrollment":5623,"conditions":10326,"interventions":10327},[89],[988],[10296,10309],{"trials":10329,"activeCount":100},[],{"trials":10331,"activeCount":100},[],{"trials":10333,"activeCount":100},[],{"trials":10335,"activeCount":100},[],{"intervention":10337,"totalTrials":118,"cells":10338},"pelitrexol",{"EARLY_PHASE1":10339,"PHASE1":10341,"PHASE2":10351,"PHASE3":10353,"PHASE4":10355,"NA":10357},{"trials":10340,"activeCount":100},[],{"trials":10342,"activeCount":100},[10343],{"nctId":10344,"briefTitle":10345,"status":166,"phases":10346,"completion":4644,"start":10347,"enrollment":352,"conditions":10348,"interventions":10350},"NCT00017524","AG2037 in Treating Patients With Advanced, Metastatic, or Recurrent Solid Tumors",[89],"2001-03",[10349],"Unspecified Adult Solid Tumor, Protocol Specific",[10337],{"trials":10352,"activeCount":100},[],{"trials":10354,"activeCount":100},[],{"trials":10356,"activeCount":100},[],{"trials":10358,"activeCount":100},[],{"intervention":10360,"totalTrials":118,"cells":10361},"[18F]DPA-714",{"EARLY_PHASE1":10362,"PHASE1":10364,"PHASE2":10374,"PHASE3":10376,"PHASE4":10378,"NA":10380},{"trials":10363,"activeCount":100},[],{"trials":10365,"activeCount":100},[10366],{"nctId":10367,"briefTitle":10368,"status":1196,"phases":10369,"primaryCompletion":2457,"completion":2457,"start":2368,"enrollment":100,"conditions":10370,"interventions":10373},"NCT05238961","Neuroinflammation in Asymptomatic Carotid Artery Disease - Imaging Substudy",[89],[10371,10372],"Critical Asymptomatic Carotid Artery Disease","Non-Critical Asymptomatic Carotid Artery Disease",[10360],{"trials":10375,"activeCount":100},[],{"trials":10377,"activeCount":100},[],{"trials":10379,"activeCount":100},[],{"trials":10381,"activeCount":100},[],{"intervention":10383,"totalTrials":118,"cells":10384},"clofarabine",{"EARLY_PHASE1":10385,"PHASE1":10387,"PHASE2":10397,"PHASE3":10399,"PHASE4":10401,"NA":10403},{"trials":10386,"activeCount":100},[],{"trials":10388,"activeCount":100},[10389],{"nctId":10390,"briefTitle":10391,"status":166,"phases":10392,"primaryCompletion":629,"completion":10393,"start":8645,"enrollment":25,"conditions":10394,"interventions":10395},"NCT00081822","Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia",[89],"2011-08",[2497],[10383,10396],"Ara-C",{"trials":10398,"activeCount":100},[],{"trials":10400,"activeCount":100},[],{"trials":10402,"activeCount":100},[],{"trials":10404,"activeCount":100},[],{"intervention":10396,"totalTrials":118,"cells":10406},{"EARLY_PHASE1":10407,"PHASE1":10409,"PHASE2":10415,"PHASE3":10417,"PHASE4":10419,"NA":10421},{"trials":10408,"activeCount":100},[],{"trials":10410,"activeCount":100},[10411],{"nctId":10390,"briefTitle":10391,"status":166,"phases":10412,"primaryCompletion":629,"completion":10393,"start":8645,"enrollment":25,"conditions":10413,"interventions":10414},[89],[2497],[10383,10396],{"trials":10416,"activeCount":100},[],{"trials":10418,"activeCount":100},[],{"trials":10420,"activeCount":100},[],{"trials":10422,"activeCount":100},[],{"intervention":10424,"totalTrials":118,"cells":10425},"Cardiac Perfusion and Metabolism with [11C] Acetate PET\u002FCT",{"EARLY_PHASE1":10426,"PHASE1":10428,"PHASE2":10438,"PHASE3":10440,"PHASE4":10442,"NA":10444},{"trials":10427,"activeCount":100},[],{"trials":10429,"activeCount":100},[10430],{"nctId":10431,"briefTitle":10432,"status":1196,"phases":10433,"primaryCompletion":10434,"completion":10434,"start":9049,"enrollment":100,"conditions":10435,"interventions":10437},"NCT03924102","Cardiac Perfusion and Metabolism With [11C] Acetate PET\u002FCT is Associated With Hematopoietic System Activation in Acute Decompensated Heart Failure: An Imaging Sub-study",[89],"2026-10-31",[10436],"Acute Decompensated Heart Failure",[10424],{"trials":10439,"activeCount":100},[],{"trials":10441,"activeCount":100},[],{"trials":10443,"activeCount":100},[],{"trials":10445,"activeCount":100},[],{"intervention":7076,"totalTrials":118,"cells":10447},{"EARLY_PHASE1":10448,"PHASE1":10450,"PHASE2":10456,"PHASE3":10458,"PHASE4":10460,"NA":10462},{"trials":10449,"activeCount":100},[],{"trials":10451,"activeCount":100},[10452],{"nctId":7070,"briefTitle":7071,"status":917,"phases":10453,"start":5942,"enrollment":19,"conditions":10454,"interventions":10455},[89],[7074],[7076,7063],{"trials":10457,"activeCount":100},[],{"trials":10459,"activeCount":100},[],{"trials":10461,"activeCount":100},[],{"trials":10463,"activeCount":100},[],{"intervention":10465,"totalTrials":118,"cells":10466},"Combination of Arixtra with chemotherapy",{"EARLY_PHASE1":10467,"PHASE1":10469,"PHASE2":10480,"PHASE3":10482,"PHASE4":10484,"NA":10486},{"trials":10468,"activeCount":100},[],{"trials":10470,"activeCount":100},[10471],{"nctId":10472,"briefTitle":10473,"status":166,"phases":10474,"primaryCompletion":10475,"completion":10476,"start":4362,"enrollment":25,"conditions":10477,"interventions":10479},"NCT00476216","Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer",[89],"2012-12","2013-12",[1251,10478],"Venous Thromboembolism",[10465],{"trials":10481,"activeCount":100},[],{"trials":10483,"activeCount":100},[],{"trials":10485,"activeCount":100},[],{"trials":10487,"activeCount":100},[],{"intervention":10489,"totalTrials":118,"cells":10490},"MVF-HER-2(628-647)-CRL 1005 vaccine",{"EARLY_PHASE1":10491,"PHASE1":10493,"PHASE2":10503,"PHASE3":10505,"PHASE4":10507,"NA":10509},{"trials":10492,"activeCount":100},[],{"trials":10494,"activeCount":100},[10495],{"nctId":10496,"briefTitle":10497,"status":1196,"phases":10498,"primaryCompletion":1013,"completion":1013,"start":10499,"enrollment":100,"conditions":10500,"interventions":10502},"NCT00017537","Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer",[89],"2000-03",[21,10501,999,988,10349],"Gastric Cancer",[10489],{"trials":10504,"activeCount":100},[],{"trials":10506,"activeCount":100},[],{"trials":10508,"activeCount":100},[],{"trials":10510,"activeCount":100},[],{"intervention":10512,"totalTrials":118,"cells":10513},"pentoxifylline",{"EARLY_PHASE1":10514,"PHASE1":10516,"PHASE2":10527,"PHASE3":10529,"PHASE4":10531,"NA":10533},{"trials":10515,"activeCount":100},[],{"trials":10517,"activeCount":100},[10518],{"nctId":10519,"briefTitle":10520,"status":917,"phases":10521,"primaryCompletion":10522,"completion":10522,"start":10523,"enrollment":8011,"conditions":10524,"interventions":10526},"NCT00593658","Pilot Study of Pentoxifylline for Hepatopulmonary Syndrome",[89],"2006-10","2004-06",[10525],"Hepatopulmonary Syndrome",[10512],{"trials":10528,"activeCount":100},[],{"trials":10530,"activeCount":100},[],{"trials":10532,"activeCount":100},[],{"trials":10534,"activeCount":100},[],{"intervention":10536,"totalTrials":118,"cells":10537},"kineret",{"EARLY_PHASE1":10538,"PHASE1":10540,"PHASE2":10550,"PHASE3":10552,"PHASE4":10554,"NA":10556},{"trials":10539,"activeCount":100},[],{"trials":10541,"activeCount":100},[10542],{"nctId":10543,"briefTitle":10544,"status":917,"phases":10545,"primaryCompletion":6003,"completion":8244,"start":10546,"enrollment":8011,"conditions":10547,"interventions":10549},"NCT02780583","Treatment of Macrophage Activation Syndrome (MAS) With Anakinra",[89],"2016-05-15",[10548],"Macrophage Activation Syndrome",[10536],{"trials":10551,"activeCount":100},[],{"trials":10553,"activeCount":100},[],{"trials":10555,"activeCount":100},[],{"trials":10557,"activeCount":100},[],{"intervention":10559,"totalTrials":118,"cells":10560},"Tazemetostat",{"EARLY_PHASE1":10561,"PHASE1":10563,"PHASE2":10574,"PHASE3":10576,"PHASE4":10578,"NA":10580},{"trials":10562,"activeCount":100},[],{"trials":10564,"activeCount":100},[10565],{"nctId":10566,"briefTitle":10567,"status":917,"phases":10568,"primaryCompletion":10569,"completion":10569,"start":10570,"enrollment":921,"conditions":10571,"interventions":10573},"NCT05983965","Study of Tazemetostat in Lymphoid Malignancies",[89],"2026-03-06","2024-09-05",[10572],"T-cell Lymphoma",[10559],{"trials":10575,"activeCount":100},[],{"trials":10577,"activeCount":100},[],{"trials":10579,"activeCount":100},[],{"trials":10581,"activeCount":100},[],{"intervention":10583,"totalTrials":118,"cells":10584},"Flavocoxid",{"EARLY_PHASE1":10585,"PHASE1":10587,"PHASE2":10598,"PHASE3":10600,"PHASE4":10602,"NA":10604},{"trials":10586,"activeCount":100},[],{"trials":10588,"activeCount":100},[10589],{"nctId":10590,"briefTitle":10591,"status":166,"phases":10592,"primaryCompletion":6801,"completion":6801,"start":10593,"enrollment":10594,"conditions":10595,"interventions":10597},"NCT00294125","Flavocoxid, A Plant-Derived Therapy, for the Treatment of Knee Osteoarthritis",[89],"2006-02",59,[10596],"Osteoarthritis",[10583],{"trials":10599,"activeCount":100},[],{"trials":10601,"activeCount":100},[],{"trials":10603,"activeCount":100},[],{"trials":10605,"activeCount":100},[],{"intervention":10607,"totalTrials":118,"cells":10608},"Standard of Care (SOC) gadolinium Breast MRI",{"EARLY_PHASE1":10609,"PHASE1":10611,"PHASE2":10624,"PHASE3":10626,"PHASE4":10628,"NA":10630},{"trials":10610,"activeCount":100},[],{"trials":10612,"activeCount":100},[10613],{"nctId":10614,"briefTitle":10615,"status":166,"phases":10616,"primaryCompletion":5385,"completion":10617,"start":10618,"enrollment":986,"conditions":10619,"interventions":10622},"NCT04340180","Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction",[89],"2026-01-20","2021-07-14",[10620,10621],"Breast Benign Tumor","Breast Malignant Tumor",[10607,10623],"reduced 1\u002F4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.",{"trials":10625,"activeCount":100},[],{"trials":10627,"activeCount":100},[],{"trials":10629,"activeCount":100},[],{"trials":10631,"activeCount":100},[],{"intervention":10623,"totalTrials":118,"cells":10633},{"EARLY_PHASE1":10634,"PHASE1":10636,"PHASE2":10642,"PHASE3":10644,"PHASE4":10646,"NA":10648},{"trials":10635,"activeCount":100},[],{"trials":10637,"activeCount":100},[10638],{"nctId":10614,"briefTitle":10615,"status":166,"phases":10639,"primaryCompletion":5385,"completion":10617,"start":10618,"enrollment":986,"conditions":10640,"interventions":10641},[89],[10620,10621],[10607,10623],{"trials":10643,"activeCount":100},[],{"trials":10645,"activeCount":100},[],{"trials":10647,"activeCount":100},[],{"trials":10649,"activeCount":100},[],{"intervention":10651,"totalTrials":118,"cells":10652},"Cohort 1: Dose Escalation",{"EARLY_PHASE1":10653,"PHASE1":10655,"PHASE2":10667,"PHASE3":10669,"PHASE4":10671,"NA":10673},{"trials":10654,"activeCount":100},[],{"trials":10656,"activeCount":100},[10657],{"nctId":10658,"briefTitle":10659,"status":917,"phases":10660,"primaryCompletion":10661,"completion":10661,"start":10662,"enrollment":118,"conditions":10663,"interventions":10665},"NCT03944902","CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients",[89],"2022-01-05","2021-09-01",[988,10664],"Resistant BRCA Wild-Type Ovarian Cancer",[10651,10666],"Cohort 2: Dose Escalation",{"trials":10668,"activeCount":100},[],{"trials":10670,"activeCount":100},[],{"trials":10672,"activeCount":100},[],{"trials":10674,"activeCount":100},[],{"intervention":10666,"totalTrials":118,"cells":10676},{"EARLY_PHASE1":10677,"PHASE1":10679,"PHASE2":10685,"PHASE3":10687,"PHASE4":10689,"NA":10691},{"trials":10678,"activeCount":100},[],{"trials":10680,"activeCount":100},[10681],{"nctId":10658,"briefTitle":10659,"status":917,"phases":10682,"primaryCompletion":10661,"completion":10661,"start":10662,"enrollment":118,"conditions":10683,"interventions":10684},[89],[988,10664],[10651,10666],{"trials":10686,"activeCount":100},[],{"trials":10688,"activeCount":100},[],{"trials":10690,"activeCount":100},[],{"trials":10692,"activeCount":100},[],{"intervention":10694,"totalTrials":118,"cells":10695},"JAN101 SR",{"EARLY_PHASE1":10696,"PHASE1":10698,"PHASE2":10708,"PHASE3":10710,"PHASE4":10712,"NA":10714},{"trials":10697,"activeCount":100},[],{"trials":10699,"activeCount":100},[10700],{"nctId":10701,"briefTitle":10702,"status":1196,"phases":10703,"primaryCompletion":10704,"completion":10705,"start":296,"enrollment":100,"conditions":10706,"interventions":10707},"NCT05893160","Effects of Sustained-release Oral Sodium Nitrite on Postoperative Pain and Recovery Following Total Knee Arthroplasty",[89],"2027-10-01","2028-08-01",[3947],[10694],{"trials":10709,"activeCount":100},[],{"trials":10711,"activeCount":100},[],{"trials":10713,"activeCount":100},[],{"trials":10715,"activeCount":100},[],{"intervention":1057,"totalTrials":118,"cells":10717},{"EARLY_PHASE1":10718,"PHASE1":10720,"PHASE2":10726,"PHASE3":10728,"PHASE4":10730,"NA":10732},{"trials":10719,"activeCount":100},[],{"trials":10721,"activeCount":100},[10722],{"nctId":1044,"briefTitle":1045,"status":166,"phases":10723,"primaryCompletion":1047,"completion":1048,"start":1049,"enrollment":1050,"conditions":10724,"interventions":10725},[89],[933,1052,1053,1054,1055],[1057,1037],{"trials":10727,"activeCount":100},[],{"trials":10729,"activeCount":100},[],{"trials":10731,"activeCount":100},[],{"trials":10733,"activeCount":100},[],{"intervention":10735,"totalTrials":118,"cells":10736},"GABA and Placebo GAD-alum",{"EARLY_PHASE1":10737,"PHASE1":10739,"PHASE2":10752,"PHASE3":10754,"PHASE4":10756,"NA":10758},{"trials":10738,"activeCount":100},[],{"trials":10740,"activeCount":100},[10741],{"nctId":10742,"briefTitle":10743,"status":166,"phases":10744,"primaryCompletion":10745,"completion":10746,"start":4072,"enrollment":10747,"conditions":10748,"interventions":10750},"NCT02002130","The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes",[89],"2021-10-15","2022-04-15",101,[10749],"Type I Diabetes",[10735,10751],"Active Oral GABA and Active GAD-alum",{"trials":10753,"activeCount":100},[],{"trials":10755,"activeCount":100},[],{"trials":10757,"activeCount":100},[],{"trials":10759,"activeCount":100},[],{"intervention":10751,"totalTrials":118,"cells":10761},{"EARLY_PHASE1":10762,"PHASE1":10764,"PHASE2":10770,"PHASE3":10772,"PHASE4":10774,"NA":10776},{"trials":10763,"activeCount":100},[],{"trials":10765,"activeCount":100},[10766],{"nctId":10742,"briefTitle":10743,"status":166,"phases":10767,"primaryCompletion":10745,"completion":10746,"start":4072,"enrollment":10747,"conditions":10768,"interventions":10769},[89],[10749],[10735,10751],{"trials":10771,"activeCount":100},[],{"trials":10773,"activeCount":100},[],{"trials":10775,"activeCount":100},[],{"trials":10777,"activeCount":100},[],{"intervention":10779,"totalTrials":118,"cells":10780},"ABT 510",{"EARLY_PHASE1":10781,"PHASE1":10783,"PHASE2":10793,"PHASE3":10795,"PHASE4":10797,"NA":10799},{"trials":10782,"activeCount":100},[],{"trials":10784,"activeCount":100},[10785],{"nctId":10786,"briefTitle":10787,"status":166,"phases":10788,"primaryCompletion":6135,"completion":6135,"start":10789,"enrollment":942,"conditions":10790,"interventions":10792},"NCT00584883","A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme",[89],"2003-08",[10791],"Brain Tumor",[10779],{"trials":10794,"activeCount":100},[],{"trials":10796,"activeCount":100},[],{"trials":10798,"activeCount":100},[],{"trials":10800,"activeCount":100},[],{"intervention":10802,"totalTrials":118,"cells":10803},"Remimazolam",{"EARLY_PHASE1":10804,"PHASE1":10806,"PHASE2":10817,"PHASE3":10819,"PHASE4":10821,"NA":10823},{"trials":10805,"activeCount":100},[],{"trials":10807,"activeCount":100},[10808],{"nctId":10809,"briefTitle":10810,"status":166,"phases":10811,"primaryCompletion":10812,"completion":4976,"start":3722,"enrollment":3343,"conditions":10813,"interventions":10815},"NCT06129188","Comparison of Procedural Sedation in TEE",[89],"2025-11-26",[10814],"Anesthesia",[10802,10816],"Propofol",{"trials":10818,"activeCount":100},[],{"trials":10820,"activeCount":100},[],{"trials":10822,"activeCount":100},[],{"trials":10824,"activeCount":100},[],{"intervention":10826,"totalTrials":118,"cells":10827},"Tarceva plus AT-101",{"EARLY_PHASE1":10828,"PHASE1":10830,"PHASE2":10840,"PHASE3":10842,"PHASE4":10844,"NA":10846},{"trials":10829,"activeCount":100},[],{"trials":10831,"activeCount":100},[10832],{"nctId":10833,"briefTitle":10834,"status":1196,"phases":10835,"primaryCompletion":10836,"completion":5167,"start":5342,"enrollment":100,"conditions":10837,"interventions":10839},"NCT00934076","Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer",[89],"2011-01",[10838],"Carcinoma, Non Small Cell Lung",[10826],{"trials":10841,"activeCount":100},[],{"trials":10843,"activeCount":100},[],{"trials":10845,"activeCount":100},[],{"trials":10847,"activeCount":100},[],{"intervention":10849,"totalTrials":118,"cells":10850},"C134 Re-Administration",{"EARLY_PHASE1":10851,"PHASE1":10853,"PHASE2":10864,"PHASE3":10866,"PHASE4":10868,"NA":10870},{"trials":10852,"activeCount":100},[],{"trials":10854,"activeCount":100},[10855],{"nctId":10856,"briefTitle":10857,"status":917,"phases":10858,"primaryCompletion":10859,"completion":10859,"start":10860,"enrollment":118,"conditions":10861,"interventions":10863},"NCT06193174","Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)",[89],"2025-03-07","2024-06-21",[10862,2671,2673,2672],"Recurrent Malignant Glioma",[10849],{"trials":10865,"activeCount":100},[],{"trials":10867,"activeCount":100},[],{"trials":10869,"activeCount":100},[],{"trials":10871,"activeCount":100},[],{"intervention":10873,"totalTrials":118,"cells":10874},"Retifanlimab, INCAGN02385, INCAGN02390",{"EARLY_PHASE1":10875,"PHASE1":10877,"PHASE2":10890,"PHASE3":10892,"PHASE4":10894,"NA":10896},{"trials":10876,"activeCount":100},[],{"trials":10878,"activeCount":100},[10879],{"nctId":10880,"briefTitle":10881,"status":1196,"phases":10882,"primaryCompletion":3064,"completion":10883,"start":10884,"enrollment":100,"conditions":10885,"interventions":10889},"NCT06290622","PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL",[89],"2028-01-31","2024-08-30",[10886,10887,10888],"Diffuse Large B Cell Lymphoma","Lymphoma, B-Cell","Lymphoma, Follicular",[10873],{"trials":10891,"activeCount":100},[],{"trials":10893,"activeCount":100},[],{"trials":10895,"activeCount":100},[],{"trials":10897,"activeCount":100},[],{"intervention":10899,"totalTrials":118,"cells":10900},"allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes",{"EARLY_PHASE1":10901,"PHASE1":10903,"PHASE2":10912,"PHASE3":10914,"PHASE4":10916,"NA":10918},{"trials":10902,"activeCount":100},[],{"trials":10904,"activeCount":100},[10905],{"nctId":10906,"briefTitle":10907,"status":1196,"phases":10908,"primaryCompletion":7391,"completion":7391,"start":10909,"enrollment":100,"conditions":10910,"interventions":10911},"NCT00002956","Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants",[89],"1996-11",[9164,4007],[10899],{"trials":10913,"activeCount":100},[],{"trials":10915,"activeCount":100},[],{"trials":10917,"activeCount":100},[],{"trials":10919,"activeCount":100},[],{"intervention":10921,"totalTrials":118,"cells":10922},"lapatinib",{"EARLY_PHASE1":10923,"PHASE1":10925,"PHASE2":10933,"PHASE3":10935,"PHASE4":10937,"NA":10939},{"trials":10924,"activeCount":100},[],{"trials":10926,"activeCount":100},[10927],{"nctId":10928,"briefTitle":10929,"status":917,"phases":10930,"primaryCompletion":5962,"completion":6890,"start":7170,"enrollment":1476,"conditions":10931,"interventions":10932},"NCT00317434","Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer",[89],[988],[10921],{"trials":10934,"activeCount":100},[],{"trials":10936,"activeCount":100},[],{"trials":10938,"activeCount":100},[],{"trials":10940,"activeCount":100},[],{"intervention":10942,"totalTrials":118,"cells":10943},"Zoledronic Acid",{"EARLY_PHASE1":10944,"PHASE1":10946,"PHASE2":10957,"PHASE3":10959,"PHASE4":10961,"NA":10963},{"trials":10945,"activeCount":100},[],{"trials":10947,"activeCount":100},[10948],{"nctId":10949,"briefTitle":10950,"status":917,"phases":10951,"primaryCompletion":10952,"completion":10952,"start":10393,"enrollment":906,"conditions":10953,"interventions":10955},"NCT01404702","Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma",[89],"2014-08",[10954],"Neuroblastoma",[10942,10956],"Aldesleukin",{"trials":10958,"activeCount":100},[],{"trials":10960,"activeCount":100},[],{"trials":10962,"activeCount":100},[],{"trials":10964,"activeCount":100},[],{"intervention":10956,"totalTrials":118,"cells":10966},{"EARLY_PHASE1":10967,"PHASE1":10969,"PHASE2":10975,"PHASE3":10977,"PHASE4":10979,"NA":10981},{"trials":10968,"activeCount":100},[],{"trials":10970,"activeCount":100},[10971],{"nctId":10949,"briefTitle":10950,"status":917,"phases":10972,"primaryCompletion":10952,"completion":10952,"start":10393,"enrollment":906,"conditions":10973,"interventions":10974},[89],[10954],[10942,10956],{"trials":10976,"activeCount":100},[],{"trials":10978,"activeCount":100},[],{"trials":10980,"activeCount":100},[],{"trials":10982,"activeCount":100},[],{"intervention":10984,"totalTrials":118,"cells":10985},"M4344+Niraparib",{"EARLY_PHASE1":10986,"PHASE1":10988,"PHASE2":10998,"PHASE3":11000,"PHASE4":11002,"NA":11004},{"trials":10987,"activeCount":100},[],{"trials":10989,"activeCount":100},[10990],{"nctId":10991,"briefTitle":10992,"status":1196,"phases":10993,"primaryCompletion":3018,"completion":401,"start":10994,"enrollment":100,"conditions":10995,"interventions":10997},"NCT04149145","Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer",[89],"2023-05",[10996],"Ovarian Cancer Recurrent",[10984,10984],{"trials":10999,"activeCount":100},[],{"trials":11001,"activeCount":100},[],{"trials":11003,"activeCount":100},[],{"trials":11005,"activeCount":100},[],{"intervention":11007,"totalTrials":118,"cells":11008},"Xtampza ER",{"EARLY_PHASE1":11009,"PHASE1":11021,"PHASE2":11023,"PHASE3":11025,"PHASE4":11027,"NA":11029},{"trials":11010,"activeCount":100},[11011],{"nctId":11012,"briefTitle":11013,"status":166,"phases":11014,"primaryCompletion":11015,"completion":11016,"start":11017,"enrollment":22,"conditions":11018,"interventions":11020},"NCT03317730","Pilot Trial of Microsphere Oxycodone (Xtampza ER) for Pain Management in Patients Receiving Radiotherapy for Locally Advanced Head and Neck Cancer",[88],"2019-12-04","2020-11-17","2018-05-01",[11019],"Locally Advanced Head and Neck Cancer",[11007],{"trials":11022,"activeCount":100},[],{"trials":11024,"activeCount":100},[],{"trials":11026,"activeCount":100},[],{"trials":11028,"activeCount":100},[],{"trials":11030,"activeCount":100},[],{"intervention":11032,"totalTrials":118,"cells":11033},"Treatment Group Live Attenuated Flu Vaccine",{"EARLY_PHASE1":11034,"PHASE1":11043,"PHASE2":11045,"PHASE3":11047,"PHASE4":11049,"NA":11051},{"trials":11035,"activeCount":100},[11036],{"nctId":11037,"briefTitle":11038,"status":166,"phases":11039,"primaryCompletion":10155,"completion":10155,"start":6027,"enrollment":2518,"conditions":11040,"interventions":11042},"NCT04080245","Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV)",[88],[11041],"Influenza, Human",[11032],{"trials":11044,"activeCount":100},[],{"trials":11046,"activeCount":100},[],{"trials":11048,"activeCount":100},[],{"trials":11050,"activeCount":100},[],{"trials":11052,"activeCount":100},[],{"intervention":11054,"totalTrials":118,"cells":11055},"[O-15]Water",{"EARLY_PHASE1":11056,"PHASE1":11067,"PHASE2":11069,"PHASE3":11071,"PHASE4":11073,"NA":11075},{"trials":11057,"activeCount":100},[11058],{"nctId":11059,"briefTitle":11060,"status":1196,"phases":11061,"primaryCompletion":375,"completion":375,"start":11062,"enrollment":100,"conditions":11063,"interventions":11065},"NCT03806751","A Noninvasive Arterial Input Estimation Method for O-15 PET and Integrated PET\u002FMR Scanning",[88],"2025-02-01",[11064],"Validation of a New Noninvasive Method to Obtain the Arterial Input Function (AIF) Directly by PET Imaging",[11054,11066],"Acetazolamide",{"trials":11068,"activeCount":100},[],{"trials":11070,"activeCount":100},[],{"trials":11072,"activeCount":100},[],{"trials":11074,"activeCount":100},[],{"trials":11076,"activeCount":100},[],{"intervention":11066,"totalTrials":118,"cells":11078},{"EARLY_PHASE1":11079,"PHASE1":11085,"PHASE2":11087,"PHASE3":11089,"PHASE4":11091,"NA":11093},{"trials":11080,"activeCount":100},[11081],{"nctId":11059,"briefTitle":11060,"status":1196,"phases":11082,"primaryCompletion":375,"completion":375,"start":11062,"enrollment":100,"conditions":11083,"interventions":11084},[88],[11064],[11054,11066],{"trials":11086,"activeCount":100},[],{"trials":11088,"activeCount":100},[],{"trials":11090,"activeCount":100},[],{"trials":11092,"activeCount":100},[],{"trials":11094,"activeCount":100},[],{"intervention":11096,"totalTrials":118,"cells":11097},"Nestle IMPACT Immunonutrition",{"EARLY_PHASE1":11098,"PHASE1":11108,"PHASE2":11110,"PHASE3":11112,"PHASE4":11114,"NA":11116},{"trials":11099,"activeCount":100},[11100],{"nctId":11101,"briefTitle":11102,"status":1196,"phases":11103,"primaryCompletion":11104,"completion":3985,"start":4694,"enrollment":100,"conditions":11105,"interventions":11107},"NCT03333148","Preoperative Oral ImmunoNuTrition to Improve Surgical Outcomes for IBD Patients (PINT)",[88],"2021-06-01",[11106],"Inflammatory Bowel Diseases",[11096],{"trials":11109,"activeCount":100},[],{"trials":11111,"activeCount":100},[],{"trials":11113,"activeCount":100},[],{"trials":11115,"activeCount":100},[],{"trials":11117,"activeCount":100},[],{"intervention":11119,"totalTrials":118,"cells":11120},"Stereotactic Body Radiation Therapy",{"EARLY_PHASE1":11121,"PHASE1":11130,"PHASE2":11132,"PHASE3":11134,"PHASE4":11136,"NA":11138},{"trials":11122,"activeCount":100},[11123],{"nctId":11124,"briefTitle":11125,"status":166,"phases":11126,"primaryCompletion":1248,"completion":9073,"start":8115,"enrollment":33,"conditions":11127,"interventions":11129},"NCT01247298","A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma",[88],[11128],"Hepatocellular Carcinoma (HCC)",[11119],{"trials":11131,"activeCount":100},[],{"trials":11133,"activeCount":100},[],{"trials":11135,"activeCount":100},[],{"trials":11137,"activeCount":100},[],{"trials":11139,"activeCount":100},[],{"intervention":11141,"totalTrials":118,"cells":11142},"Aspirin",{"EARLY_PHASE1":11143,"PHASE1":11155,"PHASE2":11157,"PHASE3":11159,"PHASE4":11161,"NA":11163},{"trials":11144,"activeCount":100},[11145],{"nctId":11146,"briefTitle":11147,"status":166,"phases":11148,"primaryCompletion":11149,"completion":11149,"start":11150,"enrollment":11151,"conditions":11152,"interventions":11154},"NCT03765619","Postoperative Aspirin and Ankle Fracture Healing",[88],"2019-11-26","2019-06-12",500,[11153],"Ankle Fractures",[11141],{"trials":11156,"activeCount":100},[],{"trials":11158,"activeCount":100},[],{"trials":11160,"activeCount":100},[],{"trials":11162,"activeCount":100},[],{"trials":11164,"activeCount":100},[],{"intervention":11166,"totalTrials":118,"cells":11167},"18F-rhPSMA-7.3",{"EARLY_PHASE1":11168,"PHASE1":11177,"PHASE2":11179,"PHASE3":11181,"PHASE4":11183,"NA":11185},{"trials":11169,"activeCount":100},[11170],{"nctId":11171,"briefTitle":11172,"status":1196,"phases":11173,"primaryCompletion":349,"completion":349,"start":11174,"enrollment":100,"conditions":11175,"interventions":11176},"NCT05707182","18F-rhPSMA-7.3 PET\u002FMRI in Prostate Cancer Active Surveillance: a Pilot Study",[88],"2025-04-30",[7816],[11166],{"trials":11178,"activeCount":100},[],{"trials":11180,"activeCount":100},[],{"trials":11182,"activeCount":100},[],{"trials":11184,"activeCount":100},[],{"trials":11186,"activeCount":100},[],{"intervention":11188,"totalTrials":118,"cells":11189},"Morphine Sulfate 150 mcg",{"EARLY_PHASE1":11190,"PHASE1":11202,"PHASE2":11204,"PHASE3":11206,"PHASE4":11208,"NA":11210},{"trials":11191,"activeCount":100},[11192],{"nctId":11193,"briefTitle":11194,"status":166,"phases":11195,"primaryCompletion":11196,"completion":11196,"start":11197,"enrollment":11198,"conditions":11199,"interventions":11200},"NCT04279054","Decreased Neuraxial Morphine After Cesarean Delivery",[88],"2023-07-05","2020-09-09",87,[10814],[11188,11201],"Morphine Sulfate 50mcg",{"trials":11203,"activeCount":100},[],{"trials":11205,"activeCount":100},[],{"trials":11207,"activeCount":100},[],{"trials":11209,"activeCount":100},[],{"trials":11211,"activeCount":100},[],{"intervention":11201,"totalTrials":118,"cells":11213},{"EARLY_PHASE1":11214,"PHASE1":11220,"PHASE2":11222,"PHASE3":11224,"PHASE4":11226,"NA":11228},{"trials":11215,"activeCount":100},[11216],{"nctId":11193,"briefTitle":11194,"status":166,"phases":11217,"primaryCompletion":11196,"completion":11196,"start":11197,"enrollment":11198,"conditions":11218,"interventions":11219},[88],[10814],[11188,11201],{"trials":11221,"activeCount":100},[],{"trials":11223,"activeCount":100},[],{"trials":11225,"activeCount":100},[],{"trials":11227,"activeCount":100},[],{"trials":11229,"activeCount":100},[],{"intervention":11231,"totalTrials":118,"cells":11232},"Open Label Placebo",{"EARLY_PHASE1":11233,"PHASE1":11246,"PHASE2":11248,"PHASE3":11250,"PHASE4":11252,"NA":11254},{"trials":11234,"activeCount":100},[11235],{"nctId":11236,"briefTitle":11237,"status":1196,"phases":11238,"primaryCompletion":11239,"completion":11240,"start":11241,"enrollment":100,"conditions":11242,"interventions":11244},"NCT04883983","OLP to Manage Pain in TJA: A Feasibility Study",[88],"2024-09","2025-10","2023-12",[173,11243],"Opioid Abuse",[11231,11245],"Patient medication as standardly prescribed",{"trials":11247,"activeCount":100},[],{"trials":11249,"activeCount":100},[],{"trials":11251,"activeCount":100},[],{"trials":11253,"activeCount":100},[],{"trials":11255,"activeCount":100},[],{"intervention":11245,"totalTrials":118,"cells":11257},{"EARLY_PHASE1":11258,"PHASE1":11264,"PHASE2":11266,"PHASE3":11268,"PHASE4":11270,"NA":11272},{"trials":11259,"activeCount":100},[11260],{"nctId":11236,"briefTitle":11237,"status":1196,"phases":11261,"primaryCompletion":11239,"completion":11240,"start":11241,"enrollment":100,"conditions":11262,"interventions":11263},[88],[173,11243],[11231,11245],{"trials":11265,"activeCount":100},[],{"trials":11267,"activeCount":100},[],{"trials":11269,"activeCount":100},[],{"trials":11271,"activeCount":100},[],{"trials":11273,"activeCount":100},[],{"intervention":11275,"totalTrials":118,"cells":11276},"Lidocaine Bolus",{"EARLY_PHASE1":11277,"PHASE1":11288,"PHASE2":11290,"PHASE3":11292,"PHASE4":11294,"NA":11296},{"trials":11278,"activeCount":100},[11279],{"nctId":11280,"briefTitle":11281,"status":917,"phases":11282,"primaryCompletion":11283,"completion":11283,"start":11284,"enrollment":118,"conditions":11285,"interventions":11286},"NCT03658109","Lidocaine Infusion or Quadratus Lumborum Block and Intrathecal Morphine, Versus Intrathecal Morphine Alone",[88],"2021-05-04","2019-09-24",[1709],[11275,11287],"Saline Bolus",{"trials":11289,"activeCount":100},[],{"trials":11291,"activeCount":100},[],{"trials":11293,"activeCount":100},[],{"trials":11295,"activeCount":100},[],{"trials":11297,"activeCount":100},[],{"intervention":11287,"totalTrials":118,"cells":11299},{"EARLY_PHASE1":11300,"PHASE1":11306,"PHASE2":11308,"PHASE3":11310,"PHASE4":11312,"NA":11314},{"trials":11301,"activeCount":100},[11302],{"nctId":11280,"briefTitle":11281,"status":917,"phases":11303,"primaryCompletion":11283,"completion":11283,"start":11284,"enrollment":118,"conditions":11304,"interventions":11305},[88],[1709],[11275,11287],{"trials":11307,"activeCount":100},[],{"trials":11309,"activeCount":100},[],{"trials":11311,"activeCount":100},[],{"trials":11313,"activeCount":100},[],{"trials":11315,"activeCount":100},[],{"intervention":11317,"totalTrials":118,"cells":11318},"FET PET\u002FMRI",{"EARLY_PHASE1":11319,"PHASE1":11329,"PHASE2":11331,"PHASE3":11333,"PHASE4":11335,"NA":11337},{"trials":11320,"activeCount":100},[11321],{"nctId":11322,"briefTitle":11323,"status":917,"phases":11324,"primaryCompletion":190,"completion":190,"start":11325,"enrollment":118,"conditions":11326,"interventions":11328},"NCT03451123","FET-PET\u002FMRI for Surgical Assessment of Pediatric Brain Tumors",[88],"2018-04-23",[11327],"Pediatric Brain Tumors",[11317],{"trials":11330,"activeCount":100},[],{"trials":11332,"activeCount":100},[],{"trials":11334,"activeCount":100},[],{"trials":11336,"activeCount":100},[],{"trials":11338,"activeCount":100},[],{"intervention":11340,"totalTrials":118,"cells":11341},"Lenalidomide",{"EARLY_PHASE1":11342,"PHASE1":11359,"PHASE2":11361,"PHASE3":11363,"PHASE4":11365,"NA":11367},{"trials":11343,"activeCount":100},[11344],{"nctId":11345,"briefTitle":11346,"status":917,"phases":11347,"primaryCompletion":9074,"completion":4643,"start":11348,"enrollment":118,"conditions":11349,"interventions":11358},"NCT00704691","Lenalidomide Therapy for Patients With Relapsed and\u002For Refractory, Peripheral T-Cell Lymphomas",[88],"2008-06",[11350,11351,11352,11353,11354,11355,11356,11357],"Peripheral T-cell Lymphomas","Adult T-cell Leukemia","Adult T-cell Lymphoma","Peripheral T-cell Lymphoma Unspecified","Angioimmunoblastic T-cell Lymphoma","Anaplastic Large Cell Lymphoma","T\u002FNull Cell Systemic Type","Cutaneous t-Cell Lymphoma With Nodal\u002FVisceral Disease",[11340],{"trials":11360,"activeCount":100},[],{"trials":11362,"activeCount":100},[],{"trials":11364,"activeCount":100},[],{"trials":11366,"activeCount":100},[],{"trials":11368,"activeCount":100},[],{"intervention":11370,"totalTrials":118,"cells":11371},"Oral Calcitriol 0.5 mcg once daily for 6 weeks",{"EARLY_PHASE1":11372,"PHASE1":11382,"PHASE2":11384,"PHASE3":11386,"PHASE4":11388,"NA":11390},{"trials":11373,"activeCount":100},[11374],{"nctId":11375,"briefTitle":11376,"status":166,"phases":11377,"primaryCompletion":5167,"completion":5167,"start":11378,"enrollment":1969,"conditions":11379,"interventions":11381},"NCT01988116","Effects of Vitamin D Replacement on Hormones Regulating Iron Metabolism in Individuals With Chronic Kidney Disease",[88],"2013-10",[9026,11380],"Anemia of Chronic Disease",[11370],{"trials":11383,"activeCount":100},[],{"trials":11385,"activeCount":100},[],{"trials":11387,"activeCount":100},[],{"trials":11389,"activeCount":100},[],{"trials":11391,"activeCount":100},[],{"intervention":11393,"totalTrials":118,"cells":11394},"Folfirinox",{"EARLY_PHASE1":11395,"PHASE1":11408,"PHASE2":11410,"PHASE3":11412,"PHASE4":11414,"NA":11416},{"trials":11396,"activeCount":100},[11397],{"nctId":11398,"briefTitle":11399,"status":917,"phases":11400,"primaryCompletion":11401,"completion":4745,"start":11402,"enrollment":1425,"conditions":11403,"interventions":11406},"NCT03600623","Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer",[88],"2020-07-30","2017-09-25",[11404,11405,5954],"Locally Advanced Pancreatic Cancer","Borderline Pancreatic Inoperable Cancer",[11393,11407],"Gemcitabine nab-Paclitaxel",{"trials":11409,"activeCount":100},[],{"trials":11411,"activeCount":100},[],{"trials":11413,"activeCount":100},[],{"trials":11415,"activeCount":100},[],{"trials":11417,"activeCount":100},[],{"intervention":11407,"totalTrials":118,"cells":11419},{"EARLY_PHASE1":11420,"PHASE1":11426,"PHASE2":11428,"PHASE3":11430,"PHASE4":11432,"NA":11434},{"trials":11421,"activeCount":100},[11422],{"nctId":11398,"briefTitle":11399,"status":917,"phases":11423,"primaryCompletion":11401,"completion":4745,"start":11402,"enrollment":1425,"conditions":11424,"interventions":11425},[88],[11404,11405,5954],[11393,11407],{"trials":11427,"activeCount":100},[],{"trials":11429,"activeCount":100},[],{"trials":11431,"activeCount":100},[],{"trials":11433,"activeCount":100},[],{"trials":11435,"activeCount":100},[],{"intervention":11437,"totalTrials":118,"cells":11438},"Pregabalin",{"EARLY_PHASE1":11439,"PHASE1":11450,"PHASE2":11452,"PHASE3":11454,"PHASE4":11456,"NA":11458},{"trials":11440,"activeCount":100},[11441],{"nctId":11442,"briefTitle":11443,"status":166,"phases":11444,"primaryCompletion":10306,"completion":10306,"start":11445,"enrollment":11446,"conditions":11447,"interventions":11449},"NCT00583869","Role of Pregabalin in Treatment of Post-Op Pain in Fracture Patients",[88],"2007-05",86,[11448],"Post-operative Pain",[11437,11437],{"trials":11451,"activeCount":100},[],{"trials":11453,"activeCount":100},[],{"trials":11455,"activeCount":100},[],{"trials":11457,"activeCount":100},[],{"trials":11459,"activeCount":100},[],{"intervention":11461,"totalTrials":118,"cells":11462},"[11C] acetate",{"EARLY_PHASE1":11463,"PHASE1":11472,"PHASE2":11474,"PHASE3":11476,"PHASE4":11478,"NA":11480},{"trials":11464,"activeCount":100},[11465],{"nctId":11466,"briefTitle":11467,"status":1196,"phases":11468,"primaryCompletion":1183,"completion":1183,"start":572,"enrollment":100,"conditions":11469,"interventions":11471},"NCT04795856","Understanding the Metabolic and Functional Derangement of Primary Mitral Regurgitation: a Feasibility Study Using Carbon 11(C-11) Acetate Cardiac Positron Emission Tomography Magnetic Resonance Imaging (PET-MRI)",[88],[11470],"Mitral Valve Regurgitation",[11461],{"trials":11473,"activeCount":100},[],{"trials":11475,"activeCount":100},[],{"trials":11477,"activeCount":100},[],{"trials":11479,"activeCount":100},[],{"trials":11481,"activeCount":100},[],{"intervention":11483,"totalTrials":118,"cells":11484},"CT scan",{"EARLY_PHASE1":11485,"PHASE1":11493,"PHASE2":11495,"PHASE3":11497,"PHASE4":11499,"NA":11501},{"trials":11486,"activeCount":100},[11487],{"nctId":11488,"briefTitle":11489,"status":166,"phases":11490,"primaryCompletion":3945,"completion":3945,"start":8052,"enrollment":7141,"conditions":11491,"interventions":11492},"NCT01673802","The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma",[88],[8935],[11483],{"trials":11494,"activeCount":100},[],{"trials":11496,"activeCount":100},[],{"trials":11498,"activeCount":100},[],{"trials":11500,"activeCount":100},[],{"trials":11502,"activeCount":100},[],{"intervention":11504,"totalTrials":118,"cells":11505},"Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.",{"EARLY_PHASE1":11506,"PHASE1":11517,"PHASE2":11519,"PHASE3":11521,"PHASE4":11523,"NA":11525},{"trials":11507,"activeCount":100},[11508],{"nctId":11509,"briefTitle":11510,"status":166,"phases":11511,"primaryCompletion":11512,"completion":11513,"start":11514,"enrollment":3113,"conditions":11515,"interventions":11516},"NCT05798481","Effect of Sublingually Generated S-nitroso-N-acetylcysteine on Systemic Blood Pressure.",[88],"2025-04-29","2025-10-05","2024-03-27",[18,787],[11504],{"trials":11518,"activeCount":100},[],{"trials":11520,"activeCount":100},[],{"trials":11522,"activeCount":100},[],{"trials":11524,"activeCount":100},[],{"trials":11526,"activeCount":100},[],{"intervention":11528,"totalTrials":118,"cells":11529},"Gallium Dotatate",{"EARLY_PHASE1":11530,"PHASE1":11543,"PHASE2":11545,"PHASE3":11547,"PHASE4":11549,"NA":11551},{"trials":11531,"activeCount":100},[11532],{"nctId":11533,"briefTitle":11534,"status":1196,"phases":11535,"primaryCompletion":11536,"completion":11537,"start":11538,"enrollment":100,"conditions":11539,"interventions":11542},"NCT03623984","Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers",[88],"2022-06-07","2023-06-07","2019-06-07",[11540,11541],"Neuroendocrine Carcinoma of Pancreas","Carcinoid",[11528],{"trials":11544,"activeCount":100},[],{"trials":11546,"activeCount":100},[],{"trials":11548,"activeCount":100},[],{"trials":11550,"activeCount":100},[],{"trials":11552,"activeCount":100},[],{"intervention":11554,"totalTrials":118,"cells":11555},"Deucravacitinib",{"EARLY_PHASE1":11556,"PHASE1":11565,"PHASE2":11567,"PHASE3":11569,"PHASE4":11571,"NA":11573},{"trials":11557,"activeCount":100},[11558],{"nctId":11559,"briefTitle":11560,"status":166,"phases":11561,"primaryCompletion":4976,"completion":4976,"start":11562,"enrollment":118,"conditions":11563,"interventions":11564},"NCT05124080","An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis",[88],"2024-03-01",[5849],[11554],{"trials":11566,"activeCount":100},[],{"trials":11568,"activeCount":100},[],{"trials":11570,"activeCount":100},[],{"trials":11572,"activeCount":100},[],{"trials":11574,"activeCount":100},[],{"intervention":11576,"totalTrials":118,"cells":11577},"regional nerve block with local anesthesia of bupivacaine with steroid",{"EARLY_PHASE1":11578,"PHASE1":11591,"PHASE2":11593,"PHASE3":11595,"PHASE4":11597,"NA":11599},{"trials":11579,"activeCount":100},[11580],{"nctId":11581,"briefTitle":11582,"status":166,"phases":11583,"primaryCompletion":11584,"completion":11584,"start":11585,"enrollment":1050,"conditions":11586,"interventions":11590},"NCT04019834","Preoperative Regional Nerve Block for Acute and Chronic Post-Operative Pain Following Mastectomy",[88],"2021-11-25","2020-07-06",[21,11587,11588,11589],"Mastectomy","Anesthesia, Local","Narcotic Use",[11576],{"trials":11592,"activeCount":100},[],{"trials":11594,"activeCount":100},[],{"trials":11596,"activeCount":100},[],{"trials":11598,"activeCount":100},[],{"trials":11600,"activeCount":100},[],{"intervention":1029,"totalTrials":971,"cells":11602},{"EARLY_PHASE1":11603,"PHASE1":11605,"PHASE2":11607,"PHASE3":11622,"PHASE4":11632,"NA":11638},{"trials":11604,"activeCount":100},[],{"trials":11606,"activeCount":100},[],{"trials":11608,"activeCount":100},[11609,11618],{"nctId":11610,"briefTitle":11611,"status":166,"phases":11612,"primaryCompletion":11348,"completion":11348,"start":11613,"enrollment":1969,"conditions":11614,"interventions":11617},"NCT00582660","Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib",[90],"2001-12",[11615,11616],"Colorectal Adenoma","Colorectal Carcinoma",[4062],{"nctId":1020,"briefTitle":1021,"status":166,"phases":11619,"primaryCompletion":1023,"completion":1024,"start":1025,"enrollment":19,"conditions":11620,"interventions":11621},[89,90],[1027],[1029,946,947],{"trials":11623,"activeCount":100},[11624],{"nctId":11625,"briefTitle":11626,"status":1196,"phases":11627,"primaryCompletion":11628,"completion":11628,"start":11613,"enrollment":100,"conditions":11629,"interventions":11631},"NCT00027976","Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses",[90,91],"2005-12",[11630],"Precancerous Condition",[1029],{"trials":11633,"activeCount":100},[11634],{"nctId":4054,"briefTitle":4055,"status":1196,"phases":11635,"primaryCompletion":4057,"completion":4058,"start":4059,"enrollment":100,"conditions":11636,"interventions":11637},[92],[1216],[1228,1229,1230,4062,4063],{"trials":11639,"activeCount":100},[11640],{"nctId":11641,"briefTitle":11642,"status":1196,"phases":11643,"primaryCompletion":1013,"completion":1013,"start":6481,"enrollment":100,"conditions":11644,"interventions":11647},"NCT00084370","Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy",[93],[11645,11646,988],"brca1 Mutation Carrier","brca2 Mutation Carrier",[1029],{"intervention":4935,"totalTrials":906,"cells":11649},{"EARLY_PHASE1":11650,"PHASE1":11652,"PHASE2":11654,"PHASE3":11665,"PHASE4":11682,"NA":11684},{"trials":11651,"activeCount":100},[],{"trials":11653,"activeCount":100},[],{"trials":11655,"activeCount":100},[11656],{"nctId":11657,"briefTitle":11658,"status":166,"phases":11659,"primaryCompletion":4695,"completion":4695,"start":11660,"enrollment":11661,"conditions":11662,"interventions":11663},"NCT02418195","miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome",[90],"2015-04-20",247,[3523],[11664],"ketamine",{"trials":11666,"activeCount":100},[11667,11678],{"nctId":11668,"briefTitle":11669,"status":917,"phases":11670,"primaryCompletion":11671,"completion":11671,"start":11672,"enrollment":8011,"conditions":11673,"interventions":11677},"NCT03109418","Intraoperative Low-dose Ketamine Infusion for Patients With Obstructive Sleep Apnea",[90,91],"2018-09-12","2016-06-02",[11674,11675,11676],"Sleep Apnea","Obstructive Sleep Apnea","Postoperative Complications",[4935],{"nctId":6936,"briefTitle":6937,"status":1196,"phases":11679,"primaryCompletion":4250,"completion":6939,"start":6940,"enrollment":100,"conditions":11680,"interventions":11681},[90,91],[6942],[6925,4935],{"trials":11683,"activeCount":100},[],{"trials":11685,"activeCount":100},[11686],{"nctId":11687,"briefTitle":11688,"status":166,"phases":11689,"primaryCompletion":3945,"completion":3945,"start":1303,"enrollment":7141,"conditions":11690,"interventions":11691},"NCT01887990","Treatment of Suicidal Ideation With Intravenous Ketamine Infusion",[93],[3527,5284],[4935],{"intervention":6337,"totalTrials":906,"cells":11693},{"EARLY_PHASE1":11694,"PHASE1":11696,"PHASE2":11698,"PHASE3":11700,"PHASE4":11706,"NA":11708},{"trials":11695,"activeCount":100},[],{"trials":11697,"activeCount":100},[],{"trials":11699,"activeCount":100},[],{"trials":11701,"activeCount":100},[11702],{"nctId":6329,"briefTitle":6330,"status":166,"phases":11703,"primaryCompletion":6332,"completion":3821,"start":6333,"enrollment":6334,"conditions":11704,"interventions":11705},[91],[6269],[6318,6337],{"trials":11707,"activeCount":100},[],{"trials":11709,"activeCount":100},[11710,11716,11725],{"nctId":11711,"briefTitle":11712,"status":166,"phases":11713,"primaryCompletion":4858,"completion":4858,"start":4164,"enrollment":352,"conditions":11714,"interventions":11715},"NCT00657358","The Effect of Intravenous Lidocaine on Normal Sensation and Pain in Healthy Volunteers",[93],[3947],[6337],{"nctId":11717,"briefTitle":11718,"status":166,"phases":11719,"primaryCompletion":5669,"completion":11720,"start":11721,"enrollment":2518,"conditions":11722,"interventions":11723},"NCT00659633","The Effect of Intravenous Lidocaine on Allodynia",[93],"2016-08","2008-12",[3947],[11724],"lidocaine",{"nctId":11726,"briefTitle":11727,"status":166,"phases":11728,"primaryCompletion":10952,"completion":10952,"start":3945,"enrollment":11729,"conditions":11730,"interventions":11731},"NCT02396537","Efficacy of Topical Lidocaine to Decrease Discomfort With Intranasal Midazolam Administration",[93],77,[3947],[6337,11732,11733],"Midazolam","0.9% Saline",{"intervention":11732,"totalTrials":906,"cells":11735},{"EARLY_PHASE1":11736,"PHASE1":11738,"PHASE2":11740,"PHASE3":11742,"PHASE4":11744,"NA":11746},{"trials":11737,"activeCount":100},[],{"trials":11739,"activeCount":100},[],{"trials":11741,"activeCount":100},[],{"trials":11743,"activeCount":100},[],{"trials":11745,"activeCount":100},[],{"trials":11747,"activeCount":100},[11748,11752,11763,11770],{"nctId":11726,"briefTitle":11727,"status":166,"phases":11749,"primaryCompletion":10952,"completion":10952,"start":3945,"enrollment":11729,"conditions":11750,"interventions":11751},[93],[3947],[6337,11732,11733],{"nctId":11753,"briefTitle":11754,"status":166,"phases":11755,"primaryCompletion":11756,"completion":11756,"start":6890,"enrollment":4670,"conditions":11757,"interventions":11759},"NCT00646646","The Effect of Sedation on Eye Movements",[93],"2008-10",[11758],"Saccadic Eye Movements",[11760,11761,11732,11762],"propofol","dexmedetomidine","saline placebo",{"nctId":11764,"briefTitle":11765,"status":166,"phases":11766,"primaryCompletion":4858,"completion":4858,"start":4132,"enrollment":11446,"conditions":11767,"interventions":11768},"NCT00853333","Sedation and Pain (The Effect of IV Sedation on Pain Perception)",[93],[3947],[11761,11769,11760],"midazolam",{"nctId":11771,"briefTitle":11772,"status":166,"phases":11773,"primaryCompletion":11774,"completion":11775,"start":7251,"enrollment":986,"conditions":11776,"interventions":11778},"NCT03089866","Effect of Sedation on Cognitive Performance in the Elderly",[],"2020-08-04","2020-09-04",[11777],"Postoperative Cognitive Dysfunction",[11732],{"intervention":5145,"totalTrials":906,"cells":11780},{"EARLY_PHASE1":11781,"PHASE1":11783,"PHASE2":11785,"PHASE3":11795,"PHASE4":11797,"NA":11803},{"trials":11782,"activeCount":100},[],{"trials":11784,"activeCount":100},[],{"trials":11786,"activeCount":100},[11787],{"nctId":11788,"briefTitle":11789,"status":917,"phases":11790,"primaryCompletion":9074,"completion":10306,"start":11445,"enrollment":6891,"conditions":11791,"interventions":11794},"NCT00599053","Early Versus Expectant Treatment of Ureaplasma Infection in Very Low Birth Weight Neonates",[89,90],[11792,11793],"Bacteria Infection","Respiratory Tract Infections",[5145],{"trials":11796,"activeCount":100},[],{"trials":11798,"activeCount":100},[11799],{"nctId":5133,"briefTitle":5134,"status":166,"phases":11800,"primaryCompletion":5136,"completion":5137,"start":5138,"enrollment":5139,"conditions":11801,"interventions":11802},[92],[5141,5142,5143],[5145,5120],{"trials":11804,"activeCount":100},[11805,11815],{"nctId":11806,"briefTitle":11807,"status":166,"phases":11808,"primaryCompletion":11809,"completion":11810,"start":11811,"enrollment":19,"conditions":11812,"interventions":11814},"NCT01464840","The Pharmacokinetics of Azithromycin Prophylaxis for Cesarean Delivery",[],"2013-05","2013-08","2011-11",[11813],"Endometritis",[5145],{"nctId":11816,"briefTitle":11817,"status":166,"phases":11818,"primaryCompletion":7234,"completion":7741,"start":5737,"enrollment":9,"conditions":11819,"interventions":11821},"NCT00549445","Effect of Macrolide Antibiotics on Airway Inflammation in People With Chronic Obstructive Pulmonary Disease (COPD)",[],[11820],"Pulmonary Disease, Chronic Obstructive",[5145],{"intervention":3978,"totalTrials":906,"cells":11823},{"EARLY_PHASE1":11824,"PHASE1":11826,"PHASE2":11828,"PHASE3":11830,"PHASE4":11840,"NA":11842},{"trials":11825,"activeCount":100},[],{"trials":11827,"activeCount":100},[],{"trials":11829,"activeCount":100},[],{"trials":11831,"activeCount":100},[11832,11836],{"nctId":6701,"briefTitle":6702,"status":166,"phases":11833,"primaryCompletion":5992,"completion":6704,"start":6705,"enrollment":5524,"conditions":11834,"interventions":11835},[91],[6707,5985],[6690,3978],{"nctId":3969,"briefTitle":3970,"status":1196,"phases":11837,"primaryCompletion":3972,"completion":3973,"start":3974,"enrollment":100,"conditions":11838,"interventions":11839},[91],[1202,3976],[3932,3978],{"trials":11841,"activeCount":100},[],{"trials":11843,"activeCount":100},[11844,11854],{"nctId":11845,"briefTitle":11846,"status":166,"phases":11847,"primaryCompletion":11848,"completion":11848,"start":4361,"enrollment":1969,"conditions":11849,"interventions":11851},"NCT01595386","Effect of Postop Steroids on Cardiovascular\u002FRespiratory Function in Neonates Undergoing Cardiopulmonary Bypass",[93],"2013-11",[11850],"Heart Disease Congenital Complex",[11852,11853],"Hydrocortisone","Normal Saline",{"nctId":11855,"briefTitle":11856,"status":1196,"phases":11857,"primaryCompletion":10476,"completion":11858,"start":4858,"enrollment":100,"conditions":11859,"interventions":11861},"NCT01043211","Analgesic Efficacy of Intravenous Lidocaine for Postoperative Pain Following Adult Spine Surgery",[93],"2014-03",[11860],"Back Pain",[11862,11853,11853],"Lidocaine Hydrochoride Injection, without epinephrine",{"intervention":11760,"totalTrials":963,"cells":11864},{"EARLY_PHASE1":11865,"PHASE1":11867,"PHASE2":11873,"PHASE3":11875,"PHASE4":11877,"NA":11879},{"trials":11866,"activeCount":100},[],{"trials":11868,"activeCount":100},[11869],{"nctId":10809,"briefTitle":10810,"status":166,"phases":11870,"primaryCompletion":10812,"completion":4976,"start":3722,"enrollment":3343,"conditions":11871,"interventions":11872},[89],[10814],[10802,10816],{"trials":11874,"activeCount":100},[],{"trials":11876,"activeCount":100},[],{"trials":11878,"activeCount":100},[],{"trials":11880,"activeCount":100},[11881,11885],{"nctId":11753,"briefTitle":11754,"status":166,"phases":11882,"primaryCompletion":11756,"completion":11756,"start":6890,"enrollment":4670,"conditions":11883,"interventions":11884},[93],[11758],[11760,11761,11732,11762],{"nctId":11764,"briefTitle":11765,"status":166,"phases":11886,"primaryCompletion":4858,"completion":4858,"start":4132,"enrollment":11446,"conditions":11887,"interventions":11888},[93],[3947],[11761,11769,11760],{"intervention":6201,"totalTrials":96,"cells":11890},{"EARLY_PHASE1":11891,"PHASE1":11893,"PHASE2":11895,"PHASE3":11897,"PHASE4":11903,"NA":11905},{"trials":11892,"activeCount":100},[],{"trials":11894,"activeCount":100},[],{"trials":11896,"activeCount":100},[],{"trials":11898,"activeCount":100},[11899],{"nctId":6194,"briefTitle":6195,"status":1196,"phases":11900,"primaryCompletion":3224,"completion":3224,"start":6197,"enrollment":100,"conditions":11901,"interventions":11902},[91],[6199],[6201,6183],{"trials":11904,"activeCount":100},[],{"trials":11906,"activeCount":100},[11907],{"nctId":11908,"briefTitle":11909,"status":1196,"phases":11910,"primaryCompletion":7766,"completion":7766,"start":6506,"enrollment":100,"conditions":11911,"interventions":11913},"NCT02357004","Mechanisms of Refractory Hypertension (Carvedilol)",[93],[11912],"Hypertensive",[6201,11914],"Chlorthalidone",{"intervention":11916,"totalTrials":96,"cells":11917},"Valacyclovir",{"EARLY_PHASE1":11918,"PHASE1":11920,"PHASE2":11930,"PHASE3":11932,"PHASE4":11934,"NA":11936},{"trials":11919,"activeCount":100},[],{"trials":11921,"activeCount":100},[11922],{"nctId":11923,"briefTitle":11924,"status":166,"phases":11925,"primaryCompletion":11926,"completion":11926,"start":5646,"enrollment":6891,"conditions":11927,"interventions":11929},"NCT04448392","Valacyclovir in Neonatal Herpes Simplex Virus Disease",[89],"2024-07-24",[11928],"Neonatal Herpes Simplex Infection",[11916],{"trials":11931,"activeCount":100},[],{"trials":11933,"activeCount":100},[],{"trials":11935,"activeCount":100},[],{"trials":11937,"activeCount":100},[11938],{"nctId":11939,"briefTitle":11940,"status":166,"phases":11941,"primaryCompletion":1173,"completion":1173,"start":11942,"enrollment":11943,"conditions":11944,"interventions":11945},"NCT00803543","Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding",[93],"2009-01",103,[27,32],[11916],{"intervention":11947,"totalTrials":96,"cells":11948},"temozolomide",{"EARLY_PHASE1":11949,"PHASE1":11951,"PHASE2":11953,"PHASE3":11961,"PHASE4":11963,"NA":11965},{"trials":11950,"activeCount":100},[],{"trials":11952,"activeCount":100},[],{"trials":11954,"activeCount":100},[11955],{"nctId":11956,"briefTitle":11957,"status":166,"phases":11958,"primaryCompletion":11756,"completion":5167,"start":5003,"enrollment":1425,"conditions":11959,"interventions":11960},"NCT00582075","Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases",[90],[1027,9141],[11947],{"trials":11962,"activeCount":100},[],{"trials":11964,"activeCount":100},[],{"trials":11966,"activeCount":100},[11967],{"nctId":11968,"briefTitle":11969,"status":917,"phases":11970,"primaryCompletion":11971,"completion":11971,"start":11972,"enrollment":971,"conditions":11973,"interventions":11974},"NCT03168919","Image-Based Quantitative Assessment of Acute Radiation-Induced Changes in Glioma",[93],"2018-06-12","2016-10-06",[8911],[11975],"Temozolomide",{"intervention":11761,"totalTrials":96,"cells":11977},{"EARLY_PHASE1":11978,"PHASE1":11980,"PHASE2":11982,"PHASE3":11984,"PHASE4":11986,"NA":11988},{"trials":11979,"activeCount":100},[],{"trials":11981,"activeCount":100},[],{"trials":11983,"activeCount":100},[],{"trials":11985,"activeCount":100},[],{"trials":11987,"activeCount":100},[],{"trials":11989,"activeCount":100},[11990,11994],{"nctId":11753,"briefTitle":11754,"status":166,"phases":11991,"primaryCompletion":11756,"completion":11756,"start":6890,"enrollment":4670,"conditions":11992,"interventions":11993},[93],[11758],[11760,11761,11732,11762],{"nctId":11764,"briefTitle":11765,"status":166,"phases":11995,"primaryCompletion":4858,"completion":4858,"start":4132,"enrollment":11446,"conditions":11996,"interventions":11997},[93],[3947],[11761,11769,11760],{"intervention":11999,"totalTrials":96,"cells":12000},"risperidone",{"EARLY_PHASE1":12001,"PHASE1":12003,"PHASE2":12005,"PHASE3":12007,"PHASE4":12009,"NA":12019},{"trials":12002,"activeCount":100},[],{"trials":12004,"activeCount":100},[],{"trials":12006,"activeCount":100},[],{"trials":12008,"activeCount":100},[],{"trials":12010,"activeCount":100},[12011],{"nctId":12012,"briefTitle":12013,"status":166,"phases":12014,"primaryCompletion":630,"completion":630,"start":12015,"enrollment":986,"conditions":12016,"interventions":12018},"NCT00204347","Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder",[92],"2003-07",[12017],"Borderline Personality Disorder",[11999],{"trials":12020,"activeCount":100},[12021],{"nctId":12022,"briefTitle":12023,"status":166,"phases":12024,"primaryCompletion":12025,"completion":12025,"start":3945,"enrollment":12026,"conditions":12027,"interventions":12030},"NCT02034253","Glutamate, Brain Connectivity and Duration of Untreated Psychosis",[],"2018-11",134,[12028,3370,12029],"Schizophrenia","Schizoaffective Disorder",[12031],"Risperidone",{"intervention":4036,"totalTrials":96,"cells":12033},{"EARLY_PHASE1":12034,"PHASE1":12036,"PHASE2":12038,"PHASE3":12040,"PHASE4":12042,"NA":12048},{"trials":12035,"activeCount":100},[],{"trials":12037,"activeCount":100},[],{"trials":12039,"activeCount":100},[],{"trials":12041,"activeCount":100},[],{"trials":12043,"activeCount":100},[12044],{"nctId":4029,"briefTitle":4030,"status":166,"phases":12045,"primaryCompletion":4032,"completion":4032,"start":1279,"enrollment":4033,"conditions":12046,"interventions":12047},[92],[879],[3994,4036,4037,4038],{"trials":12049,"activeCount":100},[12050],{"nctId":12051,"briefTitle":12052,"status":166,"phases":12053,"primaryCompletion":4072,"completion":4072,"start":4858,"enrollment":8011,"conditions":12054,"interventions":12055},"NCT01577966","Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma",[93],[10791],[12056],"Sulfasalazine",{"intervention":9029,"totalTrials":96,"cells":12058},{"EARLY_PHASE1":12059,"PHASE1":12061,"PHASE2":12063,"PHASE3":12069,"PHASE4":12071,"NA":12073},{"trials":12060,"activeCount":100},[],{"trials":12062,"activeCount":100},[],{"trials":12064,"activeCount":100},[12065],{"nctId":9022,"briefTitle":9023,"status":166,"phases":12066,"primaryCompletion":6197,"completion":6197,"start":7251,"enrollment":1050,"conditions":12067,"interventions":12068},[90],[9026,9027],[9029,9013],{"trials":12070,"activeCount":100},[],{"trials":12072,"activeCount":100},[],{"trials":12074,"activeCount":100},[12075],{"nctId":12076,"briefTitle":12077,"status":166,"phases":12078,"primaryCompletion":4361,"start":11942,"enrollment":1528,"conditions":12079,"interventions":12082},"NCT01897727","Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment",[93],[11675,12080,12081],"Resistant Hypertension","Hyperaldosteronism",[9029,12083],"BP medication uptitration",{"intervention":12085,"totalTrials":118,"cells":12086},"Active comparator: Filter TPE with citrate",{"EARLY_PHASE1":12087,"PHASE1":12089,"PHASE2":12091,"PHASE3":12093,"PHASE4":12095,"NA":12097},{"trials":12088,"activeCount":100},[],{"trials":12090,"activeCount":100},[],{"trials":12092,"activeCount":100},[],{"trials":12094,"activeCount":100},[],{"trials":12096,"activeCount":100},[],{"trials":12098,"activeCount":100},[12099],{"nctId":12100,"briefTitle":12101,"status":166,"phases":12102,"primaryCompletion":4250,"completion":12103,"start":12104,"enrollment":12105,"conditions":12106,"interventions":12109},"NCT04351438","Evaluation of Complication Rates Using Filter vs. Centrifuge and Heparin vs. Citrate Anticoagulation",[],"2024-02-04","2012-01-01",108,[12107,12108],"Therapeutic Plasma Exchange","Anticoagulant Therapy",[12085],{"intervention":12111,"totalTrials":118,"cells":12112},"Atorvastatin",{"EARLY_PHASE1":12113,"PHASE1":12115,"PHASE2":12117,"PHASE3":12119,"PHASE4":12121,"NA":12123},{"trials":12114,"activeCount":100},[],{"trials":12116,"activeCount":100},[],{"trials":12118,"activeCount":100},[],{"trials":12120,"activeCount":100},[],{"trials":12122,"activeCount":100},[],{"trials":12124,"activeCount":100},[12125],{"nctId":12126,"briefTitle":12127,"status":166,"phases":12128,"primaryCompletion":5523,"completion":5523,"start":12129,"enrollment":4107,"conditions":12130,"interventions":12132},"NCT00756886","Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study",[93],"2008-09",[12131],"Arrhythmia",[12111],{"intervention":12134,"totalTrials":118,"cells":12135},"Iron sucrose",{"EARLY_PHASE1":12136,"PHASE1":12138,"PHASE2":12140,"PHASE3":12142,"PHASE4":12144,"NA":12146},{"trials":12137,"activeCount":100},[],{"trials":12139,"activeCount":100},[],{"trials":12141,"activeCount":100},[],{"trials":12143,"activeCount":100},[],{"trials":12145,"activeCount":100},[],{"trials":12147,"activeCount":100},[12148],{"nctId":12149,"briefTitle":12150,"status":917,"phases":12151,"primaryCompletion":4072,"completion":4072,"start":8978,"enrollment":12152,"conditions":12153,"interventions":12155},"NCT01888003","The Benefits of a Preoperative Anemia Management Program",[93],51,[12154],"Anemia, Iron-Deficiency",[12134,12156],"Epoetin Alfa",{"intervention":12156,"totalTrials":118,"cells":12158},{"EARLY_PHASE1":12159,"PHASE1":12161,"PHASE2":12163,"PHASE3":12165,"PHASE4":12167,"NA":12169},{"trials":12160,"activeCount":100},[],{"trials":12162,"activeCount":100},[],{"trials":12164,"activeCount":100},[],{"trials":12166,"activeCount":100},[],{"trials":12168,"activeCount":100},[],{"trials":12170,"activeCount":100},[12171],{"nctId":12149,"briefTitle":12150,"status":917,"phases":12172,"primaryCompletion":4072,"completion":4072,"start":8978,"enrollment":12152,"conditions":12173,"interventions":12174},[93],[12154],[12134,12156],{"intervention":12176,"totalTrials":118,"cells":12177},"Definity contrast agent",{"EARLY_PHASE1":12178,"PHASE1":12180,"PHASE2":12182,"PHASE3":12184,"PHASE4":12186,"NA":12188},{"trials":12179,"activeCount":100},[],{"trials":12181,"activeCount":100},[],{"trials":12183,"activeCount":100},[],{"trials":12185,"activeCount":100},[],{"trials":12187,"activeCount":100},[],{"trials":12189,"activeCount":100},[12190],{"nctId":12191,"briefTitle":12192,"status":1196,"phases":12193,"primaryCompletion":8054,"completion":8054,"start":8115,"enrollment":100,"conditions":12194,"interventions":12196},"NCT01225016","Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound",[93],[12195],"Thyroid Nodules",[12176],{"intervention":12198,"totalTrials":118,"cells":12199},"Caffeine",{"EARLY_PHASE1":12200,"PHASE1":12202,"PHASE2":12204,"PHASE3":12206,"PHASE4":12208,"NA":12210},{"trials":12201,"activeCount":100},[],{"trials":12203,"activeCount":100},[],{"trials":12205,"activeCount":100},[],{"trials":12207,"activeCount":100},[],{"trials":12209,"activeCount":100},[],{"trials":12211,"activeCount":100},[12212],{"nctId":12213,"briefTitle":12214,"status":166,"phases":12215,"primaryCompletion":2907,"completion":2907,"start":5167,"enrollment":1735,"conditions":12216,"interventions":12220},"NCT02461693","Evaluating the Role of Expectations in Response to Caffeine Consumption: An RCT",[93],[12198,12217,12218,12219],"Affect","Cognitive Ability, General","Mood",[12198],{"intervention":12222,"totalTrials":118,"cells":12223},"Sildenafil",{"EARLY_PHASE1":12224,"PHASE1":12226,"PHASE2":12228,"PHASE3":12230,"PHASE4":12232,"NA":12234},{"trials":12225,"activeCount":100},[],{"trials":12227,"activeCount":100},[],{"trials":12229,"activeCount":100},[],{"trials":12231,"activeCount":100},[],{"trials":12233,"activeCount":100},[],{"trials":12235,"activeCount":100},[12236],{"nctId":12237,"briefTitle":12238,"status":166,"phases":12239,"primaryCompletion":12240,"completion":12241,"start":7591,"enrollment":906,"conditions":12242,"interventions":12244},"NCT02414204","Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula",[93],"2017-06-30","2018-06-30",[12243],"Improve Endothelial Function and Decrease Vascular Stenosis",[12222],{"intervention":12246,"totalTrials":118,"cells":12247},"Botulinum toxin-A",{"EARLY_PHASE1":12248,"PHASE1":12250,"PHASE2":12252,"PHASE3":12254,"PHASE4":12256,"NA":12258},{"trials":12249,"activeCount":100},[],{"trials":12251,"activeCount":100},[],{"trials":12253,"activeCount":100},[],{"trials":12255,"activeCount":100},[],{"trials":12257,"activeCount":100},[],{"trials":12259,"activeCount":100},[12260],{"nctId":12261,"briefTitle":12262,"status":917,"phases":12263,"primaryCompletion":12264,"completion":12264,"start":8604,"enrollment":963,"conditions":12265,"interventions":12266},"NCT02995967","Evaluation of Botulinum Toxin A Alone Versus Botulinum Toxin A With Hydrodistension for Treatment of Overactive Bladder",[93],"2017-12-31",[5901],[12246],{"intervention":12268,"totalTrials":118,"cells":12269},"Naltrexone HCl",{"EARLY_PHASE1":12270,"PHASE1":12272,"PHASE2":12274,"PHASE3":12276,"PHASE4":12278,"NA":12280},{"trials":12271,"activeCount":100},[],{"trials":12273,"activeCount":100},[],{"trials":12275,"activeCount":100},[],{"trials":12277,"activeCount":100},[],{"trials":12279,"activeCount":100},[],{"trials":12281,"activeCount":100},[12282],{"nctId":12283,"briefTitle":12284,"status":1196,"phases":12285,"primaryCompletion":12286,"completion":12286,"start":9386,"enrollment":100,"conditions":12287,"interventions":12289},"NCT02965768","Immune Effects of Low-dose Naltrexone in ME\u002FCFS",[93],"2022-08-25",[12288],"Fatigue Syndrome, Chronic",[12268],{"intervention":12291,"totalTrials":118,"cells":12292},"Sunitinib",{"EARLY_PHASE1":12293,"PHASE1":12295,"PHASE2":12297,"PHASE3":12299,"PHASE4":12301,"NA":12303},{"trials":12294,"activeCount":100},[],{"trials":12296,"activeCount":100},[],{"trials":12298,"activeCount":100},[],{"trials":12300,"activeCount":100},[],{"trials":12302,"activeCount":100},[],{"trials":12304,"activeCount":100},[12305],{"nctId":12306,"briefTitle":12307,"status":917,"phases":12308,"primaryCompletion":7653,"completion":1247,"start":12309,"enrollment":971,"conditions":12310,"interventions":12312},"NCT01054911","Evaluation of Patients With Bulky GIST Using Sunitinib",[93],"2009-10",[12311],"Tumor",[12291],{"intervention":11733,"totalTrials":118,"cells":12314},{"EARLY_PHASE1":12315,"PHASE1":12317,"PHASE2":12319,"PHASE3":12321,"PHASE4":12323,"NA":12325},{"trials":12316,"activeCount":100},[],{"trials":12318,"activeCount":100},[],{"trials":12320,"activeCount":100},[],{"trials":12322,"activeCount":100},[],{"trials":12324,"activeCount":100},[],{"trials":12326,"activeCount":100},[12327],{"nctId":11726,"briefTitle":11727,"status":166,"phases":12328,"primaryCompletion":10952,"completion":10952,"start":3945,"enrollment":11729,"conditions":12329,"interventions":12330},[93],[3947],[6337,11732,11733],{"intervention":11762,"totalTrials":118,"cells":12332},{"EARLY_PHASE1":12333,"PHASE1":12335,"PHASE2":12337,"PHASE3":12339,"PHASE4":12341,"NA":12343},{"trials":12334,"activeCount":100},[],{"trials":12336,"activeCount":100},[],{"trials":12338,"activeCount":100},[],{"trials":12340,"activeCount":100},[],{"trials":12342,"activeCount":100},[],{"trials":12344,"activeCount":100},[12345],{"nctId":11753,"briefTitle":11754,"status":166,"phases":12346,"primaryCompletion":11756,"completion":11756,"start":6890,"enrollment":4670,"conditions":12347,"interventions":12348},[93],[11758],[11760,11761,11732,11762],{"intervention":12350,"totalTrials":118,"cells":12351},"regadenoson",{"EARLY_PHASE1":12352,"PHASE1":12354,"PHASE2":12356,"PHASE3":12358,"PHASE4":12360,"NA":12362},{"trials":12353,"activeCount":100},[],{"trials":12355,"activeCount":100},[],{"trials":12357,"activeCount":100},[],{"trials":12359,"activeCount":100},[],{"trials":12361,"activeCount":100},[],{"trials":12363,"activeCount":100},[12364],{"nctId":12365,"briefTitle":12366,"status":166,"phases":12367,"primaryCompletion":7856,"completion":12368,"start":6134,"enrollment":12369,"conditions":12370,"interventions":12373},"NCT01842035","Heart Rate Response to Regadenoson and Sudden Cardiac Death",[93],"2022-07",90,[12371,12372],"Left Ventricular Systolic Dysfunction","Sudden Cardiac Death",[12350],{"intervention":12375,"totalTrials":118,"cells":12376},"lacosamide",{"EARLY_PHASE1":12377,"PHASE1":12379,"PHASE2":12381,"PHASE3":12383,"PHASE4":12385,"NA":12387},{"trials":12378,"activeCount":100},[],{"trials":12380,"activeCount":100},[],{"trials":12382,"activeCount":100},[],{"trials":12384,"activeCount":100},[],{"trials":12386,"activeCount":100},[],{"trials":12388,"activeCount":100},[12389],{"nctId":12390,"briefTitle":12391,"status":917,"phases":12392,"primaryCompletion":1303,"completion":1303,"start":5282,"enrollment":5623,"conditions":12393,"interventions":12395},"NCT01110187","A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide",[93],[12394],"Traumatic Brain Injury",[12375,12396],"Fosphenytoin",{"intervention":12396,"totalTrials":118,"cells":12398},{"EARLY_PHASE1":12399,"PHASE1":12401,"PHASE2":12403,"PHASE3":12405,"PHASE4":12407,"NA":12409},{"trials":12400,"activeCount":100},[],{"trials":12402,"activeCount":100},[],{"trials":12404,"activeCount":100},[],{"trials":12406,"activeCount":100},[],{"trials":12408,"activeCount":100},[],{"trials":12410,"activeCount":100},[12411],{"nctId":12390,"briefTitle":12391,"status":917,"phases":12412,"primaryCompletion":1303,"completion":1303,"start":5282,"enrollment":5623,"conditions":12413,"interventions":12414},[93],[12394],[12375,12396],{"intervention":635,"totalTrials":118,"cells":12416},{"EARLY_PHASE1":12417,"PHASE1":12419,"PHASE2":12421,"PHASE3":12423,"PHASE4":12425,"NA":12427},{"trials":12418,"activeCount":100},[],{"trials":12420,"activeCount":100},[],{"trials":12422,"activeCount":100},[],{"trials":12424,"activeCount":100},[],{"trials":12426,"activeCount":100},[],{"trials":12428,"activeCount":100},[12429],{"nctId":626,"briefTitle":627,"status":166,"phases":12430,"primaryCompletion":629,"completion":629,"start":630,"enrollment":631,"conditions":12431,"interventions":12432},[],[633],[607,635],{"intervention":12434,"totalTrials":118,"cells":12435},"Corticosteroid",{"EARLY_PHASE1":12436,"PHASE1":12438,"PHASE2":12440,"PHASE3":12442,"PHASE4":12444,"NA":12446},{"trials":12437,"activeCount":100},[],{"trials":12439,"activeCount":100},[],{"trials":12441,"activeCount":100},[],{"trials":12443,"activeCount":100},[],{"trials":12445,"activeCount":100},[],{"trials":12447,"activeCount":100},[12448],{"nctId":12449,"briefTitle":12450,"status":166,"phases":12451,"primaryCompletion":4976,"completion":12452,"start":12453,"enrollment":1969,"conditions":12454,"interventions":12456},"NCT04859764","Effect of Reparel Knee Sleeve With Knee Injection",[93],"2025-12-03","2022-06-29",[12455],"Osteoarthritis, Knee",[12434],{"intervention":12458,"totalTrials":118,"cells":12459},"Calcium and Vit D",{"EARLY_PHASE1":12460,"PHASE1":12462,"PHASE2":12464,"PHASE3":12466,"PHASE4":12468,"NA":12470},{"trials":12461,"activeCount":100},[],{"trials":12463,"activeCount":100},[],{"trials":12465,"activeCount":100},[],{"trials":12467,"activeCount":100},[],{"trials":12469,"activeCount":100},[],{"trials":12471,"activeCount":100},[12472],{"nctId":12473,"briefTitle":12474,"status":1196,"phases":12475,"primaryCompletion":169,"completion":8140,"start":4032,"enrollment":100,"conditions":12476,"interventions":12480},"NCT01107808","Calcium, Vitamin D and Metformin to Treat Insulin Resistance in Obese African American Adolescent Females",[93],[12477,12478,15,12479],"Insulin Resistance","Insulin Sensitivity","Vitamin D Deficiency",[12458,12481],"Metformin, Vit D and Calcium",{"intervention":12481,"totalTrials":118,"cells":12483},{"EARLY_PHASE1":12484,"PHASE1":12486,"PHASE2":12488,"PHASE3":12490,"PHASE4":12492,"NA":12494},{"trials":12485,"activeCount":100},[],{"trials":12487,"activeCount":100},[],{"trials":12489,"activeCount":100},[],{"trials":12491,"activeCount":100},[],{"trials":12493,"activeCount":100},[],{"trials":12495,"activeCount":100},[12496],{"nctId":12473,"briefTitle":12474,"status":1196,"phases":12497,"primaryCompletion":169,"completion":8140,"start":4032,"enrollment":100,"conditions":12498,"interventions":12499},[93],[12477,12478,15,12479],[12458,12481],{"intervention":12501,"totalTrials":118,"cells":12502},"roflumilast",{"EARLY_PHASE1":12503,"PHASE1":12505,"PHASE2":12507,"PHASE3":12509,"PHASE4":12511,"NA":12513},{"trials":12504,"activeCount":100},[],{"trials":12506,"activeCount":100},[],{"trials":12508,"activeCount":100},[],{"trials":12510,"activeCount":100},[],{"trials":12512,"activeCount":100},[],{"trials":12514,"activeCount":100},[12515],{"nctId":12516,"briefTitle":12517,"status":166,"phases":12518,"primaryCompletion":5670,"completion":5670,"start":5522,"enrollment":1063,"conditions":12519,"interventions":12520},"NCT01572948","A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD)",[93],[576],[12501],{"intervention":12522,"totalTrials":118,"cells":12523},"Doxycycline",{"EARLY_PHASE1":12524,"PHASE1":12526,"PHASE2":12528,"PHASE3":12530,"PHASE4":12532,"NA":12534},{"trials":12525,"activeCount":100},[],{"trials":12527,"activeCount":100},[],{"trials":12529,"activeCount":100},[],{"trials":12531,"activeCount":100},[],{"trials":12533,"activeCount":100},[],{"trials":12535,"activeCount":100},[12536],{"nctId":12537,"briefTitle":12538,"status":166,"phases":12539,"primaryCompletion":12540,"completion":12540,"start":4132,"enrollment":1969,"conditions":12541,"interventions":12542},"NCT01112059","Trial of Doxycycline to Reduce Sputum MMP-9 Activity in Adult Cystic Fibrosis (CF) Patients",[93],"2012-11",[35],[12522],{"intervention":12544,"totalTrials":118,"cells":12545},"Comparison of two standard of care regimens",{"EARLY_PHASE1":12546,"PHASE1":12548,"PHASE2":12550,"PHASE3":12552,"PHASE4":12554,"NA":12556},{"trials":12547,"activeCount":100},[],{"trials":12549,"activeCount":100},[],{"trials":12551,"activeCount":100},[],{"trials":12553,"activeCount":100},[],{"trials":12555,"activeCount":100},[],{"trials":12557,"activeCount":100},[12558],{"nctId":12559,"briefTitle":12560,"status":917,"phases":12561,"primaryCompletion":12562,"completion":12562,"start":12563,"enrollment":2518,"conditions":12564,"interventions":12566},"NCT03910907","Comparison of Standard of Care Guidelines for Mycoplasma Genitalium Infections Among Men With Non-gonococcal Urethritis",[],"2020-03-20","2019-11-19",[12565],"Mycoplasma Genitalium Infection",[12544],{"intervention":12568,"totalTrials":118,"cells":12569},"ferric citrate",{"EARLY_PHASE1":12570,"PHASE1":12572,"PHASE2":12574,"PHASE3":12576,"PHASE4":12578,"NA":12580},{"trials":12571,"activeCount":100},[],{"trials":12573,"activeCount":100},[],{"trials":12575,"activeCount":100},[],{"trials":12577,"activeCount":100},[],{"trials":12579,"activeCount":100},[],{"trials":12581,"activeCount":100},[12582],{"nctId":12583,"briefTitle":12584,"status":166,"phases":12585,"primaryCompletion":12586,"completion":12587,"start":1248,"enrollment":761,"conditions":12588,"interventions":12590},"NCT02888171","Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency",[93],"2019-02-12","2019-03-30",[9026,12589,5600],"Iron Deficiency",[12568,12591],"ferrous sulfate",{"intervention":12591,"totalTrials":118,"cells":12593},{"EARLY_PHASE1":12594,"PHASE1":12596,"PHASE2":12598,"PHASE3":12600,"PHASE4":12602,"NA":12604},{"trials":12595,"activeCount":100},[],{"trials":12597,"activeCount":100},[],{"trials":12599,"activeCount":100},[],{"trials":12601,"activeCount":100},[],{"trials":12603,"activeCount":100},[],{"trials":12605,"activeCount":100},[12606],{"nctId":12583,"briefTitle":12584,"status":166,"phases":12607,"primaryCompletion":12586,"completion":12587,"start":1248,"enrollment":761,"conditions":12608,"interventions":12609},[93],[9026,12589,5600],[12568,12591],{"intervention":12611,"totalTrials":118,"cells":12612},"cyclosporine ophthalmic emulsion",{"EARLY_PHASE1":12613,"PHASE1":12615,"PHASE2":12617,"PHASE3":12619,"PHASE4":12621,"NA":12623},{"trials":12614,"activeCount":100},[],{"trials":12616,"activeCount":100},[],{"trials":12618,"activeCount":100},[],{"trials":12620,"activeCount":100},[],{"trials":12622,"activeCount":100},[],{"trials":12624,"activeCount":100},[12625],{"nctId":12626,"briefTitle":12627,"status":166,"phases":12628,"completion":7400,"start":7170,"enrollment":1969,"conditions":12629,"interventions":12631},"NCT00335114","Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens Wearers",[93],[12630],"Contact Lens Wearers With Dry Eye Syndrome",[12611],{"intervention":12633,"totalTrials":118,"cells":12634},"Riperidone",{"EARLY_PHASE1":12635,"PHASE1":12637,"PHASE2":12639,"PHASE3":12641,"PHASE4":12643,"NA":12645},{"trials":12636,"activeCount":100},[],{"trials":12638,"activeCount":100},[],{"trials":12640,"activeCount":100},[],{"trials":12642,"activeCount":100},[],{"trials":12644,"activeCount":100},[],{"trials":12646,"activeCount":100},[12647],{"nctId":12648,"briefTitle":12649,"status":1196,"phases":12650,"primaryCompletion":12651,"start":12652,"enrollment":100,"conditions":12653,"interventions":12656},"NCT01770600","Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression",[93],"2013-09","2010-04",[12654,12655,3527],"Impulsivity","Active Suicidal Ideation",[12633],{"intervention":12658,"totalTrials":118,"cells":12659},"Extended Release Tolterodine LA",{"EARLY_PHASE1":12660,"PHASE1":12662,"PHASE2":12664,"PHASE3":12666,"PHASE4":12668,"NA":12670},{"trials":12661,"activeCount":100},[],{"trials":12663,"activeCount":100},[],{"trials":12665,"activeCount":100},[],{"trials":12667,"activeCount":100},[],{"trials":12669,"activeCount":100},[],{"trials":12671,"activeCount":100},[12672],{"nctId":12673,"briefTitle":12674,"status":166,"phases":12675,"primaryCompletion":5093,"completion":8054,"start":6890,"enrollment":7181,"conditions":12676,"interventions":12677},"NCT00465894","Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms",[93],[5901],[12658,12678],"Intra Vaginal Estradiol Cream",{"intervention":12678,"totalTrials":118,"cells":12680},{"EARLY_PHASE1":12681,"PHASE1":12683,"PHASE2":12685,"PHASE3":12687,"PHASE4":12689,"NA":12691},{"trials":12682,"activeCount":100},[],{"trials":12684,"activeCount":100},[],{"trials":12686,"activeCount":100},[],{"trials":12688,"activeCount":100},[],{"trials":12690,"activeCount":100},[],{"trials":12692,"activeCount":100},[12693],{"nctId":12673,"briefTitle":12674,"status":166,"phases":12694,"primaryCompletion":5093,"completion":8054,"start":6890,"enrollment":7181,"conditions":12695,"interventions":12696},[93],[5901],[12658,12678],{"intervention":12698,"totalTrials":118,"cells":12699},"Fentanyl",{"EARLY_PHASE1":12700,"PHASE1":12702,"PHASE2":12704,"PHASE3":12706,"PHASE4":12708,"NA":12710},{"trials":12701,"activeCount":100},[],{"trials":12703,"activeCount":100},[],{"trials":12705,"activeCount":100},[],{"trials":12707,"activeCount":100},[],{"trials":12709,"activeCount":100},[],{"trials":12711,"activeCount":100},[12712],{"nctId":12713,"briefTitle":12714,"status":917,"phases":12715,"primaryCompletion":12716,"completion":12716,"start":12717,"enrollment":10109,"conditions":12718,"interventions":12720},"NCT03441282","Precision Medicine in Anesthesia: Genetic Component in Opioid-induced Respiratory Depression",[],"2025-05-21","2018-10-30",[12719],"Respiratory Depression",[12698],{"intervention":12722,"totalTrials":118,"cells":12723},"Pseudoephedrine",{"EARLY_PHASE1":12724,"PHASE1":12726,"PHASE2":12728,"PHASE3":12730,"PHASE4":12732,"NA":12734},{"trials":12725,"activeCount":100},[],{"trials":12727,"activeCount":100},[],{"trials":12729,"activeCount":100},[],{"trials":12731,"activeCount":100},[],{"trials":12733,"activeCount":100},[],{"trials":12735,"activeCount":100},[12736],{"nctId":12737,"briefTitle":12738,"status":166,"phases":12739,"primaryCompletion":7368,"completion":7368,"start":12652,"enrollment":2303,"conditions":12740,"interventions":12742},"NCT01028014","Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters",[93],[12741],"Urethral Sphincter Activity",[12722,12743,12744,12745,12746,12747],"Tamsulosin","Imipramine","Cyclobenzaprine","Lactose","Solifenacin",{"intervention":12743,"totalTrials":118,"cells":12749},{"EARLY_PHASE1":12750,"PHASE1":12752,"PHASE2":12754,"PHASE3":12756,"PHASE4":12758,"NA":12760},{"trials":12751,"activeCount":100},[],{"trials":12753,"activeCount":100},[],{"trials":12755,"activeCount":100},[],{"trials":12757,"activeCount":100},[],{"trials":12759,"activeCount":100},[],{"trials":12761,"activeCount":100},[12762],{"nctId":12737,"briefTitle":12738,"status":166,"phases":12763,"primaryCompletion":7368,"completion":7368,"start":12652,"enrollment":2303,"conditions":12764,"interventions":12765},[93],[12741],[12722,12743,12744,12745,12746,12747],{"intervention":12744,"totalTrials":118,"cells":12767},{"EARLY_PHASE1":12768,"PHASE1":12770,"PHASE2":12772,"PHASE3":12774,"PHASE4":12776,"NA":12778},{"trials":12769,"activeCount":100},[],{"trials":12771,"activeCount":100},[],{"trials":12773,"activeCount":100},[],{"trials":12775,"activeCount":100},[],{"trials":12777,"activeCount":100},[],{"trials":12779,"activeCount":100},[12780],{"nctId":12737,"briefTitle":12738,"status":166,"phases":12781,"primaryCompletion":7368,"completion":7368,"start":12652,"enrollment":2303,"conditions":12782,"interventions":12783},[93],[12741],[12722,12743,12744,12745,12746,12747],{"intervention":12745,"totalTrials":118,"cells":12785},{"EARLY_PHASE1":12786,"PHASE1":12788,"PHASE2":12790,"PHASE3":12792,"PHASE4":12794,"NA":12796},{"trials":12787,"activeCount":100},[],{"trials":12789,"activeCount":100},[],{"trials":12791,"activeCount":100},[],{"trials":12793,"activeCount":100},[],{"trials":12795,"activeCount":100},[],{"trials":12797,"activeCount":100},[12798],{"nctId":12737,"briefTitle":12738,"status":166,"phases":12799,"primaryCompletion":7368,"completion":7368,"start":12652,"enrollment":2303,"conditions":12800,"interventions":12801},[93],[12741],[12722,12743,12744,12745,12746,12747],{"intervention":12746,"totalTrials":118,"cells":12803},{"EARLY_PHASE1":12804,"PHASE1":12806,"PHASE2":12808,"PHASE3":12810,"PHASE4":12812,"NA":12814},{"trials":12805,"activeCount":100},[],{"trials":12807,"activeCount":100},[],{"trials":12809,"activeCount":100},[],{"trials":12811,"activeCount":100},[],{"trials":12813,"activeCount":100},[],{"trials":12815,"activeCount":100},[12816],{"nctId":12737,"briefTitle":12738,"status":166,"phases":12817,"primaryCompletion":7368,"completion":7368,"start":12652,"enrollment":2303,"conditions":12818,"interventions":12819},[93],[12741],[12722,12743,12744,12745,12746,12747],{"intervention":12747,"totalTrials":118,"cells":12821},{"EARLY_PHASE1":12822,"PHASE1":12824,"PHASE2":12826,"PHASE3":12828,"PHASE4":12830,"NA":12832},{"trials":12823,"activeCount":100},[],{"trials":12825,"activeCount":100},[],{"trials":12827,"activeCount":100},[],{"trials":12829,"activeCount":100},[],{"trials":12831,"activeCount":100},[],{"trials":12833,"activeCount":100},[12834],{"nctId":12737,"briefTitle":12738,"status":166,"phases":12835,"primaryCompletion":7368,"completion":7368,"start":12652,"enrollment":2303,"conditions":12836,"interventions":12837},[93],[12741],[12722,12743,12744,12745,12746,12747],{"intervention":12839,"totalTrials":118,"cells":12840},"Tenofovir, Emtricitabine, Atazanavir, Ritonavir",{"EARLY_PHASE1":12841,"PHASE1":12843,"PHASE2":12845,"PHASE3":12847,"PHASE4":12849,"NA":12851},{"trials":12842,"activeCount":100},[],{"trials":12844,"activeCount":100},[],{"trials":12846,"activeCount":100},[],{"trials":12848,"activeCount":100},[],{"trials":12850,"activeCount":100},[],{"trials":12852,"activeCount":100},[12853],{"nctId":12854,"briefTitle":12855,"status":1196,"phases":12856,"primaryCompletion":8978,"completion":8978,"start":7234,"enrollment":100,"conditions":12857,"interventions":12859},"NCT01394133","Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women",[],[12858],"HIV Infected",[12839],{"intervention":12861,"totalTrials":118,"cells":12862},"Fenofibrate",{"EARLY_PHASE1":12863,"PHASE1":12865,"PHASE2":12867,"PHASE3":12869,"PHASE4":12871,"NA":12873},{"trials":12864,"activeCount":100},[],{"trials":12866,"activeCount":100},[],{"trials":12868,"activeCount":100},[],{"trials":12870,"activeCount":100},[],{"trials":12872,"activeCount":100},[],{"trials":12874,"activeCount":100},[12875],{"nctId":12876,"briefTitle":12877,"status":166,"phases":12878,"primaryCompletion":7741,"completion":7741,"start":7158,"enrollment":631,"conditions":12879,"interventions":12881},"NCT01023750","Predictors of Response to Fenofibrate",[],[12880,12477],"Hypertriglyceridemia",[12861],{"intervention":12883,"totalTrials":118,"cells":12884},"Vibegron 75mg",{"EARLY_PHASE1":12885,"PHASE1":12887,"PHASE2":12889,"PHASE3":12891,"PHASE4":12893,"NA":12895},{"trials":12886,"activeCount":100},[],{"trials":12888,"activeCount":100},[],{"trials":12890,"activeCount":100},[],{"trials":12892,"activeCount":100},[],{"trials":12894,"activeCount":100},[],{"trials":12896,"activeCount":100},[12897],{"nctId":12898,"briefTitle":12899,"status":1196,"phases":12900,"primaryCompletion":4976,"completion":9049,"start":12901,"enrollment":100,"conditions":12902,"interventions":12904},"NCT06438861","Role of Combination Therapy in Women With Refractory Overactive Bladder",[93],"2025-01-01",[12903],"Overactive Bladder Syndrome",[12883],{"intervention":11852,"totalTrials":118,"cells":12906},{"EARLY_PHASE1":12907,"PHASE1":12909,"PHASE2":12911,"PHASE3":12913,"PHASE4":12915,"NA":12917},{"trials":12908,"activeCount":100},[],{"trials":12910,"activeCount":100},[],{"trials":12912,"activeCount":100},[],{"trials":12914,"activeCount":100},[],{"trials":12916,"activeCount":100},[],{"trials":12918,"activeCount":100},[12919],{"nctId":11845,"briefTitle":11846,"status":166,"phases":12920,"primaryCompletion":11848,"completion":11848,"start":4361,"enrollment":1969,"conditions":12921,"interventions":12922},[93],[11850],[11852,11853],{"intervention":12924,"totalTrials":118,"cells":12925},"Raltegravir",{"EARLY_PHASE1":12926,"PHASE1":12928,"PHASE2":12930,"PHASE3":12932,"PHASE4":12934,"NA":12936},{"trials":12927,"activeCount":100},[],{"trials":12929,"activeCount":100},[],{"trials":12931,"activeCount":100},[],{"trials":12933,"activeCount":100},[],{"trials":12935,"activeCount":100},[],{"trials":12937,"activeCount":100},[12938],{"nctId":12939,"briefTitle":12940,"status":166,"phases":12941,"primaryCompletion":8052,"completion":7242,"start":12129,"enrollment":7141,"conditions":12942,"interventions":12944},"NCT00734344","Pilot Study of Raltegravir\u002FTruvada Versus Efavirenz\u002FTruvada for Adults With Acute IV-1 Infection",[93],[12943],"Acute HIV Infection",[12924,12945,12946,12947,12948],"Efavirenz","Emtricitibine","Tenofovir disoproxil once daily","Tenofovir disoproxil twice daily",{"intervention":12945,"totalTrials":118,"cells":12950},{"EARLY_PHASE1":12951,"PHASE1":12953,"PHASE2":12955,"PHASE3":12957,"PHASE4":12959,"NA":12961},{"trials":12952,"activeCount":100},[],{"trials":12954,"activeCount":100},[],{"trials":12956,"activeCount":100},[],{"trials":12958,"activeCount":100},[],{"trials":12960,"activeCount":100},[],{"trials":12962,"activeCount":100},[12963],{"nctId":12939,"briefTitle":12940,"status":166,"phases":12964,"primaryCompletion":8052,"completion":7242,"start":12129,"enrollment":7141,"conditions":12965,"interventions":12966},[93],[12943],[12924,12945,12946,12947,12948],{"intervention":12946,"totalTrials":118,"cells":12968},{"EARLY_PHASE1":12969,"PHASE1":12971,"PHASE2":12973,"PHASE3":12975,"PHASE4":12977,"NA":12979},{"trials":12970,"activeCount":100},[],{"trials":12972,"activeCount":100},[],{"trials":12974,"activeCount":100},[],{"trials":12976,"activeCount":100},[],{"trials":12978,"activeCount":100},[],{"trials":12980,"activeCount":100},[12981],{"nctId":12939,"briefTitle":12940,"status":166,"phases":12982,"primaryCompletion":8052,"completion":7242,"start":12129,"enrollment":7141,"conditions":12983,"interventions":12984},[93],[12943],[12924,12945,12946,12947,12948],{"intervention":12947,"totalTrials":118,"cells":12986},{"EARLY_PHASE1":12987,"PHASE1":12989,"PHASE2":12991,"PHASE3":12993,"PHASE4":12995,"NA":12997},{"trials":12988,"activeCount":100},[],{"trials":12990,"activeCount":100},[],{"trials":12992,"activeCount":100},[],{"trials":12994,"activeCount":100},[],{"trials":12996,"activeCount":100},[],{"trials":12998,"activeCount":100},[12999],{"nctId":12939,"briefTitle":12940,"status":166,"phases":13000,"primaryCompletion":8052,"completion":7242,"start":12129,"enrollment":7141,"conditions":13001,"interventions":13002},[93],[12943],[12924,12945,12946,12947,12948],{"intervention":12948,"totalTrials":118,"cells":13004},{"EARLY_PHASE1":13005,"PHASE1":13007,"PHASE2":13009,"PHASE3":13011,"PHASE4":13013,"NA":13015},{"trials":13006,"activeCount":100},[],{"trials":13008,"activeCount":100},[],{"trials":13010,"activeCount":100},[],{"trials":13012,"activeCount":100},[],{"trials":13014,"activeCount":100},[],{"trials":13016,"activeCount":100},[13017],{"nctId":12939,"briefTitle":12940,"status":166,"phases":13018,"primaryCompletion":8052,"completion":7242,"start":12129,"enrollment":7141,"conditions":13019,"interventions":13020},[93],[12943],[12924,12945,12946,12947,12948],{"intervention":11862,"totalTrials":118,"cells":13022},{"EARLY_PHASE1":13023,"PHASE1":13025,"PHASE2":13027,"PHASE3":13029,"PHASE4":13031,"NA":13033},{"trials":13024,"activeCount":100},[],{"trials":13026,"activeCount":100},[],{"trials":13028,"activeCount":100},[],{"trials":13030,"activeCount":100},[],{"trials":13032,"activeCount":100},[],{"trials":13034,"activeCount":100},[13035],{"nctId":11855,"briefTitle":11856,"status":1196,"phases":13036,"primaryCompletion":10476,"completion":11858,"start":4858,"enrollment":100,"conditions":13037,"interventions":13038},[93],[11860],[11862,11853,11853],{"intervention":13040,"totalTrials":118,"cells":13041},"Treadmill training + transfer package",{"EARLY_PHASE1":13042,"PHASE1":13044,"PHASE2":13046,"PHASE3":13048,"PHASE4":13050,"NA":13052},{"trials":13043,"activeCount":100},[],{"trials":13045,"activeCount":100},[],{"trials":13047,"activeCount":100},[],{"trials":13049,"activeCount":100},[],{"trials":13051,"activeCount":100},[],{"trials":13053,"activeCount":100},[13054],{"nctId":13055,"briefTitle":13056,"status":166,"phases":13057,"primaryCompletion":13058,"completion":13059,"start":13060,"enrollment":30,"conditions":13061,"interventions":13064},"NCT04546217","Gait Training Combined With Behavioral Strategies for People With Stroke",[93],"2023-02-10","2023-02-21","2020-10-15",[24,13062,13063],"Gait, Hemiplegic","Behavior and Behavior Mechanisms",[13040],{"intervention":12083,"totalTrials":118,"cells":13066},{"EARLY_PHASE1":13067,"PHASE1":13069,"PHASE2":13071,"PHASE3":13073,"PHASE4":13075,"NA":13077},{"trials":13068,"activeCount":100},[],{"trials":13070,"activeCount":100},[],{"trials":13072,"activeCount":100},[],{"trials":13074,"activeCount":100},[],{"trials":13076,"activeCount":100},[],{"trials":13078,"activeCount":100},[13079],{"nctId":12076,"briefTitle":12077,"status":166,"phases":13080,"primaryCompletion":4361,"start":11942,"enrollment":1528,"conditions":13081,"interventions":13082},[93],[11675,12080,12081],[9029,12083],{"intervention":13084,"totalTrials":118,"cells":13085},"Nail Polish + Efinaconazole Solution",{"EARLY_PHASE1":13086,"PHASE1":13088,"PHASE2":13090,"PHASE3":13092,"PHASE4":13094,"NA":13096},{"trials":13087,"activeCount":100},[],{"trials":13089,"activeCount":100},[],{"trials":13091,"activeCount":100},[],{"trials":13093,"activeCount":100},[],{"trials":13095,"activeCount":100},[],{"trials":13097,"activeCount":100},[13098],{"nctId":13099,"briefTitle":13100,"status":166,"phases":13101,"primaryCompletion":13102,"completion":7925,"start":1247,"enrollment":971,"conditions":13103,"interventions":13105},"NCT03022916","Real-World Evaluation of the Effect of Jublia on Nail Polish",[93],"2017-09",[13104],"Evaluation of Jublia on Nail Polish With Healthy Toenails",[13084,13106,13107],"Base Coat + Nail Polish + Top Coat + Efinaconazole Solution","Nail Polish + Top Coat + Efinaconazole Solution",{"intervention":13106,"totalTrials":118,"cells":13109},{"EARLY_PHASE1":13110,"PHASE1":13112,"PHASE2":13114,"PHASE3":13116,"PHASE4":13118,"NA":13120},{"trials":13111,"activeCount":100},[],{"trials":13113,"activeCount":100},[],{"trials":13115,"activeCount":100},[],{"trials":13117,"activeCount":100},[],{"trials":13119,"activeCount":100},[],{"trials":13121,"activeCount":100},[13122],{"nctId":13099,"briefTitle":13100,"status":166,"phases":13123,"primaryCompletion":13102,"completion":7925,"start":1247,"enrollment":971,"conditions":13124,"interventions":13125},[93],[13104],[13084,13106,13107],{"intervention":13107,"totalTrials":118,"cells":13127},{"EARLY_PHASE1":13128,"PHASE1":13130,"PHASE2":13132,"PHASE3":13134,"PHASE4":13136,"NA":13138},{"trials":13129,"activeCount":100},[],{"trials":13131,"activeCount":100},[],{"trials":13133,"activeCount":100},[],{"trials":13135,"activeCount":100},[],{"trials":13137,"activeCount":100},[],{"trials":13139,"activeCount":100},[13140],{"nctId":13099,"briefTitle":13100,"status":166,"phases":13141,"primaryCompletion":13102,"completion":7925,"start":1247,"enrollment":971,"conditions":13142,"interventions":13143},[93],[13104],[13084,13106,13107],{"intervention":13145,"totalTrials":118,"cells":13146},"Fentanyl Drug Administration",{"EARLY_PHASE1":13147,"PHASE1":13149,"PHASE2":13151,"PHASE3":13153,"PHASE4":13155,"NA":13157},{"trials":13148,"activeCount":100},[],{"trials":13150,"activeCount":100},[],{"trials":13152,"activeCount":100},[],{"trials":13154,"activeCount":100},[],{"trials":13156,"activeCount":100},[],{"trials":13158,"activeCount":100},[13159],{"nctId":13160,"briefTitle":13161,"status":1196,"phases":13162,"primaryCompletion":13163,"completion":2369,"start":13164,"enrollment":100,"conditions":13165,"interventions":13166},"NCT04495452","Precision Medicine in Anesthesia",[],"2025-12-10","2024-06-10",[12719],[13145],{"intervention":13168,"totalTrials":118,"cells":13169},"Subacromial steroid bursal",{"EARLY_PHASE1":13170,"PHASE1":13172,"PHASE2":13174,"PHASE3":13176,"PHASE4":13178,"NA":13180},{"trials":13171,"activeCount":100},[],{"trials":13173,"activeCount":100},[],{"trials":13175,"activeCount":100},[],{"trials":13177,"activeCount":100},[],{"trials":13179,"activeCount":100},[],{"trials":13181,"activeCount":100},[13182],{"nctId":13183,"briefTitle":13184,"status":917,"phases":13185,"primaryCompletion":13186,"completion":13187,"start":6092,"enrollment":5623,"conditions":13188,"interventions":13191},"NCT02246530","Non-Surgical Treatment for Rotator-Cuff Tears Using Platelet-Rich-Plasma",[93],"2021-01","2021-03",[13189,13190],"Partial Tear of Rotator Cuff","Tendinopathy of Rotator Cuff",[13168],{"intervention":13193,"totalTrials":118,"cells":13194},"Combination of Veliparib + Lapatinib",{"EARLY_PHASE1":13195,"PHASE1":13197,"PHASE2":13199,"PHASE3":13201,"PHASE4":13203,"NA":13205},{"trials":13196,"activeCount":100},[],{"trials":13198,"activeCount":100},[],{"trials":13200,"activeCount":100},[],{"trials":13202,"activeCount":100},[],{"trials":13204,"activeCount":100},[],{"trials":13206,"activeCount":100},[13207],{"nctId":13208,"briefTitle":13209,"status":166,"phases":13210,"primaryCompletion":13211,"completion":13211,"start":8907,"enrollment":986,"conditions":13212,"interventions":13214},"NCT02158507","Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer",[93],"2021-07-22",[13213],"Metastatic Triple Negative Breast Cancer",[13193],{"intervention":13216,"totalTrials":118,"cells":13217},"Gardasil 9",{"EARLY_PHASE1":13218,"PHASE1":13220,"PHASE2":13222,"PHASE3":13224,"PHASE4":13226,"NA":13228},{"trials":13219,"activeCount":100},[],{"trials":13221,"activeCount":100},[],{"trials":13223,"activeCount":100},[],{"trials":13225,"activeCount":100},[],{"trials":13227,"activeCount":100},[],{"trials":13229,"activeCount":100},[13230],{"nctId":13231,"briefTitle":13232,"status":917,"phases":13233,"primaryCompletion":13234,"completion":13234,"start":13235,"enrollment":4299,"conditions":13236,"interventions":13238},"NCT06229353","Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department",[],"2025-07-30","2024-08-08",[13237],"Human Papilloma Virus",[13216],{"intervention":13240,"totalTrials":118,"cells":13241},"Amnion",{"EARLY_PHASE1":13242,"PHASE1":13244,"PHASE2":13246,"PHASE3":13248,"PHASE4":13250,"NA":13252},{"trials":13243,"activeCount":100},[],{"trials":13245,"activeCount":100},[],{"trials":13247,"activeCount":100},[],{"trials":13249,"activeCount":100},[],{"trials":13251,"activeCount":100},[],{"trials":13253,"activeCount":100},[13254],{"nctId":13255,"briefTitle":13256,"status":1196,"phases":13257,"primaryCompletion":13258,"completion":13259,"start":13260,"enrollment":100,"conditions":13261,"interventions":13264},"NCT03770546","Amnion-Based Injections in the Shoulder",[93],"2022-12","2023-01","2021-10-30",[13262,13263],"Osteoarthritis of the Shoulder","Adhesive Capsulitis",[13240,13265],"Betamethasone",{"intervention":13265,"totalTrials":118,"cells":13267},{"EARLY_PHASE1":13268,"PHASE1":13270,"PHASE2":13272,"PHASE3":13274,"PHASE4":13276,"NA":13278},{"trials":13269,"activeCount":100},[],{"trials":13271,"activeCount":100},[],{"trials":13273,"activeCount":100},[],{"trials":13275,"activeCount":100},[],{"trials":13277,"activeCount":100},[],{"trials":13279,"activeCount":100},[13280],{"nctId":13255,"briefTitle":13256,"status":1196,"phases":13281,"primaryCompletion":13258,"completion":13259,"start":13260,"enrollment":100,"conditions":13282,"interventions":13283},[93],[13262,13263],[13240,13265],{"intervention":13285,"totalTrials":118,"cells":13286},"enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers",{"EARLY_PHASE1":13287,"PHASE1":13289,"PHASE2":13291,"PHASE3":13293,"PHASE4":13295,"NA":13297},{"trials":13288,"activeCount":100},[],{"trials":13290,"activeCount":100},[],{"trials":13292,"activeCount":100},[],{"trials":13294,"activeCount":100},[],{"trials":13296,"activeCount":100},[],{"trials":13298,"activeCount":100},[13299],{"nctId":13300,"briefTitle":13301,"status":166,"phases":13302,"primaryCompletion":5522,"completion":10475,"start":5962,"enrollment":1927,"conditions":13303,"interventions":13305},"NCT00446862","The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study",[],[13304,7596],"Fabry Disease",[13285],{"intervention":13307,"totalTrials":118,"cells":13308},"Sorafenib",{"EARLY_PHASE1":13309,"PHASE1":13311,"PHASE2":13313,"PHASE3":13315,"PHASE4":13317,"NA":13319},{"trials":13310,"activeCount":100},[],{"trials":13312,"activeCount":100},[],{"trials":13314,"activeCount":100},[],{"trials":13316,"activeCount":100},[],{"trials":13318,"activeCount":100},[],{"trials":13320,"activeCount":100},[13321],{"nctId":13322,"briefTitle":13323,"status":917,"phases":13324,"primaryCompletion":10475,"completion":13325,"start":13326,"enrollment":971,"conditions":13327,"interventions":13329},"NCT01005875","Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma",[93],"2013-06","2009-11",[1091,13328],"Liver Cancer",[13307],{"intervention":13331,"totalTrials":118,"cells":13332},"IVIG",{"EARLY_PHASE1":13333,"PHASE1":13335,"PHASE2":13337,"PHASE3":13339,"PHASE4":13341,"NA":13343},{"trials":13334,"activeCount":100},[],{"trials":13336,"activeCount":100},[],{"trials":13338,"activeCount":100},[],{"trials":13340,"activeCount":100},[],{"trials":13342,"activeCount":100},[],{"trials":13344,"activeCount":100},[13345],{"nctId":13346,"briefTitle":13347,"status":166,"phases":13348,"primaryCompletion":5167,"completion":5167,"start":9072,"enrollment":403,"conditions":13349,"interventions":13352},"NCT02043379","Post-bypass Prophylactic IVIG in Infants and Neonates",[93],[13350,13351],"Hypogammaglobulinemia","Congenital Heart Disease",[13331],{"intervention":13354,"totalTrials":118,"cells":13355},"iTBS&eCIMT",{"EARLY_PHASE1":13356,"PHASE1":13358,"PHASE2":13360,"PHASE3":13362,"PHASE4":13364,"NA":13366},{"trials":13357,"activeCount":100},[],{"trials":13359,"activeCount":100},[],{"trials":13361,"activeCount":100},[],{"trials":13363,"activeCount":100},[],{"trials":13365,"activeCount":100},[],{"trials":13367,"activeCount":100},[13368],{"nctId":13369,"briefTitle":13370,"status":917,"phases":13371,"primaryCompletion":13372,"completion":13373,"start":13374,"enrollment":963,"conditions":13375,"interventions":13378},"NCT03538795","Brain Stimulation and Rehabilitation for Adults With Chronic, Severe Arm Motor Impairment After Stroke",[93],"2019-02-14","2020-08-14","2018-06-11",[24,13376,13377],"Hemiplegia","Hemiparesis",[13354],{"intervention":13380,"totalTrials":118,"cells":13381},"Low Dose Naltrexone",{"EARLY_PHASE1":13382,"PHASE1":13384,"PHASE2":13386,"PHASE3":13388,"PHASE4":13390,"NA":13392},{"trials":13383,"activeCount":100},[],{"trials":13385,"activeCount":100},[],{"trials":13387,"activeCount":100},[],{"trials":13389,"activeCount":100},[],{"trials":13391,"activeCount":100},[],{"trials":13393,"activeCount":100},[13394],{"nctId":13395,"briefTitle":13396,"status":166,"phases":13397,"primaryCompletion":6092,"completion":6092,"start":11858,"enrollment":8011,"conditions":13398,"interventions":13399},"NCT02107014","Low Dose Naltrexone (LDN) Immune Monitoring",[93],[2460],[13380],{"intervention":11914,"totalTrials":118,"cells":13401},{"EARLY_PHASE1":13402,"PHASE1":13404,"PHASE2":13406,"PHASE3":13408,"PHASE4":13410,"NA":13412},{"trials":13403,"activeCount":100},[],{"trials":13405,"activeCount":100},[],{"trials":13407,"activeCount":100},[],{"trials":13409,"activeCount":100},[],{"trials":13411,"activeCount":100},[],{"trials":13413,"activeCount":100},[13414],{"nctId":11908,"briefTitle":11909,"status":1196,"phases":13415,"primaryCompletion":7766,"completion":7766,"start":6506,"enrollment":100,"conditions":13416,"interventions":13417},[93],[11912],[6201,11914]]